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 The editors are to be congratulated in having ob-
tained contributions from experts on a wide range 
of physical disorders in order to throw light on 
those physical disorders which have a higher rate 
of psychological disorders associated with them. 
Recognition and treatment of these disorders 
have been shown to improve the patient’s quality 
of life, and also collaboration with the treatment 
regimes for their physical illness. 
 Of course, the shoe can be fitted to the other 
foot, and one can ask to what extent do particular 
psychological disorders have higher rates of ex-
pected physical disorders. Both of these are valid 
questions, but while the second is of great scien-
tific interest, the first is more important from the 
viewpoint of patient care.
 In probing the reasons for these higher than 
expected comorbidities, it is often found that 
there is no single way in which one form of 
morbidity influences the other: each one exac-
erbates the other, and good clinical care must 
not be blind to the psychological disorders with 
which a particular physical disease is associated. 
This book provides examples of the various 
ways in which such vicious circles establish 
themselves.
 In addition to the possible factors mentioned 
by the editors in their preface that may account 
for the high comorbidity between psychological 
disorders and physical illnesses, there are a 
number of other possible relationships. First, 
the number of different pains caused by the 
physical illnesses increases the probability of de-
pression: in one primary care study, patients 
with a single pain were no more likely to be de-
pressed than those without pain, but with two 
different pains the probability of depression was 
double, and with three or more pains the prob-
ability of depression was five times higher  [1] . 
Secondly, chronic physical illness carries with it 
the risk of disability, which can be very depress-
ing for an adult who has previously been healthy. 
For example, Prince et al.  [2] showed that the 
attributable fraction of disability or handicap for 
the prediction of onset of depression among the 
elderly was no less than 0.69, and Ormel et al.  [3] 
showed similar findings in Holland. Thirdly, 
there are physical changes in some diseases 
which may underlie the development of depres-
sion, such as changes in the allostatic load. Al-
lostasis refers to the ability of the body to adapt 
to stressful conditions. It is a dynamic, adaptive 
process. Tissue damage, degenerative disease 
(like arthritis) and life stress all increase allostat-
ic load and can induce inflammatory changes 
which produce substances such as bradykinin, 
prostaglandins, cytokines and chemokines. 
These substances mediate tissue repair and heal-
ing, but also act as irritants that result in periph-
eral sensitisation of sensory neurons, which in 
turn activate central pain pathways  [4] . These 
are all ways in which a physical disorder can 




 There are also psychological disorders that 
antedate episodes of physical disorder, such as a 
depressive illness. Systematic reviews of 11 pro-
spective cohort studies in healthy populations 
show that depression predicts later development 
of coronary heart disease in all of them  [5, 6] . 
The occurrence of a depressive episode before 
an episode of myocardial infarction has been re-
ported by Nielsen et al.  [7] . Three prospective 
studies have also shown that depression is an in-
dependent risk factor in stroke  [8–10] . In pro-
spective population-based cohort studies, de-
pression has been shown to predict the later de-
velopment of colorectal cancer  [11] , back pain 
 [12] , irritable bowel syndrome  [13] and multiple 
sclerosis  [14] , and there is some evidence that 
depression may precede the onset of type 2 dia-
betes. Prince et al.  [15] argue that there is con-
sistent evidence for depression leading to physi-
cal ill-health in coronary heart disease and 
stroke, as well as depression in pregnancy po-
tentially leading to infant stunting and infant 
mortality.
 It has been hypothesised  [16] that increases in 
pro-inflammatory cytokines in depression and 
increased adrenocortical reactivity may also lead 
to atherosclerosis, and with it increased risk for 
both stroke and coronary artery disease. In the 
latter, autonomic changes in depression may 
also cause ECG changes which favour develop-
ment of coronary disease. Changes in natural 
killer cells and T-lymphocytes in depression 
may lead to lowered resistance to AIDS in HIV 
infections. Menkes and McDonald  [17] have ar-
gued that exogenous interferons may cause both 
depression and increased pain sensitivity in sus-
ceptible individuals by suppressing tryptophan 
availability and therefore serotonin synthesis. 
More prosaic explanations include reduced 
physical activity in people suffering from de-
pression  [18] .
 It is clear that relationships between the two 
forms of morbidity are complex and that causal 
relationships that may be true for one physical 
disorder may not apply to another disorder. The 
chapters of this book bring together in one place 
a comprehensive account of these comorbidities, 
and an important step has therefore been taken in 
a field in which there is still much to learn in the 
future.
 Sir David Goldberg , Institute of Psychiatry,
 King’s College, London 
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 There is little doubt about the fact that comorbid-
ity – the simultaneous presence of two or more 
diseases – is a major challenge for health services. 
The prevalence of comorbidity has increased rap-
idly and continues to grow for several reasons, 
mainly the increase in life expectancy following 
successes in medicine and socioeconomic devel-
opment. However, also playing a role are envi-
ronmental factors (such as air pollution), changes 
in lifestyle, rapid urbanization and medical fac-
tors including iatrogenic disease and the frag-
mentation of medical services which often result 
in the late recognition of comorbid diseases and 
the consequent failure to treat them. 
 An area of particular neglect is the comorbid-
ity between mental and physical disorders. One 
of the main reasons for this development is the 
long-standing separation of psychiatry from oth-
er branches of medicine. The geographic separa-
tion of mental health institutions from the hos-
pitals and departments dealing with other physi-
cal diseases is a material expression of the 
perception that psychiatric disorders are not dis-
eases like others, and a consequence of this per-
ception is the growing distance and separation 
between psychiatry and the rest of medicine. In 
practice, this has led to many psychiatrists failing 
to recognize the presence of physical illness in 
their patients and being reluctant to provide 
treatment for the physical disorder when a diag-
nosis is made. The same is true for specialists in 
other branches of medicine who pay insufficient 
attention to the presence and treatment of men-
tal disorders in their patients.
 The neglect of comorbidity of mental and 
physical illness is also linked to the fact that its 
prevalence has been, for a long time, severely un-
derestimated. This was due in part to the lack of 
recognition described above; however, it also re-
flects the fact that the stigma of mental illness 
makes patients reluctant to speak about their 
mental health problems to nonpsychiatric physi-
cians. Comorbidity of mental and physical ill-
nesses often leads to a tacit collusion with patients 
and healthcare professionals agreeing to deal with 
the physical illness as if the mental disorder did 
not exist. The fact that people with mental illness 
are often poor and less well educated may have 
also contributed to lesser utilization of health ser-
vices that might have recorded the number and 
frequency of comorbidity of mental and physical 
illness.
 The scant attention given to the comorbidity 
of mental and physical disorders is of major pub-
lic health concern. The simultaneous presence of 
mental and physical diseases worsens the prog-
nosis of both types of disorders and increases the 
personal and social cost of dealing with them. 
Complications of the comorbid diseases become 
more probable and their treatment is more com-
plex. What is particularly worrisome is that co-
morbidity of mental and physical disorders is 
becoming more frequent at a time when medi-
cine is becoming increasingly fragmented into 
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super-specialties and when the numbers of gen-
eral practitioners who can follow the rapid de-
velopment of knowledge in the many disciplines 
of medicine is diminishing.
 The reasons for the high prevalence of mental 
and physical illness are only partially clear. To an 
extent this may occur because some people with 
mental illness do not pay sufficient attention to 
their bodies and do not follow elementary rules of 
healthy lifestyle, hygiene and disease prevention. 
That many people with mental illness live in con-
ditions of poverty and deprivation where they 
may be exposed to the considerable dangers of 
violence and abuse might also be a part of the ex-
planation. People with mental illness often abuse 
alcohol and other drugs which expose them to the 
health consequences of substance misuse such as 
hepatitis and HIV infections. Although these rea-
sons are important, they do not explain all of the 
excess comorbidity. A number of biological 
changes seen in mental illness may also predis-
pose to physical ill health, including enhanced in-
flammation or endocrine dysfunction, but genet-
ic factors are also important. We are still lacking 
longitudinal studies of comorbidity that could of-
fer insights into the mechanisms. The recent find-
ings on the effects of early childhood abuse on the 
prevalence of cardiovascular diseases and on the 
prevalence of depression are good examples of 
the gains that might result from long-term and 
life-perspective studies.
 Our main goal for this book was to assemble 
and present material that will help in efforts to 
raise awareness of the magnitude and nefarious 
consequences of comorbidity of mental and phys-
ical illnesses while stimulating relevant research 
as well as the application of knowledge that is al-
ready available. We invited leading experts in the 
field of comorbidity to participate in the produc-
tion of this volume. We have tried to exemplify 
issues that arise in three main areas of concern. 
The first of these are the public health aspects of 
comorbidity focusing on the ways in which co-
morbidity can be conceptualized, on the cost that 
comorbidity presents to society and on the inter-
action of comorbidity with factors stemming 
from the context of socioeconomic development. 
In the second group of chapters we assembled re-
views of evidence that illustrate the two main ap-
proaches to the understanding of evidence about 
comorbidity. For the first approach, the chapters 
look at specific issues that arise in relation to co-
morbidity of mental disorders with disease groups 
of major public health importance, such as car-
diovascular illness, cancer and infectious diseas-
es. For the second approach we examined physi-
cal comorbidity in relation to a range of mental 
and behavioral disorders, including substance 
abuse, eating disorders and anxiety. The message 
imbedded in this way of presenting evidence – us-
ing one of the two approaches – is that both are 
necessary: taking a position of looking at comor-
bidity from only one side may hide important is-
sues and clues. The last group of chapters includes 
contributions that deal with the elements of the 
response to the problems arising from comorbid-
ity – the organization of health services (especial-
ly the role of the general practitioners), the train-
ing of different categories of health personnel and 
the multisectoral engagement necessary to pre-
vent comorbidity.
 Norman Sartorius , Geneva
 Richard I.G. Holt , Southampton
 Mario Maj , Naples 
 Background 
 Abstract 
 Diabetes and depression provide a model for under-
standing the comorbidity of mental and physical disor-
ders, as each influences the other while sharing a broad 
range of biological, psychological, socioeconomic and 
cultural determinants. Diabetes and depression may be 
viewed as: (1) categories or dimensions, (2) single prob-
lems or parts of broader categories, e.g. metabolic/car-
diovascular abnormalities or negative emotions, (3) sepa-
rate comorbidities or integrated so that depression is 
seen as part of the comprehensive, normal clinical picture 
of diabetes, and (4) expressions of a shared, complex bio-
social propensity to chronic disease and psychological 
distress. Interventions should reflect the commonalities 
among chronic mental and physical disorders and should 
include integrated clinical care and self-management 
programs along with population approaches to preven-
tion and management. Among these, peer support, self-
management and problem solving, and programs for 
whole communities are promising approaches. Self-
management and problem solving may also provide a 
coherent framework for integrating the diverse manage-
ment of tasks and objectives of those affected by diabe-
tes and depression and as a model for prevalent multi-
morbidity.  © 2015 S. Karger AG, Basel 
 Amidst growing evidence of the bidirectional re-
lationship between diabetes and depression at the 
pathophysiological, clinical, behavioral, and so-
cial levels [e.g.  1 ], their co-occurrence also pro-
vides a window on a broader range of comorbidi-
ties among mental health, psychological distress, 
and diverse chronic diseases and health condi-
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tions. Diabetes itself is an excellent model of 
chronic disease in general, and depression, with 
its broad range of influences, severity and inter-
vention strategies provides an excellent model for 
understanding psychological distress and mental 
health problems as they interact with other as-
pects of health and well-being. 
 Biological, Psychological and Socioeconomic 
Influences in Diabetes and Depression 
 How social and psychological factors ‘get under 
the skin’ to influence biological processes is cen-
tral to understanding the complexity of relation-
ships between mental health and chronic disease 
[e.g.  2 ].  Figure 1 provides a useful model in diabe-
tes and depression that recognizes how depres-
sion and stressful life events can lead to the activa-
tion of the hypothalamic-pituitary-adrenal axis 
and complex hormonal interactions in the patho-
genesis of metabolic disorders. These complex 
hormonal interactions can give rise to a wide 
range of metabolic and cardiovascular abnormal-
ities which characterize diabetes and are increas-
ingly observed in people with depression, thus 
threatening an increasing cycle of psychological 
and physical ill health  [3] . 
 Starting with epigenetic effects of early mater-
nal care, a variety of social, psychological and bio-
logical influences may interact in the etiology and 
course of both depression and diabetes, and ac-
celerate the psychological and metabolic abnor-



















(e.g. low energy, binge eating,
physical inactivity, poor treatment
compliance, poor self care)
Adverse effects of treatment




insulin injection, blood glucose
self-monitoring, dietary
restriction)
Comorbidities and premature mortality
Access to care Family/peer support 
 Fig. 1. An example of an integrative model of diabetes and depression. 
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tions of diabetes increase, associated psychosocial 
stress and reduced coping ability may contribute 
to depression. Additionally, the psychological 
burdens of diabetes treatments, such as insulin 
injection or blood glucose self-monitoring, can 
increase negative emotions and maladaptive be-
haviors and lead to a loss of interest, low energy, 
abnormal eating patterns, sleep disturbance, poor 
treatment compliance and poor concentration. 
As diabetes may exacerbate depression, likewise 
evidence indicates deleterious effects of coexist-
ing depression on clinical status, subsequent 
complications, mortality and increased health-
care expenditures  [4] .
 Following the model in  figure 1 , broad social 
and economic contexts of family and social rela-
tionships as well as organizational, economic and 
cultural factors influence depression, diabetes 
and other mental and physical disorders. Exam-
ples of these are detailed in a report available at 
http://sph.unc.edu/profiles/edwin-b-fisher-phd/.
 The Breadth of Environmental Influence: 
Neighborhood Design and Social Isolation 
 Illustrating the broad range of potential influenc-
es on mental and physical disorders, the next 
paragraphs provide examples of how neighbor-
hood and architectural design may influence so-
cial relationships and health status. 
 One study on housing involving older adults 
showed that architectural features such as 
porches and stoops encouraged greater person-
to-person contact and were positively associated 
with perceived social support. These in turn 
were associated with less self-reported depres-
sion and anxiety  [5] . Other architectural fea-
tures, such as windows, allowed for broader ob-
servation of the surrounding area, but removed 
individuals from close person-to-person contact 
and were associated with lower levels of per-
ceived social support and greater psychological 
distress  [5] .
 Research has also documented associations 
between neighborhood characteristics and diabe-
tes prevalence and management. In a natural ex-
periment in the mid-1990s, the Department of 
Housing and Urban Development randomly as-
signed approximately 4,500 women with children 
living in public housing in high-poverty urban ar-
eas to one of three conditions: housing vouchers 
to move to low-poverty areas and receive coun-
seling, unrestricted vouchers and no counseling, 
and control – no vouchers. In follow-up data 
(2008–2010), those who had been offered vouch-
ers for low-poverty neighborhoods were less like-
ly than controls to have BMI  ≥ 35 or  ≥ 40, and less 
likely to have a glycated hemoglobin  ≥ 6.5% (48 
mmol/mol). Those receiving the unrestricted 
vouchers did not differ from controls  [6] .
 A study in Quebec, Canada sheds light on spe-
cific neighborhood features that may be especial-
ly important. Individuals who reported their 
neighborhoods as having worse physical and so-
cial order (i.e. deteriorated buildings, graffiti, 
noise, trash, crime and vandalism), less social co-
hesion, and less access to services and resources 
had greater diabetes distress including emotional 
burden, dissatisfaction with medical care, diffi-
culty with treatment regimen, interpersonal im-
pacts and support for diabetes management. Even 
after controlling for confounders, such as income, 
education and race, these relationships remained 
significant  [7] .
 The complex interweaving of multiple levels of 
influence results in sharp social and economic 
stratification of both diabetes and depression. 
Failure to recognize the influence of contextual 
factors may have at least three deleterious conse-
quences. First, interventions may be less powerful 
than they might be. Second, benefits of medical or 
psychological interventions delivered to individ-
uals may be  underestimated if important contex-
tual moderators of their effects are not accounted 
for in analyses. Third, individuals may be viewed 
as responsible for problems in a manner that con-
stitutes a kind of ‘victim blaming’.
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 What Are We Preventing, Treating, and 
Managing? Key Definitional and Conceptual 
Issues 
 In order to develop comprehensive approaches to 
the effective prevention and/or management of 
diabetes and depression, it is necessary to clarify 
just how the problems and their interrelation-
ships are to be approached. The term ‘comorbid-
ity’ connotes two well-defined and distinct clini-
cal entities, occurring simultaneously and each 
tending to occur more frequently in the presence 
of the other, as simply illustrated in  figure 2 . How-
ever, the interrelationships between diabetes and 
depression may be viewed in other ways as well. 
 A Dimensional versus Categorical View of Each 
of Diabetes and Depression 
 Both depression and diabetes are commonly de-
fined categorically with specific criteria used to 
classify individuals as having either depression or 
diabetes. However, an alternative to this categori-
cal definition of depression has been a dimen-
sional characterization of mood or dysphoria, of-
ten using standardized instruments such as the 
popular Beck Depression Inventory which was 
originally developed and validated as a measure 
of depressed mood, not of categorical depression. 
As an example of the dimensional perspective in 
diabetes, the success of preventing incident dia-
betes in high-risk subjects has led to the identifi-
cation of a dimension of dysglycemia including 
varying degrees of insulin resistance and deficien-
cy that underlie manifest abnormalities in glucose 
metabolism. Supporting the dimensional per-
spective, ‘graded relationships’ between depres-
sion and both myocardial infarction and all-cause 
mortality suggest that depression ‘is best viewed 
as a continuous variable that represents a chronic 
psychological characteristic rather than a discrete 
and episodic psychiatric condition’  [8] . 
 With both depression and diabetes, categori-
cal definitions may be superimposed on the di-
mensional by defining the diagnostic category ac-
cording to a convention of some criterion score as 
in common – and changing  [9] – definitions of 
hypertension. Additionally, the International 
Classification of Diseases distinguishes three cat-
egories – mild, moderate and severe depression – 
that also reflect the practical usefulness of the di-
mensional approach.
 Single Problem versus Group of Problems 
 In addition to the difference between viewing 
problems as distinct categories or as dimensions, 
diabetes and depression may each be categorized 
as part of a broader class of problems: cardiomet-
abolic abnormalities for diabetes and negative 
emotions for depression. For example, studies of 
depression in various groups indicate high co-oc-
currence of depression, anxiety and other variet-













 Fig. 2. Simple model of 
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ies in cardiovascular risk indicate the utility of 
grouping together a set of negative emotions that 
includes depression, anxiety, hostility and stress, 
and their complex interactions in pathways relat-
ed to cardiovascular pathogenesis  [11] . Recent 
work in diabetes has also indicated that general 
measures of diabetes distress may be more closely 
related to poor metabolic control than measures 
of depressed mood alone  [12] . Parallel to the 
overlap among measures of psychological disor-
der and distress, hyperlipidemia, central adiposi-
ty and hypertension often co-occur with ‘predia-
betes’ or diabetes, leading some to refer to the 
group as comprising a ‘metabolic syndrome’  [13] . 
 Whether depression and diabetes are best 
viewed as distinct or as members of broader cat-
egories is controversial. For example, some argue 
that, however much they may co-occur, one needs 
to treat the individual cardiovascular and meta-
bolic problems encompassed by the term ‘meta-
bolic syndrome’ with appropriate medications 
for diabetes, hypertension and hyperlipidemia 
 [14] . Similarly, one may argue that beyond the co-
occurrence with anxiety, hostility and stress, de-
pressed mood alone has a specific and distinctive 
role with both diabetes and cardiovascular dis-
ease, requiring specific treatment rather than a 
more generalized approach.
 Whether diabetes or depression are best 
viewed as distinct entities or as parts of broader 
syndromes may depend on the purpose of the 
viewing. For example, Valderas et al.  [15] noted 
that the value of different models of comorbidity 
would vary according to the perspective taken by 
specialist, primary care, public health or health 
services. From the perspective of clinical care of 
individuals, differentiating among specific prob-
lems – depression, anxiety and hostility on the 
one hand and diabetes, hypertension and hyper-
lipidemia on the other – makes great sense. 
Whether with psychotherapy or psychopharma-
cology, management of depressed mood differs 
from treatment of hostility or anxiety, just as 
medication for diabetes differs from that for hy-
pertension or hypercholesterolemia. At the popu-
lation level, however, co-prevalent problems may 
share common treatment and prevention targets, 
such as healthy diet, physical activity, weight 
management and communities that encourage 
them [e.g.  6 ] for diabetes and cardiovascular dis-
ease, or, for negative emotions, socioeconomic 
well-being and communities and families that en-
courage cooperation and satisfying relationships 
among neighbors  [5] . Thus, the broader catego-
ries of cardiometabolic abnormalities and nega-
tive emotions may help guide population-wide 
prevention and treatment campaigns. At the 
same time, their individual components are duly 
the focus of clinical intervention.
 Separate ‘Comorbidities’ or Depression as Part of 
Normal Clinical Picture of Diabetes 
 Viewing diabetes and depression as part of broad-
er groupings or syndromes may also make sense 
 across the categories of mental health and medical 
illness. Research such as from the Diabetes Pre-
vention Program  [16] raises the possibility that 
depression is an early sign or precursor of diabe-
tes. Thus, as we think of the comorbidity of dia-
betes and depression, we might consider whether 
they are best viewed as distinct clinical entities 
that occasionally exist together, or as components 
of a broader syndrome encompassing both psy-
chological and physical problems. The consider-
ation of depression as part of such a broader syn-
drome would not necessarily include depressive 
disorders with specific symptoms, courses and 
outcomes such as severe depressive disorders 
with psychotic features (DSM 296.24) or depres-
sion in typical bipolar disorders. More generally, 
the term ‘depression’ needs to be understood as 
referring to mood changes that may be combined 
with a large – probably larger than currently rec-
ognized – number of problems and syndromes, 
rather than as a single entity. 
 Table 1 depicts options to view diabetes and de-
pression as: (1) distinct but comorbid conditions, 
(2) closely related conditions with appropriately 
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coordinated care and (3) clinical problems that 
normally and commonly co-occur, requiring inte-
grated care. In an integrated approach, the treat-
ment of depression becomes a routine part of dia-
betes care, just as foot care and yearly retinal 
checks. So, too, the psychological or medical treat-
ment of depression may be expanded to address its 
routine metabolic and cardiovascular dimensions. 
Consider, for example, physical activity, which is 
often included in diabetes self-management and 
increasingly recognized as helpful in reducing de-
pression. When promoting physical activity in dia-
betes self-management, one should routinely con-
sider reticence to engage in exercise as potentially 
linked to mood problems. Additionally, one should 
structure goal setting and monitoring to maximize 
the possible benefits not only of physical activity 
itself, but also of the mood-elevating effects of 
achieving a personal goal  [17] . At the same time, 
promoting physical activity as part of depression 
treatment may draw added emphasis from the rec-
ognition of its value not only in increasing mood, 
but also in reducing cardiovascular risks to which 
those with depression are prone.
 Biosocial Propensity to Chronic Disease and 
Psychological Distress 
 Bringing together a number of the points illus-
trated so far in this chapter,  figure 3 outlines a 
biosocial complex of determinants of chronic dis-
ease ranging from genetic and epigenetic effects 
(including those of maternal nurturance during 
early childhood) to community design. Given 
sufficient deficiencies in this complex, some kind 
of chronic disease (diabetes, asthma, etc.) is very 
likely as is some variety of appreciable psycholog-
ical distress or psychopathology. The particular 
 expression of this biosocial complex in one or an-
other chronic disease and one or another type of 
psychological problem may be hard to predict, 
but the likelihood of at least one of each – chron-
ic disease and psychological distress – is highly 
likely. In a casual survey of practicing primary 
care clinicians, the common response is ‘That’s 
half of my waiting room.’ 
 Figure 3 raises an important point, ‘What is 
fundamental that requires attention?’ In the sim-
pler terms of  figure 2 , that fundamental may be, 
for example, diagnosed diabetes and diagnosed 
Table 1.  Conceptualizations of the diabetes-depression relationship and implications for treatment
Conceptualization of relationship between 
diabetes and depression
Approach to treatment
Depression as a separate clinical problem 
but one that complicates diabetes 
 management, e.g. ‘There’s no way these 
folks can address their diabetes until we 
treat their depression’
Referral for specialty care
Depression and diabetes as overlapping, e.g. 
helping patients to set and reach goals for 
increasing physical activity is good for both 
diabetes and depression
Develop resources for psychological and psychiatric services that 
are closely linked to diabetes care team; include attention to 
 emotional issues in self-management programs
Integration: depression is part of the normal 
scope of diabetes and vice versa
Attention to psychosocial and emotional issues is a routine part of 
diabetes care; clinical depression as part of a range of emotional 
problems in diabetes
Reflecting the bidirectional nature of these relationships, obesity, 
metabolic syndromes, diabetes and related problems are 
 considered as part of the management of depression
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depression co-occurring in a particular individu-
al. In the more developmental, genetic terms of 
 figure 3 , what is fundamental is the biosocial 
complex of events that make expression in diabe-
tes and depression or some other varieties of 
medical and psychological morbidity highly like-
ly. The particular choice of expressions may be 
almost accidental or perhaps guided by some spe-
cific factors, but the likelihood of such expres-
sions is almost assured.
 Treatment: Integrative Clinical and 
Comprehensive Population Approaches 
 A range of pharmacologic and psychological  [18] 
interventions have been found to be useful for co-
morbid diabetes and depression. Here we high-
light those that reflect the integrative, social and 
community perspectives suggested in the preced-
ing pages. 
 Integrative Chronic Disease Care and 
Self-Management 
 Recent reports  [19, 20] have documented im-
proved clinical outcomes in diabetes through in-
tegrative care that includes team care, evidence-
based guidelines, procedures for coordinating 
care, and registry-based monitoring and prioriti-
zation of cases and strategies. Self-management 
interventions are key components of integrative 
approaches to clinical care. They teach and pro-
mote skills for doing the things in day-to-day life 
that are necessary to enhance clinical status and 
well-being  [21] . Diabetes self-management inter-
ventions have been well documented as effective 
in improving metabolic control  [22] . Notable 
within the context of the present review, reports of 
diabetes self-management and education pro-
grams have included benefits in quality of life  [23] . 
 Integrative models have also emerged in men-
tal health. Assertive community treatment focus-
es on treating individuals with severe mental ill-
ness (schizophrenia, depression, bipolar disor-
der) within the community through a team of 
professionals from psychiatry, nursing and social 
work. Rather than providing support within hos-
pital or clinical settings, community care is pro-
vided 24 h a day, 7 days a week. Research has doc-
umented the effectiveness of assertive communi-
ty treatment in reducing hospitalization days, 
inpatient psychiatric services and emergency 
room visits, especially among high utilizers of 
healthcare services  [24] . Especially pertinent to 
the present volume, integrated assertive commu-
nity treatment models have also been used to pro-
vide care for co-occurring physical and mental 
health problems  [25] .
Chronic disease
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Fig. 3. Chronic disease and 
 psychological disorders as 
 expressions of a biosocial complex 
of influences.
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 Integrating such approaches to both mental 
and physical disorders, Katon and colleagues  [26] 
developed ‘collaborative care’ models that com-
bined pharmacotherapy, psychotherapy, general 
counseling, problem solving and support provid-
ed by a depression care manager. They included 
those with depression as well as either diabetes 
and/or elevated cardiovascular risk, and found 
that collaborative care improved treatment (as in-
dicated by medication adjustments), clinical risk 
measures (glycemic control, lipids, blood pres-
sure), quality of life and social role disability  [26] . 
A 2012 meta-analysis of 69 studies of collabora-
tive care  [27] documented substantial improve-
ments on a variety of indicators, including adher-
ence to depression treatment (OR = 2.22) and re-
covery from symptoms (OR = 1.75). Such findings 
have also been replicated with low-income ethnic 
minority patients in the USA  [28] .
 Social Influences: Peer Support 
 Peer supporters, also known as ‘community 
health workers’, ‘lay health advisors’, ‘promo-
tores’ and a number of other terms, can assist in-
dividuals in self-management of diabetes and 
prevention and management of other diseases 
[e.g.  29 ]. They may also provide emotional sup-
port and encourage problem solving to address 
depression and other emotional distress. Both the 
social isolation or lack of a confidant that often 
accompany psychopathology and distress  [29] 
and the importance of simple social contact and 
emotional support suggest that simple, frequent, 
affirming and pleasant contact from a supporter 
may be especially helpful to those with emotional 
distress. 
 In a striking cluster randomized evaluation in 
Pakistan, ‘Lady Health Workers’ implemented a 
cognitive-behavioral, problem-solving interven-
tion for women who met criteria for major de-
pression during the third trimester of their preg-
nancies. Relative to controls, the intervention 
substantially reduced depression 12 months post-
partum (OR  = 0.23, p  < 0.0001)  [30] . In India, 
peer support for depression, anxiety and other 
mental health problems included education about 
psychological problems and ways of coping with 
them (e.g. deep breathing for anxiety symptoms) 
as well as interpersonal therapy, and was deliv-
ered by lay health counselors with back-up by pri-
mary care and monthly consultations from psy-
chiatrists. Results included a 30% decrease in the 
prevalence of depression and other common 
mental disorders among those with these prob-
lems at baseline, 36% reduction in suicide at-
tempts or plans, and an average of 4.43 fewer days 
with no or reduced work in the previous 30 days 
 [31] , resulting in the intervention being both cost 
saving as well as cost-effective  [32] .
 A population-based study in the USA evalu-
ated Medicaid enrollees who had made a claim 
for both community mental health and peer sup-
port services. A comparison group who had made 
only claims for community mental health services 
was matched by gender, race, age, urban/rural 
residence and principle diagnosis. Those who had 
received peer support were less likely to be hospi-
talized (OR = 0.766) and more likely to achieve 
crisis stabilization (OR = 1.345)  [33] .
 An important impact of psychological distress 
in chronic disease is its role in complicating ef-
forts to reach and engage patients in recommend-
ed care. Peer support may be an especially effec-
tive strategy for reaching the ‘hardly reached’ 
 [34] . Asthma coaches pursuing a nondirective, 
flexible, stage-based approach were able to en-
gage 89.7% of mothers of Medicaid-covered chil-
dren hospitalized for asthma. The coaches sus-
tained that engagement, averaging 21.1 contacts 
per parent over a 2-year intervention. Of those 
randomized to an asthma coach, 36.5% were re-
hospitalized over the 2 years compared to 59.1% 
receiving usual care (p < 0.01)  [35] .
 In a successful peer support intervention for 
diabetes management among patients of safety 
net clinics in San Francisco, participants were 
categorized as low, medium or high medication 
adherence at baseline. The peer support led to 
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greater reductions in glycated hemoglobin than 
in controls across all groups, but the differential 
impact of peer support was greatest among those 
initially in the low adherence group  [36] . In a 
dyadic support intervention among veterans 
with diabetes, improvements in blood glucose 
measures were substantially more pronounced 
among those with low initial levels of diabetes 
support (p for interaction  <0.001) and those 
with low health literacy (p for interaction <0.05) 
 [37] .
 Comprehensive Population Approaches to 
Interventions for Depression and Diabetes 
 Community-wide health promotion programs 
focus on populations affected or at risk. The ma-
jor community programs aiming to prevent car-
diovascular disease  [38] and encourage non-
smoking  [39] may provide lessons for compre-
hensive approaches to management of physical 
and mental disorders. The North Karelia project 
in Finland addressed heightened cardiovascular 
disease through a broad range of interventions. In 
comparison to other parts of the country, North 
Karelia showed impressive reductions in cardio-
vascular risk factors and mortality, as well as re-
ductions of cancer risk factors  [38] . 
 Several characteristics appear important in the 
North Karelia program. Its wide range of initia-
tives included development of new treatment 
guidelines for hypertension and care following 
myocardial infarction and other clinical preven-
tive approaches, community-based health educa-
tion and social marketing of preventive practices, 
and diverse engagement of community organiza-
tions, mass media and key businesses such as 
dairies, sausage factories, and food merchandis-
ing groups and grocery stores to improve the 
availability of healthy foods  [40] . Across all inter-
ventions, great attention was given to collabora-
tive planning and implementation with local or-
ganizations.
 Similar lessons may be drawn from success-
ful campaigns to encourage prevention and ces-
sation of smoking in the USA  [41] . Most nota-
bly, declines in per capita cigarette consumption 
and closely associated declines in cardiovascular 
mortality in California were attributable to a 
statewide campaign supported by taxes on ciga-
rettes that included prevention programs for 
youth, cessation programs for adults, aggressive 
counteradvertising campaigns, and communi-
ty-based program coordination and planning 
 [42] .
 Illustrating community approaches to mental 
health, the German city of Nuremberg imple-
mented a multilevel 2-year community interven-
tion to treat depression and suicide  [43] . Using 
community facilitators, the program intervened 
with three sectors of society: primary care physi-
cians to provide training and awareness about de-
pression, the general public to raise awareness 
and knowledge of services, and depressed pa-
tients to provide support. After 2 years, the pro-
gram found significant reductions in suicide acts 
and depressive symptoms, and the program was 
expanded to other regions of Europe under the 
name ‘The European Alliance against Depres-
sion’  [43] .
 How such community approaches might be 
extended to multimorbidity of physical and men-
tal disorders is unclear. One might begin with be-
haviors that community health promotion pro-
grams have been able to improve and that are also 
pertinent to diabetes and depression, such as 
healthy diet, regular physical activity, medication 
adherence, and regular clinical care, and in suc-
cessful approaches to hypertension, such as stra-
tegically directed screening. In addition to broad 
involvement of community organizations, busi-
ness and local government, intervention strate-
gies might include:
 (1) Attention to the built environment and design 
of neighborhoods and housing to promote 
physical activity as well as enhance psycholog-
ical adjustment and well-being 
(2) Engaging worksites to recognize two roles 
they may play: useful and socially influential 
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sites for implementation of programs, and 
identifying ways in which personnel policies 
and procedures might be improved to facili-
tate daily management of diabetes (e.g. blood 
glucose monitoring, healthy diet) and to re-
duce stress and enhance emotional as well as 
physical health 
(3) Community organization and social market-
ing to build social capital and promote the 
kinds of community values, social interac-
tions and approaches to conflict resolution 
that may also enhance emotional and physical 
health 
(4) Recruiting members of key audiences as peer 
supporters to build links between programs 
and those audiences as well as providing emo-
tional and tangible support to those most in 
need 
 New Media of Intervention: e-Learning, 
Telehealth, Web-Based Interventions 
 Promising results from Web-based and tele-
health interventions have spurred interest in 
new modalities for intervening with people ex-
periencing depression and diabetes  [44] . A re-
cent systematic review of Internet support 
groups for individuals with depressive symp-
toms provides evidence for the role of e-health 
in managing depression  [45] . Of the 16 studies 
reviewed, a majority (62.5%) reported a positive 
effect of Internet support on depressive symp-
toms. Although only 20% of the studies used a 
control group, other randomized control trials 
of Internet interventions have demonstrated sta-
tistically significant reductions in depression 
compared to control groups  [46] . Telephone-de-
livered cognitive-behavioral programs have also 
been successfully used with Veterans Adminis-
tration patients in the USA to reduce depressive 
symptoms and improve quality of life and func-
tioning  [17] . For patients who have been ‘hardly 
reached’ by the traditional medical care system, 
these new modalities offer a model for enhanced 
patient outreach and care. 
 Discussion 
 Articulation of the roles of social and economic 
factors is sometimes perceived as being in opposi-
tion to the articulation of individual-level factors 
or clinical treatment. The intent of the broad eco-
logical perspective taken here is an integration 
rather than opposition of multiple levels of expla-
nation. Recognition of the range of influences on 
mental health and chronic disease will best illumi-
nate the relationships between them. Understand-
ing the utilities of different perspectives on those 
relationships will best guide selection of perspec-
tives that serve specific purposes. Furthermore, 
integrating clinical, social and community ap-
proaches to prevention and management will best 
meet the global burden of multimorbidities. 
 Clinical Implications 
 There is often a tendency to see the world of clini-
cal care as separate and distinct from that of pre-
vention and population health; however, these are 
overlapping. Healthy communities may enable 
patient adherence to diabetes management and 
treatment of depression. At the same time, the 
availability of quality clinical care may provide 
both a channel for reaching populations as well as 
a resource for promoting healthy lifestyles  [47] . 
 As discussed above, peer support may be an 
especially promising strategy for integrating clin-
ical and preventive as well as individual and 
 population approaches. Peer supporters can help 
sustain the behaviors that comprise diabetes and 
depression management  [29] and provide emo-
tional support and encourage problem solving to 
address depression and other emotional distress 
 [30] while engaging those who otherwise fail to 
receive appropriate care  [35, 48] . All of these can 
assist in identifying and recruiting into treatment 
those with mental and physical disorders and in 
helping them take full advantage of the available 
resources.
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 A simple consideration that is too often unrec-
ognized cuts across all the approaches to inter-
vention outlined here. The emotional aspect is an 
important part of chronic disease care. Attention 
to depression, emotional well-being and healthy 
relationships is not a secondary consideration in 
chronic disease care, but – based on the evidence 
[e.g.  1 ] – of central importance. In diabetes and 
cardiovascular disease, for example, the recogni-
tion and treatment of depression may be as im-
portant as biological treatment targets. Further, 
knowledge gained by a comprehensive approach 
to diabetes and depression may be highly relevant 
to the care of other chronic diseases. Attention to 
depression, anxiety and stress disorders is likely 
to have impacts on health and healthcare costs far 
greater than currently appreciated.
 Integrative Role of Self-Management in 
Diabetes and Depression 
 Self-management programs in chronic disease 
may provide important models for approaches to 
mental health problems in general as well as those 
which co-occur with physical disorders. Surely the 
core elements of chronic disease self-manage-
ment – healthy diet, physical activity, adherence to 
medication regimens, stress management, prob-
lem solving, and cultivating family and friend sup-
port – would all seem equally pertinent to the man-
agement of depression. It should also be noted that 
meta-analysis of interventions for depression and 
diabetes has implicated diabetes self-management 
education in the metabolic benefits associated with 
cognitive behavioral interventions  [18] . 
 Within self-management, problem solving 
may have a special role in integration of care for 
depression and diabetes. Problem solving is cen-
tral to almost all models of self-management in 
diabetes and chronic disease. At the same time, 
problem solving has emerged as a prominent ap-
proach to psychotherapy for depression and oth-
er problems  [49] . Indeed, recent research indi-
cates that the benefits of cognitive behavior ther-
apy for depression rest largely on the more 
behavioral, skill-oriented components of prob-
lem solving and ‘behavioral activation’ within 
cognitive behavior therapy  [50] . Thus, problem 
solving can address the management of both 
mental and physical disorders. For example, help-
ing individuals set objectives for increasing phys-
ical activity, take steps to accomplish those objec-
tives, and reflect on the pleasure of reaching them 
may advance both diabetes self-management as 
well as self-management of depression.
 In addition to its effectiveness in both domains, 
an emphasis on problem solving may also provide 
a useful framework for providing coherence to the 
individual’s tasks in management of mental and 
physical disorders. Organizing overall care as 
problem solving or self-management to achieve a 
healthy diet, physical activity, adherence to medi-
cations, stress management, and maintenance of 
satisfying social and community engagements 
may provide patients a coherent framework for 
accommodating the changes that emerge inevita-
bly in the natural history of chronic disease. It may 
also avoid concerns about stigma surrounding de-
pression, other forms of emotional distress or 
chronic diseases in many cultures.
 Self-management procedures emerged largely 
out of research on self-control and related pro-
cesses in psychology, behavior therapy and health 
psychology. This might lead one to expect great 
attention to self-management approaches to de-
pression and other mental health problems that 
psychology has traditionally addressed. Yet, while 
a search of PubMed (January 13, 2014) for papers 
with ‘self-management’ and cognates of ‘diabetes’ 
in their titles yielded 762, a parallel search for pa-
pers with ‘self-management’ and cognates of ‘de-
pression’ in their titles yielded only 36. When ex-
panded to include mention in abstracts, results 
were 2,390 for ‘self-management’ with cognates of 
‘diabetes’ and 567 with cognates of ‘depression’. 
Further, many of those mentioning depression 
were focused on self-management of other diseas-
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es and simply included a measure of depression, 
not the focus of the self-management program. It 
should be noted that mental health researchers 
may use other terms like ‘psychotherapy’, ‘sup-
portive therapy’, and ‘bibliotherapy’ to refer to 
similar services as ‘self-management’. Neverthe-
less, it appears that the  combination of proactive 
medical treatment and self-management which 
constitutes the state-of-the-art in diabetes has not 
been fully recognized in mental health.
 Experience teaches that paradigm or conceptu-
al shifts do not follow from rational argument as 
often as they emerge in response to events. The 
growing burden of diabetes, depression and other 
multimorbidities may compel medicine, public 
health and mental health to move forward with im-
proved and comprehensive interventions. Closely 
related to this, the pressure of healthcare costs has 
led (e.g. US Affordable Care Act) to increased em-
phasis on primary care and integration of chronic 
disease management and behavioral health.
 The perspectives here have substantial impli-
cations for training professionals. Beyond cover-
ing chronic diseases and the behavioral health is-
sues that so often accompany them, training 
needs to inculcate an understanding of the inte-
gration of these, as they are experienced by pa-
tients and as they need to be treated by clinicians. 
Moving down the problem list from diabetes, to 
joint problem, down to depression is not an ap-
proach to organizing clinical care that reflects the 
ways in which these problems emerge and func-
tion. One might argue that such an approach is, 
indeed, bad medicine. Beyond the pitfalls of poly-
pharmacy that it engenders, it fails to recognize 
the interconnected nature of behavioral health 
and biological problems and to bring to bear evi-
dence-based models for addressing them.
 Whether through mental health, primary care, 
specialty care or community-based programs, in-
dividuals should receive services that reflect the 
co-occurrence of diabetes and other chronic dis-
eases with depression and other emotional dis-
tress and that provide integration and continuity 
of services for these. Integrating the clinical with 
social, organizational and community approach-
es as advocated here may offer a strong model not 
only for the global burdens of diabetes, depres-
sion and other mental and physical health prob-
lems, but also for more general prevention and 
healthcare in an era of aging populations, grow-
ing prevalence and burden of noncommunicable 
diseases, and  normative  multimorbidity .
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 Background 
 Abstract 
 This chapter uses a public health perspective to provide 
an overview of the key determinants and shared path-
ways for the causes of non-communicable diseases and 
common mental disorders and their outcomes. Current 
understandings about their co-occurrence, prevention 
and control will be discussed, as well as the implications 
of emerging frameworks that target modifiable risk fac-
tors. We will conclude by outlining some of the issues and 
challenges associated with wide-scale implementation 
and scale-up of public health interventions that target 
the prevention and control of these conditions when 
they co-occur in different community settings. 
 © 2015 S. Karger AG, Basel 
 Current Views on the Prevention and Control 
of Non-Communicable Diseases and Common 
Mental Disorders 
 Cardiovascular disease, type 2 diabetes mellitus, 
cancer and chronic respiratory disease are often 
referred to as ‘the big four’ non-communicable 
diseases. The World Health Organization 
(WHO) reports that these conditions account for 
almost 90% of all deaths due to non-communica-
ble disease, globally. However, in recent times, 
growing support has emerged for the need for 
common mental disorders, such as major de-
pression and anxiety, to also be recognised as 
non-communicable diseases  [1] . Indeed, it is 
now  very well established that these common 
mental disorders contribute significantly to the 
global burden of disability-adjusted life years. In 
fact, when considering disability-adjusted life 
years, rather than just cause of death, the so-
called ‘big four’ account for only half (54%) of 
non-communicable disease-related disability-
adjusted life years, with major depression the sec-
ond leading cause of disability. In response, the 
WHO Global Action Plan (2013–2016), devel-
oped to reduce the global burden of non-com-
municable diseases and preventable mortality, 
now incorporates targets and strategies related to 
mental health prevention and control  [2] . A shift 
towards a model that incorporates mental  and 
physical disorders into the same constellation of 
conditions also has important implications for 
conceptualising their prevention and manage-
ment, both as independent conditions, but even 
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more importantly, when they co-occur. Before 
further discussing the implications of such a 
model for approaches to their prevention and 
control, the key determinants and pathways that 
link high prevalence non-communicable diseas-
es to common mental disorders will be discussed. 
We shall particularly focus on the inter-relation-
ships and co-occurrence among cardiovascular 
disease, type 2 diabetes and depression. 
 Shared Determinants for Non-Communicable 
Diseases and Common Mental Disorders 
 When identifying population-wide prevention 
and control strategies for non-communicable 
diseases, the WHO has emphasised the role of the 
lifestyle determinants of these conditions. Tradi-
tionally, common mental disorders have received 
relatively little attention from this perspective, 
and treatment options that target the modifiable 
lifestyle factors known to ameliorate non-com-
municable diseases have been seldom applied to 
common mental disorders. Jacka et al.  [1] have 
argued that while contextual factors including so-
cial inequity and networks, child maltreatment, 
and neglect clearly contribute to depression risk, 
it is important that prevention and control efforts 
focus much more on those determinants with the 
‘greatest plasticity and reach’. The authors de-
scribe a growing evidence base that identifies life-
style factors (e.g. physical inactivity, smoking and 
diet quality) as important determinants for the 
development of common mental disorders such 
as depression, i.e. the same lifestyle determinants 
already known to be important determinants of 
non-communicable diseases. This evidence sug-
gests an opportunity exists to prevent and control 
mental and physical disorders that occur comor-
bidly by using a consolidated framework in which 
several overlapping, modifiable risk factors, such 
as tobacco use, unhealthy alcohol use, physical in-
activity and unhealthy diet are targeted with the 
potential to reduce both non-communicable dis-
eases  and common mental disorders. Before re-
viewing such a framework, the shared pathways 
that link the common mental disorders to non-
communicable diseases will be described. 
 Shared Pathways for Non-Communicable 
Diseases and Common Mental Disorders 
 It may seem intuitive that the occurrence of de-
pression or anxiety in those with a chronic physi-
cal condition exacerbates the risk of poor clinical 
outcomes. For example, after the occurrence of a 
life-threatening event such as acute coronary syn-
drome (heart attack), or symptoms and potential 
complications of type 2 diabetes, the associated 
worry and distress impair functioning, recovery 
and/or coping ability, and the overall burden of 
self-management may exacerbate symptoms of 
depression  [3] . For example, some estimates sug-
gest 25–46% of people with type 2 diabetes mel-
litus  [4] or cardiac disease  [5] experience symp-
toms indicative of depression. However, these 
symptoms are not just a common clinical out-
come of these conditions. Major depression has 
emerged as a powerful and robust risk factor for 
both conditions in recent years  [6] . While the 
pathways implicating depression in the patho-
genesis and outcomes of cardiovascular disease 
and/or diabetes remain unclear, they are clearly 
multifaceted. Psychophysiological, biobehav-
ioural and social influences interact to elevate the 
risk of cardiovascular disease and/or type 2 diabe-
tes in those with depression (both in its genesis 
and clinical course), accelerating the psychologi-
cal and cardiometabolic abnormalities of each 
 [3] . For example, of the former, depression and 
psychosocial stressors can lead to hypothalamic-
pituitary-adrenal axis activation and complex 
hormonal and (auto)immuno-inflammatory in-
teractions in the pathogenesis of cardiometabolic 
disorders. Such a response can elicit a host of met-
abolic and cardiovascular abnormalities which 
characterise the cardiovascular disease and diabe-
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tes over-represented in people with depression. 
This response can perpetuate a cycle of psycho-
logical and physical ill health  [3] . 
 Another explanation for this relationship is 
biobehavioural; the presence of shared risk fac-
tors like smoking, obesity, poor diet or physical 
inactivity can lead to systemic inflammation, 
which is common in the development of both de-
pression  [7, 8] and these systemic disorders  [9] . 
Further, environmental and contextual factors 
commonly linking mental and physical disorders, 
including socio-economic status and social isola-
tion, have also been shown to increase the risk of 
all of these disorders  [7, 10, 11] . Fisher et al.  [3] 
argues that these up- and downstream determi-
nants are complex in that they are interwoven at 
multiple levels. Failure to consider the role of 
such factors has potentially deleterious conse-
quences with respect to the delivery and effective-
ness of public health interventions. While these 
consequences will be discussed further in a fol-
lowing section, we will define what is meant by 
‘public health’ interventions before looking at 
those that exist for the prevention and control of 
comorbid mental and physical health disorders.
 Defining Public Health Interventions 
 The term ‘public health interventions’ can have 
different meanings, in part because the term ‘pub-
lic health’ is used in different ways. First, the term 
‘public health’, particularly ‘public health re-
search’, is often used as a general and very broad 
term to be inclusive of all epidemiologic, interven-
tion and health services research. Second, it can be 
used to imply a primary focus on the health of the 
public and whole populations, rather than being 
concerned with just the health and well-being of 
single individuals; often this focus also includes a 
particular interest in the situation as it pertains to 
disadvantaged individuals or groups, and/or an 
emphasis on this issue globally. Third, ‘public 
health’ is often taken to mean an emphasis on pre-
vention rather than a focus on treatment services 
and management of a clinical problem. With 
these theoretical differences in mind, we will now 
consider the evidence in relation to the preven-
tion and control of comorbid non-communicable 
diseases and common mental disorders. 
 Prevention and Control of Comorbid Physical 
and Mental Disorders 
 To date, the evidence base for the effectiveness 
and feasibility of real-world public health inter-
ventions for the prevention and management of 
common comorbid non-communicable diseases 
and common mental disorders is stronger for 
people with existing conditions than for primary 
prevention or secondary prevention in those at 
‘high risk’; we shall consider both of these. 
 Prevention of Comorbid Non-Communicable 
Diseases and Common Mental Disorders 
 As outlined in previous sections, there is sound 
evidence that similar lifestyle factors shown to 
precipitate the ‘big four’ non-communicable dis-
eases are also important contributors in the devel-
opment of common mental disorders. Notwith-
standing the complexity of factors contributing to 
the pathophysiology and trajectory of common 
mental disorders like depression and anxiety, this 
evidence suggests that modification of lifestyle 
behaviours as risk factors may have the potential 
to ameliorate some of the risk of common mental 
disorders. This rationale has underpinned recent 
calls for a population-based approach that inte-
grates such ‘plastic’ lifestyle factors for the univer-
sal prevention of common mental disorders  [1] . 
Recent research in this field suggests whilst the 
potential contribution of modifiable factors such 
as social inequality, social networks, and child, 
drug and alcohol abuse to depression risk should 
not be underestimated or ignored, preventive ef-
forts should also aim to address individuals’ 
health-related lifestyle behaviours. 
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 Lifestyle is a term that encompasses behav-
iours related to diet, physical activity and smok-
ing, amongst other behaviours, known to increase 
the risk of disease and poor health. There is in-
creasing evidence which identifies physical inac-
tivity as a risk factor for common mental disor-
ders  [12, 13] , with exercise shown to be effective 
in treatment studies  [14] . Further, some evidence 
exists linking smoking to an increased risk of de-
veloping common mental disorders  [15, 16] . Diet 
quality has also received much attention in recent 
times in the lifestyle-mental health research field 
 [17, 18] . For example, one notable study, the 
PREDIMED trial, identified a link between ad-
herence to the Mediterranean diet, the hallmark 
of which is the abundant use of olive oil  [19] , 
which is rich in monounsaturated fatty acids, and 
reduced depression risk  [20] . Results revealed a 
significant 40% reduction in depression risk for 
individuals with type 2 diabetes who adhered to 
the Mediterranean diet when compared with the 
control group. 
 Despite these encouraging findings, evidence 
is somewhat scarce and moreover limited by un-
derpowered sample sizes or inadequate study de-
signs. However, the primary prevention of com-
mon mental disorders remains a burgeoning area 
in public health that has garnered support in re-
cent years in light of data suggesting that, for the 
majority of people (75%), common mental disor-
ders manifest before the age of 24 years  [21] . 
Moreover, lifestyle-based strategies that target the 
primary prevention of common mental disorders 
could play an important role in the subsequent 
prevention of the ‘big four’ non-communicable 
diseases. The beneficial effects of targeting life-
style factors are likely to extend beyond that of 
psychological well-being to ameliorate the risk of 
non-communicable diseases, potentially produc-
ing a ‘double hit’ by delaying or preventing chron-
ic disease later in the lifespan. From a well-being, 
health and economic perspective, the (in)direct 
‘flow-on’ effects resulting from investment in the 
primary prevention of common mental disorders 
using this approach become apparent. We shall 
discuss the issues related to economic responsi-
bility in the following section.
 Control and Management of Comorbid 
Non-Communicable Diseases and Common 
Mental Disorders in ‘High-Risk’ Populations 
 Traditionally, non-communicable diseases and 
common mental disorders have been treated 
uniquely and independently within the public 
health sphere. From a systematic perspective, 
many healthcare systems are not designed to in-
corporate the multidisciplinary approach required 
to manage patients with co-occurring physical and 
mental disorders adequately. This is largely due to 
increasingly specialised and fragmented struc-
tures. Additionally, a range of downstream deter-
minants are likely to impede the cohesive manage-
ment of these comorbidities, including a lack of 
recognition around their high prevalence, poor 
awareness on behalf of the patient, practitioner or 
both, and deficits in physician training. 
 If we use the specific example of diabetes, a 
lack of continuity of care has been shown to 
translate to poorer clinical outcomes and sub-
optimal care provision. For example, Mitchell et 
al.  [22] provide evidence that despite greater 
 service use, those with a mental illness are less 
likely to be screened for diabetes, associated eye 
or foot complications, receive statins or diabetes 
education, or be offered HbA1c and cholesterol 
screening.
 The converse is also true. Using the example of 
heart disease, people who have been admitted to 
hospital for a coronary event are unlikely to be 
screened for depression. Stewart et al.  [23] report 
that only 3% of clinicians in Australia perform 
routine screening for depression. In order to ad-
dress these deficiencies within healthcare sys-
tems, models of the clinical management for co-
morbid mental and physical disorders have been 
developed. Perhaps the most well-known is the 
IMPACT model developed by Katon et al. [24] , 
which draws on evidence-based medical models 
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such as those described by Wagner et al.  [25] 
(chronic care model in primary care settings) and 
Lorig et al.  [26] (self-management models in 
community-based settings). The model of care by 
Katon et al. was one of the first to consider the 
concurrent management of depression, heart dis-
ease and type 2 diabetes using a collaborative care 
approach, and has been shown to be more effec-
tive for chronic disease management than stan-
dard medical care  [27] . Collaborative care models 
emphasise the ‘up-skilling’ of practice nurses as 
case managers who aim to provide continuity of 
care. This includes  [24] :
 • Encouraging support and effective 
communication to patients from clinicians 
 • Utilising evidence-based guidelines to 
promote patient self-management 
 • Monitoring risk factors 
 • Scheduling visits 
 • Providing audit information 
 Algorithms provide guidance on the direction 
of care based on severity of symptoms, often us-
ing a stepped-care approach with various health-
care professionals based on patient need. Perhaps 
the most important characteristic underpinning 
this model is its operation within existing struc-
tures of the healthcare setting, rather than amend-
ing the healthcare structure itself. It is designed to 
capitalise on existing workforce and financial in-
frastructures by refocussing the roles of the exist-
ing members and organisational structures of the 
setting.
 Collaborative care models have now been ex-
trapolated to a range of other comorbidities, such 
as depression and coronary artery bypass grafting 
 [28] , where they have demonstrated efficacy and 
feasibility, and have been shown to reduce cardio-
vascular risk in elderly people with depression 
 [29] . However, such models have been subject to 
criticism. For example, it has been argued that 
they have limited generalisability, require a cul-
tural shift in norms and roles, are too resource 
intensive to implement and there may be unnec-
essary overlap with other related programs  [30] . 
These models also depend largely on local cul-
ture, health systems, workforce and many other 
contextual factors and influences.
 Considerations for Implementation and 
Scale-Up of Prevention and Control of 
Comorbid Non-Communicable Diseases 
and Common Mental Disorders 
 Context 
 With the development and adaptation of any pub-
lic health intervention – much less one that targets 
both mental and physical disorders – one needs to 
consider particular contexts and settings. Fisher et 
al.  [3] maintains that failure to consider contex-
tual factors can result in a number of potentially 
deleterious outcomes. First, efficacy and/or effec-
tiveness of specific interventions may be diluted. 
Second, the benefits of interventions may be fur-
ther underestimated should contextual modera-
tors remain unaccounted for in analyses. Third, 
individuals participating in these interventions 
could be perceived as responsible for their condi-
tion resulting in a type of ‘victim blaming’  [3] . To 
this end, future opportunities exist to explore and 
evaluate different approaches to increase aware-
ness and understanding of these issues in both 
health professionals and patient populations. 
 Cost and Responsibility 
 There remains a need to shift the balance towards 
greater investment in not only population-based 
prevention strategies in public health, but those 
which incorporate attention being given to either 
the increased risk or the co-occurrence of non-
communicable diseases and common mental dis-
orders. The broader issue of responsibility must 
be considered, as with the primary prevention of 
any condition. Indeed, cost remains a barrier. A 
WHO report suggests a key factor underscoring 
the traditional focus on, and preference for, cura-
tive strategies are the short-term, tangible benefits 
as opposed to the longer pay-off periods required 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 15–22 ( DOI: 10.1159/000365524 )
20  Oldenburg · O’Neil · Cocker 
to see the effects of prevention  [31] . This is par-
ticularly evident as the cost of healthcare increases 
globally, thereby increasing competition for re-
sources  [31] . Because more than 80% of the 
world’s population lives in developing regions of 
the world  [32] – particularly, very populous coun-
tries, such as India, China and Indonesia, where 
non-communicable disease risk factors continue 
to increase  [33] – focus on the management of 
these comorbidities in so-called ‘low and middle 
income’ countries is of particular importance. 
 Economic Impact of the Co-Occurrence of 
Non-Communicable Diseases and Common 
Mental Disorders: A Focus on the Workforce 
 The economic impact of non-communicable dis-
eases and common mental disorders when they 
occur alone is significant. However, the associ-
ated costs, largely attributed to increased health-
care use and expenditure (e.g. specialist care, hos-
pital care and medication) and lost productive 
time, are substantially increased when non-com-
municable diseases and common mental disor-
ders co-occur. In most developed countries, the 
majority of people with non-communicable dis-
eases are able to keep working, with the latest es-
timates of workforce participation among Aus-
tralian adults with non-communicable diseases 
being 79% for men and 63% for women  [34] . As 
a result, a substantial economic burden from 
non-communicable diseases is borne by work-
places, in particular, lost productivity resulting 
from absenteeism and presenteeism (working 
while ill)  [34] . Additionally, a sizeable minority 
of employed people with non-communicable dis-
eases, an estimated 18% amongst Australian em-
ployees, will be managing another major health 
conditions such as heart disease, arthritis, de-
pression, asthma, diabetes and stroke  [34] , and 
these multimorbid disease combinations com-
monly also include depression  [35] . With an age-
ing workforce globally, a greater understanding 
of how to promote the health and productivity of 
workers with multiple chronic illnesses is a prior-
ity, as the impact of comorbid and multimorbid 
mental and physical disorders is not restricted to 
older adults outside the workforce. 
 Absenteeism from work is a major issue for 
governments across the world as it not only de-
creases productivity resulting in loss of financial 
growth, but also costs governments a significant 
amount of money annually to treat ill individuals, 
giving absenteeism a twofold economic effect 
 [36] . Aside from the economic impact of absen-
teeism, there are also social benefits for adults 
who participate in paid employment such as fi-
nancial independence, a higher standard of liv-
ing, and the potential for personal satisfaction 
and social acceptance  [37] . Data reveal absentee-
ism is higher amongst people with one or more 
chronic illnesses and that employees with a 
chronic illness have higher rates of long-term 
work disability than the general population  [37] . 
Interestingly, one study revealed that for absen-
teeism attributed to a physical illness, psycholog-
ical factors played a greater part in the decision to 
take a sickness absence than the physical illness 
itself  [37] .
 Most of the research to date on multimorbid-
ity and health and social outcomes has focused on 
quality of life  [38] , use of medical services  [39] , 
and hospitalisation and mortality  [40] , and has 
been in clinical or primary care populations  [35, 
41] , or selected older adult populations  [41] . 
However, given that many chronic diseases affect 
healthier, working age adults  [34] , this focus on 
clinical populations and clinical outcomes pro-
vides an insufficient evidence base for a public 
health approach to the health of the workforce 
 [35, 42] . Further, one recent Australian study 
demonstrated that comorbid psychological dis-
tress causes an increased risk of productivity loss, 
from both absenteeism and presenteeism, for a 
range of health conditions. Therefore, in terms of 
population health approaches to managing co-
morbid non-communicable diseases and com-
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mon mental disorders, an increased focus needs 
to be on developing evidence-based guidance to 
inform a reduction of the burden of common 
chronic diseases and comorbid depression among 
working age adults. Specifically, this includes the 
prevention of long-term work absences and the 
associated costs, generally poor outcomes of re-
turn-to-work programmes, and the development 
of decision aids for individuals and their clini-
cians to help guide management of work de-
mands and resources for employers on how best 
to manage work attendance in employees with 
comorbid non-communicable diseases and com-
mon mental disorders.
 Future Efforts in Public Health 
 There is a need to close the gap between the epi-
demic growth of common mental disorders, like 
depression, and non-communicable diseases, such 
as type 2 diabetes and cardiovascular diseases, and 
the provision of appropriate healthcare and public 
health programs that address the shared determi-
nants and pathways of these disorders. Whilst some 
public health interventions have proven effective, 
there remains a range of contextual and economic 
factors to consider for wide-scale implementation 
in different settings. Specific considerations in-
clude the responsibility of investment and cost re-
covery, and a lack of awareness and action concern-
ing comorbidity by public health and medical au-
thorities. Where there is not sufficient evidence for 
either testing and/or implementing programs for 
prevention or control, there is still an important 
need for research that is more focused on under-
standing the epidemiology and determinants of co-
morbid mental and physical conditions in different 
cultures and population groups within and be-
tween countries and different regions of the world. 
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 Background 
 Abstract 
 This chapter provides an overview on what is known 
about the economic impacts of comorbid physical and 
mental disorders. The chapter begins by briefly describ-
ing the concept of economic cost, before going on to look 
at different examples of the costs of comorbidity. There is 
an increasing, albeit still small, number of studies that 
have looked at the economic impacts of comorbid physi-
cal and mental health problems. The majority of these ex-
amples are from a US context and thought must be given 
on how they translate to other contexts. Nonetheless, 
these studies illustrate potentially substantial costs to 
healthcare systems and society as a whole, which might 
be avoided through early identification of potential risk 
factors and early intervention to mitigate the effects of 
comorbidity. The chapter ends by examining how infor-
mation on the costs of comorbidity can be used to inform 
economic arguments for investment in actions to prevent 
or alleviate some of these morbidities, and how this evi-
dence base may be strengthened further. 
 © 2015 S. Karger AG, Basel 
 This chapter provides an overview on what is 
known about the economic impacts of comorbid 
physical and mental disorders. As later chapters 
discuss, illnesses such as psychoses, bipolar dis-
order and major depression can increase the risk 
of many physical health problems, including 
obesity, diabetes, cardiovascular disease, chronic 
obstructive pulmonary disorder and some infec-
tious diseases. Poor physical health, for instance 
related to cancer or musculoskeletal health prob-
lems, may also increase the risk of developing 
mental health problems such as depression and 
anxiety-related disorders. As a result, there is 
likely to be a considerable overlap in those living 
with long-term physical and mental health prob-
lems. In England, for example, it has been esti-
mated that up to 46% of all those with mental 
health problems also have some chronic physical 
health problem, while 30% of those with long-
term physical conditions also have a mental 
health problem  [1] . 
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 All of these comorbidities will have economic 
consequences that impact right across society. 
Some of these costs may potentially be avoidable. 
Thus, there is a growing interest from policy 
makers, particularly in countries where health 
and social care spending is under great strain, 
about the potential importance of actions that 
can effectively prevent and/or reduce the impacts 
of comorbidity.
 This chapter therefore begins by briefly de-
scribing the concept of economic cost, before go-
ing on to look at different examples of the costs of 
comorbidity. It ends by examining how better in-
formation on the costs of comorbidity can be 
used to inform economic arguments for invest-
ment in actions to prevent and alleviate some of 
these morbidities, and how this evidence base 
may be strengthened further.
 What Is Meant by Economic Cost? 
 Before going further, it is worth briefly explaining 
what economists mean by cost, as this is about 
much more than simple monetary cost. In fact 
economists often talk about three different com-
ponents of cost. There may be increased direct 
costs to the healthcare systems associated with the 
management of multiple health problems, for in-
stance if mental disorders exacerbate the risk of 
adverse events and complications in chronic 
physical health problems or if recovery times are 
prolonged. This could include the salary costs of 
healthcare staff, the cost of medicines and the use 
of diagnostic procedures. In England it has been 
estimated that as much as GBP 1 in every GBP 8 
spent on chronic long-term conditions is due to 
adverse outcomes arising from poor mental 
health  [1] . There may also be direct costs for the 
provision of services that fall on other sectors 
such as social care services. In some cases there 
might be additional costs falling on other sectors, 
such as for home modifications due to physical 
disabilities. 
 There are also ‘indirect’ costs, which focus on 
the lost opportunity to contribute to economic 
productivity, such as when individuals are absent 
from the labour market due to poor health or pre-
mature death. Productivity costs for many mental 
disorders already account for more than 60% of 
all costs because of the low rate of participation in 
employment  [2] . A major reason for these costs is 
the much higher rate of mortality due to poor 
physical health. For instance, one study of men 
and women with severe mental disorders in 
 Denmark, Finland and Sweden reported that they 
lived between 20 and 15 years less than the gen-
eral population  [3] .
 Other forms of productivity loss also occur. 
Comorbid health problems may reduce partici-
pation in school or university, potentially impact-
ing on career possibilities. In fact, the long-term 
adverse costs to the economy due to children with 
mental health problems not obtaining employ-
ment in adulthood has been one key reason for 
substantial policy interest in measures to help 
support the health and well-being of children 
from a very young age  [4] . Family members may 
also give up some of their time from employment 
or other activities because of the need to provide 
care and support to a loved one.
 The third cost category is known as ‘intangi-
ble’ because it refers to impacts that are often dif-
ficult to quantify and value. Examples include the 
stigma associated with mental illness, communi-
cable disease or physical disabilities, as well as the 
grief experienced by families as a result of an un-
expected death.
 What Do We Already Know about the 
Economic Impacts of Comorbidity on 
Healthcare Systems? 
 Remarkably, health economists have not focused 
much of their energies on assessing the economic 
impact of comorbidity in any area of health, let 
alone looking at the issue of mental and physical 
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comorbidity. This may be due to the difficulties in 
attributing healthcare costs to any specific co-
morbidity, as well as the separation of the way in 
which mental and physical health services are or-
ganised in many countries. There is, however, an 
increasing, albeit still small number of studies, 
which have looked at the economic impacts of co-
morbid physical and mental health problems. 
The majority of these examples are from a US 
context and thought must be given on how they 
translate to other contexts. Nonetheless, they il-
lustrate potentially substantial costs to healthcare 
systems and society as a whole that might be 
avoided through early identification of potential 
risk factors and early intervention to mitigate the 
effects of comorbidity. The next sections provide 
an overview of some of these economic analyses, 
looking at economic impacts within and beyond 
healthcare systems. 
 Impacts on Healthcare Systems 
 Comorbidities between physical and mental 
health problems provide major challenges to 
healthcare systems; they can worsen health out-
comes, prolong recovery time and thus exacer-
bate costs to healthcare systems. Some, as shown 
in  table 1 , look at the additional excess costs to the 
healthcare system of a comorbid physical health 
problem compared to having a mental health 
problem alone, while others, as illustrated in  ta-
ble 2 , focus on the additional excess costs of a co-
morbid mental health problem to having a physi-
cal health problem alone. Much of this evidence 
is from the USA, but it provides valuable insights 
on the extra costs of comorbidities in other coun-
tries, suggesting that there is the potential to avoid 
substantial costs to healthcare systems through 
early identification and intervention. 
 Several studies focus on schizophrenia and 
physical health problems. Analysis of healthcare 
costs for more than 1,400 individuals with schizo-
phrenia who participated in the 18-month  CATIE 
trial (Clinical Antipsychotic Trials of Interven-
tion Effectiveness) in the USA reported statisti-
cally significant 25% higher costs for those who 
were obese  [5] . Data from the US Medical Expen-
diture Panel Survey of more than 571,000 indi-
viduals in 2001 and 2002 found annual healthcare 
costs for people living with schizophrenia alone 
of USD 5,990, compared with USD 11,611, 10,803, 
Table 1.  Selected examples of impact of physical comorbidity on annual healthcare costs of adults with mental dis-
orders
Study Mental disorder Comorbid physical
disorder
Relative increase in costs 
of comorbidity (mental 
disorder alone = 1)a
Chwastiak et al. [5] schizophrenia obesity 1.3:1
McDonald et al. [6] schizophrenia diabetes 1.9:1
McDonald et al. [6] schizophrenia dyslipidaemia 1.8:1
McDonald et al. [6] schizophrenia hypertension 2.1:1
McDonald et al. [6] schizophrenia heart disease 1.7:1
Centorrino et al. [8] bipolar disorder metabolic disorders 2.3:1
Welch et al. [10] depression congestive heart failure 2.0:1
Welch et al. [10] depression coronary artery disease 2.1:1
Welch et al. [10] depression diabetes 2.0:1
 All of the studies were from the USA. a All differences statistically significant p < 0.05.
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12,292 and 10,415 for those with comorbid diabe-
tes, dyslipidaemia, hypertension or heart disease, 
respectively  [6] .
 The healthcare costs of more than 31,000 older 
people with and without schizophrenia were ana-
lysed for the 10-year period from 1998 to 2008. 
Mean healthcare costs were significantly higher 
in the schizophrenia group; a key driver of greater 
healthcare costs was the significantly higher rate 
of physical health problems, including congestive 
heart failure (45.1 vs. 38.8%), chronic obstructive 
pulmonary disease (52.7 vs. 41.4%), hypothyroid-
ism (36.7 vs. 26.7%) and dementia (64.5 vs. 32.1%) 
 [7] .
 Turning to bipolar disorder, in the USA the 
medical records (spanning 1 year) of more than 
28,000 people with bipolar disorder were com-
pared with matched controls without any mental 
health problems  [8] . Those with bipolar disorder 
had a significantly higher prevalence of metabolic 
comorbidities than the general population (37 vs. 
30%). Annual healthcare costs for metabolic con-
ditions were twice those of controls (USD 531 vs. 
233). The bipolar cohort also had significantly 
higher overall medical service and prescription 
drug costs than those of the control cohort (USD 
12,764 vs. 3,140). Prescription medication costs 
for metabolic conditions were also higher, with 
bipolar cohort per-patient costs of USD 571 ver-
sus 301 for the control cohort. Analysis of data on 
67,000 members of a health insurance fund in 
seven US states also suggests that 67% of total 
healthcare costs of bipolar disorder were related 
to the treatment of comorbid physical health con-
ditions  [9] .
 Comorbid depression or anxiety disorders and 
physical health problems have also been associ-
ated with higher levels of cost to healthcare sys-
tems. One US study reported that the costs of 11 
chronic health problems are significantly greater 
when an individual has comorbid depression. 
Costs related to diabetes, coronary artery disease 
and congestive heart failure were approximately 
twice the costs of individuals without depression 
 [10] .
 Two reviews, one with 27  [11] and the other 
with 41 largely US-set studies  [12] , looked at the 
impact on healthcare resource utilisation of co-
morbid diabetes and depression. Both reviews 
consistently showed increased healthcare re-
source use to manage diabetes in people with de-
pression. For example, in one study of more than 
400,000 adults with diabetes in the USA, the costs 
of depression increased mean annual healthcare 
costs from USD 11,000 to 19,000  [13] , while in 
Australia, health service use by people with co-
morbid diabetes and depression was 49% higher 
compared to those with diabetes alone  [14] . In 
Table 2.  Selected examples of impact of mental comorbidity on annual healthcare costs of adults with mental dis-
orders
Author and country Physical disorder Comorbid mental 
disorder
Relative increase in costs 
of comorbidity (physical 
disorder alone = 1)a
Richardson et al. [25], USA asthma depression 1.5:1
Hochlehnert et al. [23], Germany cardiovascular disease depression and/or anxiety 1.5:1
Atlantis et al. [14], Australia diabetes depression 1.5:1
Le et al. [13], USA diabetes depression 1.7:1
Simon et al. [15], USA diabetes depression 1.8:1
a All differences statistically significant p < 0.05.
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another US study, the healthcare costs of manag-
ing diabetes over a 6-month period were found to 
be between 50 and 75% higher in people with ma-
jor depression than in people with diabetes alone 
 [15] . Furthermore, this study observed a signifi-
cant difference in the costs of managing one or 
more complications of diabetes in people with 
major depression compared to those with sub-
clinical thresholds of depression. Other studies 
also point to higher costs of managing complica-
tions. In the USA, the costs of managing compli-
cations of diabetes, such as diabetic neuropathy, 
in people with comorbid depression have also 
been shown to be significantly greater than in 
those without depression  [16] .
 Another US study looked at the healthcare 
costs of more than 14,000 people with depression, 
congestive heart failure, or both  [17] . People who 
also had depression had significantly higher total 
annual healthcare costs than those without: USD 
20,046 versus 11,956. Costs increased with the se-
verity of comorbidity, but mental healthcare costs 
accounted for less than 1% of total healthcare 
costs.
 Outside of the USA, significantly increased 
costs to healthcare systems have also been ob-
served when comorbidity involved depression. 
English data from more than 86,000 patients in 
the General Practice Research Database were 
used to assess whether comorbidity increases 
the costs of managing patients in primary care 
 [18] . The study found that 20% of all patients 
had more than one chronic health problem and 
that all instances of comorbidity increased the 
costs of primary healthcare compared to the 
costs of managing these conditions separately. 
Depression was found to be the most important 
cost-increasing condition, significantly increas-
ing costs in adult patients of all ages when co-
morbid with a wide range of conditions. For in-
stance, the costs of managing comorbid depres-
sion and asthma or diabetes were greater for 
patients of all ages, whilst depression and co-
morbid cancer were associated with significant-
ly higher costs in people aged 40–59 years. De-
pression and comorbid obesity, heart failure or 
epilepsy were associated with significantly high-
er primary care costs in patients aged over 60 
years. Increases in cost ranged from GBP 269 for 
people aged 40–59 years with depression and 
cancer to GBP 2,817 in people with comorbid 
depression and obesity aged 40–59 years. In 
younger adults, mean additional costs related to 
asthma and comorbid depression were GBP 
1,257, while comorbid diabetes and depression 
increased costs by GBP 2,133 in people aged 
over 60 years.
 Other examples of additional costs from 
around the world can be identified. In Singapore, 
adults attending a specialist diabetes centre over a 
1-year period who also had depression had a 30% 
chance of hospitalisation compared to 10% in the 
diabetes-alone group. They were four times more 
likely to be hospitalised for non-psychiatric con-
ditions and three times more likely to be hospital-
ised for complications of diabetes  [19] .
 In Hungary, a survey of more than 12,000 
people looking at their use of health services over 
a 12-month period found that those with comor-
bid diabetes and depression had a 2.6 times 
greater risk of a lengthy period of hospitalisation 
and had almost double the risk of multiple hos-
pital admissions compared to people with diabe-
tes alone  [20] . Another study looked at the im-
pacts of physical comorbidity on healthcare 
costs for 65,000 people receiving primary care in 
Spain in 2004. Individuals with a depressive dis-
order had a significantly greater number of co-
morbid conditions or risk factors, including 
obesity, dyslipidaemia and smoking per year 
compared to other primary care service users 
(7.4 conditions vs. 4.3). Overall the annual costs 
of care were EUR 1,084 and 684 per patient in 
the comorbid and control populations, respec-
tively  [21] . In the UK, the economic impacts of 
smoking in people with mental disorders have 
been estimated to cost primary and secondary 
care service providers GBP 720 million per an-
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num in treating smoking-related disease. The 
study also estimated that about a third of all cig-
arettes smoked in England are smoked by people 
with a mental disorder. This could mean that 
there are 2.6 million avoidable hospital admis-
sions, 3.1 million avoidable primary care consul-
tations and 18.8 million prescriptions that can 
be avoided each year  [22] .
 In Germany, analysis at one teaching hospital 
over a 2-year period again reported that the aver-
age total costs of hospitalisation for people with 
cardiovascular disease alone compared to those 
with psychiatric comorbidity (largely depression 
and anxiety disorders) differed significantly (EUR 
5,142 vs. 7,663). The average length of stay for pa-
tients with comorbidity was 13.2 days compared 
to 8.9 for patients with cardiovascular disease 
only  [23] . Furthermore, this paper highlighted 
that the funding system in that hospital did not 
fully cover the costs of comorbidity, which means 
that patients might not receive appropriate levels 
of care.
 There is also some limited information look-
ing at the association between healthcare costs 
and comorbid asthma and mental disorders. One 
systematic review found 20 studies, largely fo-
cused on depression or anxiety disorders and 
asthma. It reported increased rates of hospitalisa-
tion, emergency department visits and visits to 
primary care practitioners in people with asthma 
and a mental disorder  [24] . In the USA, a tele-
phone survey of adolescents (aged 11–17 years) 
with asthma found that those assessed to have de-
pressive disorders as well had on average 51% 
higher healthcare costs  [25] . Most of these addi-
tional costs were related to non-asthma and non-
mental health-related healthcare costs.
 Impacts beyond Healthcare Systems 
 There appear to be fewer estimates of the impacts 
of comorbidity beyond the healthcare system. 
Published estimates concentrate on indirect 
costs – mainly productivity losses from employ-
ment due to absenteeism, with much less discus-
sion of poor performance at work (presenteeism); 
there does not appear to be much information on 
the intangible costs of comorbidity. One review 
looked at the impact on participation in employ-
ment of people with coronary artery disease and 
mental disorders  [26] . Only 13 studies were iden-
tified, 10 of which focused on comorbid depres-
sion. The review concluded that people with co-
morbid depression had a reduced likelihood of 
returning to work following the onset of illness 
(odds ratio 0.37) compared to people with coro-
nary artery disease alone. A systematic review on 
comorbid diabetes and depression identified 11 
studies that looked at the impacts on productivi-
ty, but only two of these studies assigned a mon-
etary value to productivity losses and none in-
cluded losses from premature mortality or infor-
mal care  [12] . 
 Data from a cross-sectional survey of 78,000 
workers in Australia  [27] show higher relative 
risks of both absenteeism and poor functioning 
while at work in individuals with comorbid psy-
chological distress and physical health problems 
compared to those with physical health problems 
only. For instance, compared to people with no 
health problems, the risk of absenteeism from 
work was 33% higher for people who were expe-
riencing psychological distress alongside obesity, 
and 27% higher for those who had high levels of 
cholesterol. Rates of presenteeism were between 
2.5 and 5 times greater in populations with co-
morbid asthma, obesity, arthritis, diabetes and 
high cholesterol compared with the reference 
population.
 Data from the 2007 Australian National Sur-
vey of Mental Health and Wellbeing (n = 8,841) 
have also been used to compare work functioning 
and absenteeism rates in people with depression, 
cardiovascular disease, or both conditions, with a 
disease-free population  [28] . As  table  3 shows, 
compared to a population with neither condition, 
and adjusted for various social and demographic 
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characteristics, the odds ratio for people with co-
morbid depression and cardiovascular disease 
participating in work was significantly lower at 
just 0.4. This compared with odds ratios for work 
participation of 0.8 for depression or cardiovas-
cular disease only. The comorbid group were also 
10 times more likely to experience poor work 
functioning compared to the healthy workforce, 
9 times greater than for people with cardiovascu-
lar disease alone and 2.5 times greater than for 
people with depression alone. Rates of absentee-
ism were also significantly higher for the comor-
bid group.
 Data from a large Canadian survey of more 
than 130,000 people found (even after adjusting 
for socio-demographic characteristics, alcohol 
dependence and chronic physical illness burden), 
that the presence of comorbid major depressive 
disorders was associated with twice the likelihood 
of healthcare utilisation, and increased functional 
disability and work absence compared to the 
presence of a chronic physical illness without co-
morbid depression  [29] . Significant increases in 
resource use and productivity losses have also 
been reported in a population survey of more 
than 12,000 adults in Hungary  [20] . People with 
comorbid diabetes and depression were more 
than twice as likely to have lengthier stays in hos-
pital (>20 days) and to have more hospital admis-
sions. They were also more than 3 times as likely 
to have a prolonged absence (>10 days) from paid 
work and to be unemployed.
 In Finland, analysis of certified sickness ab-
sence in 33,000 public sector employees reported 
that non-cardiovascular comorbid conditions 
for employees with diabetes, including depres-
sion, accounted for over 50% of excess risk of 
sickness absence  [30] . A US study of a manufac-
turing company with 15,000 employees reported 
13.5 sick days per annum on average due to de-
pression and physical comorbidity (diabetes, 
heart disease, hypertension or back problems) 
compared to 6.6 and 8.8 days for those with a 
physical condition or depression alone. Total 
mean costs, including healthcare and disability, 
per employee with comorbidity were USD 7,906. 
This is conservative as the costs of poor perfor-
mance (presenteeism) at work were not included 
 [31] .
 Data from the UK Psychiatric Morbidity Sur-
vey also indicate that over a year individuals with 
diabetes and depression were 7.7 and 5.3 times 
more likely to take sick days and have their work 
and other activities impaired by poor health com-
pared to people with diabetes alone  [32] . The 
number of working days lost was also found to be 
significantly higher in people with comorbid dia-
betes and depression compared to diabetes alone 
in Singapore – 1.9 versus 1.4 working days lost 
over a 3-month period  [19] .
Table 3.  Work participation, work functioning and disease group in Australia [28]




Amount of difficulty in




unable to work 
(full-time workers)
(adjusted odds ratio)
Neither MDD or CVD 1.0 1.0 1.0
MDD only 0.8* 4.0* 1.7*
CVD only 0.8* 0.9 0.9
Comorbid CVD and MDD 0.4* 10.6* 3.0*
 MDD = Major depressive disorder; CVD = cardiovascular disease. * p < 0.05.
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 Strengthening the Case for Tackling 
Comorbid Mental and Physical Health 
Problems 
 This chapter has illustrated that there are sub-
stantial economic costs associated with comor-
bidity. These costs fall both within and beyond 
healthcare systems. It is not, however, enough to 
identify these costs. Given that healthcare budget 
holders have to make difficult choices on how to 
allocate scarce resources to mental health and 
other services, it is critical is to identify cost-effec-
tive ways of reducing the risks or consequences of 
comorbidity. 
 Potentially, given the high additional costs of 
comorbidity, even modest success in reducing its 
prevalence may have economic payoffs. Policy 
makers will want to know whether early interven-
tion and investment in actions to protect the 
physical health of people with mental health prob-
lems are a cost-effective use of resources, generat-
ing benefits not only to healthcare systems, but 
also more widely, perhaps reducing rates of ab-
senteeism from work or the need for informal 
family care. They may also want to know whether 
a greater focus on managing the mental health of 
people with chronic physical health problems is a 
cost-effective way of improving outcomes.
 There is a need to strengthen the evidence 
base, and in particular to look more at the cost-
effectiveness of interventions outside of a US con-
text. To date, the evidence on cost-effective ap-
proaches to manage comorbidity is modest, al-
though it supports investment, suggesting that a 
number of cost-effective interventions are avail-
able. For instance, empirical work and modelling 
studies focusing on comorbid diabetes and de-
pression includes several studies that have high-
lighted the cost-effectiveness of better integration 
between psychological and diabetes care  [33–35] . 
Only a handful of studies have considered the 
economic, as well as the clinical impact, of inter-
ventions to promote and protect the physical 
health of people with mental disorders  [36] .
 One way of strengthening the evidence base in 
the short-term is to make use of economic model-
ling techniques to take existing data on the effec-
tiveness of different actions to tackle comorbidity 
and model plausible costs and benefits under dif-
ferent scenarios in different country contexts and 
over different time periods  [37] . One recent ex-
ample of a modelling approach suggests that it 
may be cost-effective to invest in group-based ac-
tions to promote better weight management in 
people with schizophrenia and diabetes  [38] . In 
the mid to longer term it would be helpful to em-
bed economic analysis, collecting data on re-
source use, costs and economic consequences, 
into evaluations of interventions to tackle comor-
bidity. This can facilitate better comparability 
across different interventions and help policy-
makers prioritise the way in which they allocate 
resources.
 Where mental health services are largely sepa-
rate from physical health services, the provision 
of seamless care for both physical and mental 
health problems becomes more difficult to 
achieve. Therefore, another important step may 
be to evaluate the cost-effectiveness of different 
incentives and organisational structures to en-
courage a more collaborative approach to the de-
tection and management of comorbidity; there 
are often substantive silos in both the financing 
and organisation of mental health and general 
health services  [39] .
 This chapter has illustrated that economics 
can help provide powerful arguments to support 
a case for tackling comorbidity. It has shown that 
there are substantial impacts both within and be-
yond health systems linked to comorbidity. For 
too long, much of these costs remained hidden; 
this is now changing and in the future more in-
formation will be available on these additional 
costs as well. This hopefully will provide more 
impetus for actions to address an issue which 
leads not only to some avoidable costs to health 
and society, but also has profound personal hu-
man consequences. 
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 Background 
 Abstract 
 Low-income countries face a double burden of noncom-
municable and communicable diseases, which further 
strains their limited resources. In response, the global 
community has prioritized four chronic noncommunica-
ble diseases and four risk factors, not including neuropsy-
chiatric disorders. Health systems play a key role in ad-
dressing the challenges of noncommunicable diseases, 
mental health and multimorbidity, but have failed to 
tackle this effectively. Noncommunicable disease as well 
as noncommunicable/communicable disease multimor-
bidity cannot be managed from only a biomedical per-
spective, but needs to include consideration of inequality 
and poverty. The health systems in low-income countries 
are currently failing in their management of individuals 
with single noncommunicable diseases; therefore, when 
a person is exposed to multiple risk factors and/or has 
multiple conditions, the health system cannot cope, lead-
ing to poor outcomes for individuals. Eleven elements 
were found to be necessary for diabetes care in low-in-
come settings, and since diabetes makes a good tracer 
condition, these elements are presented for the issue of 
multimorbidity. They include organization of the health 
system, data collection, prevention, diagnostic tools and 
infrastructure, medicine procurement and supply, acces-
sibility and affordability of medicines and care, health-
care workers, adherence issues, patient education and 
empowerment, community involvement and positive 
policy environment. Primary healthcare has been pro-
posed as a solution, but there are numerous barriers to 
implementing this. Given health system constraints, 
there is a need to shift care back to the individual and 
their family for managing both the medical (self-care) and 
social aspects (e.g. stigma) of their conditions for better 
outcomes.  © 2015 S. Karger AG, Basel 
 Low-income countries are defined by the World 
Bank as countries where income per capita is 
USD 1,035 or less  [1] . This grouping includes 28 
countries from sub-Saharan Africa, 5 from Asia, 
3 from Central Asia and 1 in the Caribbean. Be-
cause of their low income, these countries spend 
on average only USD 22 per person per year on 
health  [2] . While traditionally it was thought that 
the burden of disease in these countries was pre-
dominantly from communicable diseases, non-
communicable diseases represent 80% of deaths 
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in low- and middle-income countries  [3] . Non-
communicable diseases and poverty have a sym-
biotic relationship, with poverty increasing expo-
sure to noncommunicable disease risk factors 
and actual noncommunicable diseases forcing in-
dividuals and households into poverty as the bur-
den of the cost of care falls on the individual in 
these countries  [3] . Noncommunicable diseases 
also impact health systems, economies and coun-
tries as a whole, as every 10% increase in noncom-
municable diseases is associated with a 0.5% de-
crease in economic growth. 
 In September 2011, the United Nations held 
its second health-related general assembly on 
noncommunicable diseases after its 2001 meet-
ing on HIV/AIDS. Four diseases were prioritized 
by the World Health Organization, namely car-
diovascular diseases, cancer, chronic respiratory 
diseases and diabetes, which were chosen since 
they contribute the largest amount to morbidity 
and mortality  [4] . In 2013, the World Health Or-
ganization’s noncommunicable disease global 
action plan was endorsed and aims to provide a 
guide to attain nine voluntary global targets, in-
cluding the overall goal of a 25% relative reduc-
tion in premature mortality from cardiovascular 
disease, cancer, diabetes and chronic respiratory 
disease by 2025  [4] . Although neuropsychiatric 
disorders contribute an estimated 13% of the 
global burden of disease  [5] , they are not formal-
ly included in the World Health Organization’s 
global noncommunicable diseases action plan. 
Mental health is mentioned in the context of 
comprehensive care for noncommunicable dis-
eases needing to include ‘primary prevention, 
early detection or screening, treatment, second-
ary prevention, rehabilitation and palliative care 
and attention to improving mental health’  [4] .
 Health systems play a key role in addressing 
the challenges of noncommunicable diseases, 
mental health and multimorbidity. The manage-
ment of these requires care be provided over a 
long period of time, which needs the input from 
a multidisciplinary team of healthcare workers, 
access to medicines and diagnostic tools, patient 
empowerment, and coordination of different ele-
ments of the health system  [6] . 
 Multimorbidity in a Low-Income Context 
 With the number of people aged 65 years or above 
projected to increase from approximately 524 
million in 2010 to about 1.5 billion in 2050, with 
the highest increase in developing countries, the 
issue of multimorbidity needs to be addressed. It 
is estimated that 1 in 4 adults suffer from multi-
morbidity, with most evidence coming from 
high-income countries  [7] . Studies from low-in-
come countries have found that 53.7% of people 
aged above 60 years had two or more chronic 
conditions in Bangladesh  [8] , 66.7% of people 
with diabetes also had hypertension in Cameroon 
 [9] and in a nationally representative sample in 
South Africa it was found that 29.6% had two or 
more of the following conditions: hypertension, 
diabetes, asthma, depression, angina, stroke and 
arthritis  [10] . 
 Synergies to address and integrate care for 
communicable and noncommunicable diseases 
have not been addressed  [11] . The links between 
the four main noncommunicable diseases are 
clearly established through their shared risk fac-
tors and high rates of comorbidity  [8, 9] . In low-
income country settings, however, there is not 
only the existence of comorbidity of noncommu-
nicable diseases, but also comorbidity of non-
communicable diseases with communicable dis-
ease  [12] .
 The issue of multimorbidity can be linked to 
the causal pathways of the diseases  [13] . For ex-
ample, there is a link between a high burden of 
tuberculosis with smoking and harmful alcohol 
use  [14–16] , or mental health with sexual behav-
ior, alcohol and tobacco use  [17] . Another way of 
looking at multimorbidity is that having one con-
dition means the individual is more likely to de-
velop another  [13] . For example, diabetes has 
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been associated with a threefold incident risk of 
tuberculosis  [18–20] , HIV/AIDS causes Kaposi 
sarcoma and lymphoma  [21] , and people with 
HIV/AIDS are more likely to have mental disor-
ders  [22] . 
 It is not only the condition that may lead to 
another condition, but also the treatments for 
these. One particular example relevant to low-in-
come countries is the link between antiretroviral 
treatment and the metabolic syndrome  [18] , in-
creased rate of cardiovascular risk factors  [23] , 
diabetes  [24] , and other cardiac, neurological and 
musculoskeletal conditions  [25] . 
 Finally, the last aspect is that proper manage-
ment of both conditions is necessary in order to 
ensure good outcomes from each disease per-
spective. Good tuberculosis management is nec-
essary for good diabetes management, and good 
diabetes management helps ensure the success of 
tuberculosis treatment; however, the medicines 
used to treat tuberculosis may worsen blood glu-
cose control  [19, 20] . Management of depression 
is also necessary to ensure proper outcomes for 
noncommunicable diseases  [26] .
 Addressing these situations needs to be done 
not only from a biomedical perspective, but also 
from a socioeconomic angle, taking into account 
inequalities and poverty.  Table 1 details these in-
terlinkages as well as the underlying issues of age-
ing and poverty.
 The challenge in low-income countries is that 
there is a knowledge, treatment and outcome gap 
for noncommunicable diseases and multimor-
bidity. In Mozambique the prevalence of hyper-
tension is 33.1%, but only 14.8% of people who 
have hypertension are aware they have it  [27] . Of 
those aware, 51.9% receive treatment and of those 
receiving treatment, only 39.9% are controlling 
their hypertension. That means for every 100 
people with hypertension, only 3 know they have 
the disease, receive treatment and have controlled 
hypertension. A nationally representative survey 
in South Africa found that despite the high preva-
lence of mental disorders and related disability, 
these conditions, especially depression, were less 
likely to be treated than physical disorders  [28] . 
Data from the World Health Organization show 
that between 76 and 85% of people with mental 
health problems in low- and middle-income 
countries receive no treatment for their disorder 
and that resources for mental health are primar-
ily assigned to mental hospitals  [29] .
 The health systems in low-income countries 
are currently failing in their management of indi-
viduals with single conditions. Therefore, when a 
person has multiple conditions or multiple risk 
factors for these conditions, the health system is 
not organized in a manner that can face such a 
situation, which leads to poor outcomes for indi-
viduals.
























people with diabetes are more 
prone to depression
Communicable disease person with HIV/AIDS
and tuberculosis
people with HIV/AIDS more 
likely to have mental disorders
 Underlying issues include, for example, ageing and poverty.
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 The Health System Barriers to Care for 
Multimorbidity in Low-Income Countries 
 A health system is defined as all the ‘activities 
whose primary purpose is to promote, restore and 
maintain health’  [30] . Health systems have three 
main objectives: (1) to improve the health of the 
populations they serve, (2) respond to the popula-
tion’s expectations and (3) provide financial pro-
tection against the costs of ill-health  [30] . 
 Health systems do not work in isolation of the 
other sociopolitical elements of a given country, 
and therefore different models of health systems 
exist  [31, 32] . Certain key factors that health sys-
tems need to perform are procurement and sup-
ply of medicines, disposables and equipment, 
healthcare workers in sufficient numbers and 
with the right skills for the given population and 
disease burden, and sustainable financing and 
healthcare costs that do not overburden the poor 
and have a financial, budgetary and regulatory 
framework  [31, 32] . Research into diabetes in 
low-income countries  [33] found that 11 ele-
ments were necessary for diabetes care. Diabetes 
makes a good tracer condition for health systems, 
from which the lessons learnt can be applied to 
other chronic conditions  [34–36] .
 The first element is organization of the health 
system. Currently, health systems in low-income 
countries are not organized to manage noncom-
municable disease, let alone individuals with 
multiple conditions, and are more focused on in-
fectious diseases  [37] . Many health system re-
sponses in low-income countries for HIV/AIDS 
and tuberculosis have focused on vertical pro-
grams only addressing these specific conditions 
and not tackling all the challenges faced by indi-
viduals in the health system  [38] . Although these 
have shown some success, they fail to take a per-
son-centered focus and do not manage all the 
conditions the individual may have, but only the 
one that is being funded, leading to fragmenta-
tion of healthcare  [39] . This fragmentation also 
exists because care in urban areas is hospital based 
whereas in rural areas health services focus on a 
specific disease (e.g. HIV/AIDS) or selective ser-
vices (e.g. maternal health)  [39] . In parallel, the 
use of traditional medicine is widespread, with 
80% of the population in Sub-Saharan Africa re-
lying on this as their primary source of care  [13] , 
which has as of yet not been integrated for the 
management of noncommunicable diseases.
 Although primary healthcare has been pro-
moted in low-income countries, it has not been 
able to address the challenge of noncommunica-
ble disease or play a role in prevention and health 
promotion  [13, 37] . Noncommunicable disease 
care is still the remit of specialists in specialist 
centers; for example, mental health in low-in-
come countries is still predominantly focused on 
hospital care  [40] . As these specialist centers are 
limited, this also causes problems for referrals 
and counterreferrals. Specifically for the issue of 
multimorbidity, the degree of overspecialization 
may mean multiple referrals, if feasible, are made 
to different specialists for the individual’s multi-
ple conditions.
 When providing care for a person both over a 
long period of time and with multiple conditions, 
another element the health system needs to pro-
vide is data collection. Data are needed at all levels 
of the health system in order to inform policies, 
medicine procurement, and staffing and individ-
ual care. However, there is a general lack of qual-
ity health information systems in many low-in-
come countries  [37] . At the level of the individual, 
poor use of patient records means that previous 
consultations or other conditions are not taken 
into account, thus leading to an unstructured 
monitoring of clinical care  [37] . There is also a 
lack of a recall system to ensure continuity of care 
 [38] . In terms of studies, very few have looked at 
the issue of multimorbidity in low-income coun-
tries except for the issue of HIV/AIDS and tuber-
culosis.
 Another area where studies are lacking from 
low-income countries and which is important for 
the issue of multimorbidity is prevention. As 
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mentioned previously, primary healthcare in 
low-income countries does not fulfill its role in 
terms of prevention and health promotion  [33] . 
This is linked to lack of training, human resourc-
es and culturally appropriate materials to ensure 
wider knowledge of noncommunicable disease 
and their risk factors in these settings. For exam-
ple, asthma and chronic respiratory disease are 
underrecognized, underdiagnosed, undertreated 
and insufficiently prevented. With one of the 
main risk factors in low-income countries being 
the use of biomass fuel, local healthcare workers 
need the knowledge about these conditions in 
their specific context to enable them to play a pre-
ventive role and not only provide care  [41] . The 
World Health Organization has also developed 
‘best buys’ for noncommunicable diseases for the 
four common risk factors (tobacco use, harmful 
use of alcohol, unhealthy diets and physical inac-
tivity) and for cardiovascular disease, diabetes 
and cancer  [42] . However, many low-income 
countries lack the capability of implementing, en-
forcing and sustaining these.
 As prevention also includes screening mea-
sures, diagnostic tools and infrastructure are 
needed. However, health infrastructure is poor at 
all levels of the health system with, for example, 
19 and 39% of primary healthcare facilities in 
Tanzania and Senegal, respectively, having access 
to electricity, water and sanitation  [13] . In addi-
tion, basic equipment is lacking in these facilities 
and access to diagnostic tools for diabetes has 
been seen to be poor in low-income countries 
 [43] . There are also financial constraints for the 
individual if they need to pay for the test as well 
as budget limits that impact a prescribers’ ability 
to ask for certain tests  [38] .
 Besides diagnostic tools and infrastructure, 
health systems need to be able to procure and 
supply medicines to manage multimorbidity. 
 Looking at the issue of insulin in low-income 
countries, a variety of factors impact its procure-
ment and supply, such as budget allocation for 
medicines, adequate buying procedures, quantifi-
cation of needs, efficient procurement, efficient 
distribution, rational prescription and proper 
compliance  [43] .
 Mental health is an example highlighting the 
challenge of medicine procurement and supply 
with such issues as prescription regulations, avail-
ability and use of certain treatments, and limited 
expenditure (low-income countries spend 10 
times less than lower-middle and 1,547 less than 
high-income countries, respectively)  [40] . Ulti-
mately, all of these factors impact the affordabil-
ity and accessibility of medicines. Accessibility is 
linked not only to distribution, but also to where 
the individual lives, with urban areas having bet-
ter access than rural areas. In terms of affordabil-
ity, government policies will impact this; for ex-
ample, insulin is free in Nicaragua, while individ-
uals have to pay for this in Mali because of the 
government policy of cost recovery  [43] . Generic 
medicines to treat noncommunicable disease 
were found to be less available than medicines for 
communicable conditions in both the public 
(36.0 vs. 53.5%) and private sectors (54.7 vs. 
66.2%)  [44] . Specifically, antiasthmatic inhalers 
were available to 30.1% in the public sector and to 
43.1% in the private sector. In terms of affordabil-
ity, it has been found that 1 month of treatment 
for coronary heart disease costs 18.4 days’ wages 
in Malawi while for insulin in Mali the annual 
cost represented 38% of per capita gross domestic 
product  [43, 45] . These conditions also place a 
huge financial burden on countries, with diabetes 
care representing 5% of the total budget for the 
Ministry of Health in Nicaragua and insulin rep-
resenting 10% of the total medicines budget in 
Mozambique  [43] .
 An essential element of the health system is 
healthcare workers. Issues of availability, rational 
use and training need to be addressed  [46] . Low-
income countries face a severe shortage of health-
care workers and the human resources present 
are inequitably distributed  [13] . Specifically for 
mental health in the Africa region of the World 
Health Organization, there is significant varia-
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tion in the number of psychiatrists, ranging from 
more than 10 per 100,000 to fewer than 1 per 
100,000  [47] . There is also a low focus of these 
human resources on community care  [40] . Over-
all, this problem is linked to an internal and ex-
ternal ‘brain drain’ with doctors preferring the 
private over public sector, urban over rural areas, 
and tertiary levels of care versus primary care 
 [48] . In addition, this internal brain drain to non-
governmental organizations specifically in the 
area of HIV/AIDS has impacted the availability 
of health professionals, e.g. 50% of medical 
 graduates in Uganda were found to be working 
for an HIV-related nongovernmental organiza-
tion  [49] .
 It is important to define the role of different 
cadres of healthcare workers in managing non-
communicable disease and the role of specialists, 
such as in the initiation of treatment versus fol-
low-up and continuation of treatment and how 
this is linked to treatment guidelines that are 
adapted to the local context or include the best 
clinical evidence. Another issue is actual training 
and how this training currently focuses on clini-
cal management of certain diseases and not the 
issue of multimorbidity. Current training of 
health professionals, especially doctors, does not 
include the preventive role they can play.
 Patient education is lacking both as health 
professionals are not trained in this area, have 
very little time for this, and also lack the materi-
als and the means to deliver this. In addition, the 
view of certain diseases may impact how health 
professionals educate and empower their pa-
tients. For example, in some settings people with 
mental health problems are shackled and beaten 
because of traditional beliefs about the causes of 
these conditions  [47] . Therefore, issues of stig-
ma also need to be addressed not only for indi-
viduals with these conditions, but also in the 
wider community. There is also the issue of us-
ing Western concepts of disease. For example, 
Patel et al.  [50] while studying depression in 
Zimbabwe found a variety of presentations and 
descriptions for this condition including super-
natural causes. The health system may provide 
the majority of aspects that a person with a non-
communicable disease requires; however, the 
burden of care falls on the individual and their 
family as the majority of the time spent manag-
ing a noncommunicable disease is done outside 
of the health system  [51] .
 Adherence is impacted by education about the 
condition and the financial burden of care. In 
low-income countries, patient education is lack-
ing for noncommunicable disease and there is 
still a large financial burden of care. In a system-
atic review of adherence to cardiovascular medi-
cations in resource-limited settings, Bowry et al. 
 [52] found that poor adherence was due to these 
factors as well as negative perceptions about med-
icines and their side effects.
 Community involvement and patient associa-
tions can play a role in patient education and em-
powerment, thereby impacting adherence, with 
the proper support from the health system. Many 
types of patient organizations (e.g. diabetes asso-
ciations) exist, with varying roles, such as advo-
cacy, training for patients and healthcare work-
ers, and acting as a support group for patients and 
families, as well as being a provider of care  [53] . 
The 2011  Mental Health Atlas  [40] found that 
39% of low-income countries had associations 
compared with 80% of high-income countries. It 
is not only the number of these organizations that 
is important, but also that many of them focus on 
specific diseases, such as cancer societies, diabetes 
associations, etc.
 Overall, the health system elements described 
above need to be present and supported by a pos-
itive policy environment. In low-income coun-
tries, there is a large reliance on external funding 
for specific disease programs  [13] . Due to this it 
was found that 30% of countries do not have a 
specified budget for mental health  [47] . In paral-
lel, in order to address the issue of noncommuni-
cable disease properly, a multisectorial approach 
is needed that not only includes the health sector, 
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but also education, trade and agriculture  [33] . For 
mental health there is also a need to include police 
and judicial systems. Although many low-income 
countries have started to develop national non-
communicable disease plans, these fail to recog-
nize the true issue of multimorbidity and include 
mental health  [54] . In low-income countries, only 
48.7% of countries have a mental health policy in 
comparison to 77.1% of high-income countries 
 [40] .
 Conclusion 
 There is both the need to address prevention and 
the wider determinants of noncommunicable 
disease as well as ensuring access to affordable 
care  [37] . Primary healthcare has been proposed 
as a solution to address this challenge as it enables 
a shift in focus to managing the individual and 
not the specific condition; however, there are nu-
merous barriers to delivery of noncommunicable 
disease interventions and not all noncommuni-
cable disease interventions, due to their complex-
ity, can be integrated in primary healthcare. This 
is even more relevant for multimorbidity where-
by the complexity of the individual may mean 
that primary healthcare does not have the human 
and resource capacity to manage this. 
 Each level of the health system has a role to 
play in multimorbidity prevention and manage-
ment, and thus needs certain materials and hu-
man resources to be available. Also, a certain lev-
el of organization and coordination between dif-
ferent levels of the health system and different 
sectors within the same institution (inpatient and 
outpatient services, pharmacy, laboratory, etc.) 
need to be in place for patient management and 
referral. Guidelines need to be developed and 
used as well as data to ensure efficient and effec-
tive care and help define referral pathways from 
different levels of the health system to avoid over-
use of hospital care and ensure prompt referral to 
specialists only when needed.
 An innovative approach to addressing the is-
sue of noncommunicable diseases in low-income 
countries was a Twinning project between Diabe-
tes UK (UK-based diabetes association) and 
 Mozambique  [55] . This project showed that by 
taking a systematic approach to developing dia-
betes care, including activities addressing all 11 
elements presented above, it was able to improve 
healthcare worker knowledge, access to medi-
cines and the government’s response not only to 
diabetes, but also all noncommunicable diseases 
 [56] .
 In looking at lessons from low-income coun-
tries in improving access to psychological treat-
ments, Patel et al.  [57] found that the two main 
barriers were a lack of human resources and the 
acceptance of the treatments proposed in differ-
ent sociocultural contexts. The human resource 
challenge in low-income countries will not be 
solved quickly, and with the rising burden of 
noncommunicable disease and multimorbidity, 
solutions need to be found. Specifically looking 
at mental health, Petersen et al.  [58] propose 
task-shifting to nonspecialists. These nonspecial-
ists need to shift the power back to the individual 
and their family, and have informed and active 
individuals in their own care who are able to have 
a partnership with their healthcare providers 
 [59] .
 One lesson from HIV/AIDS that may be useful 
for multimorbidity is to involve local communi-
ties actively  [60] . As chronic diseases are mainly 
managed outside the formal health system, indi-
viduals need the skills to be able to care for them-
selves. Parallel to the ageing population, commu-
nity-based care is necessary. This will of course 
require trained healthcare workers to be involved, 
but by involving civil society, traditional healers 
and other groups, the issues of knowledge and 
stigma can effectively be addressed, ensuring bet-
ter management, medically and socially, and 
therefore better outcomes for people with multi-
ple conditions. 
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 Abstract 
 Depression, diabetes and dementia are three disorders 
associated with staggering morbidity and mortality 
worldwide. The association between depression and dia-
betes has been well established. Furthermore, both de-
pression and diabetes have been shown to increase the 
incidence of dementia individually and synergistically. 
The metabolic-brain axis appears to be a key mediator 
connecting depression, diabetes and dementia. Brain re-
gions important for cognition and emotional regulation 
may be damaged by the effects of hyperglycemia and 
insulin resistance. Indeed, insulin resistance and de-
creased insulin in the central nervous system (CNS) re-
sults in decreased intracellular glucose levels in frontal 
and subcortical regions, neurotoxicity, decreased neuro-
plasticity, decreased signaling, decreased synaptic con-
nectivity and disturbances in neural circuitry. The afore-
mentioned changes may be attributable to brain 
bioenergetics wherein there is a bias toward energy con-
servation. The insulin pathway also has a bidirectional in-
teraction with amyloid-β oligomer formation, one of the 
hallmarks of Alzheimer’s disease. As well, depression may 
further facilitate neural circuit damage through the in-
flammatory pathway, hypothalamic-pituitary-adrenal 
axis dysregulation, monoamine changes and lowering of 
neurotrophic support to the CNS. Stress and psychosocial 
determinants of health may also be key mediators in how 
these systems interact. The involvement of several path-
ways may present new potential drug targets for the 
treatment and prevention of dementia using a lifetime 
approach. Systemic and intranasal insulin, oral diabetic 
medications, exercise, dietary changes, bariatric surgery 
and improved screening practices with early treatment 
of depression and diabetes all show promise in the treat-
ment and prevention of comorbid depression, diabetes 
and dementia.  © 2015 S. Karger AG, Basel 
 Depression has been recognized by the World 
Health Organization (WHO) as one of the lead-
ing causes of disability worldwide, affecting an 
estimated 350 million people globally  [1] . De-
pression has also been identified as a risk factor 
and poor prognostic indicator for several medi-
cal comorbidities including, but not limited to, 
metabolic disorders such as diabetes, metabolic 
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syndrome and obesity  [2] . According to WHO 
estimates, diabetes, which now affects more than 
350 million people globally, will be the seventh 
leading cause of death by 2030  [3] . Moreover, de-
pression and diabetes have a well-established 
link as numerous investigators have shown a bi-
directional association between these disorders 
 [4] . Both depression and diabetes have been in-
dependently associated as risk factors for the de-
velopment of cognitive impairment and demen-
tia  [5, 6] . Furthermore, depression and diabetes 
have been recognized as having a synergistic ef-
fect in increasing the risk for dementia above and 
beyond the effects that depression or diabetes 
would have on the risk of developing dementia 
independently. More specifically, comorbid type 
2 diabetes mellitus and major depressive disor-
der have been documented to increase the inci-
dence of Alzheimer’s disease greatly later in life 
 [7] . 
 Alzheimer’s disease is the leading cause of de-
mentia, the sixth leading cause of mortality and 
the third most costly disease in the USA  [8–10] . 
It is progressive in nature and is ultimately fatal 
 [10] . Currently, available treatments are only pal-
liative as there are no agents that have been 
shown to have disease-modifying properties 
 [11] . Therefore, primary prevention represents a 
priority research vista for identifying and target-
ing modifiable risk factors of Alzheimer’s dis-
ease. Modifiable risk factors that are addressed in 
this review are type 2 diabetes and major depres-
sive disorder.
 The overarching aim of this review is to review 
the potential pathophysiologic mechanisms 
which may account for this observed association 
between Alzheimer’s disease, type 2 diabetes and 
major depressive disorder. There is also a brief 
discussion about preventative and therapeutic 
options with particular emphasis on a lifetime ap-
proach to dementia. Evidence for the association 
between diabetes, depression and dementia has 
been extensively reviewed and can be found else-
where  [7, 12–14] .
 Mechanisms Linking Depression, Diabetes 
and Dementia 
 Evidence from preclinical and clinical studies has 
suggested several potential mechanisms connect-
ing diabetes, depression and dementia. Essential 
to this discussion is the recognition that the neu-
ral networks implicated in cognitive and emo-
tional function and dysfunction have significant 
overlap, as shown in  figure 1  [15] , which is central 
to the observed interactions between cognition 
and mood. It has been amply documented that 
cognitive dysfunction and changes in mood are 
key symptoms that have been observed to appear 
together in  individuals diagnosed with major de-
pressive disorder  [6, 16] . Therefore, the observed 
symptoms of Alzheimer’s disease and major de-
pressive disorder may be associated with a spec-
trum of structural and functional changes of 
shared neural circuits of the frontal and subcorti-
cal regions  [6, 16] . Likewise, the epidemiological 
observation and proposal of major depressive dis-
order as a prodrome of Alzheimer’s disease may 
be indicative of progressive damage to these neu-
ral circuits with repeated major depressive epi-
sodes  [6, 13, 16] . 
 In addition, central to the discussion of mech-
anisms involved in diabetes, depression and de-
mentia is the bidirectional relationship of the 
body’s metabolic milieu and neural circuitry 
 [17] . Pathologic metabolic processes may dam-
age these foregoing neural circuits. Evidence for 
such damage to neural circuits is shown through 
impaired cognition and altered brain connectiv-
ity in people with diabetes, independent of vas-
cular pathology, as demonstrated through func-
tional imaging techniques, such as electroen-
cephalography, magnetoencephalography and 
functional magnetic resonance imaging  [18, 19] . 
The damage to frontosubcortical circuits by 
metabolic pathology, namely diabetes, insulin 
resistance, and obesity, may thus impair cogni-
tion and affect mood  [18, 20] .
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 Impaired Central Insulin and Glucose Supply 
 Insulin, produced by the pancreas, enters the 
blood stream allowing for its systemic circulation 
and systemic effects  [21] . To enter the central ner-
vous system (CNS), blood-borne insulin is trans-
ported across the blood-brain barrier via a satu-
rable, receptor-mediated process  [15] . Once in 
the CNS, insulin may exert a plethora of impor-
tant effects, including, but not limited to, promot-
ing glucose uptake in specific regions, neurogen-
esis, neuroplasticity, synaptic strengthening and 
preventing neurodegeneration  [22, 23] . CNS in-
sulin and glucose have also been proposed to be 
an important modulator of the reward system 
and appetite  [24] . 
 The previous understanding that insulin had 
no effect on the brain has now been abolished 
with the discovery of insulin receptors in numer-
ous brain regions  [25] . Notably, insulin receptors 
have been identified in regions involved with cog-
nition and emotion including the hypothalamus, 
olfactory bulb, cerebral cortex, substantia nigra, 
basal ganglia, hippocampus and amygdala  [25] . 
As such, altered insulin levels and signaling, as 
seen in type 2 diabetes, may have important CNS 
consequences.
 Type 2 diabetes is characterized by hypergly-
cemia, insulin resistance with compensatory hy-
perinsulinemia, and subsequent pancreatic de-
compensation, resulting in hypoinsulinemia at 
later stages, unless treated  [21] . Preliminary evi-
dence indicates that the blood-brain barrier insu-
lin transporters may be downregulated in chron-
ic hyperinsulinemia  [15] and that, consequen-
tially, CNS insulin levels may be decreased 
 [26–28] . As previously discussed, CNS insulin is 
an important signaling molecule in numerous 
CNS processes. Therefore, in the setting of type 2 
diabetes where CNS insulin has been decreased 
because of blood-brain barrier receptor down-
regulation, several deleterious effects may ensue 
 [23, 26] .
Cingulate














 Fig. 1. The neural basis of cognitive and emotional processes. Reprinted with permission from 
Wood and Grafman  [15] . 
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 The simplest deleterious effect to conceptual-
ize is a decrease in intracellular glucose, second-
ary to decreased CNS insulin levels, as certain 
brain regions, notably the medial temporal lobe 
and hippocampus, have insulin-dependent glu-
cose uptake  [26] . GLUT4 receptors in the hippo-
campus have been shown to facilitate insulin-de-
pendent glucose uptake  [29] . In type 2 diabetes 
animal models of insulin resistance, there is de-
creased glucose uptake in the hippocampus  [26] . 
Therefore, metabolically active CNS tissue im-
portant for cognition and emotion receive subop-
timal levels of glucose and thus may have subop-
timal function.
 CNS insulin not only increases glucose uptake 
in particular regions, but also acts as a growth fac-
tor through its downstream effects. In brief, in vi-
tro  studies and animal models have shown that 
when insulin binds its receptor, the phos-
phoinositide-3 kinase pathways are activated, 
which promotes the production and release of 
several growth factors including brain-derived 
neurotrophic factor (BDNF) and vascular endo-
thelial growth factor  [30] , thereby promoting 
neuronal survival, synaptogenesis and dendritic 
arborisation  [23] . Similarly, long-term potentia-
tion cascades, important for learning and memo-
ry, are promoted by insulin  [26] . Indeed, animal 
models have shown a strong trophic effect of in-
sulin on hippocampus size and benefits in cogni-
tion and memory  [22, 23, 26, 27, 31] . Further-
more, in animal models, inhibiting the binding of 
insulin to hippocampal cells has a marked nega-
tive effect on hippocampus size and function (as 
manifested through impaired memory)  [26, 31] .
 Taken together, insulin acts as a growth factor 
and mediator of glucose uptake in the hippocam-
pus and other areas of emotion and cognition, 
promoting the health of these neural circuits. 
Therefore, insulin resistance may lead to de-
creased CNS insulin levels, leading to decreased 
hippocampal glucose uptake and decreased 
growth factor signaling, which may lead to im-
paired neurogenesis and ultimately hippocampal 
atrophy. In keeping with this hypothesis, imaging 
and postmortem studies have found hippocam-
pal atrophy in type 2 diabetes, major depressive 
disorder and Alzheimer’s disease  [32] .
 Bioenergetics 
 Numerous energetically ‘expensive’ processes are 
continually occurring in the brain. These energet-
ically intensive processes include, but are not lim-
ited to, maintenance of an electrochemical gradi-
ent in cells, neurogenesis, cellular depolarization 
and repolarization, synaptogenesis, and release 
and reuptake of neurotransmitters  [33, 34] . In ad-
dition, brain topology studies have shown that 
higher functioning neural circuits have a greater 
volume and length of connections, and as such, 
are even more energetically expensive  [35] . 
 To support these processes, the brain, while 
representing only 2% of total body mass, con-
sumes 25% of the body’s available glucose  [34] . 
Furthermore, Peters et al. [24] hypothesized that 
the ‘selfish brain’ ensures adequate energy for it-
self through modulating appetite, prioritizing glu-
cose supply to the brain above other organs and 
decreasing energy demands. In support of this hy-
pothesis, empirical data have shown that carbohy-
drate intake is increased in humans after a stress-
ful intervention (a model shown to increase brain 
energy consumption by 10–15%)  [36, 37] . In ad-
dition to postintervention changes in food con-
sumption, participants had increased blood glu-
cose with a blunted insulin response. Since brain 
glucose uptake is largely insulin independent, this 
pattern is indicative of a preferential bias of brain 
glucose uptake relative to other organs when brain 
energy demands are increased  [37] .
 Low CNS insulin and intracellular glucose lev-
els, as seen in type 2 diabetes with downregulated 
blood-brain barrier insulin transport and insulin 
resistance, may lead to the perception of low en-
ergy availability and thus may trigger down-
stream mechanisms to conserve energy  [24, 38] . 
To conserve energy, neurogenesis is prevented as 
it requires great consumption of energy  [24, 29, 
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39] . Animal models of type 2 diabetes have re-
ported that N-methyl- D -aspartate (NMDA) sig-
naling for the purpose of long-term potentiation 
is inhibited as it too is energetically expensive 
 [40] .
 Ultimately, energy deficits perceived by the 
brain (e.g. lowered CNS insulin and glucose in the 
case of type 2 diabetes) may negatively impact 
neuroplasticity, optimal neural circuitry and thus 
optimal function  [24, 29, 39] . In keeping with this 
view, when the frontosubcortical regions are 
forced to reduce energy expenditure by allocating 
resources to less demanding neural circuits, the 
domains of mood and cognition may be impaired 
to conserve energy in times of perceived energy 
depletion  [17, 24, 38] . Furthermore, chronic per-
ceived bioenergetic depletion may lead to chronic 
and progressive impairment of these circuits  [17] . 
Taken together, comorbid mood and cognitive 
symptoms, commonly observed and reported in 
epidemiological studies as the co-occurence of 
major depressive disorder and Alzheimer’s dis-
ease, may represent late-stage bioenergetic bias. 
More specifically, older individuals with type 2 di-
abetes experience years of brain insults resulting 
from glycemic dysregulation and aberrant insulin 
levels, affecting neuroplasticity and neural func-
tion, leading to bioenergetic bias towards energy 
conservation rather than higher functioning  [17] .
 Insulin-Amyloid Pathway 
 Another mechanism whereby hyperinsulinemia 
with insulin resistance and low CNS insulin may 
impact function is through the insulin-amyloid 
pathway. Amyloid-β protein oligomers have been 
strongly implicated in the pathoetiology of Al-
zheimer’s disease  [41] . What induces amyloid-β 
oligomer formation is not yet fully understood; 
however, a strong interaction between amyloid-β 
and insulin has been identified  [41, 42] . Notably, 
insulin and amyloid-β compete for the same de-
grading enzyme, namely, insulin degrading en-
zyme, thereby indirectly affecting each other’s 
systemic and central concentration  [43, 44] . Fur-
thermore, insulin degrading enzyme levels are re-
duced in type 2 diabetes animal models  [14, 18] . 
Moreover, insulin has been shown to modulate 
amyloid-β removal, reduce amyloid-β load and 
prevent pathogenic binding of amyloid-β  [28, 43] . 
 The interaction between insulin and amyloid-β 
is bidirectional. More specifically, accumulating 
amyloid-β can bind to insulin receptors and 
downregulate insulin signaling, thus impairing 
neurogenesis and function through the previous-
ly discussed mechanisms  [45] . The foregoing bi-
directional interaction may perpetuate a deleteri-
ous positive feedback loop whereby insulin resis-
tance promotes increased amyloid-β and 
amyloid-β induces further insulin resistance  [26] . 
This loop may provide another reason for the 
high prevalence of Alzheimer’s disease in people 
with type 2 diabetes  [26] .
 Neuroplasticity, Inflammation, Oxidative Stress 
and the Hypothalamic-Pituitary-Adrenal Axis 
 Neuroplasticity is the brain’s ability to change in 
response to environmental stimuli  [46] . The in-
ability of the brain to change at a molecular, cel-
lular, structural and ultimately functional level 
is an important cause of impaired cognition and 
mood. Diabetes and depression have been 
shown to impair neuroplasticity through the in-
flammatory pathway, oxidative stress, depletion 
of neurotrophic factors and hypothalamic-pitu-
itary-adrenal (HPA) axis derangement, leading 
to impaired neurogenesis, impaired long-term 
potentiation and neurotoxicity  [47, 48] . 
 A proinflammatory state has been shown to be 
associated with stress (physical, emotional, psy-
chological), inflammatory medical comorbidities 
(infection, obesity, diabetes, metabolic syndrome, 
autoimmune diseases, cardiovascular disease) 
and psychiatric comorbidities (mood disorders, 
anxiety disorders, psychotic disorders)  [49] . The 
cytokines produced, most notably TNF-α, IL-6 
and IL-1β, in this proinflammatory state have 
been associated with ‘sickness behavior’ includ-
ing depressive symptoms of lethargy, anhedonia 
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and cognitive decline  [49] . The downstream ef-
fects of the proinflammatory state include de-
rangement of monoamine levels, pathologic mi-
croglial cell dysfunction, increased oxidative 
stress, HPA axis activation and structural changes 
of the subcortical regions, all of which may lead to 
decreased neuroplasticity and dysfunctional 
emotional and cognitive processing  [50] .
 More specifically, proinflammatory cytokines 
have been shown to cause tryptophan depletion 
and increased serotonin turnover, both well-
known causes of altered mood and cognition 
 [51] . Increased oxidative stress also accompanies 
the elevated metabolic rate induced by a proin-
flammatory state, thus increasing cellular damage 
at the molecular level ultimately leading to neuro-
toxicity  [51] .
 Also implicated in the inflammatory pathway 
are microglial cells, the macrophages of the CNS. 
Microglial cells are important for normal brain 
function and synaptic pruning; however, in a 
chronic inflammatory state, microglial cells may 
induce high levels of neural death through patho-
logic synaptic pruning leading to impairment of 
the cognitive and mood neural circuits  [52, 53] .
 The proinflammatory state is also associated 
with activation of the HPA axis leading to hyper-
cortisolemia as well was impaired HPA negative 
feedback through decreased glucocorticoid re-
ceptor expression, translocation and signaling 
 [54] . Of note, diabetes and depression as well as 
stress all have the ability to activate the HPA axis, 
inducing hypercortisolemia  [54, 55] which leads 
to further hyperglycemia and thus to poorer con-
trol of diabetes and increased insulin require-
ments  [21] . Chronic exposure to high levels of 
cortisol can also cause neurotoxicity in the hip-
pocampus, leading to impaired cognition and 
mood symptoms  [56] . This neurotoxic effect is 
amplified in the presence of insulin resistance 
 [26] . Notably, cortisol has also been implicated in 
altering metabolism of amyloids and may thus ex-
hibit pro-Alzheimer’s disease properties through 
the amyloid mechanism as well  [57] .
 Brain-Derived Neurotrophic Factor 
 Low levels of BDNF are commonly observed in 
people with type 2 diabetes, impaired glucose tol-
erance, major depressive disorder and Alzheim-
er’s disease  [58] . This observation may suggest 
another common mechanism of pathogenesis of 
these diseases. For example, during a major de-
pressive episode, hippocampal 5-HT2A receptors 
are upregulated, which may lead to decreased 
BDNF and a subsequent decrease in hippocampal 
volume  [59] . Moreover, BDNF is one of the 
downstream targets of insulin receptor activation 
 [30] . Therefore, in the setting of insulin resistance 
where signaling is diminished, BDNF levels are 
also lower  [26] . The low levels of BDNF, as seen 
in both type 2 diabetes and major depressive dis-
order, may thus increase vulnerability to hippo-
campal dysfunction and atrophy secondary to in-
adequate growth factor stimulation  [26, 31, 60] . 
 Monoamine Changes 
 The monoamine pathway has been the primary 
therapeutic target of major depressive disorder 
for decades. Causes of monoamine derangement 
are numerous, including the previously discussed 
inflammatory pathway  [49] and CNS insulin  [26] . 
Monoamines, notably serotonin, norepinephrine 
and dopamine, are now also being recognized as 
having significant roles in cognition  [61] . For ex-
ample, serotonin receptors are found abundantly 
in cognitive regions such as the hippocampus, 
prefrontal cortex and septum, where they play an 
important role in cognition, most notably cre-
ation of episodic memories as evidenced by tryp-
tophan depletion studies  [62] . Norepinephrine 
plays a significant role in alertness and arousal, 
thus affecting cognitive function in the domains 
of working memory, memory consolidation, at-
tention and executive function  [61] . Dopamine 
levels are also salient to cognition, motivation and 
the reward system  [63] . In sum, the monoamine 
system can be altered by depression and type 2 
diabetes and has large effects on both cognition 
and emotion. Therefore, it may provide another 
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pathophysiologic nexus to account for the inter-
play between depression, diabetes and cognitive 
impairment  [61] . 
 Microbiota-Gut-Brain Axis 
 Many decades ago, the vast and dynamic ecosys-
tem of the gut microbiota was hypothesized to af-
fect mental health; however, only recently has this 
idea been revisited  [64] . Currently, there is only 
limited evidence for the bidirectional interaction 
between the gut and the CNS, but interest across 
the fields of psychiatry, neurology, gastroenterol-
ogy and endocrinology is increasing  [65] . Preclin-
ical evidence suggests that this interaction may 
provide mechanisms whereby the gut microbiota 
may induce metabolic, behavioral, mood and 
cognitive changes  [65] . This field is still in its in-
fancy but is being implicated as an etiologic factor 
in dictating eating habits, BDNF levels, HPA axis 
activity, inflammation and oxidative stress, all of 
which are important factors in the mechanisms of 
affective and cognitive dysfunction, as previously 
discussed  [64, 65] . In brief, the gut may have bi-
directional communication with the brain to in-
duce behaviors that increase the risk of diabetes 
as well as may be the nidus of a chronic inflam-
matory state which may induce sickness behav-
ior, hypercholesterolemia, hyperglycemia, hyper-
cortisolemia and ultimately neural damage, af-
fecting cognitive and emotional function  [64, 65] . 
 Microangiopathy 
 Microvascular (nephropathy, neuropathy, reti-
nopathy) and macrovascular (stroke, myocardial 
infarction) complications of diabetes are well es-
tablished in the literature  [21] . Moreover, it has 
now been well-established that the brain has in-
creased susceptibility to microvascular disease, 
independent of the presence of large vessel dis-
ease, in people with diabetes  [66] . Postmortem 
and imaging analyses has revealed these microan-
giopathic changes to be associated with the devel-
opment of depression, cognitive impairment and 
dementia, particularly vascular dementia and Al-
zheimer’s disease  [67] . Microangiopathic chang-
es may be linked with amyloid-β oligomer forma-
tion  [68] . The proposed mechanism and evidence 
in support of the microangiopathy-cognitive-af-
fective connection have been reviewed elsewhere 
 [66, 67, 69] . 
 Common Psychosocial Determinants 
 A separate but not mutually exclusive explana-
tion of the connection between diabetes, depres-
sion and dementia may be due to the psychosocial 
risk factors that are shared by these disease pro-
cesses  [17] . Epidemiological studies provide evi-
dence for low socioeconomic status, childhood 
adversity, medical comorbidities, addiction and 
psychiatric comorbidities as being common risk 
factors for type 2 diabetes and major depressive 
disorder  [70–72] . Therefore, one potential expla-
nation for the observed association may be com-
mon etiologic factors  [17] . As shown in  figure 2 , 
both common biological and psychosocial factors 
may be creating a pathological nexus between pe-
ripheral metabolism and brain function. Taken 
together, certain life circumstances may predis-






















 Fig. 2. Role of humoral factors in normal and pathologi-
cal nexus between peripheral metabolism and brain 
functions. Reprinted with permission from Kaidanovich-
Beilin et al.  [17] . 
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2 diabetes and major depressive disorder, which 
could synergistically damage the neural circuits 
of emotion and cognition, thereby increasing the 
risk of cognitive impairment and dementia  [17] . 
 Implications for Treatment and Prevention 
 As shown, numerous mechanisms may be in-
volved in the interaction of diabetes, depression 
and dementia, and may present new therapeutic 
targets. Therefore, in this section, the focus will be 
placed on selected new and novel therapeutic and 
preventative options that target components of 
the mechanisms previously discussed. Emphasis 
will be placed on (1) the benefit of early detection 
and treatment of major depressive disorder and 
diabetes, (2) the importance of lifestyle modifica-
tions, namely exercise and dietary changes, and 
(3) novel metabolic therapeutic options which 
hold promise for improving mood and cognition 
in the context of major depressive disorder, type 
2 diabetes and Alzheimer’s disease. 
 As previously discussed, no disease-modify-
ing agents are currently identified for Alzheim-
er’s disease  [10] . Therefore, prevention through 
risk factor modification has been a focus of Al-
zheimer’s disease research and public health ef-
forts  [10, 73] . Understanding the pathophysiol-
ogy of Alzheimer’s disease as occurring over a 
lifetime, rather than only in old age when symp-
toms begin to manifest, is essential to this pre-
ventative approach. Epidemiologic and mecha-
nistic data strongly suggest both depression and 
diabetes to be modifiable risk factors of Alzheim-
er’s disease. Therefore, screening programs to al-
low for early detection and treatment of both ma-
jor depressive disorder and type 2 diabetes may 
be extremely helpful in the prevention of Al-
zheimer’s disease. Indeed, evidence suggests that 
an estimated 10–15% of Alzheimer’s disease cas-
es are attributable to depression and a 25% re-
duction in depression prevalence would result in 
approximately 830,000 fewer Alzheimer’s disease 
cases worldwide  [74] . Similarly for type 2 diabe-
tes, appropriate therapy achieving adequate gly-
cemic, lipid and blood pressure control has been 
shown to decrease the risk of cognitive impair-
ment, Alzheimer’s disease and vascular dementia 
 [75, 76] . Taken together, screening for major de-
pressive disorder in people with type 2 diabetes 
and vice versa would thus have clear benefits for 
early detection and treatment for both condi-
tions while reducing the risk of developing Al-
zheimer’s disease  [77] .
 From a public health perspective, exercise 
and a healthy diet have been promoted because 
of their positive impact on cardiovascular health 
 [78] . Evidence consistently documents the im-
portance of exercise and a healthy diet and their 
impact on diabetes, depression and dementia 
 [14, 79–83] . For example, exercise has been 
shown repeatedly to have a positive effect on 
mood and cognition in individuals with depres-
sion  [32, 83] . Likewise, among individuals with 
Alzheimer’s disease, exercise has been shown to 
improve mood and cognition both in the short 
and long term  [80, 81] . In type 2 diabetes, life-
style management has long been a part of first-
line therapy with clear effects on cognition, 
mood and Alzheimer’s disease prevention  [10, 
84, 85] . Therefore, lifestyle management should 
also be emphasized from a mental health per-
spective, rather than only for its cardiovascular 
benefits.
 From a pharmacologic perspective, increasing 
interest has been developing for the use of dia-
betic medications for improvement of mood and 
cognition. For example, recent studies have been 
conducted investigating the role of insulin in 
mood and cognition  [22] . As previously dis-
cussed, CNS insulin plays a key role in brain func-
tion, and CNS insulin levels are reduced in people 
with Alzheimer’s disease  [27] . Intravenous ad-
ministration of insulin has been investigated for 
its effects on cognition and emotion. Several in-
vestigators have shown that in both human and 
animal models, intravenous insulin administra-
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tion can increase hippocampal neural activity and 
improve mood and cognition (most reproducibly 
declarative memory) in the short and long term 
 [86, 87] . However, concerns of the systemic ef-
fects and risks, namely hypoglycemic events, were 
a limiting factor to their wider promotion  [88, 
89] . Therefore, interest has shifted to intranasal 
insulin administration, whereby insulin directly 
enters the CNS, bypassing the blood-brain barri-
er, presumably via the olfactory and trigeminal 
nerves  [88, 89] . Intranasal administration has 
been shown to increase the level of insulin in the 
CNS while not affecting the systemic concentra-
tion of insulin or glucose  [88–90] . Furthermore, 
in human and animal studies, intranasal insulin 
has been shown to improve mood and cognition 
reproducibly in healthy, obese and Alzheimer’s 
disease subjects  [91] . Moreover, intranasal insu-
lin has benefited disparate measures of neurocog-
nition in adults with bipolar disorder, a group 
highly susceptible to cognitive dysfunction  [92] .
 Oral diabetic medication, particularly thia-
zolidinediones and incretins have also produced 
interesting results. Pioglitazone, a thiazolidinedi-
one, is an insulin sensitizer that has been shown 
to also have effects on cognition  [87, 93] . Indeed, 
cognitive improvements as well as a reduction in 
the development of Alzheimer’s disease have 
been observed in people with type 2 diabetes 
treated with pioglitazone  [87, 93] . Incretins, gas-
trointestinal hormones which delay gastric emp-
tying and increase insulin release from the pan-
creas, have also shown great promise to treat met-
abolic, cognitive and affective symptoms 
simultaneously  [22, 94] . In a recent review by Mc-
Intyre et al.  [94] , the positive effects of incretins, 
specifically glucagon-like peptide-1, were dis-
cussed. In brief, glucagon-like peptide-1 may im-
prove glycemic control, improve cognition and 
mood, and decrease the risk of Alzheimer’s dis-
ease through its neuroprotective effects, ability to 
reduce amyloid-β load and through promotion of 
long-term potentiation and neuroplasticity  [22, 
94] .
 Bariatric surgery produces vastly improved 
glycemic control and significant sustained re-
duction in weight far beyond the effects of med-
ical therapy alone  [95–97] . This significant im-
provement in diabetic control, in theory, may 
decrease the risk of depression and cognitive im-
pairment later in life by preventing neural de-
generation from the previously described mech-
anisms. However, to the authors’ knowledge, 
there have been no studies to assess the effect of 
bariatric surgery on mood, cognition and risk of 
Alzheimer’s disease development. Therefore, 
this effect may be an interesting topic for future 
research.
 Conclusion 
 Several mechanisms have been proposed to ac-
count for the well-documented association be-
tween diabetes, depression and dementia. The 
metabolic-brain axis appears to be a key media-
tor connecting these conditions. Brain regions 
important for cognition and emotional regula-
tion may be damaged by the effects of hypergly-
cemia and insulin resistance. Indeed, a decreased 
insulin effect and thus decreased intracellular 
glucose levels in frontal and subcortical regions 
results in neurotoxicity, decreased neuroplasti-
city, decreased signaling and decreased synaptic 
connectivity resulting in an overall effect of dys-
functional neural circuits. Major depressive dis-
order may further facilitate neural circuit dam-
age through the inflammatory pathway, HPA 
axis deregulation, monoamine changes and low-
ering of central BDNF levels. Stress and psycho-
social determinants of health may also be key me-
diators and etiologic factors in these interactions. 
Taken together, several mechanistic pathways 
may be involved, presenting new potential drug 
targets for the treatment and prevention of de-
mentia using a lifetime approach. Systemic and 
intranasal insulin, insulin sensitizers, incretins, 
exercise, dietary changes, bariatric surgery, im-
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proved screening and early treatment practices of 
type 2 diabetes and major depressive disorder 
have all been implicated for potential use in the 
treatment and prevention of dementia. Further 
research is most definitely indicated as the litera-
ture reviewed here shows great promise for fur-
ther studies of the metabolic-brain axis which 
could revolutionize the understanding, treat-
ment and prevention of cognitive and affective 
disorders. 
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 Abstract 
 People with schizophrenia or bipolar disorder have in-
creased morbidity and shortened life expectancy com-
pared with the general population. The prevalence of 
many physical illnesses is increased in people with se-
vere mental illness and accounts for around three quar-
ters of all deaths; cardiovascular disease is the most 
common cause of death. The increased prevalence of 
cardiovascular disease is explained, at least in part, by 
increased rates of traditional cardiovascular risk factors 
including diabetes, dyslipidaemia, obesity and smok-
ing, but mental illness is an independent risk factor for 
cardiovascular disease and mortality. Despite national 
and international guidance and an increasing aware-
ness of physical health issues in people with severe 
mental illness, the level of screening for and manage-
ment of cardiovascular risk factors remains poor. While 
there are additional challenges in managing cardiovas-
cular risk in people with severe mental illness, the prin-
ciples are similar to those in the general population. A 
multidisciplinary approach involving healthcare profes-
sionals within psychiatry, general practice and medical 
specialties as well as and clear patient pathways are 
needed to reduce the health inequalities experienced 
by people with severe mental illness. 
 © 2015 S. Karger AG, Basel 
 Cardiovascular disease is the leading cause of 
mortality worldwide, accounting for approxi-
mately 30% of all deaths. Similarly, mental illness 
is also common, affecting 1 in 10 people at any 
one time. A degree of comorbidity is therefore to 
be expected but it is clear that mental illness oc-
curs more commonly among people with cardio-
vascular disease than expected and vice versa  [1] . 
 The relationship between cardiovascular dis-
ease and mental illness is complex and bi-direc-
tional, with mental illness being both a cause and 
consequence of cardiovascular disease. For exam-
ple, cross-sectional studies have shown that the 
prevalence of depression is increased in people 
with cardiovascular disease with up to 40% of 
people having either major or minor depression 
following a myocardial infarction  [2] . Further-
more, longitudinal studies indicate that depres-
sion increases the risk of myocardial infarction, 
coronary heart disease, cerebrovascular disease 
and other cardiovascular diseases by up to 2-fold 
in both men and women, independent of other 
risk factors  [3, 4] , and increases mortality follow-
ing a myocardial infarction  [5, 6] . Similarly, anxi-
ety is an independent risk factor for incident cor-
onary heart disease and cardiac mortality  [7] .
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 This chapter, however, will review the associa-
tion between severe mental illness (schizophrenia 
and bipolar disorder) and cardiovascular disease 
as an example of this complex relationship. It will 
explore the reasons for the comorbidity and the 
steps needed to reduce cardiovascular disease in 
people with severe mental illness. Severe mental 
illness is associated with a 3-fold increased risk of 
premature death and shortened life expectancy by 
approximately 10–20 years  [8] . Although suicide 
accounts for the highest  relative risk of mortality, 
being up to 20-fold more common than the gen-
eral population, a range of physical illnesses oc-
curs more frequently in people with severe men-
tal illness and which are the cause of approxi-
mately three quarters of all deaths, with 
cardiovascular disease being the most common 
cause of death  [8] .
 Epidemiology of Cardiovascular Disease in 
Severe Mental Illness 
 Cardiovascular morbidity and mortality are in-
creased approximately 2- to 3-fold in people with 
severe mental illness  [8] . The  relative risk is more 
markedly increased in younger individuals with 
severe mental illness, in whom the prevalence of 
cardiovascular disease is 3.6-fold higher com-
pared with a 2.1-fold increase in people who are 
older than 50 years  [9] . While the morbidity and 
mortality associated with cardiovascular disease 
have fallen in the general population over the last 
20 years, these benefits have not been shared by 
people with severe mental illness, which has led to 
a widening health inequality gap. 
 Aetiology of Cardiovascular Disease in Severe 
Mental Illness 
 There are numerous reasons for the increased 
rate of cardiovascular disease in people with se-
vere mental illness, including an increased preva-
lence of modifiable cardiovascular risk factors, 
such as obesity, smoking, diabetes and dyslipi-
daemia ( table  1 ), as well as intrinsic biological 
changes that occur during psychosis  [10] . Not 
only do modifiable cardiovascular risk factors oc-
cur more commonly, but they appear at a young-
er age; in the US Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE), over a quar-
ter of men with schizophrenia, aged 20–29 years, 
at baseline had metabolic syndrome, a proxy for 
cardiovascular risk, compared with fewer than 
10% in the general US population  [11] . The im-
plication of this finding is that healthcare profes-
sionals need to pay attention to cardiovascular 
risk factor management in people with severe 
mental illness from diagnosis. 
Table 1.  Estimated prevalence of modifiable cardiovascular risk factors in people with schizo-
phrenia and bipolar disorder, and relative risk compared with the general population (adapted 
from De Hert et al. [10])
Modifiable risk factor Schizophrenia  Bipolar disorder
prevalence relative risk pre valence relative risk
Smoking 50–80% 2–3 54–68% 2–3
Dyslipidaemia 25–69% ≤5 23–38% ≤3
Diabetes 10–15% 2–3 8–17% 1.5–3
Hypertension 19–58% 2–3 35–61% 2–3
Obesity 45–55% 1.5–2 21–49% 1–2
Metabolic syndrome 37–63% 2–3 30–49% 2–3
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 Obesity 
 The global prevalence of obesity has increased 
dramatically over the last three decades, driven by 
changes in diet and physical activity. These de-
mographic changes appear to have affected peo-
ple with severe mental illness to a greater extent 
than the general population as studies that pre-
date the 1980s did not consistently report higher 
rates of obesity in those with severe mental illness 
 [12] . By contrast, more recent studies have shown 
that obesity is approximately 2-fold more com-
mon in people with schizophrenia or bipolar dis-
order. The mean baseline BMI in the CATIE 
study was 29.7 kg/m2, with 37% of men and 73% 
of women having central obesity as defined by a 
waist circumference in excess of 102 and 88 cm, 
respectively. 
 Obesity occurs early in the natural history of 
schizophrenia with a significant proportion of 
people with first-episode psychosis being over-
weight prior to any treatment. Weight gain 
 frequently occurs rapidly following treatment 
initiation. Seventeen per cent of people with 
schizophrenia in the European First Episode 
Schizophrenia Trial were overweight at baseline 
prior to treatment and 37–86% had gained more 
than 7% of their initial body weight during the 
first year of treatment, depending on medica-
tion choice  [13] .
 Body composition is also altered in people 
with severe mental illness; higher waist-to-hip ra-
tios and increased visceral fat have been found 
even in people with first episode psychosis; other 
studies have not replicated these findings, but 
note marked weight gain and increasing girth 
during treatment with antipsychotic medication 
 [12] .
 The cause of obesity in people with schizo-
phrenia includes genetic and lifestyle factors as 
well as illness and treatment effects. Individuals 
with schizophrenia are more likely to consume a 
diet that is rich in fat and refined carbohydrates 
while containing less fibre, fruit and vegetables 
than the general population  [14] . The lower levels 
of physical activity and social and urban depriva-
tion experienced by those with schizophrenia 
may contribute further to the increased obesity 
rates.
 Diabetes 
 It is estimated that between 10 and 15% of people 
with severe mental illness have diabetes  [10] . The 
onset occurs on average 10 years earlier, with 
women appearing to have a greater risk of diabe-
tes than men  [15] . Type 1 diabetes is not in-
creased and so the 2- to 3-fold excess is explained 
by an increase in type 2 diabetes. The prevalence 
of undiagnosed diabetes is also considerably 
higher in people with schizophrenia than the 
general population with as many as 70% of cases 
being undiagnosed. This may reflect a reluctance 
of people with severe mental illness to volunteer 
symptoms and the overlap between some symp-
toms of diabetes and mental illness, leading to 
less screening in people with severe mental ill-
ness. 
 Like obesity, the rates of diabetes may be in-
creased because of lifestyle factors, but there is 
also evidence of a genetic link between the two 
conditions. There is a high prevalence of meta-
bolic abnormalities in the first degree relatives of 
people with severe mental illness, and between 17 
and 50% of people with schizophrenia have a 
family history of type 2 diabetes  [15] . Although 
these findings may result from shared familial en-
vironment, genome-wide association studies 
have suggested a shared genetic linkage between 
severe mental illness and diabetes  [16] .
 Dyslipidaemia and Hypertension 
 A meta-analysis including 11 papers on dyslipi-
daemia showed that the major lipid abnormalities 
seen in people with severe mental illness are low-
er levels of HDL cholesterol and hypertriglyceri-
daemia, although not all studies have shown this 
 [17] . By contrast, total cholesterol was not higher 
in people with severe mental illness. Overall, dys-
lipidaemia is reported in 25–69% of people with 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 54–65 ( DOI: 10.1159/000365531 )
 Cardiovascular Disease and Severe Mental Illness 57
severe mental illness. The same meta-analysis in-
cluded 12 papers on hypertension and found a 
non-significant 11% increase in the prevalence of 
hypertension (1.11, 95% CI: 0.91–1.35)  [17] . 
 Smoking 
 Smoking rates are high in people with severe 
mental illness (50–80%). In the USA, 68% of 689 
schizophrenia patients who took part in the 
 CATIE study were smokers compared to 35% of 
age-matched controls. In the UK general popula-
tion, 20% of men and 19% of women are current 
smokers, but the odds of people with schizophre-
nia being current smokers are 5.3 times higher 
and the odds are greater for men than women at 
7.2 and 3.3, respectively  [18] . People with severe 
mental illness are also heavier smokers both in 
terms of total number of cigarettes smoked and 
amount of smoke inhaled. 
 Intrinsic Biological Changes in Severe Mental 
Illness 
 Severe mental illnesses are associated with a num-
ber of biological changes that affect intermediate 
metabolism and consequently cardiovascular risk 
 [15] . These include hypothalamic-pituitary-adre-
nal axis dysfunction, manifesting as subclinical 
hypercortisolism and blunted diurnal cortisol 
rhythm, altered immune function (e.g. altered cy-
tokine expression) and altered platelet function. 
 Antipsychotic Medication and Cardiovascular 
Disease 
 There are concerns that antipsychotics may 
contribute to cardiovascular risk by inducing 
weight gain and worsening lipid profile and 
blood glucose. Weight gain is the most common 
side effect seen with second-generation antipsy-
chotics, affecting between 15 and 72% of pa-
tients  [12] . Most weight gain occurs early in 
treatment, but patients may continue to gain 
weight for at least 4 years after the initiation of 
treatment, albeit at a slower rate. There is a hi-
erarchy of weight gain between second-genera-
tion antipsychotics, with clozapine and olanzap-
ine being associated with the greatest weight 
gain, but no agent should be considered as 
weight neutral. There is an intermediate risk of 
weight gain with quetiapine and risperidone, 
while aripiprazole, amisulpride and ziprasidone 
have little effect on weight. Some first-genera-
tion antipsychotics, for example chlorproma-
zine, and other psychotropic medications, such 
as certain antidepressants, are also associated 
with a high risk of weight gain. 
 Predicting weight gain with treatment is diffi-
cult because there is marked inter-individual 
variation in treatment-induced weight change. 
Other factors associated with weight gain are 
younger age, lower initial BMI, family history of 
obesity, concomitant cannabis use and a tenden-
cy to overeat at the time of stress  [12] . The best 
predictor of long-term weight gain is the change 
in the first 4–6 weeks of treatment, emphasising 
the need for regular weight measurement during 
the early phase of treatment.
 The relationship between antipsychotics and 
diabetes is complex because of the long natural 
history of diabetes and the potential confounding 
effects of other diabetes risk factors in people 
with severe mental illness  [19] . The earliest case 
report linking antipsychotics with diabetes was in 
1956 when a man developed haemolytic anaemia 
and diabetes 2 weeks after stopping chlorproma-
zine  [20] . Since then, cases of diabetes and dia-
betic ketoacidosis have been seen in people re-
ceiving various first- and second-generation an-
tipsychotics  [19] . Although these studies provide 
evidence of causality, particularly when the glu-
cose was measured before treatment initiation 
and where the diabetes entered remission after 
treatment discontinuation, the small numbers 
make it difficult to determine whether these are 
isolated cases or whether they can be extrapolat-
ed to the wider body of people receiving antipsy-
chotic medication.
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 A large number of pharmaco-epidemiologi-
cal studies have indicated that people receiving 
antipsychotics have a higher prevalence of dia-
betes than the general population and that peo-
ple receiving second-generation drugs have a 
slightly increased risk of diabetes compared 
with those receiving first-generation drugs. 
One meta-analysis found that the relative risk 
of diabetes in those prescribed a second-gener-
ation antipsychotic was 32% (15–51%) higher 
than those receiving a first-generation antipsy-
chotic. There was, however, considerable varia-
tion between studies  [21] , and a further system-
atic review of cohort studies found no consis-
tent difference in diabetes risk between 
second-generation antipsychotics either as a 
group when compared with first-generation an-
tipsychotics or between individual drugs  [22] .
 Over the last decade, randomised controlled 
trials reporting treatment-emergent diabetes 
have begun to appear in the literature. A system-
atic review of 22 of these trials found no consis-
tent significant difference in treatment-emergent 
glucose abnormalities between antipsychotics, ei-
ther when compared with other antipsychotics or 
with placebo  [23] . However, caution is needed 
when interpreting this analysis as the primary 
aim of many of these studies was to assess anti-
psychotic efficacy rather than metabolic side ef-
fects, and as such are underpowered to address 
this issue. The reporting of metabolic data was in-
consistent and duration of many studies was too 
short to assess diabetes risk. Furthermore, several 
studies have shown small increases in glucose 
concentration in people receiving second-gener-
ation antipsychotics during the studies, which 
may translate into meaningful differences in the 
rate of diabetes over the many years that people 
with severe mental illness take antipsychotics 
 [24] . A more recent meta-analysis comparing the 
metabolic side effects of different second-genera-
tion antipsychotics found that olanzapine pro-
duced a greater increase in glucose than amisul-
pride, aripiprazole, quetiapine, risperidone and 
ziprasidone, but a similar increase as clozapine 
 [24] .
 Overall it appears that there is a causative link 
between antipsychotics and diabetes, but the risk 
is probably low and the majority of people receiv-
ing antipsychotics will not develop diabetes as a 
result of their medication  [19] .
 Antipsychotic treatment is also associated 
with increases in LDL cholesterol and triglycer-
ides and decreased HDL cholesterol. In a meta-
analysis of 48 studies comparing different sec-
ond-generation antipsychotics, olanzapine pro-
duced a greater increase in total cholesterol than 
aripiprazole, risperidone and ziprasidone, but no 
differences with amisulpride, clozapine and que-
tiapine were seen  [24] . These differences may re-
flect the propensity to weight gain, but there may 
be other direct mechanisms as hypertriglyceri-
daemia may occur following treatment despite 
only modest weight gain.
 The effect of antipsychotics on blood pressure 
is variable; although weight gain may lead to in-
creased blood pressure, this may be offset by ad-
renergic blockade by the antipsychotics  [17] .
 Overall it appears that many antipsychotics 
have an adverse effect on cardiovascular risk fac-
tors. However, it is important to understand that 
these are surrogate markers and may not translate 
into increased cardiovascular events and mortal-
ity. Indeed, the opposite is suggested by several 
large epidemiological studies. A UK study of over 
46,000 people found that while exposure to first-
generation antipsychotics, particularly high dos-
es, was associated with excess cardiovascular 
mortality, this increase was not seen in people re-
ceiving second-generation antipsychotics  [9] . 
Similarly in a large Finnish study of 66,881 people 
with schizophrenia, total mortality was lowest in 
individuals receiving clozapine and olanzapine, 
with no difference in cardiovascular mortality be-
tween drugs  [25] . A more recent Finnish study 
examining the impact of the first- and second-
generation antipsychotics on mortality in people 
with first-onset schizophrenia found that the use 
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of second-generation antipsychotics, especially 
clozapine, olanzapine and quetiapine, was associ-
ated with reduced risk of all-cause mortality in 
people with schizophrenia  [26] . By contrast, 
 first-generation antipsychotics, specifically le-
vomepromazine, thioridazine and clorprothix-
ene, were associated with increased risk of all-
cause mortality and levomepromazine with an 
increased likelihood for cardiovascular death. As 
these studies are both observational, there may be 
other explanations or confounders underlying 
the results  [25, 26] .
 Screening for Cardiovascular Risk Factors 
 The increased prevalence of cardiovascular dis-
ease and its modifiable risk factors in people with 
severe mental illness provides a strong rationale 
to screen for cardiovascular risk factors. Screen-
ing should begin prior to the onset of treatment 
or as soon as is reasonably possible, 2–3 months 
later to assess the acute metabolic effects of the 
antipsychotics, and thereafter on an annual basis 
unless significant treatment changes are contem-
plated ( table 2 ). 
Table 2.  Recommended screening based on currently available guidelines
Baseline 2–3 months Annual Target
Medical history to include
family history, ethnicity, 
smoking, alcohol, diet, exercise
✓ ✓ ✓
Height ✓
Weight1 ✓ Every week during first
6–8 weeks of treatment and at
every clinic visit thereafter, but
at least quarterly
✓ BMI <25 kg/m2
Blood pressure ✓ ✓ ✓ <140/90 mm Hg
Glucose2 ✓ ✓ ✓ Fasting glucose <6.0 mmol/l
Non-fasting glucose <7.8 mmol/l
Glycated haemoglobin3 ✓ ✓ ✓ <6.0% (42 mmol/mol) if no history of 
diabetes; target should be individualised 
for people with diabetes but likely
6.5–7.5% (47–58 mmol/mol)
Lipid profile4 ✓ ✓ ✓ Total cholesterol <5.0 mmol/l, <4.0 
mmol/l if established CVD or diabetes
LDL-cholesterol <3.0 mmol/l, <2.0 mmol/l 
if established CVD or diabetes
30% reduction in patient starting statins
Electrocardiogram ✓ ✓ ✓ To assess QTc interval
 1 Additional information can be obtained by measuring waist circumference; target men <94 cm, women <80 cm. Lower values 
should be sought in people from non-white European populations. 2 Either a fasting or non-fasting sample can be used. Fasting 
samples are more reproducible, but may be logistically more difficult to obtain. A formal 75-gram oral glucose tolerance test is 
only needed rarely. 3 Note glycated haemoglobin may be normal in situations where there is a rapid onset of diabetes and so is 
less suited to the 2- to 3-month sample. 4 Either a fasting or non-fasting sample can be used. Fasting samples are needed to as-
sess LDL cholesterol and triglycerides, but cardiovascular risk can be calculated using the total:HDL cholesterol ratio which is 
largely unaffected by eating.
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 Cardiovascular risk assessment should include 
a detailed medical history to assess risk factors, 
physical examination to include weight and blood 
pressure, a blood test to assess lipids and glycae-
mia, and an electrocardiogram  [10] . It is known 
that waist circumference is more closely associat-
ed with cardiovascular disease than BMI, but in 
some settings, such as within the UK primary care, 
there has been reluctance to undertake this mea-
surement. The close correlation between weight 
and waist circumference for most of the popula-
tion would suggest that while additional informa-
tion may be obtained from a waist measurement, 
weight is a pragmatic and practical alternative.
 A fasting blood sample is required to interpret a 
full lipid profile, but a non-fasting sample is accept-
able where logistical difficulties prevent the patient 
from attending in a fasting state. The sensitivity and 
specificity for diabetes, particularly if the glucose 
measurement is combined with glycated haemoglo-
bin, does not differ greatly and most 10-year cardio-
vascular risk engines use the total and HDL choles-
terol, which are largely unaffected by eating. Al-
though it may be easier to obtain a non-fasting 
sample, clinicians should not assume that patients 
with severe mental illness are unable to attend fasted 
as several studies have shown that this is feasible  [27] .
 Current Screening Practises 
 Despite clear guidance from both national and in-
ternational bodies  [10, 28–30] , it is clear that 
many people with severe mental illness are not 
being screened for cardiovascular risk factors. In 
an audit of 50 in-patients and 50 out-patients 
with severe mental illness in Hampshire, UK, 
documented evidence that blood pressure had 
been measured was found in only 32% of case 
notes, and glucose (16%), lipids (9%) and weight 
(2%) were assessed even less frequently  [31] . This 
was despite a high prevalence of metabolic syn-
drome in these patients and a significant number 
at high risk of cardiovascular disease. 
 The effectiveness of national guidelines and 
campaigns has been questioned by a study of US 
psychiatrists which showed that US Food and 
Drug Administration guidelines and a joint posi-
tion statement of the American Psychiatric Asso-
ciation, American Diabetes Association and North 
American Association for the Study of Obesity had 
no effect on screening rates for diabetes  [32] . There 
is a lack of clarity among mental healthcare profes-
sionals about whose responsibility physical health 
screening is  [33] . In some countries, such as the 
UK, the responsibility for screening is placed with-
in primary care  [28] . This may be appropriate be-
cause many people with mental illness have fre-
quent contact with their primary care doctor and 
primary care doctors have all the skills and training 
to address this issue. However, some people with 
severe mental illness only see their mental health 
team and under this circumstance it is important 
the screening occurs in this setting. It is clear that 
good communication is needed between primary 
care and mental health teams to ensure that the 
patient does not fall between the two settings. 
Mental healthcare professionals have also ex-
pressed concern about their lack of understanding 
about what should be measured and when and 
how to interpret the results  [33] . Lack of access to 
necessary equipment may be a further barrier.
 It is well recognised that people with severe 
mental illness are less likely to take advantage of 
health screening  [34] and health services. Since to 
a large extent care is not offered unless requested, 
people with severe mental illness may be disadvan-
taged. The Disability Rights Commission has high-
lighted that instead of receiving holistic care, many 
people with mental illness describe how their phys-
ical illnesses are overshadowed by the mental ill-
ness, with healthcare professionals concentrating 
on the latter to the detriment of the former  [35] . 
 Assessment of Cardiovascular Risk 
 Cardiovascular risk is usually assessed by the use 
of locally relevant risk engines. These have not 
been validated in people with severe mental ill-
ness who are typically younger, have higher blood 
pressure and are more likely to smoke than the 
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populations used to derive cardiovascular disease 
risk scoring systems, such as Framingham and 
QRISK. As traditional risk factors only partially 
explain the excess cardiovascular disease seen in 
people with severe mental illness, it is possible 
that these traditional risk engines may underesti-
mate cardiovascular risk in people with severe 
mental illness. However, pending further re-
search, they provide a guide for the initiation of 
primary preventative measures. 
 Managing Cardiovascular Risk Factors 
 While there are additional challenges in ensuring 
that the person with severe mental illness under-
stands the aims and rationale for treatment, car-
diovascular risk factor management is essentially 
along similar lines to the general population. 
 Smoking 
 Healthcare professionals should provide smokers 
with information about the risks of smoking and 
encourage them to quit. Interventions for smoking 
cessation range from basic advice to pharmaco-
therapy coupled with either individual or group 
psychological support. Smokers with schizophre-
nia are less likely to quit than the general popula-
tion, with one meta-analysis reporting the smok-
ing cessation rate for people with schizophrenia to 
be 9% compared with 14–49% in the general popu-
lation (OR 0.19, 95% CI: 0.14–0.24)  [18] . This low-
er rate is partly attributable to an increased sever-
ity of nicotine dependence, fewer attempts to stop 
smoking, lower motivation to quit and less access 
to interventions  [36, 37] . However, the rates of 
smoking cessation in people with schizophrenia 
can be increased with appropriate support  [38] . 
 The three main pharmacotherapies are nico-
tine replacement therapy, the antidepressant bu-
propion and the nicotinic receptor partial agonist 
varenicline. Of these, bupropion is both safe and 
effective in increasing the rates of abstinence in 
people with schizophrenia. A meta-analysis 
showed that those taking bupropion with co-in-
terventions (group therapy alone or in combina-
tion with nicotine replacement therapy) for up to 
12 weeks were 3 times more likely to be abstinent 
6 months after starting treatment, compared with 
those taking a placebo  [39] . Bupropion, however, 
is contraindicated in people with bipolar disor-
der. Varenicline may also improve smoking ces-
sation rates in people with schizophrenia, but 
there have been reports of suicidal ideation and 
behaviours from people on varenicline.
 Obesity 
 The pessimism surrounding treatment of obesity 
in people with severe mental illness has been chal-
lenged by a number of recent observational stud-
ies and randomised controlled trials of lifestyle 
and pharmacological interventions. A recently 
published meta-analysis of non-pharmacological 
interventions in people with schizophrenia has 
shown that these led to a mean reduction in 
weight of 3.12 kg over a period of 8–24 weeks 
 [40] . In addition, there were commensurate re-
ductions in waist circumference and improve-
ments in other cardiovascular risk factors. The 
benefits of these programmes were seen irrespec-
tive of the duration of mental illness treatment, 
whether the intervention was delivered to an in-
dividual or in a group setting, whether the inter-
vention was based on cognitive behavioural ther-
apy or a nutritional intervention, or whether it 
was designed to promote weight loss or prevent 
weight gain. Out-patient interventions appeared 
more effective than in-patient settings. The meta-
analysis acknowledges a number of limitations of 
the trials, including the small numbers of partici-
pants and the lack of long-term follow-up. Most 
studies do not extend beyond 12 weeks and hence 
their applicability to the long-term nature of 
schizophrenia remains uncertain. The few studies 
reporting long-term effects suggest that these 
may be persistent after the end of the programme 
for up to 1 year, but others suggest that long-term 
behaviour change is difficult to achieve  [41] . 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 54–65 ( DOI: 10.1159/000365531 )
62  Holt 
 There are several longer-term observational 
studies of the effects of weight management pro-
grammes. Menza et al.  [42] showed that a 52-
week multimodal weight control programme led 
to significant improvements in weight, BMI, gly-
cated haemoglobin, blood pressure, levels of exer-
cise and nutritional knowledge in 20 of the 31 
participants who completed the programme. An-
other study of 33 people with schizophrenia in 
Taiwan demonstrated a mean 3.7 and 2.7 kg re-
duction in body weight after 6 months and 1 year, 
respectively, following a 10-week multimodal 
weight control program  [43] . A long-term 
(8 years) observational study of a group interven-
tion demonstrated that further weight loss is 
achievable with ongoing support  [44] . In this 
study of well-motivated patients, there was a pro-
gressive statistically significant reduction in mean 
weight and BMI throughout the follow-up with 
no suggestion of a plateau. The mean weight loss 
was approximately 10% at 1 year (approx. 10 kg), 
with 61% achieving a 7% weight loss. By the end 
of the programme, 92% (n = 130) had lost some 
weight. The only predictor of weight loss was the 
number of sessions attended; gender, age, diag-
nosis and treatment were not related to weight 
loss. This suggests that an intervention of greater 
intensity or stronger focus may be needed in peo-
ple with severe mental illness compared with the 
general population. Although previous studies 
have suggested that lifestyle interventions are 
hard to maintain in people with schizophrenia 
without support  [41] , there may be other factors 
that contributed to the achieved weight loss in 
this clinic. The model of care offered a multimod-
al programme that incorporated nutrition, exer-
cise and some degree of behavioural interven-
tions on the premise that weight management 
should not be viewed in isolation and is best com-
bined with a holistic approach to lifestyle man-
agement. The clinic first utilised a group ap-
proach as a pragmatic low cost way forward, but 
the group setting and peer support was also ap-
preciated by many participants. Lifestyle changes 
were not imposed on patients by healthcare pro-
fessionals, but were chosen by the participants 
themselves. Furthermore, many of the initial 
health behaviours, such as high intake of sugary 
carbonated beverages, were readily amenable to 
change. The stepwise change made the process 
simple, achievable and sustainable.
 Several pharmacological agents have been tried 
to reverse or prevent antipsychotic-induced weight 
gain  [45] . No drug has been found to be particu-
larly effective, but a recent systematic review 
showed that there was preliminary evidence that 
metformin may attenuate weight gain in both 
adult and adolescent patients taking second gen-
eration  antipsychotics  [46] . The review included 
14 articles, 8 of which were double-blind, placebo-
controlled studies. The studies lasted 8–16 weeks 
and used doses ranging from 500 to 2,550 mg daily. 
Most of these studies showed a modest reduction 
in weight with metformin (approx. 1 kg), while 
those treated with placebo gained weight. Where it 
was measured, insulin resistance appeared to im-
prove in those treated with metformin. The review 
concluded that although there was no clear sub-
stantial evidence that metformin, as an adjuvant to 
second generation antipsychotic use, will decrease 
weight gain and improve metabolic effects, the re-
sults are encouraging and additional studies of 
longer duration were recommended.
 Dyslipidaemia 
 Although target levels of total cholesterol and LDL 
cholesterol are the same as the general population 
(<5.0 and <3.0 mmol/l, respectively), tighter goals 
of <4.0 and <2.0 mmol/l may be appropriate for 
individuals with established cardiovascular disease 
or diabetes. No cardiovascular disease outcome 
trials with statins have been performed specifically 
in people with severe mental illness, but these 
drugs are as effective in lowering total and LDL 
cholesterol as the general population  [47] . Fur-
thermore, there is no evidence that lipid-lowering 
medication is associated with suicide or traumatic 
deaths in people with severe mental illness. 
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 Diabetes 
 The treatment of diabetes in people with severe 
mental illness should follow currently available 
treatment algorithms, although oral antidiabetes 
agents that induce less weight gain may have ad-
vantages given the high prevalence of obesity in 
people with severe mental illness  [48] . The addi-
tional challenges of managing comorbid diabetes 
and mental illness, however, require close collabo-
ration between mental and diabetes services. As 
hyperglycaemia is associated with an increased 
risk of diabetes complications, neuropathy, reti-
nopathy and nephropathy, glycaemic targets 
should be determined for each individual with dia-
betes. The precise target is dependent on a number 
of factors including disease duration, risk of hypo-
glycaemia, life expectancy and comorbidities in-
cluding macrovascular disease as well as patient at-
titude and resources; however, glycated haemoglo-
bin targets between 6.5 and 7.5% (48–58 mmol/
mol) would be usual  [48] . 
 Prevention of diabetes is also an important 
consideration as lifestyle intervention pro-
grammes involving dietary modification, weight 
loss and increased physical activity have been 
shown to reduce the incidence of type 2 diabetes 
 [49] . As these programmes share many features 
with lifestyle weight loss programmes used in 
people with severe mental illness, it is hoped that 
the programmes may also lead to diabetes pre-
vention, although this has not been formally as-
sessed. Metformin may also be considered  [10] .
 Hypertension 
 The management of hypertension in severe men-
tal illness should follow the same treatment algo-
rithms as the general population, with recom-
mended target blood pressure levels of <140/90 
mm Hg. Patients should be advised to reduce 
smoking and salt intake. European and UK 
guidelines emphasise the need to choose antihy-
pertensive agents best suited to the individual pa-
tient’s needs as the achieved blood pressure is 
more important than the agent used to achieve 
this. 
 Conclusion 
 The increased rates of cardiovascular disease in 
people with severe mental illness provide a clini-
cal imperative to screen and manage cardiovascu-
lar risk factors with a systematic approach. In the 
past, the physical health needs of people with se-
vere mental illness have largely been ignored, cre-
ating significant heath inequalities. Contrary to 
expectation, individuals with severe mental ill-
ness are as motivated about their physical health 
as the rest of the population, but often lack aware-
ness and fail to prioritise physical well-being  [50] . 
Providing a supportive environment in which 
cardiovascular risk factors can be managed sys-
tematically is likely to have a significant impact 
on cardiovascular morbidity and mortality in 
people with severe mental illness. 
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 Abstract 
 Eating disorders, including anorexia nervosa and bulimia 
nervosa, are complex psychiatric diseases characterized 
by severe disturbances in eating behavior, often resulting 
in dramatic consequences for the physical health of pa-
tients. Even though appearing after the beginning of an 
eating disorder and therefore not representing their pri-
mary cause, physical impairments play an important role 
in the development of psychopathology, its course and 
prognosis, and in the most severe cases may also repre-
sent a significant threat to the patient’s life. They contrib-
ute, together with suicide, to the high mortality of pa-
tients with eating disorders. Indeed, anorexia nervosa has 
the highest mortality of any psychiatric diagnosis, esti-
mated at 10% within 10 years of diagnosis, while mortal-
ity for bulimia nervosa is lower, occurring at approximate-
ly 1% within 10 years of diagnosis. With a few exceptions, 
the physical complications resolve with the recovery of 
body weight and the discontinuation of aberrant eating 
and purging behaviors. The burden of physical complica-
tions demands prompt clinical consideration and appro-
priate treatment.  © 2015 S. Karger AG, Basel 
 Eating disorders, including anorexia nervosa 
and bulimia nervosa, are complex psychiatric 
diseases characterized by severe disturbances in 
eating behavior often resulting in dramatic con-
sequences for the physical health of patients. 
Anorexia nervosa is characterized by restricted 
eating, obsessive fears of being fat and the volun-
tary pursuit of thinness with an inability to 
maintain a normal healthy body weight. Despite 
increasing emaciation and a body weight below 
85% of the ideal, individuals with anorexia are 
dissatisfied with the perceived size and shape of 
their body, and engage in unhealthy behaviors to 
perpetuate weight loss or prevent weight gain. 
There are two subtypes of anorexia nervosa: an-
orexia nervosa binge-eating/purging subtype, 
where patients engage in binge-eating/purging 
behaviors, and anorexia nervosa restricting sub-
type, where patients exclusively restrict their 
food intake. 
 Bulimia nervosa is characterized by recurrent 
episodes of uncontrolled binge eating coupled 
with inappropriate compensatory behaviors, 
such as vomiting, laxative abuse, food restriction 
and/or excessive exercising, in order to prevent 
weight gain due to the patient’s pathological fear 
of becoming fat. Generally, because of the inges-
tion of some food in the course of bingeing, peo-
ple with bulimia nervosa have a normal body 
weight.
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 Anorexia and bulimia are perhaps the most 
intriguing combinations of psychological and 
physical pathology. Even though appearing after 
the beginning of an eating disorder and therefore 
not representing their primary cause, physical 
comorbidity plays an important role in the devel-
opment of psychopathology, its course and prog-
nosis, possibly through the essential contribution 
that nutritional alterations typical of these dis-
eases exert on the brain biochemical function. 
The physical complications observed in eating 
disorders have been considered a consequence of 
nutritional derangements because of the similar-
ities with the alterations observed in simple star-
vation. People with bulimia are not starving, but 
the loss of food from vomiting or use of laxatives, 
the biased selection of macro-/micronutrients 
typical of the bingeing episodes, and the alterna-
tion of gorging and severe dieting might lead to 
malnutrition, resulting in some of the adverse ef-
fects of simple starvation. What remain uncer-
tain are the mechanisms by which starvation 
during anorexia and malnutrition with bulimia 
induces and maintains the physical complica-
tions of the syndromes. In particular, it is unclear 
why some patients show the full spectrum of 
physical complications while others with a very 
similar psychopathological picture do not. More-
over, it is not clear what influence is exerted by 
peripheral physical complications on the course, 
response to treatments and prognosis of eating 
disorders. These problems must be addressed in 
the future.
 This chapter provides a brief review of the 
most common physical complications occurring 
in patients with eating disorders  [1–5] ( table 1 ).
 Alterations of Skin and Related Organs 
 In both subtypes of anorexia nervosa, cutaneous 
alterations occur as a consequence of starvation, 
self-induced vomiting and abuse of purging drugs 
 [6, 7] . 
 Brittle hair and eyelashes and loss of hair and 
eyebrows are present in people with both sub-
types of anorexia nervosa, while the skin is often 
covered by a fine, down-like hair known as ‘la-
nugo’, growing especially on the face, superior lip, 
back, arms and legs. Fragile nails and a dystrophic 
aspect of the skin, which is dry and scaling, pale 
or yellowish like old paper or brownish like dirt 
because of cornification, occur because of nutri-
tional deficiencies and starvation-linked hypo-
thyroidism that develops early in the disease. The 
yellowish color of the skin is partly due to the hy-
percarotenemia, which is typically observed in 
people with anorexia in contrast to involuntary 
starvation when hypocarotenemia is characteris-
tic. In people with anorexia, the phenomenon is 
linked to the excessive consumption of carrots, 
pumpkins and similar yellowish vegetables, but 
possibly also to an acquired defect in the absorp-
tion, use or metabolism of carotene. Skin thick-
ness and median collagen content are significant-
ly reduced. Spontaneous cuts are frequently ob-
served at the corners of the lips and near the nails.
 The presence of skin trauma and calluses on 
the dorsal surface of hands, secondary to using 
the hands as an instrument to induce vomiting, is 
characteristic and was first described in 1979 by 
Russell (Russell sign)  [7] . The lesions appear in 
people with anorexia nervosa binge-eating/purg-
ing subtype, and can be anywhere on the dorsum 
of the hand, but more frequently at the metacar-
pophalangeal joint of each finger. They rapidly 
progress to hyperpigmentation of the calluses and 
scarring. It has been reported that these lesions 
may disappear in the later course of the disease, as 
many patients train themselves to vomit reflex-
ively. Poor wound healing is frequent. Facial der-
matitis, seborrheic dermatitis and acne are occa-
sionally observed.
 Peripheral edema, especially pretibial, may oc-
cur in 20% of people with anorexia mostly of the 
restrictive subtype, often during the refeeding 
phase. A mild form may occur in people with the 
restrictive subtype of anorexia without a clear etio-
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logical cause in those with normal plasma proteins, 
and in particular albumin levels. A more severe 
form is associated with purging and chronic laxa-
tive abuse, which leads to marked hypoprotein-
emia and subsequent lowering of plasma osmotic 
pressure and passage of fluids from the vascular 
tree into tissues. This severe form of edema is rap-
id in onset and may lead to life-threatening shock, 
renal infarction and cardiovascular collapse due to 
an inability to maintain fluid volume  [1] .
 In people with the binging subtype of anorex-
ia, vomiting strain may lead to the appearance of 
cutaneous petechiae, especially on the face, and 
hemorrhage of the conjunctiva, possibly linked to 
fragility of venous and capillary walls, reduced 
platelet number and increased capillary vessel 
permeability. With repeated vomiting, subcuta-
neous emphysema of the neck has been described, 
in some cases associated with spontaneous pneu-
momediastinum.
 Stable erythema, linked to the abuse of phenol-
phthalein-containing laxatives or ipecac, has been 
reported in people with anorexia. Cutaneous al-
terations linked to vitamin deficiency, including 
scurvy or pellagra, have been infrequently report-
ed. More frequent are signs of self-injury, such as 
excoriated acne and erythema ab igne.
 In bulimia, lesions of the skin, hair and other an-
nexes are similar to those observed in anorexia, 
only occurring less frequently  [8] . The most fre-
Table 1.  The most common physical complications of eating disorders
Anorexia nervosa
Skin and related organs: yellow-orange dry and dystrophic skin (especially on the palmar surfaces of hands and on 
the plantar surfaces of feet), lanugo hair, especially on the face and on the back, brittle falling out hair, Russell’s sign
Oral cavity: tooth enamel erosion, caries, gingivitis, salivary gland hypertrophy
Gastrointestinal system: gastroesophageal reflux disease, esophagitis, delayed gastric emptying, esophageal 
 erosions and ulcers, hepatomegaly, fatty liver disease, constipation, hemorrhoids, rectal prolapse
Cardiovascular system: bradycardia, hypotension, tricuspid and mitral valve prolapse, arrhythmias caused by 
 electrolyte abnormalities, electrocardiographic alterations (low voltage, prolonged QRS and QT interval, T wave and 
ST segment depression, T wave inversion), reduced cardiac output
Skeletal system: osteopenia, osteoporosis, muscle wasting, bone fractures
Metabolic changes: hypoglycemia, hypothermia, dehydration, hypercholesterolemia, ketosis, ketonuria, 
 hyperuricemia, hypoproteinemia, metabolic alkalosis
Electrolyte alterations: hypochloremia, hypokalemia, hyponatremia, hypomagnesemia, hypophosphatemia
Hematologic changes: vitamin B12 and/or iron deficiency anemia, neutropenia
Endocrine system: amenorrhea, lower T3, hypercortisolism, high GH and reduced IGF-I
Bulimia nervosa
Skin and related organs: dry and dystrophic skin, Russell’s sign, peripalpebral petechiae, conjunctival hemorrhages, 
perioral ulcerations
Oral cavity: tooth enamel erosion, caries, gingivitis, salivary gland hypertrophy
Gastrointestinal system: gastritis, esophagitis, esophageal erosions and ulcers, gastroesophageal reflux, dysphagia 
and odynophagia, inflammations of the colon, hepatomegaly, fatty liver disease
Electrolyte alterations: hypokalemia
Cardiovascular system: bradycardia, hypotension, cardiac arrhythmias
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quent alteration is the Russell sign, which is due to 
self-induced vomiting. Peripheral edema may be 
seen although less frequently than in anorexia, pos-
sibly due to the loss of electrolytes through vomit-
ing and the relative poor consumption of proteins 
in these patients. Subcutaneous emphysema may 
be present secondary to recurrent severe vomiting 
strain. Signs of self-injury are frequent.
 Oral Pathology 
 Dental caries is frequent in anorexia, being related 
to starvation in the restricting type and to both 
vomiting and excessive carbohydrate intake in the 
bingeing-purging type  [9] . There is delayed forma-
tion and missing tooth enamel, as well as erosion 
(perimolysis) of the maxillary lingual surfaces, es-
pecially of the anterior teeth. A frequent oral pa-
thology is angular cheilosis, a stomatitis character-
ized by pallor and maceration of the mucosa at the 
corners of the mouth, which may result in painful 
linear fissures and consequent scars. It is mostly 
observed in the binging subtype of anorexia, and is 
caused by the caustic effect of regurgitated gastric 
acid content, but may also be an expression of an 
underlying vitamin deficiency, especially of ribo-
flavin (B 2 ) and pyridoxine (B 6 ) – in this case being 
seen also in the restrictive subtype of anorexia. 
 Gingival health is impaired in anorexia, pos-
sibly due to the chronic irritation produced by the 
regurgitated gastric acid content, often associated 
with painful pharyngeal erythema. Hypertrophy 
of the salivary glands (sialadenosis) is common in 
the binging subtype of anorexia, again linked to 
repeated vomiting, with occlusion of the salivary 
ducts by fragments of nondigested food. Gener-
ally the hypertrophy is painless, mostly bilateral, 
and more frequent in the parotids, which may en-
large up to five times their normal size. The hy-
pertrophy of the glands may be more evident in 
the case of concomitant masseteric hypertrophy, 
especially present in people with the binging sub-
type of anorexia affected by bruxism  [10] .
 The oral alterations reported for the binging 
subtype of anorexia are also present in bulimia 
nervosa  [10] . Most of the dental problems are re-
lated to the frequent vomiting resulting in enam-
el injury and dental caries, which may also be in-
duced by the ingestion of large amounts of carbo-
hydrates. Enamel biopsies (postmortem) reveal a 
preserved thickness of the surface, with normal 
hardness measurements suggesting that oral hy-
giene and use of fluoride may minimize the ero-
sive effect of vomiting on tooth enamel. Sialade-
nitis is extremely frequent in bulimia, and is often 
related to hyperamylasemia. The phenomenon 
has been attributed to excessive food intake and a 
reflex stimulation of the glands during vomiting.
 Gastrointestinal Complications 
 The esophagus is frequently affected in both types 
of anorexia nervosa. Pathologies include stenosis, 
esophagitis (which causes epigastric or substernal 
burning pain radiating to the jaw or down both 
arms), erosions and ulcers of the gastroesopha-
geal junction and esophageal rupture. These le-
sions are due mostly to vomiting, the frequently 
spastic motility of the esophagus and a neuropa-
thy linked to vitamin deficiencies. Superior mes-
enteric artery syndrome occurs frequently in an-
orexia  [11] . 
 In the restrictive type of anorexia, gastric vol-
ume is normal or reduced, the wall’s smooth mus-
cle is atrophic and atonic, and antral mobility is 
abnormally low; gastric emptying is always slow 
and delayed for solid food and hypertonic liquids 
 [11] . These abnormalities are partly responsible 
for the postprandial early feeling of gastric fullness 
and the very frequent belching observed in people 
with anorexia. Complications secondary to bing-
ing in the bulimic type of anorexia include gastric 
dilatation, which is rarely associated with rupture.
 During refeeding, gastric bloating and other 
nonspecific abdominal discomforts usually per-
sist. Complaints of esophageal reflux may occur 
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even without self-induced vomiting, and is gener-
ally secondary to diminished competence of the 
gastroesophageal sphincter.
 Gastritis and pyloric erosions are not frequent, 
but dilatation of the proximal duodenum and je-
junum are frequently reported. Gastric perfora-
tion is a rare complication of the restrictive type 
of anorexia.
 Constipation, mostly due to the drastically re-
duced caloric intake, constantly follows weight 
loss in anorexia, and is generally worsened by the 
abuse of laxatives. Abdominal pain is generally 
diffuse but without tenderness. Decreased colonic 
transit and pelvic floor dysfunction occur in un-
dernourished people with anorexia, and normal-
ize after refeeding. Colonic lesions are mostly sec-
ondary to chronic constipation and laxative abuse. 
Inflammation, atony and dilatation and the so-
called cathartic colon characterized by thinness, 
atrophy and superficial ulcers of the mucosa, re-
tention cysts and mononuclear infiltration of the 
submucosa are very frequent observations. Occa-
sionally, ischemic necrosis of the segmental ileum 
and cecum has been reported, possibly resulting 
from poor blood supply linked to severe malnutri-
tion and dehydration. Rectal prolapse occurs, pos-
sibly due to constipation or increased intra-ab-
dominal pressure from forced vomiting  [12] .
 Esophagitis, disordered esophageal motility 
including lower than normal esophageal sphinc-
ter pressure, relaxed sphincter pressure, reduced 
mean esophageal body contraction and ampli-
tude, altered waveform morphology, and reduced 
progression occur infrequently in bulimia nervo-
sa, while gastroesophageal reflux, dysphagia and 
odynophagia are often observed  [13] .
 Gastric capacity is generally increased in rela-
tion to the frequency and severity of the binging 
and the amount of daily food intake  [14] . The sen-
sation of maximal fullness occurs sooner than the 
maximally tolerated gastric pain, which is mostly 
reduced. Intragastric pressure reached at maxi-
mum tolerance is normal. Gastric emptying is 
slower in bulimia nervosa than in normal subjects, 
probably due to reduced intragastric pressure for 
a given volume and a lower gradient between the 
stomach and duodenum. Rectal prolapse has been 
reported to occur secondary to constipation, laxa-
tive abuse, overzealous exercise and increased in-
tra-abdominal pressure from forced vomiting.
 Hepatic and Pancreatic Pathology 
 In both types of anorexia nervosa, deficiencies of 
many specific food components may lead to he-
patic abnormalities, including hepatomegaly, in-
creases in serum concentrations of lactate dehy-
drogenase, aspartate and alanine transaminase, 
and reduction of cholinesterase and plasma pro-
teins. Diffuse liver steatosis may be observed in 
the most severe forms of the disorder, occasion-
ally evolving in cirrhosis and disappearing with 
refeeding. Lower than normal plasma concentra-
tions of glutathione are observed, with higher 
than normal levels of homocysteine, glycine and 
glutamine, which points to a decreased utilization 
of these amino acids for glutathione synthesis and 
an impairment of transsulfuration  [15] . 
 Morphological and functional pancreatic ab-
normalities are frequent in both types of anorex-
ia, sometimes persisting long after recovery  [16] . 
Morphological changes include atrophy with re-
duced acinar cells and zymogen granules, in-
creases of fibrous interstitial tissue, cystic dilata-
tion of pancreatic ducts and diffuse calcification. 
The most specific functional abnormality is a re-
duction of pancreatic enzyme secretion. Amylase 
and elastase-1 serum concentrations, specific in-
dices of pancreatic dysfunction, are increased. 
Pancreatitis may be present, but occurs more fre-
quently during refeeding. Amylase levels are gen-
erally elevated, correlating with vomiting fre-
quency. The occurrence of pancreatitis may be 
facilitated by the duodenal stasis followed by du-
odenal-pancreatic reflux.
 Similar alterations may be present in bulimia 
nervosa  [16] .
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 Cardiovascular Complications 
 Cardiovascular abnormalities occur in up to 87% 
of people with anorexia  [17] . They include sinus 
bradycardia and much less frequently tachycar-
dia, ventricular arrhythmia resulting from elec-
trolyte disturbances, lower than normal heart rate 
variation between supine and standing posture, 
lower than normal ratios of low- and mid-fre-
quency to high-frequency power (which may rep-
resent a balance between the activities of the car-
diac sympathetic symptoms), cardiac failure, re-
duced atrial and left ventricular volume, reduced 
mean cardiac output, and reduced mean ascend-
ing aortic velocity. Bradycardia of less than 60 
beats/min during the day and around 30 beats/
min at night, related to an energy-conserving 
slowing of the metabolic rate, is possibly linked to 
vagal hypertonus. Heart rate variability correlates 
inversely with BMI  [18] . 
 As reported in simple starvation, electrocar-
diographic alterations occur frequently in people 
with both types of anorexia  [19] . They are repre-
sented by low voltage, prolonged Q time, in-
creased QT dispersion, longer QRS intervals, a 
shift to the right of the QRS axis, diminished am-
plitude of the QRS complex and T wave, depres-
sion of the ST tract, inversion of the T wave, oc-
casional U waves linked to hypokalemia and hy-
pomagnesemia, and premature atrial and 
ventricular heart beats. Ventricular tachyarrhyth-
mias, however, are less frequent. The inversion of 
the T wave and the prolonged Q time, which in-
creases the risk of tachyarrhythmias, prevail in 
people with the bingeing subtype of anorexia, 
with more severe hypokalemia and hypomagne-
semia. Sometimes, however, electrocardiograph-
ic impairments occur also in people without evi-
dent electrolytic alterations, possibly linked to hy-
pertonus of the central autonomic system. Most 
of the electrocardiographic changes are revers-
ible, often improving rapidly with correction of 
electrolytic disturbances and a return to normal 
nutrition and hydration. During the refeeding pe-
riod, a too rapid weight gain may lead to conges-
tive heart failure and arrhythmias, possibly relat-
ed to hypophosphatemia occurring during the 
first weeks of nutritional rehabilitation.
 Hypotension, both systolic and diastolic, of 
less than 90/60 mm Hg occurs in up to 85% of 
people with anorexia  [20] , usually as a result of 
chronic volume depletion and orthostatic chang-
es resulting in frequent bouts of dizziness and oc-
casionally frank syncope. Decreased thickness of 
ventricular walls, with consequent decreased 
myocardial contractility and subsequent hypovo-
lemia and reduction of cardiac cavities concur to 
decrease blood pressure.
 People with bulimia may show some of the 
cardiovascular changes seen in anorexia nervo-
sa, but these are much less frequent and less se-
vere  [21] . A slightly longer mean QT has been 
reported. Hypotension is very uncommon in 
this disorder. Arrhythmias due to electrolytic 
disturbances may occur in people with severe 
purging behaviors.
 Pulmonary Disease 
 Pulmonary alterations do not occur frequently in 
anorexia nervosa  [22] , but can occur as a conse-
quence of vomiting or refeeding phenomena. 
Pneumomediastinum has been observed in the 
bulimic subtype of anorexia with and without 
vomiting. The pathology is due to alveolar rupture 
and subsequent tracking of air along perivascular 
planes to the mediastinum and subcutaneous area. 
Subcutaneous emphysema is diagnosed by palpa-
tion of the skin overlying the thorax, which reveals 
a ‘crunchy’ sensation, and is also heard over the 
pericardium being synchronous to systole. During 
rapid refeeding, pulmonary edema may result 
from congestive heart failure with dyspnea, or-
thopnea and paroxysmal nocturnal dyspnea. On 
examination, dullness to percussion of the lung 
fields and crackles or wheeze on auscultation may 
be found. 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 66–80 ( DOI: 10.1159/000365532 )
72  Monteleone · Brambilla 
 Pulmonary alterations are infrequent in buli-
mia nervosa  [22] , and are linked mainly to vomit-
ing and ingestion of the material in the lungs or 
to a rapid increase in intra-alveolar pressure with 
alveolar rupture and pneumomediastinum. Pul-
monary edema due to congestive heart failure is 
generally observed only in long-lasting and ex-
tremely severe cases.
 Renal Disease 
 Impaired renal function occurs in 70% of starving 
people with anorexia, with alterations of glomer-
ular filtration rate and concentration capacity, 
acute or chronic renal failure, increased blood 
urea, pitting edema, hypokalemic nephropathy, 
pyuria, hematuria, and proteinuria. An increased 
risk of urolithiasis has been noted, possibly linked 
to a combination of high dietary oxalate intake 
(from tea, spinach, rhubarb, almonds and cashew 
nuts), chronic dehydration, low urinary excretion 
and purging. Hypokalemic nephropathy due to 
the chronic abuse of diuretics or laxatives may oc-
cur. This pathology can lead to chronic renal fail-
ure with polyuria, polydipsia and increased se-
rum creatinine concentration. High serum levels 
of uric acid have been seen and along with in-
creased creatinine are considered a poor prog-
nostic feature of the disease  [22] . 
 Renal impairment is not frequent in bulimia 
nervosa  [22] , unless the pathology is extremely 
severe; in such cases, abnormalities similar to an-
orexia are seen.
 Musculoskeletal Abnormalities 
 The most common alterations of the muscular 
system observed in people with anorexia are mus-
cular weakness, hypotonia and atrophy, which 
become evident when starvation is markedly se-
vere  [23] . A primary myopathy with prominent 
atrophy of type II fibers is the major abnormality 
and differs from that observed in simple starva-
tion, which is represented by a mix of type I and 
II fiber atrophy. Electromyographic studies have 
revealed increased polyphasic potentials parallel 
to increases in plasma creatinine-phosphokinase 
concentrations. Possible causes of this myopathy 
are the reduced total body potassium levels and 
caloric and protein deficiency, together with in-
creased physical activity. No muscular alterations 
have been reported in people with bulimia. 
 When anorexia has its onset in childhood, pa-
tients have reduced skeletal growth, resulting in 
short stature. Bone accretion and maturation, 
characteristic of adolescence, are generally re-
tarded, and bone maturation may even totally 
cease during active phases of the disease  [24] . 
Treatment and weight restoration induce a 
growth catch-up, which, however, does not reach 
the expected growth rate. Around a quarter to a 
third of people with anorexia suffer from osteo-
porosis, represented by reduced peak bone mass, 
decreased mineral density, decreased total body 
mineral content, pathological fractures and verte-
bral collapse. These alterations correlate with ill-
ness duration and BMI. It is not clear whether 
strenuous weight-bearing exercise can improve 
bone density in people with anorexia. Osteoporo-
sis and osteopenia also occur in men with anorex-
ia, but with greater severity than in women. Bilat-
eral osteonecrosis of the talus has been reported 
in anorexia  [25] .
 Increased bone fractures are also observed in 
bulimia, although less frequently than in anorex-
ia. It is unknown whether the phenomenon is re-
lated to osteoporosis (which generally has not 
been demonstrated in bulimia) or to increased 
behavioral impulsivity  [26] .
 Hematological Changes 
 In two thirds of patients with anorexia, neutro-
penia and reduced monocytes occur, with white 
blood cell numbers lower than 5,000/mm 3 . Rel-
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ative lymphocytosis and multilobular polymor-
phonuclear leukocytes are very frequently seen. 
This alteration could result from bone marrow 
hypoplasia and its gelatinous transformation 
with markedly reduced cell production. Gelati-
nous transformation and cellular necrosis de-
rive from insufficient medullar nutrition, the 
former occurring when the caloric deficiency 
develops gradually and the latter when the star-
vation is acute and extremely rapid, or when 
other threatening events (e.g. a severe infection) 
occur concomitantly. People with anorexia may 
have bone marrow suppression secondary to 
excessive consumption of phenolphthalein-
containing laxatives. The alteration disappears 
with normal nutrition and weight recovery  [23, 
27] . 
 Anemia, usually of the normochromic and 
normocytic type with preserved hemoglobin, is 
observed in at least one third of people with an-
orexia  [27] . Occasionally, macrocytic anemia 
may be observed, with elevated mean cell volume 
due to vitamin B 12 deficiency. Acanthocytosis, a 
disorder of the red blood cell membrane, is also 
observed and is likely linked to abnormalities of 
cholesterol metabolism. Iron deficiency anemia 
occurring in anorexia may be normochromic 
when hemoglobin is above 11 g/dl, or microcytic, 
hypochromic and with anisocytosis when hemo-
globin is below 11 g/dl. Thrombocytopenia has 
been described in nearly one third of people with 
anorexia. Purpura and petechiae are infrequent in 
anorexia.
 People with bulimia do not seem to have sig-
nificant hematological abnormalities.
 Metabolic Changes 
 In anorexia, glucose metabolism is impaired and, 
even though glucose concentration may be low-
normal, the glucose response to a glucose toler-
ance test is diabetic-like or flat. Insulin and gluca-
gon concentrations are normal or reduced, and 
inversely correlated with the degree of weight 
loss. Glucose ingestion results in prolonged insu-
lin peaks  [28] . 
 Lipid alterations occur in 50% of people with 
anorexia, with hypercholesterolemia linked to an 
increase in LDL cholesterol and elevated fasting 
free fatty acid concentration  [29] . The cholester-
ol alteration does not correlate with thyroid dys-
function, severity of weight loss, type of food 
consumption, vomiting or laxative abuse. It may 
be related to diminished activity of the 
5-α-reductase enzyme system. Decreased con-
centrations of n–6 polyunsaturated fatty acids 
have been found. Plasma levels of HDL choles-
terol, VLDL cholesterol and triglycerides are 
normal or increased.
 Hypercholesterolemia has been observed in 
bulimia  [1] .
 People with anorexia generally have a re-
duced concentration of total blood proteins 
 [15] . In particular, globulin levels, more than 
albumin, are lower than normal. Muscular 
mass destruction, typical of the disease, is re-
sponsible for protein catabolism. Dehydration, 
hypovolemia, diminished plasma renal flow 
and diminished glomerular filtration induce an 
increase of serum urea. Reduced urinary excre-
tion of methylhistidine, a specific index of 
muscular catabolism, has been observed. Very 
low albumin levels seem to be highly predictive 
of death. Reduced blood levels of the essential 
amino acids, threonine, valine, isoleucine, leu-
cine, and normal or reduced tryptophan levels 
(including normal or reduced tryptophan to 
neutral amino acid ratio) have been reported. 
The tryptophan/neutral amino acid ratio seems 
to be higher in people with anorexia who are 
actively exercising. Uric acid is often elevated 
as an expression of strenuous physical activity 
combined with starvation resulting in muscle 
destruction.
 No significant protein alterations have been 
observed in bulimia nervosa.
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 Electrolyte and Vitamin Alterations 
 In anorexia, electrolytic alterations occur fre-
quently as a consequence of starvation and mal-
nutrition, vomiting, and laxative and diuretic 
abuse, with ensuing fluid depletion and hypovo-
lemia  [30, 31] . Hypokalemia, hypochloremia 
and hypochloremic metabolic alkalosis with in-
creased pCO 2 are the most frequently observed 
alterations. Phosphate and calcium concentra-
tions are generally normal, but vomiting, diar-
rhea and abuse of diuretics may result in severe 
hypophosphatemia, which may also be seen dur-
ing refeeding as a result of transfer of phosphate 
into cells for phosphorylation of glucose and for 
protein synthesis. A quarter of people with an-
orexia  [32] develop hypomagnesemia, refractory 
hypocalcemia caused by increased urinary cal-
cium excretion with renal calculi production, 
and hypokalemia, which return to normal after 
magnesium replacement. Iron deficiency and 
decreased total iron-binding capacity may oc-
cur, generally as a consequence of a lack of iron-
rich foods. Zinc is low in plasma, urine and tis-
sues linked to the duration and severity of the 
disease, and zinc deficiency is due to starvation, 
reduced intestinal absorption of the metal or in-
creased excretion through sweating. Zinc defi-
ciency per se induces anorexia with related 
weight loss, delayed growth and sexual develop-
ment, depressed mood, loss of taste, hair loss, 
and skin alterations resembling those of anorex-
ia. All metal alterations normalize after nutri-
tional rehabilitation. 
 Hypercarotenemia, normal plasma levels of 
vitamin A binding protein and retinol-binding 
protein are observed especially in the restrictive 
subtype of anorexia following severe starvation 
and weight loss  [33] . Riboflavin and pyridoxine 
deficiencies have been reported. Vitamin B 12 and 
folate concentrations in blood are generally low. 
Vitamin B 12 and vitamin C-related pellagra and 
scurvy have been infrequently reported. Blood 
25-hydroxyvitamin D, 1,25-dihydroxyvitamin 
and 24,25-dihydroxyvitamin concentrations are 
reduced while vitamin D-binding protein values 
are normal.
 Endocrine Consequences 
 Hypothalamic-Pituitary-Gonad Axis 
 Amenorrhea is the most frequent clinical endo-
crine alteration occurring in underweight wom-
en with anorexia, and has long been considered 
a key criterion for the diagnosis of anorexia  [34, 
35] . Only recently has it been excluded from the 
definition of the disorder in the fifth edition of 
the Diagnostic and Statistical Manual of Mental 
Disorders, since it has been recognized that 
menstruation may still occur even in severely 
malnourished patients or, on the contrary, it 
may be absent even when body weight is nor-
mal. Hypogonadotropic hypogonadism with re-
duced secretion of luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), estrogens 
and progesterone are at the basis of amenorrhea. 
In the acute phase of anorexia, circadian gonad-
otropin secretion is similar to that of the prepu-
bertal stage, with secretory pulses almost com-
pletely absent during the day and occasionally 
present at night. The hypothalamic-pituitary-
gonad (HPG) axis response to the administra-
tion of the gonadotropin-releasing hormone 
(GnRH) results in low or absent secretion of LH 
and FSH (with a preponderance of the FSH re-
sponse over the LH), as occurs before pubertal 
maturation. Since estrogens are synthesized 
from androgens in the fat tissue and exert a pos-
itive feedback on hypothalamic GnRH secre-
tion, a critical minimum amount of fat tissue 
seems to be necessary for normal HPG axis 
functioning  [36] . Therefore, in low-fat tissue pa-
tients with anorexia, a lack of aromatization of 
androgens to estrogens, with a consequent hy-
poestrogenemia is probably responsible for 
HPG axis dysfunction. However, since in some 
women amenorrhea precedes weight loss or per-
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sists after the recovery of body weight  [37] , fac-
tors other than weight changes may be involved 
in the HPG axis dysfunction, including the ex-
aggerated physical activity of some women with 
anorexia. Indeed, in female athletes, menstrual 
dysfunction has been found to correlate with the 
intensity of physical exercise rather than with fat 
mass. 
 Men with anorexia nervosa are characterized 
by low levels of testosterone and LH, but normal 
response of the HPG axis to the administration of 
GnRH  [38, 39] . Moreover, the exocrine testis 
function seems to be preserved as suggested by 
the occurrence of normal blood concentrations of 
inhibin B, which is a marker of gonadal exocrine 
activity  [39] . Therefore, in men with anorexia 
nervosa, malnutrition seems to have less impact 
on the gonadal axis.
 Oligomenorrhea or amenorrhea occur in al-
most half of women with bulimia  [35] , especially 
when there is a chronic course of bulimic at-
tacks. Normal or decreased levels of plasma go-
nadotropins, with reduced circadian pulsatility, 
and diminished concentrations of estrogens and 
progesterone may be observed. LH secretion is 
more deranged in its amplitude than in the fre-
quency of secretory pulses, and the LH response 
to GnRH is normal or even enhanced. These ir-
regularities have been ascribed to food deficien-
cy and especially to protein malnutrition. In ad-
dition, since binging episodes increase plasma 
prolactin levels, it is possible that repeated hy-
perprolactinemia could impair HPG axis activi-
ty due to the inhibitory action of this hormone 
on GnRH release.
 Hypothalamic-Prolactin Axis 
 Normal baseline concentrations of prolactin are 
generally observed in people with anorexia, even 
though slightly reduced or increased plasma lev-
els may be found  [40] . Normal diurnal and in-
creased nocturnal concentrations of prolactin 
have been observed in acutely ill patients. The 
prolactin response to thyrotropin-releasing hor-
mone (TRH) is normal. Paradoxical responses 
to both GnRH and GHRH have been detected in 
the acute phase of the disease  [41] . 
 Normal, decreased or increased baseline pro-
lactin levels can be observed in people with buli-
mia, with a prolactin response to TRH that is gen-
erally normal  [41] .
 Hypothalamic-Pituitary-Thyroid Axis 
 In acutely ill patients with anorexia, triiodothy-
ronine (T 3 ) levels are lower than normal, re-
versed T 3 (rT 3 ) levels (which are biologically in-
active) are increased, and thyroxine and thyroid-
stimulating hormone (TSH) levels are normal 
 [42] . The lower T 3 levels have been attributed to 
a reduced peripheral deionization of thyroxine 
with a simultaneous increased formation of rT 3 , 
which delineates a ‘low T 3 syndrome’. This rep-
resents a metabolic adaptation to the chronic re-
duction in caloric intake since it decreases rest-
ing energy expenditure  [43] . In spite of the re-
duced secretion of T 3 , TSH is not increased in 
acutely ill patients with anorexia. This could be 
due to the fact that during low-energy expendi-
ture, a reduction in endogenous metabolic pro-
cesses occurs in all cells of the organism, includ-
ing pituitary thyrotropes, which respond as if the 
low T 3 levels are sufficient for metabolic needs; 
in such a condition, TSH secretion does not in-
crease. Even if TSH secretion is unaltered in an-
orexia, its central regulation is deranged. The 
TSH response to exogenous TRH is delayed and 
sometimes lower than normal. Finally, atrophy 
of the thyroid gland may occur in underweight 
people with anorexia. This alteration has been 
related to the low insulin-like growth factor-I 
(IGF-I) levels since thyroid size is clearly influ-
enced by this peptide. 
 Basal thyroxine and T 3 concentrations are pre-
served in people with bulimia, even though low 
circulating T 3 levels have been observed. Baseline 
concentrations of TSH are mostly normal in bu-
limia, whereas the TSH response to TRH can be 
found to be either normal, blunted or delayed  [1] .
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 Hypothalamic Growth Hormone-IGF-I Axis 
 In emaciated people with anorexia, plasma levels 
of growth hormone (GH) are increased and the 
plasma concentration of IGF-I and GH-binding 
protein is reduced  [44] . The concentration of the 
IGF-binding proteins, especially that of the IGF-
binding protein-3, is reduced during starvation, 
although increased levels of circulating IGF-
binding proteins resulting in a decrease of free 
IGF-I have also been reported  [45] . In under-
weight people with anorexia, the decreased IGF-
I production increases GH secretion because of 
diminished negative feedback. Concomitantly, 
primary or secondary hypothalamic or suprahy-
pothalamic changes may further affect GH pro-
duction. Increased GH levels correlate negatively 
with the amount of calories ingested and de-
crease with improved nutritional intake even be-
fore significant weight recovery has taken place. 
Since GH-binding protein represents the GH re-
ceptor extracellular domain, its reduced blood 
levels mirror a reduced sensitivity to GH. The 
decrements of IGF-I and GH-binding protein in 
severely undernourished people with anorexia, 
an expression of a resistance to GH, are probably 
the reason why GH hypersecretion in these indi-
viduals does not result in acromegalic symptom-
atology. 
 The hypothalamic GH-IGF-I axis dysregula-
tion may contribute to the development of osteo-
penia since IGF-I has a trophic effect on the bone. 
In prepubertal subjects, the ‘resistance’ to GH 
may be one of the causes for the growth delay or 
cessation persisting following treatment, result-
ing in a final height lower than that genetically 
determined  [46] . Recombinant human IGF-I or 
GH have been used in people with anorexia to 
prevent bone loss or bone fractures, and to facili-
tate a more rapid metabolic recovery. Recombi-
nant human IGF-I in severely osteopenic women 
with anorexia increases bone turnover markers in 
the short term, leading to amelioration of bone 
density after 9 months, with the latter effect being 
potentiated by concomitant oral contraceptive 
administration. Moreover, it has been shown that 
the recombinant human GH in people with an-
orexia achieves medical and cardiovascular sta-
bility more rapidly  [47] .
 Normal or increased GH levels with a normal 
circadian rhythm are reported in people with bu-
limia, while circulating IGF-I is reduced  [1] .
 Hypothalamic-Pituitary-Adrenal Axis 
 Abnormalities of the hypothalamic-pituitary-ad-
renal (HPA) axis are frequently present in people 
with anorexia, including increased plasma levels 
of cortisol with normal blood concentrations of 
adrenocorticotropic hormone (ACTH), and in-
creased urinary cortisol levels in the acute phase 
of the disease  [48] . The circadian rhythm of 
ACTH is well preserved, but plasma cortisol con-
centrations are higher than normal throughout 
the day and have an increased number and ampli-
tude of cortisol secretory bursts, especially during 
the middle afternoon when values of the hor-
mone should be at their lowest point. These data 
suggest that the HPA axis in the acute phase of 
anorexia is hyperactive. Dynamic studies of HPA 
axis function tend to demonstrate that hypotha-
lamic and/or suprahypothalamic alterations may 
cause the higher than normal activity of the axis 
 [49] . Indeed, most people with anorexia cannot 
suppress cortisol production during the dexa-
methasone suppression test; the cortisol respons-
es to ACTH stimulation are enhanced while the 
ACTH response to corticotropin-releasing factor 
(CRF) is reduced/normal in underweight individ-
uals with anorexia  [50] . Since these alterations re-
vert with the recovery of body weight, they are 
considered a consequence of malnutrition, al-
though this is controversial  [51] . In experimental 
animals, CRF provokes anorexia, increased phys-
ical activity and reduced sexual behavior, which 
would support a role for this peptide in the devel-
opment and/or maintenance of some anorexic 
symptoms. Clinically, it is intriguing that the hy-
percortisolemia of people with anorexia never 
leads to the development of Cushingoid features. 
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 The adrenal glands also secrete androgen de-
hydroepiandrosterone (DHEA) and DHEA sul-
fate (DHEAS) under the regulation of the CRF-
ACTH system. Evidence for a decreased produc-
tion of both DHEA and DHEAS in underweight 
people with anorexia has been widely reported, 
with a dissociation in the adrenal secretion be-
tween cortisol and androgen similar to that ob-
served in the pubertal stage of sexual maturation 
 [52] . This suggests that people with postpubertal 
acute anorexia may regress to a prepubertal secre-
tory aspect of the reproductive axis (see below), 
also affecting the HPA androgen system. This re-
duction, together with the increase in cortisol lev-
els, leads to decreased DHEA to cortisol and 
DHEAS to cortisol ratios similar to that occurring 
in the pubertal stage of sexual maturation  [53] .
 In people with bulimia, HPA axis activity is 
only slightly altered, with morning plasma corti-
sol concentrations either normal or increased, 
while urinary excretion of free cortisol and 17-hy-
droxycorticosteroids as well as cortisol responses 
to CRF or ACTH are normal. The most widely 
reported alteration of the HPA axis in bulimia is 
the nonsuppression of cortisol to a dexametha-
sone challenge in 20–60% of patients, without sig-
nificant correlations with severity and chronicity 
of the illness, concomitant depressive symptoms, 
or previous history of anorexia. This alteration 
disappears after successful treatment of bulimia, 
and is not predictive of treatment outcome  [54] .
 Conclusions 
 In people with eating disorders, physical compli-
cations are very common and usually occur as 
consequences of nutritional derangements sec-
ondary to aberrant eating and abnormal com-
pensatory behaviors. In the most severe cases, 
these complications represent a significant 
threat to the patient’s life. In emaciated people 
with anorexia, especially in those who vomit 
and/or abuse diuretics and laxatives, immediate 
Table 2.  Main signs and symptoms of the physical com-










Yellow-orange dry and dystrophic skin (especially on
 the palmar surfaces of hands and on the plantar 
surfaces of feet)
Lanugo hair
Edema (ankles, around eyes)




















Hematemesis (vomiting of blood)











Hands and feet swelling
Sensitive teeth
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risks come from electrolytic perturbations and 
starvation-induced cardiovascular and renal 
complications. These complications may lead to 
the development of severe arrhythmias and sud-
den death. Individuals with a chronic course of 
anorexia are exposed to consequences of the 
progressive impairment in bone density, which 
increases the likelihood of pathological frac-
tures. On the other hand, some of the somatic 
alterations occurring in the acute phase of an-
orexia seem to have a protective effect. Indeed, 
in emaciated people with anorexia, the impaired 
function of the reproductive axis and the re-
duced activity of thyroid gland aim to preserve 
residual energy stores for vital functions and re-
duce basal metabolic needs. 
 In bulimia, physical complications are less se-
vere and occur less frequently than in anorexia. 
Therefore, they rarely represent a serious threat 
to the patient’s life. The most harmful complica-
tions are represented by esophageal and/or gas-
tric ruptures, secondary to the massive ingestion 
of food in the course of binge episodes, and car-
diac arrhythmias induced by severe electrolytic 
imbalance following vomiting and diuretic or lax-
ative abuse.
 Although, with a few exceptions, physical 
complications resolve with the recovery of body 
weight and the discontinuation of aberrant be-
haviors, they contribute, together with suicide, to 
the high mortality of patients with eating disor-
ders. Indeed, anorexia has the highest mortality of 
any psychiatric diagnosis, estimated at 10% with-
in 10 years of diagnosis, and is the leading cause 
of death in young females 15–24 years of age. 
Mortality for bulimia is approximately 1% within 
10 years of diagnosis. It is important to remember 
that even if most of the physical complications of 
eating disorders do not represent life-threatening 
conditions, they increase the patients’ burden of 
suffering, impair their quality of life and, there-
fore, need clinical consideration and appropriate 
treatment. Therefore, psychiatrists who have pa-
tients with anorexia nervosa and bulimia nervosa 
should be alerted to identify those signs and 
symptoms that express malnutrition-related 
physical complications ( table 2 ) and collaborate 
with medical experts who specialize in the treat-
ment of physical alterations. This will ensure the 
simultaneous correction of psychopathological 
and physical aberrations in order to obtain a full 
and fast recovery from the diseases. 
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 Abstract 
 Anxiety and related disorders are the most prevalent 
mental disorders in the general population. There is a 
strong bidirectional association between anxiety and re-
lated disorders and co-occurring general medical condi-
tions. The co-occurrence of anxiety and related disorders 
and general medical conditions is associated with signif-
icant impairment, morbidity and economic costs. At the 
same time, recognition of anxiety and related disorders 
in people with medical illness may be challenging when 
comorbid with physical illness due in part to overlap in 
symptomatology. Furthermore, there is a relatively lim-
ited evidence base of randomized controlled trials in this 
population. Additional work is needed to improve screen-
ing for anxiety and related disorders in medical illness, to 
enhance diagnosis and assessment, and to optimize 
treatment.  © 2015 S. Karger AG, Basel 
 Anxiety disorders, obsessive-compulsive and re-
lated disorders, and trauma- and stressor-related 
disorders are the most prevalent psychiatric dis-
orders in the general population  [1, 2] , with gen-
eralized anxiety disorder the most common anxi-
ety disorder in primary care populations  [3] . In-
deed, these anxiety and related disorders occur 
frequently with a range of general medical disor-
ders  [4, 5] , including gastrointestinal disease  [6] , 
pulmonary disease  [7, 8] , cardiovascular disease 
 [9] , endocrine disorders  [10] , dermatological dis-
orders  [11] and cancer  [12] , as well as neuropsy-
chiatric disorders such as chronic pain  [13, 14] , 
migraines  [15] , dementia  [16] and Parkinson’s 
disease  [17] . In this chapter we review the epide-
miology of comorbid anxiety and related disor-
ders and physical illness, the growing evidence of 
a bidirectional relationship between these sets of 
conditions  [18] and relevant randomized con-
trolled trials in this area. 
 Epidemiology 
 Anxiety and related disorders are the most com-
mon psychiatric disorders worldwide, with a 
12-month prevalence worldwide of between 4 
and 20%  [2] . The onset of anxiety and related dis-
orders usually happens in childhood or adoles-
cence, with many individuals first presenting 
with physical symptoms in primary care settings 
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 [4] . Anxiety and related disorders are prevalent 
throughout life  [19–22] . Furthermore, while the 
prevalence of comorbid anxiety and related disor-
ders in those with chronic medical illness is not as 
well studied as depression in medical conditions, 
studies which have been done indicate it is as 
common  [22–25] . A large cross-sectional study 
demonstrated that generalized anxiety disorder 
was the most prevalent anxiety disorder in pri-
mary care settings  [3] . 
 Systematic reviews have established that anxi-
ety disorders are particularly prevalent in gastro-
intestinal disorders, pulmonary disease, cardio-
vascular disease, endocrine disease and cancer, as 
well as neuropsychiatric disorders such as chron-
ic pain and migraines. In irritable bowel syn-
drome, up to 95% of patients have generalized 
anxiety disorder or panic disorder  [26] . Similar-
ly, panic disorder and generalized anxiety disor-
der were more prevalent in those with peptic ul-
cer disease  [27] . In asthma, anxiety disorders oc-
cur in at least 25% of patients  [28, 29] . In multiple 
studies of adolescents and adults with asthma, 
the prevalence of panic disorder and agorapho-
bia is almost three times that of the general popu-
lation  [30, 31] . Another anxiety disorder that co-
occurs with respiratory illness is generalized anx-
iety disorder  [31] .  Table  1 outlines medical 
conditions associated with anxiety symptoms 
and disorders.
 The co-occurrence of anxiety and general 
medical conditions is associated with significant 
impairment, morbidity and economic costs  [36, 
40–42] . For example, in a study of almost 500 
medically ill persons diagnosed with anxiety dis-
orders, those with posttraumatic stress disorder, 
panic disorder and social anxiety disorder were 
found more likely to be frequent consumers of 
healthcare, and to remain unable to maintain 
their roles and responsibilities, including work 
 [43] . Medical comorbidities with anxiety disor-
ders have also been shown to elevate suicide risk 
 [44] . Adequate management of anxiety symp-
toms can improve outcomes of physical ill-health, 
and reduce the use of healthcare resources  [4, 45] . 
In addition, some work suggests that quality of 
life and functional ability may be improved with 
optimal treatment of comorbid general medical 
and anxiety disorders  [46–48] .
 Etiology 
 There is a growing body of evidence for a strong 
bidirectional association between anxiety and re-
lated disorders and co-occurring general medical 
Table 1.  Common medical conditions associated with anxiety




peptic ulcers [27], celiac disease [33], irritable bowel syndrome [26]
Musculoskeletal disorders fibromyalgia/chronic fatigue syndrome [34], arthritis [35]
Neurological disorders migraines [15], epilepsy, neurodegenerative illness [17]
Cardiorespiratory disease asthma [30], angina [25], chronic obstructive pulmonary disease [7], mitral valve 
 prolapse [36], cystic fibrosis [8], obesity [24, 37, 38]
Chronic pain burns [14], cancer [12]
Infectious disease HIV [39], tuberculosis [39]
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conditions  [14, 29, 49] . On the one hand, medical 
disorders may lead to fears about diagnosis, hos-
pitalization, painful procedures and a foreshort-
ened lifespan, while certain medical disorders 
may be linked physiologically to the development 
of anxiety and related disorders  [50] . On the oth-
er hand, anxiety and related disorders may lead to 
vulnerability for various medical conditions. 
There may also be underlying factors that con-
tribute to susceptibility for both anxiety disorders 
and physical conditions  [51] . 
 There is ongoing work to determine the pre-
cise nature of the relationships between anxiety 
disorders and physical illness in a number of ar-
eas. Thus, in irritable bowel syndrome, it has been 
suggested that infection or inflammation of the 
gastrointestinal tract lead to anxiety  [29] , while in 
asthma it has been postulated that increased par-
tial pressure of carbon dioxide is responsible for 
panic attacks  [52] . On the other hand, neurotrans-
mitter disturbances and hypothalamic-pituitary-
adrenal axis dysfunction have been postulated to 
play a key role in explaining how anxiety symp-
toms and disorders lead to medical illnesses  [53] .
 The common underlying factors that may 
contribute to both anxiety disorders and comor-
bid physical illness have also received ongoing 
study. Genetic factors may, for example, predis-
pose to both general medical conditions and anx-
iety disorders  [54, 55] . In the World Mental 
Health Surveys, there were strong relationships 
between early adversity and subsequent onset of 
both anxiety disorders and various physical dis-
orders, including chronic spinal pain, chronic 
headache, heart disease, asthma, diabetes and hy-
pertension  [56, 57] .
 Clinical Features 
 Recognition of anxiety disorders in people with 
medical illness can be challenging for several rea-
sons. Firstly, anxiety symptoms are an under-
standable response to the diagnosis of medical 
conditions. A medical condition can be sufficient 
enough to be a stressor for an individual to de-
velop an adjustment disorder, and in some cases 
even posttraumatic stress disorder. Secondly, 
anxiety symptoms may overlap with symptoms of 
an underlying medical disorder; thus, since pa-
tients with cancer may have insomnia and fatigue, 
conditions such as generalized anxiety disorder 
are overlooked. Similarly, medications used in the 
treatment of physical disorders may lead to anxi-
ety symptoms  [20, 49, 58] . 
 In a patient with anxiety symptoms, a range of 
different diagnoses can be considered.  Table  2 
tabulates the main features of key anxiety and re-
lated disorders. Posttraumatic stress disorder is 
the anxiety and related disorder that is most com-
monly associated with gastrointestinal, cardiac, 
endocrine, chronic pain, migraines and Parkin-
son’s disease  [14, 22] . Symptoms of generalized 
anxiety disorder arguably most closely resemble 
those of many general medical conditions, par-
ticularly in the older population  [20] . Panic disor-
der may, however, mimic a number of physical 
illnesses. Indeed, a broad range of different anxi-
ety and related disorders have been associated 
with various physical illnesses.
 Management 
 Early identification of anxiety symptoms and dis-
orders in individuals with chronic illness is im-
portant in determining better outcomes for indi-
viduals with both sets of disorders  [60–62] . The 
therapeutic alliance and collaboration between 
medical professionals may contribute to success-
ful management of symptoms  [50] . There is, 
however, a paucity of robust evidence in the treat-
ment of chronically ill patients with comorbid 
anxiety and related disorders  [51] . 
 Cognitive behavioral therapy has been un-
dertaken in a number of studies of individuals 
with medical illness and anxiety and related dis-
orders. A systematic review of 32 psychotherapy 
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trials in patients with irritable bowel syndrome 
and anxiety disorders indicates the efficacy of 
cognitive behavioral therapy in reducing somat-
ic distress  [63–65] . A systematic review of 20 
studies of cognitive-behavioral interventions in 
nearly 3,000 participants found that they may be 
effective in the management of HIV-/AIDS-as-
sociated anxiety  [66] . Cognitive behavioral ther-
apy has also been shown to reduce anxiety symp-
toms and distress in patients with cardiac disease 
and anxiety in one randomized controlled trial 
 [67] .
 Behavioral strategies in anxiety disorders and 
comorbid medical illnesses include biofeedback, 
relaxation training and meditation  [68, 69] . Two 
randomized controlled trials examining the ef-
fects of biofeedback in the management of asth-
ma  [69] , and another two randomized controlled 
trials looking at relaxation therapy showed a re-
duction in the use of bronchodilator agents and 
improved quality of life  [70] .
 Hypnotherapy and interpersonal therapy are 
other treatment modalities showing promise in 
the management of pain related to procedures for 
Table 2.  Anxiety and related disorders commonly seen in medically ill adult patients [14, 59]
Generalized anxiety
disorder
characterized by a pervasive and excessive worry about everyday life events; this 
worry is difficult to control and is accompanied by somatic symptoms which impair 
the individual’s functioning
Specific phobia characterized by excessive, irrational and persistent fear of specific objects, situations 
or activities such as heights, flying and spiders
Social anxiety disorder characterized by an intense and excessive fear of scrutiny and humiliation in social 
situations which then leads to avoidance of these situations, or development of panic 
attacks when the situations are endured
Panic disorder characterized by recurrent unexpected panic attacks described as discrete events in 
which the individual experiences symptoms that peak within a few minutes and 
 resolve spontaneously, coupled with anticipatory anxiety about future panic attacks
Posttraumatic disorder a disorder in which the individual experiences a traumatic event; the disorder is then 
characterized by recurrent distressing re-experiencing phenomena, increased  arousal, 
persistent avoidance of reminders and stimuli associated with the event, and 
 negative cognitions and mood
Hypochondriasis characterized by preoccupation with having a severe disease; the individual cannot 
be reassured despite medical investigations
Obsessive-compulsive
disorder
characterized by recurrent intrusive distressing thoughts or images (obsessions) 




characterized by anxiety symptoms which are directly related to the physiological 
effects of a substance or medication
Adjustment disorder
with anxiety




characterized by excessive, developmentally inappropriate anxiety upon separation 
of the child from the home or from significant attachment figures
Anxiety disorder not
otherwise specified
diagnosed when the individual’s symptoms are severe and distressing but do not 
meet diagnostic criteria for any other anxiety disorder
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cancer therapies  [71, 72] , but rigorous studies are 
lacking in this area  [14, 64] .
 In patients with physical illness and anxiety 
and related disorders, there are relatively few ran-
domized controlled trials to guide treatment 
choices. Thus, medications should be selected 
based on studies of efficacy in anxiety disorders, 
and on minimizing adverse events and drug-drug 
interactions. The selective serotonin reuptake in-
hibitors sertraline, citalopram and escitalopram 
have relatively few adverse events and are safe in 
interaction with other agents  [73] . The serotonin-
noradrenaline reuptake inhibitors venlafaxine 
and duloxetine have the potential advantage of 
being beneficial for pain symptoms, but venlafax-
ine has the disadvantage of requiring blood pres-
sure monitoring  [74] . Drugs such as mirtazapine 
and the tricyclic antidepressants may be effica-
cious in the treatment of some anxiety disorders, 
but carry a significant side-effect profile and may 
have worrisome drug-drug interactions  [74] . 
Benzodiazepines and sedative-hypnotic agents 
may be helpful for anxiety symptoms, but should 
be used cautiously due to concerns of dependence 
 [6] . The second-generation antipsychotic que-
tiapine is anxiolytic at low doses, and is effica-
cious in the treatment of some anxiety and related 
disorders  [50] , but its metabolic, cardiac and au-
tonomic side-effect burden should be taken into 
consideration.
 Conclusion 
 Anxiety and related disorders are frequently co-
morbid with chronic medical conditions. There is 
growing understanding of the bidirectional rela-
tionships between these sets of disorders. Recog-
nition can be delayed due to the similarity of pri-
mary anxiety symptoms and anxiety secondary to 
general medical conditions. Pharmacotherapy 
management can be effective, but clinicians need 
to be aware of the side-effect burden of psycho-
tropics in medical conditions as well as potential 
drug-drug interactions. There is a growing data-
base of studies of cognitive-behavioral therapy 
showing efficacy in individuals with anxiety dis-
orders and comorbid medical illness. Further 
work is needed to improve screening for anxiety 
and related disorders in medical illness, to en-
hance diagnosis and assessment, and to optimize 
treatment. 
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 Abstract 
 Over many years, it has been shown that cancer repre-
sents a significant proportion of excess mortality for peo-
ple with mental illness. In this chapter, we probe this re-
lationship in more detail, and examine the progression 
of factors that play a role in this finding. Against expecta-
tions, people with mental illness are no more likely to 
develop cancer, even though they have higher exposure 
to major risk factors including smoking, drug and alcohol 
use, and obesity. However, even though people with 
mental illness are just as likely to be diagnosed with can-
cer, they are more likely to die from it. The reasons for 
this are multifactorial, including lower rates of routine 
cancer screening (either because it is not recommended 
or people with mental illness do not follow through on 
the recommendation to do so), the increased length of 
time it takes to be diagnosed after presenting with symp-
toms, more advanced stage at diagnosis including meta-
static cancer at diagnosis, and reduced likelihood of 
 surgical intervention. We discuss the complexities asso-
ciated with providing medical care for people with co-
morbid psychiatric disorders and the difficulties faced 
both by people with mental illness and the people who 
provide them with medical care. 
 © 2015 S. Karger AG, Basel 
 Overview of Excess Mortality and Mental 
Illness 
 It is well known that people with mental illness 
have higher mortality rates and reduced life ex-
pectancy compared to people without mental ill-
ness. Our own work using record linkage systems 
in Western Australia has shown that the gap in 
life expectancy for people with and without men-
tal illness has increased since 1985, to 12 years for 
women and 16 years for men, principally because 
improvements in life expectancy for the general 
population have not extended to people with 
mental illness  [1] . 
 While mental illness is associated with an in-
creased risk of suicide, much of the excess mortal-
ity associated with mental illness is actually due to 
common physical health conditions, in particular 
cardiovascular disease, respiratory diseases and 
cancer  [1, 2] . With a particular focus on cancer – 
the topic of this chapter – we have previously re-
ported that cancer diagnosis rates are comparable 
between people with and without mental illness; 
at the same time, however, not only is case fatality 
after a cancer is diagnosed substantially worse in 
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people with a history of mental illness, but sur-
vival times are also much shorter ( fig. 1 )  [2–4] . In 
order to reduce the excess mortality attributable 
to cancer, it is important to understand the un-
derlying factors as to why people with mental ill-
ness have worse case fatality associated with can-
cer. There are obvious and immediate avenues to 
examine, in particular whether lifestyle factors 
place people with mental illness at greater risk of 
developing cancer. For instance, are they less like-
ly to participate in cancer screening activities, 
leading to differences in how soon diagnoses are 
made and therefore presenting with more ad-
vanced disease? Do people with mental illness re-
ceive differential treatment once they are diag-
nosed? Are they more likely to reject lifesaving 
treatments or not comply with aftercare require-
ments? All of these factors may go some way to 
developing a more rounded understanding of 
why people with mental illness experience greater 
cancer mortality. In this chapter we address each 
of these questions, reviewing the evidence as to 
where the greatest discrepancies lie and which as-
pects of cancer diagnosis and treatment deserve 
further attention. 
 The Evolution of Mental Illness and Cancer 
Research 
 Study of the relationship between poor physical 
health and high mortality in people with mental 
illness has a long history. In 1841, William Farr 
 [5]  reported to the Royal Statistical Society on 
mortality within the major asylums in England. 
At that time, high mortality was principally as-
cribed to infectious diseases and the generally 
poor conditions within asylums. Around the 
same time, the Commissioners in Lunacy were 
established to oversee the conditions and care 
provided in asylums and workhouses in  England. 
The commissioners were among the first to note 
that in spite of the general poor health of people 
with mental illness, cancers were not often seen, 
and they suggested in their 1909 report that peo-
ple with mental illness may have a certain immu-
nity to cancer  [6] . With the dawn of the com-
puter age, new methods of research in mental 
illness became viable. The Oxford Record Link-
age Study, established in the 1960s, was the first 
study to undertake a systematic analysis of the 
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 Fig. 1. Survival since diagnosis of all 
cancers by contact with mental 
health services. WA = Western 
 Australia.  Reproduced with 
 permission from  JAMA Psychiatry 
 [3] . 
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and mental illness, using administrative data 
from mental health services in the Oxford region 
 [7] . At that time, the main question of interest 
was whether an association between a physical 
illness and a mental illness could reveal some-
thing about the aetiology of both conditions. 
The relationships between cancer and schizo-
phrenia and between rheumatoid arthritis and 
schizophrenia have received particular attention 
 [8] . The strong negative correlation between 
these conditions led to hypotheses that there 
might be specific genes involved in the aetiology 
of these diseases. 
 As more data were accumulated over time and 
the pattern of association between schizophrenia 
and cancer was observed to be more complex, 
more nuanced hypotheses were advanced. These 
included the idea that certain neuroleptic drugs 
may have a tumour-suppressing effect, that this 
effect may vary depending on the stage of cancer 
during neuroleptic treatment, that the effect may 
vary depending on cancer morphology, or there 
may be an interaction between neuroleptics, lev-
els of specific hormones and genetic susceptibility 
to certain types of tumours  [9–12] . However, to 
date this line of investigation has not led to any 
significant advance in the understanding of the 
aetiology or treatment of either schizophrenia or 
cancer.
 Cancer and Excess Mortality 
 While much of the early research focussed on 
the possibility of people with mental illness be-
ing at reduced risk for developing cancer, the 
possibility that cancer may be a cause of excess 
mortality was first reported by Katz et al.  [13] in 
1967, who found that cancer mortality amongst 
psychiatric patients in New York was higher 
than in the general population, though only for 
patients with shorter periods of hospitalisation. 
Patients with psychiatric hospital stays of more 
than 10 years had lower cancer mortality rates. 
Since then, there have been numerous studies on 
cancer mortality and mental illness, and most 
studies published in the last decade have found 
higher standardised mortality ratios associated 
with cancer  [3, 4, 14–17] . However, these find-
ings have not always been consistent, and have 
varied according to the years of study, the men-
tal illness and type of cancer examined, and the 
study populations and methodologies that each 
study used. For example, the results of earlier 
studies typically found no excess mortality at-
tributable to cancer  [18–21] , and in some cases 
lower standardised mortality ratios were ob-
served  [22, 23] . 
 Incidence and Case Fatality Rates 
 There is considerable research demonstrating 
that people with mental illness engage more fre-
quently in behaviours that are associated with 
cancer risk. For example, people with mental ill-
ness have higher rates of smoking and smoke 
more cigarettes on average  [24] , and despite 
wanting to quit smoking find it much harder 
than people without mental illness to do so  [25] . 
Drug and alcohol addiction is also more com-
mon in people with mental disorders  [26] , and 
many psychiatric disorders are treated with med-
ications which, in addition to other lifestyle and 
diet factors, result in increased incidence of obe-
sity  [27] . Additionally, a common side effect of 
antipsychotic medications is hyperprolactinae-
mia, an excess of the hormone prolactin. Hyper-
prolactinaemia is also associated with an in-
creased risk of breast cancer in women  [28] , and 
possibly prostate cancer in men  [29] , though oth-
ers have noted that hyperprolactinaemia is also 
associated with hypogonadism, which may be 
protective against breast and prostate cancer 
 [30] . 
 Because of these lifestyle and medication side-
effect risk factors, it may seem reasonable to hy-
pothesise that increased exposure to these cancer 
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risk factors would cause more cancers in people 
with mental illness. If this were the sole reason for 
worse cancer mortality, then we would expect 
that people with mental illness would be at great-
er  risk of developing cancer, and as such we would 
see an increased  incidence of cancer amongst peo-
ple with mental illness. Despite the high rates of 
exposure to demonstrated carcinogens in people 
with mental illness, there is in fact no clear evi-
dence that people with mental illness are more 
likely to develop cancer, or at least be any more 
likely to be diagnosed with cancer. Studies that 
have examined both cancer incidence and mor-
tality in populations of people with mental illness 
indicate that cancer incidence rates for people 
with mental illness are generally comparable with 
the rest of the population, though this pattern ap-
pears to depend on the type of cancer and the se-
verity of mental illness. Many studies have found 
that cancer rates are lower amongst people with 
schizophrenia in particular  [31–34] . However, 
not all studies have found this pattern amongst 
people with schizophrenia  [15] , and as such, this 
pattern for people with schizophrenia may reflect 
methodological or cohort differences  [35] . While 
some studies have found an increased incidence 
of smoking-related cancer, such as lung cancer, in 
people with mental illness  [36, 37] , the over-
whelming majority of studies that examine psy-
chiatric disorders, other than schizophrenia, have 
found no increased risk of cancer incidence in 
psychiatric populations  [3, 4, 15, 36, 38–41] . In 
addition, people with severe mental illness do not 
have a greater incidence of melanoma, but have 
worse case fatality even though melanoma is a 
cancer that cannot be attributed to concurrent 
lifestyle factors such as diet, drugs, alcohol or to-
bacco, as it is mainly related to childhood sun ex-
posure  [3] .
 In the case of cancers that are associated with 
risk factors such as smoking, alcohol and other 
drugs, comparable rates of cancer incidence in 
people with and without mental illness may im-
ply some other, as yet unknown, factor that re-
duces incidence of cancer in people with mental 
illness. Some exceptions are apparent, for exam-
ple a systematic review of the incidence of breast 
cancer amongst women with schizophrenia 
found that while the incidence rates of breast 
cancer varied across the studies, those with larger 
samples and better quality indicators found high-
er rates of breast cancer in women with schizo-
phrenia  [42] . A possible explanation for this 
finding, if true, may relate to the increased likeli-
hood of hyperprolactinaemia for people who are 
administered antipsychotic medication. Howev-
er, we have not observed any increase in breast 
cancer in women with severe mental illness in 
our own work in Western Australia and Nova 
Scotia  [2–4] .
 Brain tumours are a notable exception to the 
finding that the incidence of cancer is compa-
rable in psychiatric and general populations. A 
number of studies have identified higher rates of 
brain cancer diagnosis following diagnosis of 
mental illness. A likely explanation for this find-
ing is the general difficulty of diagnosing brain 
cancers, and the common early presentation of 
brain cancer sufferers with symptoms of mental 
distress including depression and memory im-
pairment. This may lead to people with brain tu-
mours being referred for mental health treat-
ment prior to the diagnosis of their tumour  [2, 
43] .
 Factors Related to Higher Case Fatality 
 Less studied than cancer incidence, but more 
consistent in its findings, is the higher case fatal-
ity following cancer diagnosis in people with co-
morbid mental illness. This has been consistently 
reported from a number of large record linkage 
and cohort studies including our own record 
linkage work using the populations of Western 
Australia and Nova Scotia  [3, 4] . This worse case 
fatality from time of diagnosis deserves addition-
al focus and attention. Here we examine the can-
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cer screening rates for people with mental illness 
and further treatment discrepancies that occur 
following diagnosis. 
 Screening Rates 
 Another possible explanation for the comparable 
rate of cancer diagnosis in people with mental ill-
ness despite high exposure to known carcinogens 
is the hypothesis that cancers do occur more fre-
quently in people with mental illness, but are less 
likely to be detected because of lower rates of 
screening and access to general healthcare. As life 
expectancy is substantially reduced in people with 
mental illness, and mortality from other causes of 
death is substantially higher, more people with 
mental illness who have cancer may die before 
that cancer is diagnosed. To date, the results 
about the extent to which people with mental ill-
ness receive routine cancer screening have been 
mixed. For example, in a study of privately in-
sured women with, and without, claims for men-
tal illness, women with a mental disorder were 
significantly less likely to receive mammography, 
particularly women with more severe disorders 
 [44] . Similar patterns have been observed in other 
studies with different populations of patients 
 [45–48] , though others have found that women 
with mental illness were more likely  [49] , or at 
least equally likely, to receive mammography 
 [50] . In a narrative review of 17 studies examining 
the uptake of screening services by people with 
mental illness, Happell et al.  [51] showed a 20–
30% reduced likelihood of breast, cervical and 
colorectal cancer screening for patients with se-
vere mental illness in the majority of studies. The 
pattern was most commonly observed for people 
with more severe disorders, with up to a 60% re-
duced likelihood  [52] . Taken together, the evi-
dence suggests that people with mental illness are 
less likely to receive preventive cancer screening 
services than those without  [53] . As a result, can-
cers may be more advanced by the time the diag-
nosis is made, with poorer outcomes associated 
with the delay in diagnosis. 
 The question of why people with mental illness 
may receive less cancer screening remains unre-
solved. For instance, some research points to the 
possibility that people with mental illness are less 
likely to be offered screening for cervical, breast, 
prostate or colorectal cancer by their primary 
physicians  [54] , or if screening is recommended, 
are less likely to adhere to recommended screen-
ing  [55] . In their systematic review, Lord et al. 
 [56] identified the relationship with the primary 
care physician as perhaps the most important fac-
tor to explain deficits in receipt of cancer screen-
ing and other preventive health measures. They 
note that proactive contact from the primary care 
physician, and the use of peer support workers, 
are two interventions where there is some evi-
dence to support their effectiveness in boosting 
screening rates.
 Delay to Diagnosis and Stage of Cancer at 
Diagnosis 
 Differences in screening rates aside, there is a 
growing body of literature documenting other 
disparities in cancer treatment for people with 
mental illness, including the length of time it 
takes to be diagnosed with cancer after presenting 
with symptoms. In a study of patients with oe-
sophageal cancer, O’Rourke et al.  [57] found that 
cancer patients who had a DSM-IV diagnosed 
psychiatric comorbidity waited a median of 90 
days between reporting symptoms and receiving 
a diagnosis, compared to 35 days for patients 
without mental illness. They were also more like-
ly to have advanced disease at the time of diagno-
sis (37 vs. 18%) and also had a decreased likeli-
hood of receiving surgical therapy (38 vs. 59%). In 
other research, the proportion of people with can-
cer who had metastases at presentation was sig-
nificantly higher in psychiatric patients (7.1 vs. 
6.1%), though larger gaps were observed for spe-
cific types of cancer  [3] . For example, for people 
with breast cancer the difference was 6.3 vs. 4.5%, 
and lung cancer 0.6 vs. 0.2%. No differences in 
rates of cancer with metastases were found for 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 88–98 ( DOI: 10.1159/000365541 )
 Cancer and Mental Illness 93
other sites. Though statistically different, these 
difference rates are small in absolute terms, and 
cannot account for the significantly larger differ-
ences in case fatality for cancer patients. These 
patterns, reinforced by findings from another re-
cent study  [58] , suggest that the elevated mortal-
ity associated with cancer is unlikely to be primar-
ily the result of the cancer being more advanced 
by the time it is diagnosed. 
 Medical Care after Diagnosis: Surgical 
Intervention 
 There are apparent disparities in other ongoing 
treatment options, including rates of surgical in-
tervention and the time it takes to get to surgery. 
In our recent work using the Western Australian 
Data Linkage System  [3] , psychiatric patients had 
a reduced likelihood of surgery after diagnosis 
for all types of cancer, and for those who did have 
surgery, the length of time between cancer diag-
nosis and surgery was longer (see  fig.  2 for 
trends). Men were less likely to have a colorectal 
resection, and women were less likely to have 
surgery for colorectal, breast and cervical cancer. 
The psychiatric diagnosis also mattered – 
colorectal resections occurred less frequently for 
patients who were diagnosed with dementia, af-
fective psychoses, other psychoses and depres-
sion. Psychiatric patients also received 10.3 ses-
sions of chemotherapy on average, compared to 
12.1 for the general population, and were less 
likely to receive radiotherapy for breast cancer 
(2.6 vs. 4.1%), colorectal cancer (1.6 vs. 3.9%) and 
uterine cancer (13.0 vs. 21.1%). To summarise, 
although the cancer incidence in psychiatric pa-
tients is no higher than in the general population, 
psychiatric patients are more likely to have me-
tastases at diagnosis and less likely to receive spe-
cialised interventions. Together, these may ex-
plain the greater case fatality found in people 
with a psychiatric disorder. 
 Though our focus here has been on cancer 
outcomes for people with a prior history of men-
tal illness, for many people, the onset of mental 
illness can occur following cancer diagnosis and 
treatment  [59] , particularly post-traumatic 
stress disorder and depressive and anxiety disor-
ders. Research indicates that people with comor-
bid diagnoses of cancer and mental illness have 



















WA population, female Fig. 2. Time from diagnosis to 
 surgical removal of the tumour by 
contact with mental health services. 
WA = Western Australia. 
 Reproduced with permission from 
 JAMA Psychiatry  [3] . 
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to treatment regimens  [60, 61] . In this respect, 
issues surrounding treatment disparities apply 
to all people with mental illness, irrespective of 
their psychiatric history prior to a cancer diag-
nosis. However, different types of mental illness 
offer different challenges to people with mental 
illness and to the practitioners who treat them, 
and the types of mental illness that arise follow-
ing the development of cancer are somewhat 
narrower in scope than the range of illnesses that 
develop over a lifetime. Research that compares 
treatment outcomes for people whose onset of 
mental illness was before or after cancer may of-
fer further insights as to why disparities occur.
 Comorbidities and Challenges for Health and 
Mental Healthcare Providers 
 People with mental illness who also have physical 
health problems are often more likely to be among 
the more complex cases with multiple presenting 
symptoms and problems. For example, in a small-
scale review of 29 people with schizophrenia and 
lung cancer  [62] , potentially curable cancers were 
identified in 17 individuals, with 5 of the 17 re-
ceiving less than best practice care. Issues that re-
sulted in disparities in care included other physi-
cal comorbidities that complicated the treatment 
and ethical issues with patients not consenting to 
invasive treatments. Irrespective of the presence 
of mental illness, patients with complex needs 
who have multiple comorbidities have worse out-
comes and are more poorly served by standard 
medical care  [63] . With the high level of speciali-
sation now required to deliver high-quality 
healthcare for any condition, it is clear that few 
healthcare providers are well equipped to deal ef-
fectively with diverse and challenging health 
problems simultaneously  [64] . 
 Equitable access to healthcare has become an 
important focus of research in the gaps in phys-
ical health outcomes associated with mental ill-
ness, and a number of contributing issues have 
been noted in the literature  [65, 66] . First, there 
is the long established separation of mental and 
physical healthcare, with many mental health 
service users not receiving ongoing physical 
healthcare, and many psychiatrists reluctant to 
diagnose and treat physical health conditions. 
Additionally, stigma is seen as a major issue in 
the equitable delivery and access to general 
healthcare. Unfortunately, mental illness can 
rob people of aspects of personality that others 
find most endearing, and even among health 
professionals there are many who find it diffi-
cult to provide the same level of concern and 
support to people with mental illness. Also, the 
way that healthcare is delivered in developed 
countries generally results in greater benefit to 
those who have the best understanding of health 
conditions and the healthcare system. People 
with mental illness may also have limited means 
to pay for healthcare or might not be covered by 
health insurance. Many mental illnesses are as-
sociated with cognitive impairments and disad-
vantages that can impact people’s ability to 
maximise their use of healthcare options. These 
include smaller support networks and impacts 
on motivation, concentration, assertiveness and 
communications ability. In some cases these 
deficits have been used as justification not to 
provide health interventions. For instance, 
some cancer surgeries are highly invasive and 
debilitating, and pose substantial demands dur-
ing recuperation. Similarly, chemotherapies and 
other more experimental drug treatments can 
have significant side effects and exact a toll on 
the patient.
 The issue of obtaining informed ethical con-
sent to risky treatments or treatments with sub-
stantial side effects also requires sensitive consid-
eration. Some people with mental illness require 
a higher level of support to understand the impli-
cations of treatments, which may require more 
time commitment from the practitioner. Compli-
ance with aftercare may also require a higher lev-
el of support. However, in the same way that 
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physical disability is not a valid reason for not 
providing access to healthcare, any cognitive or 
behavioural impairment associated with mental 
illness should be recognised as a component of 
the illness that deserves support.
 Finally, another aspect of medical care for peo-
ple with both mental illness and cancer is end-of-
life palliative care, which shares some similarities 
with the recovery model of mental healthcare that 
is based on respect, dignity, and valuing both life 
and the individual  [67] . Results from limited re-
search on this issue have been contradictory. 
Some work suggests that people with severe men-
tal illness may be less likely to receive palliative 
care  [67] . In contrast, our own preliminary work, 
using data from the Western Australian Data 
Linkage System for the period 1988–2007, indi-
cates that people with a history of mental illness 
who were dying of cancer received the same level 
and duration of palliative care prior to death as 
the general population, with an average of 19 days 
of palliative care [unpubl. data]. In spite of the 
challenges that people with mental illness may 
pose to palliative care environments, they may es-
pecially benefit from such care when making dif-
ficult end-of-life decisions or deal with significant 
pain, as they are less likely to have strong person-
al support networks  [67] . Again, the issue of stig-
ma and the cognitive and behavioural conse-
quences of mental illness can affect the way peo-
ple are received and treated in the palliative care 
environment  [68, 69] .
 Conclusions 
 With significant advances in the treatment and 
understanding of mental illness, and large-scale 
change in mental health service delivery to com-
munity-based care, there have been significant 
shifts in treatment goals and expectations. There 
are now effective treatments available for most 
mental health conditions  [70] , and a major focus 
of mental healthcare is on recovery from mental 
illness and valuing the contribution people with a 
history of mental illness make to their communi-
ties  [71, 72] . This has led to a much greater focus 
on the human cost of the high physical comorbid-
ity associated with mental illness, the wasted life 
seen in the substantial gaps in life expectancy 
 [73] . 
 Mental illnesses are common, and people 
with mental illness suffer a disproportionate 
burden associated with physical illness, includ-
ing higher mortality from cancer. Bringmann et 
al.  [74]  estimate that up to one third of cancer 
patients have a psychiatric history. As such, 
dealing with comorbid mental illness is a signif-
icant component of cancer care. Though people 
with mental illness may not be at any higher risk 
than anyone else for developing cancers, the 
clearly worse outcomes once cancer is diagnosed 
highlight the role that preventive and treatment 
services are likely to play in reducing these dis-
parities. There is insufficient research at present 
to definitively identify the contribution that in-
dividual issues make to the overall gaps in out-
comes, but it is highly likely that a range of fac-
tors contribute. Further research into ways to 
improve health service delivery to people with 
comorbid mental health problems is required. It 
appears that reduced access to screening, delays 
in diagnosis, differential access to and uptake of 
treatment options, and impacts of other comor-
bidities may all play a role. Clearly, these issues 
are not straightforward to resolve as shown by 
the lack of major progress anywhere in the 
world. There is a small and developing evidence 
base supporting some directions for improving 
physical healthcare for people with mental ill-
ness, although none of this literature is specific 
to cancer. These include variations on the theme 
of more holistic care models including multidis-
ciplinary teams and co-location, use of peer sup-
porters and addressing stigma in the healthcare 
profession  [66]. 
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 Abstract 
 Emil Kraepelin, the founder of modern psychiatric clas-
sification, and the Nobel laureate Julius Wagner von Jau-
regg highlighted the role of infections and the immune 
system in psychiatric disorders. It is well known that infec-
tions can trigger various psychiatric syndromes and influ-
ence the course of psychiatric disorders. Psychiatric 
symptoms during virulent infections, often presenting as 
encephalitis or meningitis, normally are diagnosed as 
mental disorders due to a general medical condition. On 
the other hand, an expanding research field underpins 
the view that infections and activation of the immune sys-
tem may play a causative role in major psychiatric disor-
ders such as schizophrenia or major depression. Also in 
other psychiatric syndromes, such as Tourette’s syn-
drome, inflammation – partially based on infections – is 
involved. For this mild smoldering inflammatory process, 
the ‘mild (chronic) encephalitis’ concept was developed. 
In this chapter, findings related to immune activation and 
inflammation in schizophrenia, major depression and To-
urette’s syndromes as examples for this concept are de-
scribed. Moreover, encouraging results from randomized 
clinical trials in schizophrenia and major depression 
showing a benefit of anti-inflammatory therapy in these 
psychiatric disorders are discussed as examples for im-
munomodulating treatment approaches in psychiatric 
disorders. Further immunotherapies used in Tourette’s 
syndrome or pediatric autoimmune disorders associated 
with streptococci are highlighted as further examples for 
such a therapeutic approach.  © 2015 S. Karger AG, Basel 
 Humans are constantly being assaulted by infec-
tious agents. Fortunately, we have evolved a com-
plex process, the immune response, to help fight 
and clear infection  [1] . The immune response 
evoked by an infectious agent may or may not 
generate clinical symptoms, depending on the ex-
act type and degree of response. Infectious dis-
eases are well known to provoke psychiatric 
symptoms. As early as 1890, Emil Kraepelin, one 
of the founders of modern psychiatry, described 
during an influenza epidemic 11 cases of psychi-
atric disorders that presented with different 
symptoms such as depressed mood, a paranoid 
and hallucinatory syndrome, involuntary move-
ments, cognitive deterioration, and a delirious 
state  [2] . Later, Kraepelin postulated in his pro-
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grammatic essay ‘Objectives and methods of psy-
chiatric research’ to make the immunological de-
fense and adaption system a focus of psychiatric 
research  [3, 4] . There are also numerous descrip-
tions of an association between chronic inflam-
mation of the central nervous system (CNS) and 
psychopathological states  [5] . For example, symp-
toms of depression and schizophrenia have been 
described in a certain form of multiple sclerosis 
 [6] . The same is true for viral CNS infection with 
herpes simplex virus types 1  [7] and 2  [8, 9] and 
measles  [10] . Autoimmune processes, such as 
poststreptococcal disorders, lupus erythematodes 
and scleroderma, may present primarily as a psy-
chopathological syndrome  [11–18] . This line of 
evidence led to the concept of ‘mild encephalitis’ 
 [19] . 
 In modern diagnostics, psychiatric symptoms 
coexisting with severe infections are diagnosed as 
‘mental disorders due to a general medical condi-
tion’. Infections can cause a broad spectrum of 
psychiatric symptoms, e.g. delirium, psychotic 
disorder or mood disorder ( table 1 )  [20] .
 Factors influencing the psychiatric presenta-
tion of infections are the subject of intense re-
search and might include the pathogen, individu-
al medical history and locus of infection. Infec-
tions of the CNS, such as meningitis and 
encephalitis, are believed to be more commonly 
associated with psychiatric symptoms than those 
of the peripheral organs, although peripheral in-
fections are also well known to cause psychiatric 
disturbances. An example is ‘sickness behavior’ as 
a model for depressive disorder, as described be-
low.
 The ‘Sickness Behavior’ Model in Major 
Depression 
 ‘Sickness behavior’, the reaction of an organism to 
infection and inflammation, is well established as a 
model for depression in animals and humans  [21, 
22] . The model is based on the observation that in-
creased levels of proinflammatory cytokines, such 
as tumor necrosis factor-α (TNF-α) and interleu-
kin-6 (IL-6), are associated with depressive-like 
behavior in animals, including decreased drive and 
motivation, lack of energy and appetite, tiredness, 
and weight loss. The involvement of cytokines in 
the regulation of sickness behavior in humans has 
been studied by administering the bacterial endo-
toxin lipopolysaccharide to healthy volunteers 
 [23] . Levels of anxiety, depression and cognitive 
impairment were found to be related to the levels 
of circulating cytokines  [23, 24] . 
 The findings of these studies, together with the 
sickness behavior model, have led to the hypoth-
esis that ‘cytokines sing the blues’, i.e. cytokines 
and a proinflammatory immune state are in-
volved in the pathogenesis of major depression 
 [25, 26] . This view is supported by recent litera-
ture showing signs of a proinflammatory immune 
state in major depression.
Table 1.  Diagnostic criteria DSM-IV: psychopathological states due to a general medical condition
293.0 Delirium due to a general medical condition
Dementia due to a general medical condition
294.0 Amnestic disorder due to a general medical condition
293.8x Psychotic disorder due to a general medical condition
293.83 Mood disorder due to a general medical condition
293.89 Anxiety disorder due to a general medical condition
Sexual dysfunction due to a general medical condition
780.5x Sleep disorder due to a general medical condition
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 Components and Functions of the Immune 
System 
 The innate immune system, which includes nat-
ural killer cells and monocytes, for example, as 
the first barrier against infection, is phylogeneti-
cally the oldest part of the immune system. The 
adaptive immune response with the antibody-
producing B lymphocytes and the T lympho-
cytes (helper T cells) is the pathogen- and anti-
gen-specific component of the immune system. 
Cytokines regulate all cellular components of 
the immune system and are involved in both the 
innate and the adaptive immune response. Help-
er T cells are of two types: T helper 1 (Th-1) and 
2 (Th-2). Th-1 cells produce the characteristic 
‘type 1’ activating cytokines such as IL-2 and 
interferon-γ. However, since not only Th-1 cells, 
but also certain monocytes/macrophages (M1) 
and other cell types, produce these cytokines, 
this type of immune response is called the type 1 
immune response. The humoral, antibody-pro-
ducing arm of the adaptive immune system is 
mainly activated by the type 2 immune response. 
Th-2 and certain monocytes/macrophages (M2) 
produce mainly IL-4, IL-10 and IL-13  [27] . An-
other terminology system differentiates cyto-
kines as being proinflammatory and anti-in-
flammatory. Proinflammatory cytokines such as 
TNF-α and IL-6 are primarily secreted from 
monocytes and macrophages, and activate other 
cellular components of the inflammatory re-
sponse. While TNF-α mainly activates the type 1 
response, IL-6 activates the type 2 response, in-
cluding antibody production. Anti-inflammato-
ry cytokines such as IL-4 and IL-10 help to 
downregulate the inflammatory immune re-
sponse ( table 2 ). 
 The Proinflammatory Immune State in Major 
Depression 
 Elevated plasma concentrations of C-reactive 
protein (CRP) are a common marker of an in-
flammatory process. CRP levels have been repeat-
edly observed to be higher in people with depres-
sion than in healthy controls, for example in se-
verely depressed in-patients  [28] , and high CRP 
levels have been found to be associated with the 
severity of depression  [29] . Higher CRP levels 
have also been found in both men  [30, 31] and 
women  [32, 33] in remission after a depressive 
state. In a sample of older healthy persons, CRP 
levels and IL-6 levels were predictive of cognitive 
symptoms of depression 12 years later  [34] . In 
comparison to acute inflammatory diseases, such 
as pneumonia, however, the CRP increase is 
slight. 
 Characteristics of immune activation in ma-
jor depression include increased numbers of cir-
culating lymphocytes and phagocytic cells, up-
regulated serum levels of markers of immune ac-
tivation, higher serum concentrations of positive 
Table 2.  Components of the innate and adaptive immune system
Component Innate Adaptive




Humoral Complement, APP, mannose-
binding lectin Antibody
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acute phase proteins coupled with reduced levels 
of negative acute phase proteins, and increased 
release of proinflammatory cytokines such as IL-
1β, IL-2, TNF-α and IL-6 (through activated 
macrophages) and interferon-γ (through acti-
vated T cells)  [35–41] . Interferon-α is well docu-
mented to induce severe depressive symptoms, 
including suicidality, in about one third of pa-
tients  [42] . Different research groups  [43–45] 
have described increased numbers of peripheral 
mononuclear cells in major depression, and, in 
accordance with findings of increased mono-
cytes and macrophages, an increased level of ne-
opterin, a marker for activated macrophages, 
has also been described  [46–49] . The role of cel-
lular immunity, cytokines, and the innate and 
adaptive immune systems in depression has 
been recently reviewed  [50, 51] .  Table 3 summa-
rizes several examples for immune markers in 
major depression.
 Although immune activation is well estab-
lished in major depression and infections are 
well known to trigger depressive symptoms, 
the association between infection and major 
depression has not been properly studied. In 
contrast, the etiology of immune activation in 
major depression is the subject of intense re-
search.
 Infections and Autoimmune Disorders as Risk 
Factors for Major Depression 
 The results of a prospective population-based 
Danish register study in 3.6 million people born 
between 1945 and 1996 support the view that an 
infection or autoimmune disease significantly in-
creases the risk of a depressive disorder. Partici-
pants were followed up from 1977 to 2010, for a 
total of 78 million person-years. All people diag-
nosed with an affective disorder according to 
ICD-8, ICD-9 or ICD-10 and at least one in- or 
outpatient hospital contact due to an affective dis-
order (including bipolar disorder) were included. 
Every previous hospital contact due to an autoim-
mune disorder or infection (apart from HIV/
AIDS) was then recorded. Over 91,000 cases of af-
fective disorder were identified, of which approx-
imately 30,000 had previously been diagnosed 
with infection and >4,000 with an autoimmune 
disease. The results show that hospitalization for 
infection significantly increased the risk for later 
mood disorder by 63% [incidence rate ratio (IRR) 
1.63 (95% CI: 1.61–1.66)] and hospitalization for 
autoimmune disease significantly increased it by 
45% [IRR 1.45 (95% CI: 1.39–1.52)]. Both risk fac-
tors interacted and increased the risk to an IRR of 
2.35 (95% CI: 2.25–2.46). The findings do not sup-
port the hypothesis that primarily CNS infections 
Table 3.  Examples for immune markers reflecting immune activation in major depression
Disease-related markers Markers for antidepressant 
response
















[Müller et al., unpubl. data]
Kynurenine/quinolinic acid
[Müller et al., unpubl. data]
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 99–113 ( DOI: 10.1159/000365542 )
 Infectious Diseases and Mental Health 103
result in later symptoms of mood disorders as, for 
example, the risks were higher for hepatitis infec-
tion [IRR 2.82 (95% CI: 2.58–3.08)] than for sepsis 
or CNS infections. Interestingly, the risk for mood 
disorder increased with the proximity of time to 
the infection, with the highest risk within the first 
year [IRR 2.70 (95% CI: 2.60–2.80)]  [52] . Since 
only infections and autoimmune disorders result-
ing in a hospital contact were recorded, the risk 
for a mood disorder might be higher when all in-
fections are considered. 
 Infection and Autoimmunity Presenting with 
Symptoms of Schizophrenia 
 There are numerous descriptions of an associa-
tion between (chronic) inflammation of the CNS 
and schizophrenia  [5] . For example, symptoms of 
schizophrenia have been described in the enceph-
alitic form of multiple sclerosis  [6] , in viral CNS 
infection with herpes simplex virus types 1  [7] 
and 2  [8] , and measles  [10] , and also in autoim-
mune processes such as poststreptococcal disor-
ders  [11–14] , lupus erythematodes and scleroder-
ma  [15–18] . Schizophreniform symptoms in pri-
mary infectious diseases are diagnosed according 
to DSM-IV as a mental disorder due to a general 
medical condition (whereas in earlier times the 
diagnosis was ‘organic brain disorder’). However, 
we do not know whether schizophreniform 
symptoms are ‘secondary’ to an infection or auto-
immune process or the infection is a comorbid 
condition in a person with a ‘primary’ diagnosis 
of schizophrenia. 
 Inflammation and the Effect on 
Neurotransmission in Schizophrenia 
 Signs of inflammatory degradation products have 
been described in schizophrenic brain tissue  [53] 
and in the cerebrospinal fluid of about 50% of 
people with schizophrenia  [54] . Furthermore, a 
blunted type 1 and (compensatory) increased 
type 2 cytokine pattern have been repeatedly ob-
served in people with unmedicated schizophrenia 
 [55] . Recently published reviews on the imbal-
ance of types 1 and 2 and pro- and anti-inflamma-
tory immune systems as well as innate immunity, 
including the monocytic system, in schizophrenia 
have indicated that an inflammatory process 
plays an important role in the pathophysiology of 
(at least) a subgroup of people with schizophrenia 
 [56, 57] . 
 Over the last five decades, research on the neu-
robiology of schizophrenia has focused over-
whelmingly on disturbances of dopaminergic 
neurotransmission  [58] . A disturbance of the do-
pamine system is clearly involved in the patho-
genesis of schizophrenia, although the mecha-
nism is unclear and antipsychotic antidopami-
nergic drugs still show unsatisfactory therapeutic 
effects.
 IL-1β, which can induce the conversion of rat 
mesencephalic progenitor cells into a dopaminer-
gic phenotype  [59–61] , and IL-6, which is highly 
effective in decreasing the survival of fetal brain 
serotonergic neurons  [62] , seem to have an im-
portant effect on the development of the neu-
rotransmitter systems specifically involved in 
schizophrenia, although the specificity of these 
cytokines is a matter of discussion. Maternal im-
mune stimulation during pregnancy increased 
the number of mesencephalic dopaminergic neu-
rons in the fetal brain, and the increase was prob-
ably associated with a dopaminergic excess in the 
midbrain  [63] . Persistent pathogens might be key 
factors that drive imbalances of the immune reac-
tion  [18] . Nevertheless, many questions remain 
unanswered about how immunity and immune 
pathology in virus infections interact in order to 
show clinical symptoms  [64] .
 Much evidence indicates that a lack of gluta-
matergic neurotransmission, mediated via 
NMDA antagonism, is a key mechanism in the 
pathophysiology of schizophrenia  [65] . Kynuren-
ic acid, the only NMDA receptor antagonist 
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known to occur naturally in the human CNS  [66] , 
is one of at least three neuroactive intermediate 
products of the kynurenine pathway. In schizo-
phrenia, a predominant type 2 immune response 
inhibits the enzyme indoleamine 2,3-dioxygen-
ase, resulting in an increased production of kyn-
urenic acid and consequently in NMDA receptor 
antagonism  [65, 67] . The recent finding of NMDA 
receptor antibodies in about 10% of patients with 
acute and unmedicated schizophrenia is especial-
ly interesting in this regard ( fig. 1 ).
 Findings regarding kynurenic acid in schizo-
phrenia vary. Elevated kynurenic acid has mainly 
been described in the cerebrospinal fluid  [68–70] 
and in the brains of people with schizophrenia 
 [71, 72] , as well as in animal models of schizo-
phrenia  [73] . However, no increased kynurenic 
acid levels have been described in the peripheral 
blood of people with first-episode schizophrenia 
 [74] or in other groups of people with schizophre-
nia  [75] . Increased neopterin values are to be 
mentioned here again  [76] . Antipsychotic medi-
cation, however, affects kynurenine metabolites 
and has to be regarded as an interfering variable 
 [74, 75, 77] .
 Infection as a Possible Pathogenetic Factor in 
Schizophrenia 
 The proposed involvement of immune activation 
and inflammation in the pathogenesis of schizo-
phrenia has led to the hypothesis that infectious 
agents may be involved. Many recent studies have 
focused on members of the virus family of Her-
pesviridae  [78] , Borna virus  [79] , intracellular 
 bacteria like  Chlamydia  [80]  and the protozoan 






























 Fig. 1. The enzyme indoleamine 2,3-dioxygenase (IDO) is activated by proinflammatory cytokines 
[and prostaglandin E 2 (PGE 2 )] and inhibited by anti-inflammatory cytokines. IDO degrades kyn-
urenine, serotonin and melatonin, and influences the concentrations of these neuroactive me-
tabolites and neurotransmitters. The enzyme KMO [kynurenine 3-monooxygenase (identical with 
kynurenine 3-hydroxylase)] drives the metabolism to the neurotoxic metabolite quinolinic acid. 
The enzyme KAT (kynurenine aminotransferase) drives the metabolism to kynurenic acid. 
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Cytomegalovirus and  T. gondii have been stressed 
for many years  [82] . These agents are the focus of 
research because of their ability to establish persis-
tent infections within the CNS and the occurrence 
of neurological and psychiatric symptoms in some 
individuals infected with these agents  [83] . 
 The group of Danish researchers mentioned 
above performed a study in schizophrenia similar 
to their study in affective disorders [127]. They 
found that severe infections and autoimmune 
disorders also additively increased the risk of 
schizophrenia and schizophrenia spectrum dis-
orders. However, this large-scale study did not 
confirm infections in the parents, including intra-
uterine infections, as definite risk factors. Despite 
its large scale, the study’s sensitivity was not very 
high because only infections associated with a 
contact to a Danish hospital were recorded, 
meaning that the risk factors which were identi-
fied may only have been the ‘tip of the iceberg’.
 Animal models of schizophrenia show that 
stimulation of the maternal immune system by 
viral agents leads to typical symptoms in the off-
spring. Evidence for pre- or perinatal exposure to 
infections as a risk factor for schizophrenia has 
been obtained not only from animal models, but 
also from studies with various viruses in humans. 
Increased risk for schizophrenia in the offspring 
was also observed after respiratory infections or 
genital or reproductive tract infections.  T. gondii 
infection in mothers was also described to be a 
risk factor. Interestingly, recent animal research 
showed that stressful events in later stages of life 
(during puberty, an especially vulnerable phase in 
life) unmask latent neuropathological conse-
quences of prenatal immune activation  [84] . This 
animal model might explain the delay between an 
early inflammation and the onset of schizophre-
nia years later.
 Both infections before birth and infections, 
particularly of the CNS, during later stages of 
brain development increase the risk for later 
schizophrenia. Antibody titers against viruses 
have been examined in the sera of people with 
schizophrenia for many years, but the results have 
been inconsistent due to reasons such as interfer-
ing factors not being controlled for. Antibody lev-
els are associated with the medication state, a 
finding which partly explains earlier controver-
sial results. In one of our own studies, people with 
schizophrenia had higher titers of different patho-
gens than controls, a phenomenon that we call the 
‘infectious index’.
 Prenatal immune activation – regardless of 
whether it is triggered by infection – is an impor-
tant risk factor for schizophrenia. In humans, in-
creased maternal levels of the proinflammatory 
cytokine IL-8 during pregnancy were shown to 
increase the risk for schizophrenia in the off-
spring, whatever the reason for the increase in IL-
8. Moreover, increased maternal IL-8 levels in 
pregnancy were also significantly related to de-
creased brain volume, leading to lower volumes 
of the right posterior cingulum and the left ento-
rhinal cortex, and higher volumes of the ventri-
cles in the offspring with schizophrenia ( fig. 2 ).
 Cyclooxygenase-2 Inhibition as an Example of 
an Anti-Inflammatory Therapeutic Approach 
in Schizophrenia and Major Depression 
 An immune-based therapeutic approach for psy-
chiatric disorders was first proposed decades ago 
when the Nobel laureate Julius Wagner von Jau-
regg developed a vaccination therapy for psycho-
ses  [85] . He treated patients successfully with vac-
cines derived from attenuated  Mycobacterium  tu-
berculosis ,  Plasmodium malariae or  Salmonella 
Typhi, all of which stimulate a type 1 immune re-
sponse  [86] . This therapy showed the best results 
in syphilis infection, but Wagner von Jauregg also 
administered the vaccination therapy for other 
psychiatric disorders. After the introduction of 
penicillin and as a consequence of the overwhelm-
ing success of the neurotransmitter approach in 
psychiatry, the therapeutic vaccination approach 
was not pursued further. In the past decade, the 
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emerging limitations of the neurotransmitter ap-
proach for pathogenetic research have resulted in 
increased interest in other therapeutic approach-
es, including the possible use of modern anti-in-
flammatory agents in schizophrenia  [87] . The cy-
clooxygenase-2 (COX-2) inhibitor celecoxib was 
studied as an add-on to risperidone in a prospec-
tive, randomized, double-blind study of acute ex-
acerbation of schizophrenia; patients receiving 
celecoxib had a statistically significant better out-
come and showed an increase in the type 1 im-
mune response  [88] . The clinical effects of COX-2 
inhibition in schizophrenia are especially pro-
nounced in cognition  [89] . The efficacy of thera-
py with a COX-2 inhibitor seems most pro-
nounced in the first years of the schizophrenia 
disease process  [90, 91] . A recent study also found 
a beneficial effect of acetylsalicylic acid in schizo-
phrenia spectrum disorders  [92] . A recent meta-
analysis on the use of nonsteroidal anti-inflam-
matory drugs in schizophrenia found a signifi-
cant benefit of add-on treatment with nonsteroidal 
anti-inflammatory drugs on positive and negative 
symptoms and on the total symptomatology over 
all studies  [93] . A second meta-analysis on the 


















 Fig. 2. Pathoetiological model of psychiatric disorders with special emphasis on the influence of 
infections, inflammation and the immune system. Besides other environmental factors such as 
stress (chronic stress depletes the immune response), pathogens are an important factor. Immune 
genes are involved in psychiatric disorders. The activation or inhibition of the immune response 
influences the noradrenergic, serotonergic, dopaminergic and glutamatergic neurotransmission 
and the (neuroprotective and/or neurotoxic) tryptophan/kynurenine system, and through these 
mechanisms contributes to the psychopathology of psychiatric disorders. Anti-inflammatory 
drugs show beneficial effects in disorders such as schizophrenia or major depression. 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 99–113 ( DOI: 10.1159/000365542 )
 Infectious Diseases and Mental Health 107
found a benefit only in the early stages of the dis-
ease, in particular in first manifestations of schizo-
phrenia  [94] . 
 COX-2 inhibitors also showed interesting ef-
fects in animal models of depression. Treatment 
with the COX-2 inhibitor celecoxib, but not with 
a COX-1 inhibitor, prevented the dysregulation 
of the hypothalamic-pituitary-adrenal axis, in 
particular the increase of cortisol, one of the key 
biological features associated with depression 
 [95, 96] . This effect was expected because prosta-
glandin E 2 , which stimulates the hypothalamic-
pituitary-adrenal axis in the CNS  [97] , is inhibit-
ed by COX-2 inhibition. The functional effects of 
IL-1 in the CNS, which include sickness behavior, 
were also shown to be antagonized by treatment 
with a selective COX-2 inhibitor  [98] .
 COX-2 inhibitors also affect the CNS seroto-
nergic system, either directly or via CNS immune 
mechanisms. In a rat model, treatment with rofe-
coxib was followed by an increase of serotonin in 
the frontal and temporoparietal cortex  [99] . 
COX-2 inhibitors would be expected to show a 
clinical antidepressant effect since a lack of sero-
tonin is one of the main factors in the pathophys-
iology of depression. The antidepressant action of 
COX-2 inhibitors may be mediated through inhi-
bition of IL-1 and IL-6 release. In the depression 
model of bulbectomized rats, a decrease in hypo-
thalamus cytokine levels and a change in behavior 
have been observed after chronic celecoxib treat-
ment  [100] . In another animal model of depres-
sion, however, the mixed COX-1/COX-2 inhibi-
tor acetylsalicylic acid showed an additional anti-
depressant effect by accelerating the antidepressant 
effect of fluoxetine  [101] . In an open-label pilot 
study in humans, acetylsalicylic acid also acceler-
ated the antidepressant effect of fluoxetine and 
increased the response rate to monotherapy with 
fluoxetine in depressed nonresponders  [102] . A 
significant therapeutic effect of the COX-2 inhib-
itor celecoxib in major depression was also found 
in a randomized, double-blind pilot add-on study 
 [103] . Another randomized, double-blind study 
in 50 patients with major depression also showed 
a significantly better outcome with the COX-2 in-
hibitor celecoxib plus fluoxetine than with fluox-
etine alone  [104] . A similar result was obtained 
with a celecoxib add-on approach to sertraline in 
major depression  [105, 106] . A meta-analysis on 
the use of COX-2 inhibitors in major depression 
found an overall benefit of celecoxib add-on ther-
apy  [107] .
 Interestingly, etanercept, which blocks the in-
teraction of TNF-α with the TNF-α cell surface 
receptors, showed a highly significant antidepres-
sant effect  [108] . A study with another TNF-α re-
ceptor blocker, infliximab, found no overall ben-
efit in treatment-resistant patients with major de-
pression, but did find a benefit in those with 
higher levels of inflammatory markers, such as 
CRP, TNF-α or soluble TNF receptors  [106] .
 Although those preliminary data have to be in-
terpreted cautiously and further research is need-
ed to evaluate the therapeutic effects of COX-2 
inhibitors in major depression, the results are en-
couraging for further studies on the inflammato-
ry hypothesis of depression and the pathogenesis, 
course and therapy of the disease.
 Childhood Infections: A Common Cause for 
Mental Disorders? 
 Maternal infection during pregnancy and child-
hood infections are risk factors for later schizo-
phrenia, especially in combination with stress 
during puberty  [84, 109] . Furthermore, infections 
in later life are risk factors for both major depres-
sion  [52] and schizophrenia  [110] . In major de-
pression, an inflammatory process seems to play 
a role in a subgroup of patients, but no specific 
infectious pathogens have been described. Stress 
and other environmental factors may contribute 
to the proinflammatory state. For example, ani-
mal models indicate that early life separation is 
associated with increased cytokine levels and pas-
sive behavior  [111] and that early childhood stress 
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disrupts the regulation of innate immune resis-
tance to a challenge (lipopolysaccharide, viral in-
fection), resulting in enhanced immunological 
and behavioral responses to immune activation 
in animals  [112] . In people with depression, ear-
ly-life stress is associated with enhanced inflam-
matory responsiveness to stress  [113] . Moreover, 
a relationship between early childhood stress, in-
flammatory markers and depression in adult pa-
tients has been described  [114, 115] . Overall, 
studies indicate that stress and adverse events in 
childhood seem to be risk factors for an inflam-
matory state in adulthood. 
 The Concepts of Pediatric Autoimmune 
Neuropsychiatric Disorder Associated with 
Streptococcal Infections, Pediatric Infection-
Triggered Autoimmune Neuropsychiatric 
Disorder and Pediatric Acute-Onset 
Neuropsychiatric Syndrome as Infectious 
Disorders Presenting as (Neuro-) Psychiatric 
Symptoms 
 There are further examples for the involvement of 
infections in psychiatric disorders. Pediatric au-
toimmune neuropsychiatric disorder associated 
with streptococcal infections (PANDAS) mani-
fests with tics, Tourette’s syndrome and/or obses-
sive-compulsive symptoms  [116] , and is a conse-
quence of streptococcal infection. However, not 
only  Streptococcus but also other infectious agents 
such as  Borrelia burgdorferi  [117] or  Mycoplasma 
pneumoniae  [118, 119] may directly or indirectly 
cause this syndrome. Therefore, the concept of 
pediatric infection-triggered autoimmune neuro-
psychiatric disorder, a postinfectious syndrome 
not restricted to streptococcal infection, was in-
troduced  [116, 120] . The broader concepts of pe-
diatric acute-onset neuropsychiatric syndrome 
 [121] and childhood acute neuropsychiatric syn-
dromes, which define a much broader clinical 
spectrum encompassing etiologically diverse en-
tities, were recently proposed to overcome the 
criticism that the postinfectious syndrome might 
present with behavioral symptoms or comorbidi-
ties other than tics and obsessive-compulsive 
symptoms. Exploratory studies aiming to identify 
clinical or cognitive features that could discrimi-
nate PANDAS from other pediatric obsessive-
compulsive and tic disorders have presented 
methodological limitations and are therefore in-
conclusive. Given the uncertainties regarding the 
clinical definition of PANDAS, it is not surprising 
that the evidence for a postinfectious, immune-
mediated pathophysiology has to be further elu-
cidated and specified  [122] . However, therapeutic 
studies based on the PANDAS concept have 
shown that immunomodulating therapies, such 
as intravenous γ-immunoglobulin or plasma-
pheresis, have highly significant advantages com-
pared to placebo  [123] . 
 The conceptual and terminological heteroge-
neity discussed above reflects the difficulties not 
only of postinfectious (auto-)immune syn-
dromes, but also of infection- and immune-medi-
ated disorders in psychiatry in general: the patho-
physiological process is not fully elucidated, spe-
cific mechanisms still need to be explored and 
further scientific efforts are necessary. On the 
other hand, similar to the neurotransmitter-cen-
tered biological approach in psychiatry in which 
therapies were developed first and biological ex-
planations came later, effective therapeutic ap-
proaches are on the way and may provide post 
hoc validation of the discussed concepts.
 Conclusions 
 The possible influences of infection and immune 
processes on the pathogenesis of major psychiat-
ric disorders resulting in inflammation have long 
been neglected. Increasing evidence for a role of 
proinflammatory cytokines in major depression 
and schizophrenia, the strong influence of pro- 
and anti-inflammatory cytokines on the trypto-
phan/kynurenine metabolism and – related to 
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that mechanism – the influence of cytokines on 
the glutamatergic neurotransmission support the 
view that infection, psychoneuroimmunology 
and inflammation rightly should be a focus of 
psychiatric research. This view is fostered by the 
results of (immuno-) genetic findings and the ex-
hibited therapeutic effects of anti-inflammatory 
drugs in schizophrenia and major depression. On 
the other hand, it is possible that immunological 
research in patients may be susceptible to arte-
facts; interfering variables such as medication, 
smoking, stress, sleep and others play an impor-
tant role and cannot always been controlled. This 
can be shown by the example of stress: stress is 
not only – according to the ‘vulnerability-stress-
model’ of schizophrenia – a condition sine qua 
non in schizophrenia, it is also a confounding fac-
tor for research of the immune system and in-
flammatory processes. 
 These considerations show that further re-
search is needed to clarify the role of infection and 
of the immune system in psychiatric disorders. 
Recent results encourage placing further empha-
sis on this fascinating field. Therapeutic studies, 
including meta-analyses, support the view that 
therapeutic progress based on anti-inflammatory 
and/or immunomodulating approaches are not 
only of theoretical interest, but may have an im-
portant clinical impact and might lead to a para-
digm change in psychiatric therapy. 
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 Abstract 
 Increasingly, the identification, assessment and treat-
ment of unhealthy use of alcohol and other drugs often 
occur within general medical settings. Within this cli-
mate, there is a growing awareness of the physical effects 
connected to acute or chronic use of substances of abuse. 
By examining these associations and their purported bio-
logical causative mechanisms, greater clinical attention – 
in the form of screening, identification and treatment – to 
co-occurring medical conditions as well as to the use of 
illicit substances itself may be possible. In this review, we 
examine recent peer-reviewed literature regarding three 
substances of abuse (cocaine, marijuana and opioids) 
and their direct associations with physical disorders. We 
group the association of diseases based on organ sys-
tems and critically examine the literature regarding the 
evidence to supporting those associations and causative 
mechanisms. There is good evidence to support the as-
sociation of cocaine, marijuana and opioid use with a va-
riety of physical health conditions. Unfortunately, while 
the causative evidence of these associations is prelimi-
nary, we could conclude that the use of these substances 
can incite a host of medical illnesses or complicate their 
treatment. When combined with societal, mental health 
and public health harms associated with the use of illicit 
substances, co-occurring or incident physical health con-
ditions associated with substance use may present a sub-
stantial healthcare cost to the individual as well as to the 
healthcare system at large, resulting in a debilitating 
strain on often limited time and resources. 
 © 2015 S. Karger AG, Basel 
 Alcohol and illicit drug use and related use disor-
ders impact mental, physical and environmental 
health. Identification and treatment of addictive 
disorders are the responsibility of all healthcare 
providers. Currently, the education and training 
of healthcare professionals to address co-occur-
ring physical and mental health conditions asso-
ciated with alcohol and illicit drug use and related 
use disorders may not be a focus of medical edu-
cation and training. Because they have not been 
exposed to sufficient undergraduate or graduate 
medical education regarding screening, assess-
ment, and treatment of alcohol and illicit drug 
use, providers may feel inadequately equipped to 
engage the complex intersection between mental 
and physical health presented by ongoing alcohol 
and substance use. In some countries, a concerted 
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effort has been undertaken in primary care to ed-
ucate generalist healthcare providers about ad-
diction and alcohol and illicit drug-related physi-
cal and medical health disorders  [1–4] . While 
much attention has been devoted to physical con-
ditions resulting from alcohol use  [5–8] , less at-
tention has been directed to the associations be-
tween physical conditions and other illicit drug 
use  [9, 10] . 
 A pressing need exists for better understand-
ing among healthcare providers of the serious 
health and healthcare implications of illicit sub-
stance abuse, particularly for physical health con-
ditions. The purpose of this review is to examine 
the co-occurring and comorbid relationships be-
tween major drugs of abuse and physical illness. 
Similar to previous efforts, we examined the re-
cent peer-reviewed literature regarding evidence 
of the associations of illicit substance use on 
physical health conditions  [9, 10] . We investigat-
ed the literature to detail physical health issues 
associated with the use of three of the most com-
mon substances of abuse (cocaine, marijuana 
and opioids). While physical illnesses associated 
with use of other broad categories of drugs of 
abuse, such as stimulants and hallucinogens, may 
mirror the health effects of cocaine (stimulants) 
or marijuana (hallucinogens), for simplicity and 
brevity we concentrated our review on only co-
caine, marijuana and opioids. Although each 
substance may invite risk of physical illness due 
to the nature of taking the substance (e.g. injec-
tion or inhalation), or social and environmental 
problems associated with use (e.g. risky sexual 
practices, trauma or other criminal activity), we 
concentrated our review on the direct associa-
tions between the substance in question and 
physical health. For many of these associations, 
we examined purported pathophysiological rea-
sons for the association with physical ill-health. 
Thus, we provide a brief description of physical 
health conditions related to use of these three 
substances, organized according to generalized 
bodily systems.
 Immune System 
 Cocaine 
 An increasing body of evidence, both from clini-
cal epidemiological and laboratory studies, points 
to an association between cocaine use and an al-
tered innate immune response that involves a de-
crease in monocyte expression of several cyto-
kines  [11] . As a weak agonist for sigma receptors, 
cocaine has also been found to alter cytokine re-
lease from both proinflammatory and anti-in-
flammatory T cells  [12] . These studies suggest 
that cocaine use can have a direct effect on the 
innate immune system and thus increase the like-
lihood of greater risk for infectious diseases. 
Adulterants in cocaine, specifically levamisole, 
which is found in more than half of the cocaine in 
the USA  [13] , has a direct effect on the immune 
system. Leukopenia (especially neutropenia), 
agranulocytosis and vasculitis have been associ-
ated with levamisole. 
 Marijuana 
 Despite strong evidence that cannabinoid type 2 
receptors are found predominantly on cells in-
volved in immunity and inflammation and can 
decrease activity of immune cells  [14] , no link has 
been shown between marijuana use and hemato-
poietic or lymphatic disorders. 
 Opioids 
 Some of the opioids, including fentanyl, metha-
done, loperamide and β-endorphin, have been 
found to increase the levels of interleukin-4 (IL-4) 
in human type 2 T cells while other opioids, such as 
morphine and buprenorphine decrease the levels 
of IL-4  [15] . However, a study of male long-term 
daily opium users in Iran did not show a change in 
IL-4 levels compared to controls  [16] , although 
there were higher levels of other cytokines associ-
ated with either cellular or humoral immunity 
(interferon-γ, IL-10 and IL-17), indicating that 
some opioids have an effect on the immune re-
sponse and the ability to react to infectious agents. 
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 Infection 
 Cocaine 
 Besides the effect of cocaine on the innate immune 
system, cocaine use can increase the risk of infec-
tions through risky behavior associated with drug 
use, e.g. unprotected sex, multiple sexual partners, 
needle sharing and contaminated drug parapher-
nalia. Unhealthy living conditions and malnutri-
tion can also influence the risk for infections. 
 Marijuana 
 Marijuana users may be more vulnerable to infec-
tion than the general public. Combined with can-
nabinoids’ suppression of the inflammatory re-
sponse and natural immunity  [17] , marijuana use 
may promote greater susceptibility and decreased 
resistance to a wide array of infections. The com-
mon practice of shared or communal use of 
bongs, pipes and marijuana cigarettes may fur-
ther promote transmission of airborne and fluid-
based diseases, such as tuberculosis  [18, 19] . 
Among other diseases for which marijuana use 
has been correlated with infection are  Neisseria 
meningitidis  [20, 21] , oral candidiasis  [22, 23] and 
sexually transmitted disease  [24] . As well, mari-
juana users with chronic hepatitis C may be at 
greater risk of developing steatosis and fibrosis in 
the liver  [25, 26] . 
 Opioids 
 Use of opioids is often associated with risky be-
havior, thus increasing the likelihood of being in-
fected by human immunodeficiency virus (HIV), 
hepatitis B and C, and other sexually transmitted 
pathogens. Intravenous use of opioids can in-
crease the risk of cellulitis and endocarditis. 
 Cancers 
 Cocaine 
 There appears to be an increased risk of develop-
ing non-Hodgkin’s lymphoma in frequent users 
of cocaine compared to those who used amphet-
amines, lysergic acid diethylamide (LSD) or 
methaqualone  [27] . 
 Marijuana 
 There appears to be a link between marijuana use 
and some cancers in long-term users. However, 
many studies are hampered by selection bias, 
small sample size, lack of adjustment for concur-
rent tobacco use and other problems. Marijuana 
use has been linked to bladder cancer  [28] , cancer 
of the head and neck  [29, 30] , and lung cancer 
 [31–33] . Marijuana use has also been associated 
with testicular germ cell tumors  [34–36] . Smoked 
marijuana tar contains carcinogens similar to 
those found in cigarettes  [37] , and while studies 
are still inconclusive, it is reasonable to suspect 
that marijuana smoking may contribute to other 
cancers as well, including oral and pharyngeal 
cancer. 
 Hematopoietic Disorders 
 Cocaine 
 Cocaine has a role in coagulopathy. Recent re-
search has found that use of cocaine increases von 
Willebrand factor release from the endothelium 
 [38] . An increase in plasma von Willebrand fac-
tor can enhance platelet aggregation and throm-
bus formation, leading to increased risk for sys-
temic thrombi in large and small vessels. Cocaine 
use is associated with thrombi formation in coro-
nary stents  [39] and atherosclerotic lesions and 
total thrombus occlusion in the main coronary 
arteries in long-term cocaine users  [40] . 
 Marijuana 
 A determination has yet to be made regarding 
whether cannabis arteritis is a distinct and sepa-
rate disease from the thromboangiitis obliterans 
seen in cigarette smokers. Over 50 cases of can-
nabis arteritis have been reported since 1960 in 
marijuana users who did not smoke tobacco  [41] , 
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and cases of arteritis have been described in regu-
lar marijuana users who were moderate users of 
tobacco  [42] . Cannabis arteritis may contribute 
to juvenile peripheral obstructive arterial disease 
 [41] . In addition, arteriographic studies have 
found distal abnormalities similar to thromboan-
giitis obliterans, with changes in the architecture 
of the vasa nervorum  [42] . 
 Cardiovascular Disease 
 Cocaine 
 The surge of catecholamines in the plasma soon 
after use of cocaine can cause significant diffuse 
and focal coronary vasospasm. Additionally, the 
increase in heart contractility and heart rate and 
resultant high blood pressure can cause cardiac 
ischemia, vasospasm and infarction. Cocaine-re-
lated endothelin-1 release from the endothelium 
and alterations in platelet aggregation and for-
mation of vessel thrombi can contribute to the 
increased risk of acute myocardial infarction in 
cocaine users. Young cocaine users may experi-
ence chest pain, ischemia, arrhythmias and acute 
myocardial infarction. Atherosclerotic lesions 
are not primarily associated with cocaine-related 
infarcts  [43] . However, myonecrosis and coro-
nary stenosis is often found in cocaine users with 
previous infarctions. Asymptomatic cocaine us-
ers may have significant cardiac disease (myocar-
dial dysfunction, tissue edema or fibrosis)  [44] 
and cocaine-users may have a higher risk than 
nonusers in developing silent acute myocardial 
infarction. The young age of cocaine users may 
be a survival benefit for those who experience a 
resuscitated cardiac arrest  [45] . Compared to 
noncocaine users, cocaine users often survive the 
arrest without neurological sequelae. However, 
the likelihood of young cocaine users experienc-
ing a nonfatal acute myocardial infarction was 
higher than those who were not cocaine users. 
Twenty-five percent of nonfatal acute myocardi-
al infarction in 18- to 45-year-olds has been at-
tributed to cocaine use. Cocaine users may also 
be more susceptible to developing coronary ar-
tery aneurysm  [46] . Compared to a control group 
of individuals with similar cardiovascular risk, 
30.4% of cocaine users (mean age 44 years) had 
coronary artery aneurysms, compared to only 
7.6% in a control group. Although rare, postpar-
tum coronary artery dissection has been reported 
in a 25-year-old woman who had been using co-
caine  [47] . Arrhythmias, in addition to tachycar-
dia, may occur in cocaine users and have been 
attributed to ischemia and electrolyte imbalance. 
However, cocaine sequestration in myocytes may 
interfere with calcium storage and release and 
normal excitation and contraction, thus predis-
posing the heart to lethal arrhythmias  [48] . Oxi-
dative stress and direct myocardial toxicity has 
been suggested as another reason for the myocar-
dial cell death associated with ischemia and acute 
myocardial infarction in cocaine users  [49] . Car-
diac oxidative stress occurs soon after cocaine 
enters the vascular system, leading to myocyte 
dysfunction and an increase in the number of in-
flammatory cells in the heart. 
 Marijuana 
 Marijuana use has already been associated with 
some clinical cardiovascular issues, specifically 
heart palpitations, orthostatic hypotension and 
acute increase in heart rate  [50, 51] . Long-term 
users may experience an increase in heart rate, 
potentially resulting in cardiac ischemia and the 
arrhythmic effects of the catecholamines  [52] . 
These users may delay pursuing medical help in 
response to the pain normally associated with 
ischemia because of marijuana’s effect as an anal-
gesic and dissociative agent, further exacerbating 
damage over time. There are competing data re-
garding marijuana and mortality risk with acute 
myocardial infarction. While marijuana has been 
shown to increase the risk of acute myocardial in-
farction within an hour of use when compared to 
nonsmokers  [53] , a longitudinal study taken over 
the course of 15 years did not find an increased 
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risk of acute myocardial infarction in users  [54] . 
Furthermore, no statistically significant associa-
tion has yet been found between marijuana use 
and general mortality  [55] . It should be noted that 
marijuana users often have other cardiovascular 
risk factors, such as higher alcohol and overall ca-
loric intake, which increase postmyocardial in-
farction mortality in those individuals with coro-
nary heart disease  [56] . 
 Opioids 
 Cardiovascular effects of opioids include some 
risk of infective endocarditis (associated with in-
travenous opiate use) and cardiac arrhythmias, 
especially long QT syndrome and torsades de 
pointes. Long QT syndrome is a condition asso-
ciated with an abnormal gene coding for a pro-
tein component of myocardial cell potassium-
voltage gated channels that is important in repo-
larization, resulting in a lengthening of the 
depolarization/repolarization cycle  [57] . Other 
risks for long QT syndrome include hypokale-
mia. Long QT syndrome can lead to the develop-
ment of torsades de pointes, a potentially lethal 
ventricular arrhythmia. In a randomized trial 
comparing the rate-adjusted QT length (QTc) in 
opioid-dependent subjects, the QTc increased in 
those subjects treated with the opioids levometh-
adyl (21%) and methadone (12%), but not in 
those treated with buprenorphine  [58] . Signifi-
cant risk factors for the development of a pro-
longed QTc in individuals on methadone main-
tenance therapy include the presence of conges-
tive heart failure and other cardiac disease, 
elevated HbA 1c and use of cocaine  [59] . Conges-
tive heart failure and poor glycemic control in-
crease the risk for mortality. 
 Oral, Ear, Nose and Throat Disorders 
 Cocaine 
 Midline nasal and oral destructive lesions are 
significant complications of insufflation of co-
caine  [60] . Lesions can include ischemic and 
necrotic changes to the mucosa, perichondri-
um, nasal septum (including perforation), hard 
and soft palate, and sinuses. Lacrimal duct ob-
struction and destruction of the nasal turbi-
nates may also be seen. Because similar lesions 
may be seen in patients with granulomatosis, 
sarcoidosis and lymphoma, diagnosis can be 
difficult, particularly since antineutrophil cyto-
plasmic antibody tests may be positive in all of 
these conditions. Sniffling, nasal crusts, nose-
bleeds and sinus problems are common prob-
lems in cocaine users who may also have burns 
to their upper airway. Depressed hearing and 
diminished sense of smell have also been re-
ported. 
 Marijuana 
 Similar to tobacco, marijuana smoking increases 
the risk of a number of oral diseases and disor-
ders, including xerostomia, tooth decay, peri-
odontitis, severe gingivitis and mucosal abnor-
malities  [23] , as well as leukoedema and traumat-
ic ulcers of the mouth  [61] . It should be noted that 
it is not yet clear whether the higher incidence of 
caries and periodontal disease in marijuana 
smokers is a direct effect of use or a byproduct of 
attendant poor hygiene  [62] . 
 Opioids 
 A recent article suggests that nasal mucosal ne-
crosis found in a small number of patients is re-
lated to heroin snorting  [63] . 
 Respiratory Disease 
 Cocaine 
 Bronchial and lung dysfunction in cocaine us-
ers include cough, black sputum, hemoptysis 
and chest pain  [9] . Some studies have reported 
an exacerbation of asthma symptoms in those 
who smoke crack cocaine  [64] and a higher in-
cidence of out-of-hospital asthma deaths  [65] . 
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Although crack cocaine users are less likely to 
have hemoptysis, respiratory distress and ab-
normal pulmonary function tests than those 
participants who use tobacco  [66] , cocaine us-
ers are more likely to have an increase in al-
veolar macrophages and endothelin-1 (a po-
tent vasoconstrictor) in bronchial alveolar la-
vage samples, suggesting that microvascular 
injury is associated with heavy crack cocaine 
smoking. 
 Marijuana 
 Studies suggest that marijuana users are at an el-
evated risk of experiencing increased mucus pro-
duction as well as symptoms of chronic bronchi-
tis  [67–70] . Cannabis may also be an allergen for 
some  [71] . A recent report found that forensic 
laboratory workers handling hashish or marijua-
na for 16–25 years developed marijuana hyper-
sensitivity  [72] . Others may be at risk for develop-
ing an allergy to the drug. 
 Opioids 
 Respiratory depression is a major adverse effect 
of many of the opioids and can cause death in 
users. As many as 58% of the deaths related to 
drug abuse in Ontario, Canada, between 2006 
and 2008 were related to opioid use, with over 
one third of these associated with oxycodone use 
 [73] . Respiratory depression and death may also 
occur with opioid use in neonates, the elderly 
and obese, and those with cardiopulmonary dis-
ease. Opioid respiratory depression has also 
been reported in noncancer patients using meth-
adone or transdermal fentanyl for chronic pain 
 [74] . Other opioid-related respiratory condi-
tions have also been reported. Use of methadone 
was found to be associated with sleep apnea in a 
study of 392 patients using the opioid for chron-
ic pain  [75, 76] . Exacerbation of asthma symp-
toms can occur in heroin users  [77, 78] , possibly 
associated with histamine release by the opioid. 
Aspiration pneumonia is also associated with 
opiate use. Chest wall rigidity in adults  [79] and 
infants  [80] can occur with fentanyl use in pro-
cedural events, but can also occur with illegiti-
mate use of the drug. 
 Gastrointestinal Disorders 
 Cocaine 
 Cocaine use has been implicated in ischemic dis-
ease of the digestive system, with ischemia and/or 
infarction being reported in the mesentery vessels 
 [81] , and occlusive disease of the small and large 
bowel  [82] . Frequently, the onset of abdominal 
pain is in temporal proximity to use of either 
crack or intravenous cocaine. The mortality rate 
associated with ischemic colitis has been found to 
be higher in cocaine users than noncocaine users 
 [83] . 
 Marijuana 
 A number of articles, including a case series  [84] , 
have been published on cases of chronic marijua-
na users who were diagnosed with cannabinoid 
hyperemesis, characterized by cyclical, chronic 
vomiting and severe abdominal pain, and often 
accompanied by a compulsion to take hot baths 
or showers. The authors report that discontinu-
ing marijuana use causes symptoms to dissipate 
and further assert that the illness is often under-
diagnosed and underreported. 
 Hepatobiliary Disease 
 Cocaine 
 Hepatotoxicity in cocaine users is likely the result 
of direct toxicity mediated by oxidative stress and 
mitochondrial dysfunction occurring during me-
tabolism of cocaine  [85] . It is likely that cocaine-
induced oxidative cell stress leads to cell damage, 
fibrosis and abnormal liver function. This mecha-
nism also occurs in the kidney and many body 
systems, including the cardiovascular, central 
nervous, immune and reproductive systems  [86] . 
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 Metabolic, Nutritional and Endocrine 
Disorders 
 Marijuana 
 Although some research has shown that overac-
tivity of cannabinoid receptors may lead to ab-
dominal obesity, dyslipidemia and hyperglyce-
mia  [87] , there is little clinical evidence that mar-
ijuana use is associated with development of 
diabetes mellitus or hyperlipidemia. 
 Cocaine 
 While cocaine use has not been found to have an 
effect on the development of diabetes mellitus, 
cocaine use has been shown to increase the risk of 
diabetic ketoacidosis and for hospitalization of 
recurrent diabetic ketoacidosis  [88] . Noncompli-
ance with the therapeutic regimen is thought to 
be a contributing factor in diabetic ketoacidosis. 
 Renal and Male Urogenital Disorders 
 Cocaine 
 The risk for rhabdomyolysis and acute renal fail-
ure is significant for those who use cocaine. Co-
caine has direct toxic effects on skeletal muscle 
and, along with severe vasoconstriction, can cause 
muscle ischemia and release of myoglobin and 
other cell contents from damaged cells  [89] . Myo-
globin is freely filterable in glomeruli, but accu-
mulates in the distal tubules, resulting in obstruc-
tion. The effect of vasoconstriction on the renal 
vessels by cocaine, and a possible direct toxic ef-
fect of cocaine and myoglobin on renal tissue, 
contributes to the development of acute renal fail-
ure. However, with aggressive therapy, almost 
80% of the individuals survive and most recover 
adequate renal function. 
 Genital ulcer disease found in male cocaine us-
ers is generally related to unprotected sex and 
contact with partners with sexually transmitted 
diseases and immune dysfunction associated with 
cocaine use.
 Marijuana 
 Glomerular, interstitial and renal vascular disease 
may all be associated with marijuana use  [90] , 
though that link is not definite  [91] . Marijuana 
may contribute to male infertility  [92] , decrease 
spermatogenesis and circulating testosterone lev-
els  [93] , and has been linked to inhibited orgasm 
and painful sex  [94] . 
 Opioids 
 A recent study found that morphine use can ac-
celerate chronic kidney disease  [95] . Glomerular 
podocytes appear to be affected by morphine-in-
duced oxidative stress, leading to albuminuria 
and renal dysfunction. 
 Female Reproductive System 
 Cocaine 
 Genital ulcer disease and pelvic inflammatory dis-
ease have been reported in women who use cocaine. 
Both conditions are likely due to sexually transmit-
ted diseases associated with risky behavior and un-
protected sex, as well as immune dysfunction. 
 Marijuana 
 There is a potential link between female infertility 
and marijuana, either as a lone agent or in concert 
with other illicit substances  [96] . A case control 
study found that women who used marijuana with-
in 1 year of attempting to conceive were not likely 
to become pregnant  [97] . Additionally, marijuana 
users are six times more likely to develop  Tricho-
monas vaginalis infections than nonusers  [98] . 
 Pregnancy 
 Cocaine 
 A comparison of 18 studies describing pregnancy 
complications found increased risk for preterm 
labor, placenta abruptio, fetal death, placenta pre-
via and spontaneous abortion  [9] . Infants of co-
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caine-using mothers are more at risk for de-
creased weight and length than infants of nonco-
caine users. Infants of cocaine-using mothers 
were also found to be more at risk for transient 
atrial and ventricular arrhythmias than infants of 
noncocaine-using mothers  [99] . At birth, neo-
nates may experience some autonomic dysregula-
tion, but withdrawal symptoms are generally 
minimal  [100] . Cocaine is not likely to be a direct 
fetal teratogen, although some evidence exists for 
alteration of cerebral development  [101] . 
 Marijuana 
 Young women using marijuana during pregnan-
cy may often have infants with low birth weight 
and decreased length. However, a direct link to 
these consequences as a result of marijuana use is 
unclear. Often lack of prenatal care, social prob-
lems or poor economic conditions may be associ-
ated with these infant outcomes. 
 Opioids 
 As seen with other drugs of abuse, use of opioids 
during pregnancy can have detrimental effects on 
newborns, including low birth weight and length. 
Often, infants are exposed in utero to a number of 
drugs, including cocaine, heroin, cannabinoids and 
benzodiazepines, and their related side effects. 
Newborns of opioid-using mothers are particularly 
at risk for neonatal abstinence syndrome, which 
typically occurs within the first 3 days of life  [102] . 
Methadone and buprenorphine have both been 
used to manage opioid dependence in pregnant 
women. In the newborn, buprenorphine appears to 
be less likely to alter cardiac function and produces 
fewer severe side effects than methadone  [103] . 
 Dermatologic Disorders 
 Cocaine 
 Cutaneous vasculopathy is a dermatologic condi-
tion seen in cocaine users, especially in women 
 [104] . Retiform rashes with purpuric plaques are 
found predominantly on the lower extremities, 
but can also develop on the face and ears. Leuko-
penia and neutropenia may be seen, and labora-
tory tests for antineutrophil cytoplasmic antibod-
ies can be positive, suggesting an immune reac-
tion. Thrombotic vasculopathy and small-vessel 
vasculitis may be found on skin biopsies. Levam-
isole contamination in cocaine often contributes 
to the development of these skin lesions. 
 Neurological Disorders 
 Cocaine 
 The major harms associated with cocaine abuse 
of the nervous system are related to cerebrovascu-
lar disease. Cocaine users are at risk for develop-
ment of subarachnoid hemorrhage associated 
with ruptured aneurysms, ischemic stroke and 
hemorrhagic stroke  [105] . Compared to nonus-
ers, cocaine users are more likely to experience 
an  aneurysm rupture and less likely to survive 
subarachnoid hemorrhage than nonusers. Isch-
emic strokes are also seen in cocaine users and 
may be associated with hypertension, vasospasm, 
arteritis and increased platelet aggregation  [106] . 
Cocaine users with ischemic stroke are often 
younger than nonusers and are more likely to 
smoke tobacco. Morbidity and mortality are sim-
ilar in both cocaine users and nonusers. Seizures 
may also occur after cocaine use, especially in 
women, when high doses are used, with chronic 
use of cocaine, and in users previously experienc-
ing seizures  [107] . 
 Marijuana 
 Use of marijuana has been associated with vascu-
lar disease in the central nervous system, with 
several cases of ischemic strokes documented in 
recent literature  [108–110] , including a study 
finding increased risk of stroke in marijuana us-
ers  [111] . Marijuana use may increase the risk of 
the movement disorder tardive dyskinesia  [112] . 
In a study of the incidence of tardive dyskinesia in 
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a group of people with chronic schizophrenia, 
women and older patients who smoked marijua-
na while taking antipsychotic drugs were more 
likely to develop repetitive and involuntary move-
ments than other patients. Links between mari-
juana and transient amnesia  [113] , ataxia  [114] , 
propriospinal myoclonus  [115] and spasticity 
 [116] have yet to be fully explored. 
 Opioids 
 Opioids are often abused because of their stimula-
tory effects on the nervous system. However, in 
large doses, opioids can have a detrimental effect 
on the central nervous system and can lead to de-
lirium and coma. Hydromorphone, on the other 
hand, can cause neuroexcitation, as reported in a 
study of 156 hospice patients receiving the drug 
while in an inpatient setting  [117] . An increased 
risk of hydromorphone-induced neuroexcitation 
was associated with large doses and longer dura-
tion of drug use, increased age of the patient, and 
increased serum creatinine. Symptoms often as-
sociated with hydromorphone-induced neuroex-
citation include tremor, myoclonus and agitation. 
Cognitive dysfunction is also commonly seen 
 [118] . Spongiform leukoencephalopathy is a rare 
sequela of inhalation of heated heroin smoke. In 
one study, postmortem findings in 4 patients with 
spongiform leukoencephalopathy showed signifi-
cantly higher numbers of apoptotic cells in both 
the cerebellum and corpus callosum  [119] . Cere-
bral vacuolar degeneration was also found, par-
ticularly around microvessels. Sequelae include 
hydrocephalus and cerebellar swelling  [120] . Al-
though rare or possibly underreported, seizures 
can occur with opioid use, including generalized 
tonic-clonic seizures and status epilepticus  [121] . 
 Musculoskeletal Disease 
 Cocaine 
 As previously mentioned, two musculoskeletal 
conditions, rhabdomyolysis with acute renal fail-
ure and midline destructive lesions of the face and 
oral cavity, are strongly associated with cocaine 
use. Although no other significant musculoskel-
etal disorders have been reported with cocaine 
use, the inclusion of levamisole in cocaine has the 
potential of leading to untoward rheumatic con-
sequences  [122] . 
 Conclusion 
 In this review, we relate the recent literature re-
garding the physical health associations of the use 
of three drugs of abuse (cocaine, marijuana and 
opioids) and a variety of physical illnesses ( ta-
ble 1 ). The use of cocaine, marijuana and opioids 
has been shown to impart a plethora of physical 
illnesses, many with purported and examined 
pathophysiological mechanisms. While associa-
tions of these conditions are known, the causative 
rationales for these conditions are less known. 
More research is certainly needed to examine 
causation of these drugs with physical illness. It 
may be that when more people use certain drugs 
(e.g. legalization of marijuana and increase in opi-
oid prescription drug misuse), their related phys-
ical health conditions will become more readily 
apparent. 
 For the clinician, our findings that use of illicit 
substances, namely cocaine, marijuana and opi-
oids, have some evidence in the peer-reviewed lit-
erature of physical health consequences may not 
be a surprise. Clinicians often treat patients who 
use illicit substances and often appreciate the del-
eterious social and environmental harms associ-
ated with this use. Often, patients who use illicit 
substances have co-occurring mental health con-
ditions and these are readily appreciated by clini-
cians. However, what may be less known are the 
physical health conditions that may be directly at-
tributable to use of illicit substances. Certainly, we 
found that significant evidence exists of a myriad 
of physical health conditions that may be directly 
attributable to illicit substance use.
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Table 1.  Conditions clinicians are likely to see with use of three commonly abused substances
System Cocaine Marijuana Opioids
Immune
system
altered cytokine release leading to 
 increased risk of infections; leukopenia, 
agranulocytosis, vasculitis associated 
with additive levamisole
no association with altered 
immunity, inflammation
altered cytokine function; 
increased risk of altered 
 cellular, humoral immune 
response
Infection increased due to risky behavior, 
 unhealthy living conditions,  malnutrition
higher risk for Neisseria, 
Candida, sexually 
 transmitted diseases, 
chronic hepatitis C with 
liver steatosis, fibrosis
increased risky behavior 
 associated with HIV, hepatitis 
B and C, other sexually 
 transmitted disease; 
 intravenous use and increased 
cellulitis, endocarditis
Cancer increased risk of non-Hodgkin’s 
 lymphoma
increase risk of bladder 
cancer, cancer of head and 
neck, lung; testicular germ 




increased risk of coagulopathy (VWF), 
thrombus formation; atherosclerotic 








high blood pressure, cardiac ischemia, 
vasospasm, infarction; increased 
systemic vessel thrombi, AMI, silent 
infarct; arrhythmias; coronary aneurysms 
cardiac palpitations, 
 orthostatic hypotension, 
tachycardia; increased risk 
of silent AMI and infarct 
soon after use; coexisting 
cardiac risk factors
infective endocarditis; 
 arrhythmias including long 
QT-syndrome, torsades de 




midline nasal, oral destructive lesions 
with insufflation, positive ANCA test; 
sinus disease; upper airway burns
xerostomia, periodontitis, 
gingivitis, mucosal lesions, 
ulcers




bronchial, lung dysfunction, cough, 
hemoptysis, chest pain; exacerbation of 
asthma symptoms; increased 
microvascular injury
increased mucus 
 production, signs and 
symptoms of chronic 
 bronchitis; increased risk 
for marijuana allergy
respiratory depression and 
death (oxycodone), 
 particularly in neonates, 
 elderly, obese, those with 
cardiopulmonary disease; 
increased sleep apnea; 
 exacerbation of asthma 
 symptoms (heroin); aspiration 
pneumonia; chest wall rigidity
Gastrointestinal
disorders
mesenteric ischemia, infarction, 
occlusive disease of small and large 
bowel; increased risk of death from 
ischemic colitis
cannabinoid hyperemesis, 
often associated with 




liver fibrosis, abnormal liver function 





increased risk of diabetic ketoacidosis 
secondary to noncompliance to 
treatment regime
possible abdominal 
 obesity, dyslipidemia, 
hyperglycemia
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 Clinicians, particularly general practitioners 
or primary care providers, should screen and as-
sess for illicit substances among their patients. If 
they identify a patient who uses an illicit sub-
stance, our review of literature relates that they 
should consider evaluating for physical health 
conditions associated with that use. Even mental 
health providers should consider assessing for 
these physical health conditions, as patients with 
illicit substances may not seek care with a general 
practitioner or primary care provider. A proac-
tive approach for assessing and treating these 
physical health conditions associated with illicit 
use may be valuable, as patients who use illicit 
substances may not seek medical care, and cer-
tainly may not establish longitudinal healthcare 
services, such as a general practitioner or primary 
care provider. In addition, attention in healthcare 
professional schools and training programs re-
garding the association of illicit substances and 
physical health may be warranted. In sum, physi-
cal health conditions associated with use of illicit 
Table 1.  Continued




increased risk of rhabdomyolysis, acute 
renal failure; genital ulcer disease 
secondary to unprotected sex
glomerular, interstitial, 
renal vascular disease; 
possible infertility with 
decreased  spermatogenesis 
and testosterone; erectile 
dysfunction
acceleration of chronic renal 





genital ulcer disease, pelvic 
 inflammatory disease
infertility; increased risk of 
Trichomonas infection
Pregnancy increased risk of preterm labor, placenta 
abruptio, fetal death, placenta previa, 
spontaneous abortion; transient atrial 
and ventricular arrhythmias; decreased 
birth length and weight
decreased birth length and 
weight
decreased birth length and 




cutaneous vasculopathy (retiform rash, 
purpuric plagues); leukopenia, 
 neutropenia; small vessel disease; 




cerebrovascular disease (ischemic, 
 hemorrhagic stroke); aneurysm rupture, 
subarachnoid hemorrhage; seizures
cerebrovascular disease 
(ischemic stroke); increased 
risk for tardive dyskinesia; 
transient amnesia; ataxia; 
propriospinal myoclonus, 
spasticity








rhabdomyolysis with acute renal failure; 
midline destructive lesions (face, oral 
cavity); rheumatoid findings with 
 levamisole
 AMI = Acute myocardial infarction; ANCA = antineutrophil cytoplasmic antibody; VWF = von Willebrand factor.
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drugs is a significant concern for all patients who 
use illicit substances and should be a concern for 
their healthcare providers as well as healthcare 
provider educators.
 This review has significant limitations related 
to our approach which should temper overreach-
ing or generalizing our findings. We reviewed 
only the recent (over the last 2 decades) peer-re-
viewed literature, and only that which was pub-
lished in English. It may be that some published 
studies remained undiscovered in the process of 
our electronic review. We did not cover other il-
licit drugs of abuse, but much of the literature on 
amphetamines is similar to the literature on co-
caine and much of the literature on hallucinogens 
is similar to the literature on marijuana. We did 
not examine the behavioral, mental health, social 
and environmental problems that afflict persons 
who use substances of abuse, and we did not con-
centrate this review on the associations made 
through the route of drug administration (e.g. in-
crease in hepatitis C and HIV through injections 
of illicit drugs) as these were not direct drug as-
sociations to physical illness, but due to the route 
of exposure. While we critically examined the lit-
erature, much of the literature examines associa-
tions rather than causations, or exists in the form 
of case reports, case series or descriptive studies. 
Conclusions regarding the specificity and strength 
of the association with drugs of abuse and physi-
cal illness should be tempered unless there is evi-
dence of biological mechanisms to support the as-
sociation.
 Despite these limitations, drugs of abuse un-
questionably cause physical health effects. Some 
of the diseases connected to cocaine, marijuana 
and opioid use possess strong evidence of disease 
association. These diseases are often serious, re-
sulting in a significant burden on healthcare sys-
tems to finance, treat or support long-term man-
agement of these conditions. All healthcare pro-
viders should be aware of these associations and 
discuss these associations with patients who use 
these substances. By doing so, illicit use, as well as 
the physical harm and diseases associated with 
that use, may be diminished or even eliminated. 
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 Management of Comorbidity of Mental and Physical Illness 
 Abstract 
 The rising prevalence of chronic conditions also implies 
a rise in multimorbidity. Comorbid diseases are impor-
tant because they influence the diagnostic process, the 
therapeutic approach, the effect of the treatment and 
ultimately the patient’s outcome. Most studies on chron-
ic diseases have focused on patients with a single condi-
tion and the evidence on how to manage coexisting 
chronic diseases is lacking. Moreover, most health sys-
tems have been developed to tackle diseases through 
vertical disease-oriented programs. This chapter dis-
cusses the challenges of multimorbidity (including men-
tal illness) from a primary care perspective and the role 
of family physicians or general practitioners in the man-
agement of multimorbidity. Strong primary care sys-
tems can enable a comprehensive approach to multi-
morbidity, shifting the paradigm from ‘disease 
orientation’ towards ‘goal orientation’. 
 © 2015 S. Karger AG, Basel 
 The Epidemiological Transition towards 
People with Multiple Chronic Conditions 
 Due to the aging of the population and the rising 
prevalence of chronic diseases, the number of 
people suffering from more than one disease will 
continuously increase. Anderson et al.  [1] have 
reported that in the general population, 50% of 
those aged over 65 years have at least 3 chronic 
conditions, and 20% of those aged over 65 years 
have at least 5 chronic conditions. The lack of 
comparability between studies precludes giving 
an overall estimate on the prevalence of multi-
morbidity since this is very dependent on the way 
multimorbidity is measured  [2, 3] . However, re-
gardless of the measure used, the prevalence of 
multimorbidity is high and will rise further. This 
is especially the case in older persons, where mul-
timorbidity will become the rule rather than the 
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exception in clinical care. The comorbidity of 
mental and physical disorders is the least well re-
searched, with many studies excluding patients 
with psychiatric comorbidity, despite the mental 
comorbidity creating important challenges for 
clinical management. 
 General Practice: From a Comorbidity to a 
Multimorbidity Perspective 
 In the 1980s and 1990s, the focus of chronic care 
was on single diseases. Comorbidity was includ-
ed as a MeSH term for the first time in 1989. Most 
research on the coexistence of chronic diseases 
originated from fundamental research and fo-
cused on the underlying mechanisms of comor-
bidities. In the case of chronic obstructive pul-
monary disease (COPD), abundant comorbidity 
research has indicated that selected comorbidi-
ties, such as atherosclerotic disease, depression, 
chronic kidney disease and cognitive impair-
ment, are found more frequently among people 
with COPD  [4–7] . The same applies for diabetes, 
rheumatoid arthritis and many other diseases for 
which comorbidities have been documented. 
 The term ‘multimorbidity’ was introduced in 
the 1990s and is not yet a MeSH term. It is impor-
tant to distinguish the concepts of comorbidity 
and multimorbidity  [8] . Comorbidity always im-
plies an index disease, whereas multimorbidity is 
defined as any co-occurrence of medical condi-
tions within a person. From the perspective of 
primary healthcare, the construct of multimor-
bidity is particularly relevant because general 
practitioners deal with the broad spectrum of dis-
eases affecting these patients and do not necessar-
ily put one disease or body system at the forefront. 
When it comes to mental illness, Gunn et al.  [9] 
clearly demonstrated that the number of (physi-
cal) chronic conditions is directly related to the 
presence of depressive symptoms  [9] . Moreover, 
as is the case for most chronic conditions, in pa-
tients with multimorbidity there is a clear social 
gradient for every age group, with multimorbid-
ity being more prevalent in the most deprived 
groups  [10] , while deprivation is frequently linked 
to depressive symptoms.
 Moreover, from the patients’ perspective, the 
distinction between index diseases and comorbid 
diseases is often irrelevant because the impact of 
diseases on their lives crosses the boundaries of 
individual diseases. In fact, as indicated in one of 
the latest reviews on COPD and comorbidities 
 [4] , whatever the underlying mechanism of co-
morbidities, the personal, clinical, prognostic and 
therapeutic impact on the patient asks for a shift 
from comorbidity to multimorbidity.
 How Does the Health System Address 
Patients with (Several) Chronic Conditions 
Today? 
 In recent years, not only Western countries, but 
also developing countries, have started ‘chronic 
disease management programs’  [11, 12] in order 
to improve care for long-term chronic condi-
tions. A recent survey of ‘chronic disease manage-
ment’ in 10 European countries illustrated that 
disease-management programs in most countries 
are organized around a single chronic condition, 
e.g. diabetes, sometimes focusing on subgroups 
within a specific chronic disease, e.g. disease-
management programs that only include people 
with type 2 diabetes  [12] . Incentives have been 
defined in order to stimulate both patients and 
providers to adhere to guidelines. This develop-
ment has led to important results, e.g. in process 
and (biomedical) outcome indicators defined by 
the UK Quality and Outcomes Framework  [13] . 
Moreover, the ‘chronic disease management’ ap-
proach has led to an acceleration of task-shifting 
from physicians to nurses, dieticians and health 
educators.  
 Disease-management programs also have in-
creased the attention given to interventions that 
improve the knowledge and skills of patients in 
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dealing with their chronic condition, e.g. self-
management of diabetes. Despite some criticism 
regarding equity  [14, 15] , the sustainability of the 
quality of improvement and comprehensiveness 
versus a reductionist nature of the programs  [16] , 
these programs in general have received positive 
feedback from providers, patients and politicians. 
However, the continuous development of single-
disease programs may also entail a growing mis-
match between the needs of people living with 
multimorbidity and the resources offered by a 
health system that increasingly focuses on dis-
ease-defined care.
 Why Primary Care? 
 Although much has been learned from vertical 
disease-oriented programs, better outcomes 
could be reached by addressing diseases through 
an integrated approach in a strong primary care 
system. An example is Brazil, where therapeutic 
coverage for HIV/AIDS reaches almost 100%, 
which is far higher than HIV/AIDS programs in 
other countries with less robust primary care. 
Vertical disease-oriented programs for HIV/
AIDS, malaria, tuberculosis and other infectious 
diseases encourage duplication and the inefficient 
use of resources. They produce gaps in the care of 
patients with multimorbidity  [17, 18] and cause 
inequity for patients who do not have the ‘right’ 
disease  [19] . Horizontal primary care provides 
the opportunity for integration and addresses the 
problem of inequity, providing access to the care 
for all health problems, thereby avoiding ‘ineq-
uity by disease’  [20] . 
 The Case of Jennifer 
 Jennifer is 75 years old. Fifteen years ago she lost her hus-
band. She has been a patient at the practice for 15 years 
now. She has been through a difficult medical history: hip 
replacement surgery for osteoarthritis, hypertension, type 
2 diabetes, COPD and episodes of depression. 
 According to the guidelines, Jennifer is faced 
with a lot of tasks: joint protection, aerobic exercise, 
muscle strengthening, a range of motion exercising, 
self-monitoring of blood glucose, avoiding environ-
mental exposure that might exacerbate COPD, wear-
ing appropriate foot wear, limiting intake of alcohol 
and maintaining body weight. She has to receive pa-
tient education regarding diabetes self-management, 
foot care, osteoarthritis and the COPD medication 
delivery system training. Her medication schedule 
includes 11 different drugs, with a total of 20 admin-
istrations a day. The clinical tasks for the general 
practitioner in relation to this patient include vacci-
nation, blood pressure control at all clinical visits, 
evaluation of self-monitoring of blood glucose, foot 
examination, laboratory tests, and psychological as-
sessment and support in episodes of depression. 
Moreover, referrals are needed for physiotherapy, 
retinal examination, pulmonary rehabilitation and 
psychotherapy.
 Jennifer lives independently at home, with some 
help from her youngest daughter, Elisabeth. I visit her 
regularly and each time she starts by saying: ‘Doctor, 
you must help me’. Then a succession of complaints 
and unwell feeling follows. Sometimes it has to do with 
her heart, another time with lungs, then the hip and 
sometimes depression. Each time I suggest – accord-
ing to the guidelines – all sorts of examinations that do 
not improve her condition. Her requests become more 
and more explicit, while my feelings of powerlessness, 
inadequacy and irritation increase. Moreover, I have 
to cope with guidelines that are contradictory: for 
COPD she sometimes needs corticosteroids, which al-
ways worsens her diabetes control. The adaptation of 
the medication for the blood pressure (once too high, 
once too low) does not meet with her approval, nor 
does my interest in her HbA 1C and lung function test 
results.
 How Can We Build an Evidence Base for 
Multimorbidity? 
 Clinical decisions must be based on adequate 
knowledge of diseases (medical evidence), but at 
the same time they must take into account pa-
tient-specific aspects of medical care (contextual 
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evidence) and efficiency and equity (policy evi-
dence)  [21] . As far as medical evidence is con-
cerned, in primary healthcare we are confronted 
with the tension between the results of actual 
clinical research on the one hand and the needs 
of daily clinical practice on the other hand. As 
the case of Jennifer illustrates, questions arise 
about which evidence to follow in the case of 
multimorbidity. Treatment according to the 
guidelines for one condition (corticosteroids for 
COPD) may interfere with the guidelines for an-
other (glycemic control in type 2 diabetes). 
There is a lot of evidence available on the man-
agement of COPD and type 2 diabetes for peo-
ple younger than 75 years and without comor-
bidity, but there is little, if any, evidence about 
how to treat a 75-year-old woman who has both 
disorders.  
 This problem implies a need for research on 
the effectiveness of diagnostic and therapeutic 
interventions that take into account these as-
pects of patients in primary care. The challenge 
of multimorbidity illustrates the lack of appro-
priate evidence. Most available evidence to 
treat chronic diseases has been collected in sin-
gle-disease trials, often excluding patients with 
comorbid diseases. A possible solution to tack-
le the evidence gap for multimorbidity may be 
to engage in the development of randomized 
clinical trials or guidelines on patients with 
specific combinations of diseases  [22, 23] . 
However, a practice-based cross-sectional anal-
ysis of the medical records of 543 patients aged 
over 65 years in primary care has shown that 
patients with multimorbidity have complex and 
unique combinations of problems [24]. 
 The low prevalence of disease combinations at 
the practice level will hamper the usefulness of 
randomized trials and guidelines for providers. 
Moreover, many of the strongest associations 
show a contribution of a psychiatric problem or 
a social problem which demands a tailored ap-
proach. Luijks et al.  [25] showed that general 
practitioners agreed on the need to adapt man-
agement of multimorbidity to the personal cir-
cumstances of these patients, such as vitality, per-
sonal preferences and socioeconomic conditions. 
They stressed the importance of tailoring care to 
the individual and trying to understand the 
meaning of illness for a person. A personal pa-
tient-doctor relationship and continuity of care 
were considered major facilitators in the man-
agement of multimorbidity, and the presence of 
mental health problems was regarded as a com-
plicating factor. In order to build a useful and rel-
evant evidence base for multimorbidity, there is 
a need to explore new generic ways and para-
digms to approach patients with multimorbidity 
which allow tailoring care to focus on the needs, 
goals and expectations of each individual patient 
 [26–28] .
 From Problem-Oriented Towards 
Goal-Oriented Care 
 Jennifer eventually said, ‘Doctor, I want to tell 
you what really matters to me. On Tuesday and 
Thursday, I want to visit my friends in the neigh-
borhood and play cards with them. On Saturday, 
I want to go the supermarket with my daughter. 
And for the rest of the week, I want to be left in 
peace. I do not want to continually change the 
therapy anymore, especially not having to do this 
and to do that’. In the conversation that followed, 
it became clear to me how Jennifer had formu-
lated the goals for her life. At the same time I felt 
challenged to identify how the guidelines could 
contribute to the achievement of Jennifer’s goals. 
I have enjoyed visiting Jennifer ever since. I know 
what she wants and how much I can (merely) 
contribute to her life. 
 Jennifer’s case clearly illustrates the need for 
a paradigm-shift for chronic care: from problem 
oriented to goal oriented. In 1991, Mold et al. 
 [27] recognized that the problem-oriented mod-
el, which focuses on the eradication of disease 
and the prevention of death, is not well suited to 
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the management of chronic illness. Therefore, 
they proposed a goal-oriented approach that en-
courages each individual to achieve the highest 
possible level of health, which is defined by the 
individual instead of the health system. This 
represents a more positive approach to health-
care, characterized by a greater emphasis on in-
dividual strengths and resources. What really 
matters for patients is their ability to function 
(functional status) and social participation. 
Goal-oriented care assists an individual in 
achieving their maximum individual health po-
tential in line with their individually defined 
goals. Exploring the goals of patients will re-
quire adequate communication with patients to 
allow providers to explore and elicit personal 
goals. At a practice level, providers should in-
creasingly pay attention to goal-oriented care 
and provide an atmosphere of open communi-
cation attentive and supportive to patients who 
should be encouraged to introduce their own 
goals in clinical decision-making.
 The Need for New Types of Evidence 
 In order to understand the goals of the patients 
better, new research frameworks and research 
disciplines will be needed. This will require in-
put from disciplines that contribute to the un-
derstanding of provider-patient interaction 
such as medical philosophy, sociology and an-
thropology. Research methods will have to shift 
from purely quantitative (randomized clinical 
trials) towards qualitative approaches looking 
at understanding through in-depth interviews 
and focus groups. We will have to look for re-
search tools and approaches that explore sub-
jective determinants of well-being, and not only 
biomedical measurements. In the new research 
designs, patients with multimorbidity will be 
the rule (instead of an exclusion criterion) and 
complexity will be embraced instead of avoided 
 [29] .  
 The International Classification of Function-
ing (ICF)  [30] might become as important as 
the International Classification of Diseases 
(ICD), as it draws a conceptual framework in 
which different domains of human functioning 
are defined. These domains are classified from 
an eco-, bio- and psychosocial viewpoint by 
means of a list of body functions and structures, 
and a list of domains of activity and participa-
tion. As an individual’s functioning and disabil-
ity depends on the context, the ICF includes a 
list of environmental factors and the concept of 
personal factors in its framework. The ICF is 
part of the ‘Family of International Classifica-
tions’ (FIC) and meets the standards for health-
related classifications as defined by the World 
Health Organization (WHO). Although the 
ICD has a dominating role in healthcare data 
management, the WHO aims to reach the same 
level with the ICF, a classification that defines 
functional status irrespective of the underlying 
health condition.
 Implications for the Health System 
 At a policy level, healthcare systems should be-
come more attentive to goal-oriented care and 
support providers to engage in the labor-inten-
sive process of goal-oriented care. This will re-
quire both a fundamental reflection on time man-
agement, task delegation and payment systems. 
Family physicians should be encouraged to pro-
vide less and longer proactive patient contacts in-
stead of more and shorter reactive consultations. 
Practice nurses and other primary care providers 
should be increasingly encouraged to engage in 
chronic care. Moreover, taking into account the 
social gradient, with deprived patients being 
more prone to multimorbidity  [31, 32] , social 
workers should be included in the team approach. 
The current focus on fee for (technical) services 
does not seem well suited to a goal-oriented ap-
proach in healthcare. 
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 Multimorbidity, Goal-Oriented Care and 
Equity 
 When implementing goal-oriented care, there 
may be a threat to equity, as the way goals are 
formulated by patients might be determined by 
a number of factors including social class. More-
over, integrating the patient’s context implies 
the risk of taking the context for granted; people 
living in poverty will generally have been obliged 
to take on lower expectations in terms of quan-
tity and quality of life than well-educated people. 
Therefore, ‘goal-oriented medical care’ could 
contribute to an increase in social inequities in 
health. Therefore, the primary care team should 
engage in an approach of intersectoral action for 
health (interacting with sectors like employ-
ment, housing and education) and address the 
social determinants and ‘upstream causes’ of ill 
health. 
 The Role of the General Practitioner 
in the Management of Patients with 
Multimorbidity 
 The role of the general practitioner in the man-
agement of multimorbidity is situated at differ-
ent levels. The general practitioner is the pro-
vider with a comprehensive view on both the 
biomedical and personal health status of the pa-
tient. They are in the frontline to detect the evo-
lution from ‘single disease’ to ‘comorbidity’ and 
‘multimorbidity’ in individual patients, and are 
able to integrate disease-specific guidelines to 
the personal situation of the patient. They are 
able to define medical priorities and integrate 
them with the personal goals and preferences of 
the patient, thereby supporting a timely shift 
from ‘problem orientation’ to ‘goal orientation’. 
The general practitioner can be involved in the 
facilitation of ‘goal definition’ by the patients 
and is well placed to integrate these goals in clin-
ical decision-making for multimorbidity and 
build an individual care plan together with the 
patient. Through continuity of care, the general 
practitioner can be attentive to the fact that goals 
of patients can change over time as the context 
changes. This approach will, however, require 
more focus on the individual patient-provider 
interaction and on appropriate communication 
skills to facilitate goal definition and patient em-
powerment. 
 Other primary care providers, such as nurses, 
physiotherapists, occupational therapists, social 
workers, dieticians and others, also have invalu-
able insights into the patients’ situation, which 
should be integrated in the care for the patient. 
Shared decision-making, starting with patient 
goals and involving the patient and other care 
providers, will avoid gaps in the process and en-
courage empowerment of the patient. Especially 
in a context of multimorbidity, there is a need 
for a shift from ‘chronic disease management’ 
towards ‘participatory patient management’, 
with the patient at the center of the process. 
Moreover, as definition of ‘goals’ may often be 
related to values, the providers in the primary 
care team will have to act as reflective practitio-
ners that contribute to reconcile individual and 
community health requirements. It is clear that 
this process will require more time investment 
at first, e.g. to engage in a goal-setting encounter 
with the patient; however, in the long term, 
goal-oriented care might prove to be more rel-
evant, effective and efficient, and require less 
time spent on targets not of interest to that indi-
vidual patient.
 At the meso-level, general practitioners may 
have an important ‘signaling’ role in order to 
document and draw attention to problems of in-
equity. Institutions for health professionals’ ed-
ucation are challenged to train providers that 
are not only ‘experts’, or excellent ‘profession-
als’, but also ‘change agents’  [33] who continu-
ously improve the health system and question 
the relevance of knowledge and care. General 
practitioner education will have to provide the 
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needed support and training of providers and 
the coordination of the different primary care 
organizations. General practitioners should be 
able to reflect on the equitable distribution of 
resources, taking into account social determi-
nants, on the organization of the healthcare ser-
vices and the features of the health system in or-
der to tailor care to this growing group of com-
plex patients.
 At the macro-level, this will also require dialogue 
and communication methodologies between the 
health sector and persons in need of healthcare as 
well as with other stakeholders within the society 
involved in healthcare at the practice, research and 
policy levels in order to guarantee the essential char-
acteristics of an effective health system including 
relevance, equity, quality, cost-effectiveness, sus-
tainability, people-centeredness and innovation. 
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 Management of Comorbidity of Mental and Physical Illness 
 Abstract 
 This chapter addresses the importance of training on co-
morbidity and the principles of learning. It covers the 
methods and structuring of such training, the content on 
which it is based, and what is known in the field. It includes 
illness versus disease management, holistic approaches, 
patient and doctor roles regarding shared decision-mak-
ing, adherence and self-management, polypharmacy, in-
terprofessional and team communication, and effective 
consultation and communication skills. We highlight 
methods which are learner-centred, aiming at active en-
gagement in a collaborative endeavour with the trainer. 
We emphasise the need to recognise the broader sys-
tems’ factors which support or undermine integration of 
learning into everyday practice. Training should address 
cognitive (knowledge), emotional and motivational (at-
titudes), and behavioural (skills) elements of learning. 
Whilst undergraduates will need more didactic elements 
and proscribed activities, postgraduate training benefits 
from flexibility to the learners’ working context. Training 
the trainers is an important component of an education 
strategy so that teachers use a learner-centred approach 
consistent with the patient-centred consultation model 
needed to manage comorbidity.  © 2015 S. Karger AG, Basel 
 Physical and mental comorbidity has not been 
well addressed in medical education, especially in 
systems-based curriculum designs. Increasing 
specialisation of healthcare delivery also threat-
ens integrated managemant. Training is impor-
tant for a commitment to understanding comor-
bidity from the start of clinical training about pa-
tient care. For clinical practice to develop, it 
requires active engagement, adjustments in daily 
working and broader support from the health-
care system  [1] ( fig. 1 ). 
 The crowded curriculum in medicine puts 
each discipline in competition with one anoth-
er over what is most important for the first-
year medical student, foundation trainee or in-
tern to know. The only way to cover the mate-
rial adequately  and ensure an appropriate 
attitude towards patient care is to work coop-
eratively and in an interdisciplinary manner. 
From the outset, we need to model ways of in-
tegrating mental and physical health care 
knowledge so that students will see their pa-
tients in a way which allows them to feel con-
fident in both spheres.
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 Our students and trainees are embarked upon 
a trajectory of life-long learning. We describe 
how this occurs, including brief coverage of theo-
ries of adult learning and how these inform train-
ing design and techniques. Examples of model 
programmes, including the use of communica-
tion skills training and other forms of active expe-
riential learning, are included. All learners have to 
be convinced that their efforts are worthwhile, re-
alistic and manageable, and will bring about de-
sired outcomes. Good practice demonstrated by 
excellent teachers and practitioners is a strong 
positive influence. Clinicians and lecturers need 
to model respect for the psychological aspects of 
illness. The power of the role model in learning is 
well documented and so engagement of faculty by 
training the trainers and postgraduate education 
is essential for transformative learning and incor-
poration into clinical practice. Not surprisingly 
therefore, the shift from paternalism to partner-
ship in the doctor-patient relationship is best mir-
rored by a shift to a more collaborative trainer-
trainee relationship. Training and new skills/ap-
proaches must be supported and reinforced by 
the clinical environment, otherwise formalised 
learning is not sustained  [2, 3] .
 Educational Theories, Principles and 
Implications for Training 
 Important and influential educationalists of our 
time, including Kolb  [4] , Schon  [5] , Dewey  [6] 
and Vygotsky  [7] , have addressed conditions of 
effective learning. Kolb’s learning cycle explains 
how learning takes place when (1) having a con-
crete experience, followed by (2) observation of 
and reflection on that experience leads to (3) for-
mation of abstract concepts (analysis) and gen-
eral principles (conclusions) which are then (4) 
used to test hypotheses in future situations. All 
four stages are needed, although one can enter at 
different points and no one stage is an effective 
learning procedure on its own. Schon’s work on 
the reflective practitioner powerfully shows that 
learners need to be processing information and 
feelings while developing insight and responding 
to changing situations. 
 Dewey  [6]  emphasised the importance of the 
emotional element in learning. Negative emo-
tions, such as extreme anxiety, will act as barriers 
to engagement in learning. Trainers must estab-
lish a supportive, whilst appropriately ‘challeng-


























 Fig. 1. A model for managing long-
term conditions [42]. 
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should always be linked to what one is trying to 
achieve, so goals of the consultation need to be 
clarified and agreed  [8, 9] . Feedback framed in 
terms of what is effective and examples of any 
missed opportunities are conducive to useful 
learning. Emotional involvement is a key feature 
of learning. The feedback conversation is central 
and includes checking how the learner is feeling, 
preferably in a small, supportive group setting 
 [10] . Learners then need to set goals for imple-
menting their learning, based on a collaborative 
evaluation of the importance of and confidence in 
being able to apply the new knowledge and behav-
iour. Vygotsky highlights: ‘the distance between 
the actual developmental level as determined by 
independent problem solving and the level of po-
tential development as determined through prob-
lem solving under adult guidance…’ [ 7 , p. 86].
 Designing learning activity pitched at a level in 
order to challenge without overwhelming the 
learner should: 
 (1) Consider the learners’ agenda ( table 1 ), the pa-
tients’ agenda (‘what I want doctors to help me 
with’), the trainers’ agenda (evidence-based 
practice) and the service agenda (the pragmat-
ic approach) 
(2) Make it real by designing training character-
ised by relevance, experience, activity and 
learner-centredness  [11] 
(3) Pitch training to the level and context of the 
learner 
(4) Ensure feedback and include follow-up action 
plans 
 Undergraduates have limited clinical experi-
ence and will benefit from an approach which 
involves more teaching, coaching and real pa-
tients or problem-based learning scenarios in-
corporating comorbidity. Involving the ‘pa-
tient’s voice’ and expert patients in education is 
memorable and helps students and trainees un-
derstand patients’ particular expertise  [12] . Stu-
dents are strongly motivated by assessment 
rather than seemingly distant clinical practice; 
therefore, assessments such as objective struc-
tured clinical examinations should incorporate 
identification of comorbidity. Online resources 
with case studies, video clips and principles of 
practice help the novice develop an understand-
ing  [13] . Early years’ experience of meeting pa-
tients and carers using reflective learning as-
signments and progressing to role-play utilising 
actors, particularly for more complex consulta-
tions, provides a vertical integration in a cur-
riculum.
 Postgraduate learners bring their own clinical 
experience. Incorporating their particular situa-
tions maximises relevance and engages motiva-
tion. From their own reflections in identifying 
Table 1.  Examples of learners’ needs
Pass the assessment
Manage time in consultation – get there quicker
Be able to deal with the situation if they ‘take the lid off it’
Helpful strategies, skills, examples of questions and phrasing
A good history and diagnosis
Not miss pathology
Develop a management plan




Connect patients to other healthcare professionals/refer/support
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the challenges of these interactions, they can 
practice new strategies in role-play and receive 
constructive feedback. Good postgraduate train-
ing programmes develop skills for working in 
partnership by involving patients with long-term 
conditions as co-facilitators alongside trainers 
 [14] .
 Training Goals 
 Training needs to incorporate some explanation 
of comorbidity and the potentially dangerous im-
plications of not identifying it within the consul-
tation. As it will inevitably require more effort ini-
tially on the clinician’s part to explore comorbid-
ity, conviction and skills are needed. Training 
outcomes include (1) acceptance of the biopsy-
chosocial model of health and awareness of issues 
in comorbidity, (2) knowledge of what to manage 
and how, and what to refer, and (3) communica-
tion and interpersonal skills. 
 The Biopsychosocial Disease-Illness Model and 
Patient-Centred Care  
 In 1989, McWhinney  [15]  described the disease-
illness framework and the need to explore both 
biomedical and psychosocial information to un-
derstand the patient and his/her situation ( fig. 2 ). 
The patient’s experience and beliefs are hugely 
significant, although historically often neglected 
because a patient’s views and expectations will af-
fect adherence to medications and the actions he/
she takes regarding lifestyle changes. Discussing 
raised glycated haemoglobin levels with a patient 
distracted by depression about having diabetes is 
unhelpful. Engaging patient understanding and 
managing his/her healthcare in collaboration 
with the physician will have better outcomes 
 [16] . 
 As one patient explained, ‘You’re always hop-
ing there will be a cure, which is why you end up 
being so depressed, when there isn’t one… . 
Within secondary care in particular, there’s still 





























 Fig. 2. Disease-illness framework and patient-centred communication. Adapted from  McWhinney 
 [15] .
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management’  (Shani Evans, 2008)  [14] . Students 
need to recognise that partnership between pa-
tients and clinicians in a co-creating health rela-
tionship is essential both for patients’ well-being 
and tackling escalating costs of care  [17] .
 Issues in Comorbidity: The Dialectic between the 
Physical and the Mental 
 The curriculum needs to include the following 
six themes which should cover the basic under-
standing of comorbidity for students and junior 
trainees. 
 (1) The Interdependence of Mind and Body: 
How the Psychological Can Impact the Physical 
and Vice Versa 
 A psychological understanding and a framework 
of illness and the emotional responses to it are vi-
tal to a well-functioning and quality health ser-
vice. This perspective becomes increasingly perti-
nent as survival from disorders that used to be 
life-threatening becomes more commonplace. 
Diabetes, HIV and renal disease are a few exam-
ples of diseases that cannot be cured but can be 
managed; and yet the psychological effect of a 
long-term disorder that will change lives and im-
poverish expectations is also important. Students 
must learn the goals after survival include reduc-
ing suffering, increasing emotional well-being, 
pain control, functional ability and vitality. A cli-
nician teacher’s role includes sharing awareness 
of common psychiatric comorbidities and how to 
manage them in a patient-centred way. 
(2) Presentations of Illness That Can Confound 
Diagnosis 
 Medical students and young doctors have to 
struggle with large amounts of new knowledge 
and tend to prefer clear facts that are easy to di-
gest. As their learning progresses they will be able 
to recognise when patients’ presentations do not 
follow the usual pattern of a disease profile. Dis-
crepancies in symptoms or repeat presentations 
by the same person who is not getting better may 
suggest a misdiagnosis and even the possibility of 
medically unexplained symptoms. 
 Physical manifestations of psychological dis-
tress are well understood, such as dry mouth or 
tachycardia when anxious. Some symptoms are 
less obviously associated with a trauma. They 
may convey meaning unknown to the sufferer 
and require more careful history taking to eluci-
date. 
 Medically unexplained symptoms are not so 
easy to understand on the surface, but may be 
simpler to demonstrate clinically. In a simulated 
clinical setting, for example, by exploring psycho-
social information students can easily be encour-
aged to divine the likely association of headaches 
in a person whose partner has just died of a brain 
tumour, or one who complains of memory prob-
lems when stressed and exhausted from looking 
after their elderly mother who has Alzheimer’s 
disease. The common factor here is encouraging 
students’ curiosity and getting them to ask appro-
priate questions. Exploring a symptom can be lik-
ened to detective work.
 How can we engage students and trainees ful-
ly in the current governmental commitment to 
offer ‘parity of esteem’ as in the USA for mental 
health issues as for physical ones  [18] ? We need 
medical schools to collaborate with psychiatry 
and psychology departments in order to ensure 
that the psychological perspective becomes part 
of teaching all systems and permeates across 
most aspects of training. Psychiatry is not just a 
discipline like medicine or surgery: it is also a 
way of understanding pathological processes 
that engages the medical model, but also views 
patients from their own psychological and social 
perspective. Especially valuable can be educa-
tional methods bringing together specialists 
from different fields of medicine and surgery 
(gastroenterology, cardiology, gynaecology, pri-
mary care, psychologists, psychiatrists) in clini-
cal forums to discuss patients, encouraging the 
skills needed to communicate effectively and 
manage care  [19] . Similar methods in under-
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graduate teaching from multispecialist groups 
are needed to prevent development of negative 
attitudes towards patients with medically unex-
plained symptoms  [20] .
(3)  Risk Factors for Mental Health Difficulties in 
Physical Illness: Particularly Long-Term 
Conditions 
 Some physical health conditions often go hand in 
hand with a psychiatric morbidity. A common 
example is one of anxiety and depression experi-
enced with severe breathing problems  [21] . Stu-
dents starting their clinical attachments will often 
come across such patients who may be the subject 
of their first clerking. In a medical school focused 
on clinical skills and listening and attending to a 
patient’s agenda, the student may be struck by the 
worries and concerns of patients with asthma or 
bronchitis. Their task may be to take a history and 
then examine the patient physically. They will 
also ask about the impact of illness on the per-
son’s life. They will understand that work may be 
limited, exercise impossible and enjoyment cur-
tailed. Managing long-term conditions holistical-
ly can have a significant positive effect on pa-
tients’ mental health and quality of life. If psychi-
atry is integrated into teaching from the outset 
(including how to perform a mental state exami-
nation), students may feel able to ask about mood 
symptoms as a result and even enquire about sui-
cidal thoughts. Fostering an understanding of 
these principles and supporting learners who are 
commonly anxious about asking such potentially 
upsetting questions is a key goal of educators. Stu-
dents adjust to knowing that patients with psychi-
atric symptoms  can be on medical wards and not 
just in a psychiatry setting. They also learn that 
psychiatric symptoms are commonplace, associ-
ated with physical conditions and treatable if rec-
ognised. 
 The importance of understanding the inter-
relationship of conditions and the medications 
used to treat them are also crucial. Patients dis-
pensed medications from multiple providers are 
at greater risk of an adverse drug reaction and are 
more likely to suffer from the prescribing cascade 
 [22] . Medication for physical illness can cause 
mental health symptoms and conversely drugs 
taken for mental health problems may cause 
physical symptoms and predispose to physical 
disease. How students will be guided to consider 
these issues and how to approach them requires 
teaching faculty who are committed to an inte-
grated way of viewing health.
(4)  Learners’ Own Physical and Mental Health: 
Knowing One’s Self and Being Aware of 
Assumptions and Judgments 
 Being aware of one’s own views and reactions to 
other people’s misfortunes is essential to enable 
learners to behave in a non-partisan, professional 
manner that does not seek to judge but merely to 
inform. Knowing something about the nature 
and management of addictions is also enormous-
ly important when deciding on the best course of 
action in the treatment of physical problems in 
people with substance misuse, alcoholism or ad-
diction (e.g. liver failure). Religious and cultural 
diversity among patients and students will influ-
ence understanding, personal attitudes and com-
munication. 
 Mental health problems may remain uncov-
ered for patients whose doctors do not explore 
this aspect of the patient’s psychosocial history 
 [23] . Whilst patients may drop cues from de-
meanour or language, they are less likely to raise 
these worries directly. Doctors commonly use 
distancing tactics such as focusing only on bio-
medical facts, premature reassurance or jollying 
patients along rather than pursue cues, and thus 
miss significant mental health problems. Key 
communication skills are associated with in-
creased disclosure. Teaching learners to observe 
demeanour, note speech quality, listen, allow si-
lence and express empathy are particularly im-
portant. Skills training helps the healthcare pro-
fessional to engage the patient and discuss with 
them their ideas, concerns and expectations in 
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conjunction with addressing biomedical facts 
 [24] .
 Mental illness carries stigma. Those most at 
risk of this way of thinking are the medical stu-
dents and doctors themselves. Students often fear 
a mental health diagnosis because of ignorance, 
stigma and a belief that it will prevent their quali-
fying as a doctor  [25] . Stress, one of our biggest 
difficulties in busy, demanding and responsible 
jobs, can cause much physical and mental ill 
health. Sometimes alleviated by alcohol use, which 
may become a problem in itself, it is more danger-
ous when we fail to recognise it in ourselves.
 Students and trainees can experience distress-
ing situations in their own lives as well as in clin-
ical practice. A curriculum which includes teach-
ing about stress, its impact on doctors and the 
available support services enables students and 
trainees to recognize when this may be an issue 
and where to get help.
 Experiential learning is also powerful. For ex-
ample, clinical skills training combining the ability 
to ‘break bad news’ sensitively while attempting to 
understand the unique perspective of the person 
with a particular physical or indeed ‘mental illness’ 
diagnosis is one learning strategy that is used  [26] . 
Role-playing the clinician can be very helpful in 
that one is exposed to a range of affects from the 
simulated patient and one learns how to manage 
each. If students are asked to play the patient as well 
as the doctor, this adds a power to the scenario, but 
can be challenging. These methods can really assist 
medical students and trainees to empathise. Exer-
cises such as having a conversation whilst breath-
ing through a straw to simulate the experience of 
someone with chronic obstructive pulmonary dis-
ease (COPD) [Kim C, pers. commun., 2013] and 
the ‘hearing voices’ audiotaped exercise used to il-
lustrate the experience of patients with psychosis 
 [27] help learners imagine the lived experience of 
disability and appreciate of the patients’ suffering. 
By being in the patients’ ‘shoes’, the potential con-
sequences of a doctor choosing to listen attentively 
or maintaining distance can be understood. Train-
ers must be skilled in facilitating such situations 
and be prepared to listen and support students who 
are upset or having difficulties. Preferably they will 
have received training in role-play methods using 
ground rules for safety.
 (5) Risk Factors for Physical Health Difficulties 
in People with Mental Illness 
 Depressed people are less likely to be able to man-
age their illness, medications or lifestyle changes 
 [16, 17] . Difficulties exercising and keeping fit are 
often associated with feeling unmotivated, anx-
ious about facing the world or being indifferent to 
one’s own future. Drugs used in treating psychot-
ic disorders often cause weight gain, induce dia-
betes mellitus and risk heart disease. Enabling 
students to discover these issues early on in their 
training through talking to patients with chronic 
mental health problems, and their families, also 
encourages a more compassionate and thought-
ful view of the complexity of psychiatric disorder. 
Interestingly, there is some evidence that al-
though the coexistence of depression and multi-
ple physical conditions is associated with in-
creased illness burden, such patients benefit most 
from the Chronic Disease Self-Management Pro-
grams, and students and trainees should learn 
about these approaches  [28] . 
 (6) Consultation Skills to Identify and Plan 
Management for Comorbidity 
 Goals for the consultation include an open, respect-
ful, empathic, accurate and constructive consulta-
tion based on both the patient’s and doctor’s agen-
da, focussing on gathering relevant biomedical and 
psychosocial information and shared decision-
making. The very important therapeutic function 
of the consultation, in and of itself, is well known. 
 To operationalise the disease/illness and 
shared decision/partnership care, a number of 
consultation guides for skills training have been 
developed  [29–31] . These frameworks define the 
skills that, when used in context, are known to be 
helpful. Particularly important are listening (and 
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silence), observing non-verbal cues, listening to 
quality of speech and responding to cues using 
empathic reflection.
 Training Issues 
 Barriers to Identifying Comorbidity 
 Whilst clinicians may be aware of comorbidity, 
they can also feel time pressured and powerless to 
manage the problems, as well as lack confidence or 
strategies to deal with all the issues, and thus act to 
avoid being overwhelmed by a variety of patient 
needs. Training must take account of the fact that 
clinicians may control and limit the interview as a 
way of avoiding emotional difficulties  [32] . 
 Comorbidity may mean that patients are al-
ready seeing, or will need to see, other members 
of the healthcare team. Accessing and transfer-
ring patient information between healthcare pro-
viders is not easy where multiple information sys-
tems of patients’ data exist. If clinicians see only 
problems and no ways of efficiently dealing with 
these, they may be reticent to explore comorbid-
ity and may focus narrowly or exclusively on the 
primary presenting problem. Similarly, students 
and trainees need to have a strategy of how to re-
spond. These can include listening attentively, ac-
knowledgement of the problem and advocacy by 
offering, with the patient’s permission, to talk to 
the doctor or attending physician. Trainees may 
in addition be able to offer simple advice, help pa-
tients to problem solve, book a longer appoint-
ment and refer to colleagues. Without plans for 
what to do next, students and trainees will likely 
not ask about comorbidity. Training should in-
corporate strategies for the next steps.
 Skills for Patients and Clinicians to Understand 
Each Other 
 The doctor-patient interaction is recognised as 
one of unequal power which brings with it a num-
ber of challenges for open communication. Pa-
tients frequently hint rather than say what their 
problems are. If the doctor overly controls the na-
ture of information gained and the type of infor-
mation the patient gives, an inadequate problem 
definition may occur. Skills are needed to pick up 
on cues, create trust and gain an accurate compre-
hensive history, and these skills can be taught  [33] . 
 Teaching Consultation and Communication 
Skills 
 Communication skills training promoting patient-
centred approaches in clinical consultations is best 
designed on a blended learning skills-based and at-
titude development approach with incorporation 
of peer support using a variety of training tech-
niques  [32, 34–36] . Group problem-solving discus-
sions on how to respond to comorbidity and practi-
cal management planning addresses learners’ con-
cerns about ‘taking the lid off’ problems and not 
having confidence or strategies to tackle them. 
Without this, application in practice will be com-
promised  [36] . Case studies, such as those below 
can be used to discuss goals for a consultation, 
practical management strategies and to practice 
communication skills. 
 Case Study 1 
 Mr. Peters, 58 years of age, was admitted through the ac-
cident and emergency department with acute shortness of 
breath, and is now on intravenous antibiotics. He has a 
5-year history of COPD and has had three chest infections 
already this year. Mr. Peters had smoked 20 cigarettes a 
day for 40 years, but has now cut down. COPD is signifi-
cantly affecting his life. 
 The patient’s ideas: ‘My lungs are damaged from 
working on the buses, exhaust fumes in the garage and 
stress. I know smoking is bad but helps with stress and 
I’ve cut down but not quit.’
 The patient’s concerns: ‘My breathing is bad and I 
can’t do much or go far. I retired early on health 
grounds and miss my mates. I’m worried about all the 
hospital admissions, but staff are wonderful, I feel safer 
in hospital and enjoy the company.’
 The patient’s expectations: ‘I want the doctor to 
give me a stronger drug to help breathing. He’ll prob-
ably ‘‘have a go at me’’ again about quitting smoking.’
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 Two years later, Mr. Peters, has become increasingly 
isolated, rarely goes out, is now having panic attacks 
about his COPD, cannot sleep and often wakes in the 
night to use his nebulizer. When he cannot breathe his 
wife phones an ambulance. He is scared he is dying and 
his wife feels distraught and does not know how to cope.
 Case Study 2 
 Erica Johnson is a 31-year-old woman of African-Carib-
bean parentage. She developed schizophrenia in her mid-
20s. Although compliant with treatment, a depot antipsy-
chotic medication for the past 3 years and no hospital ad-
missions, her general health is suffering. She has gained a 
lot of weight and is now morbidly obese, has developed 
type II diabetes and has raised blood pressure. Her self-
esteem is at an all-time low and she feels depressed. Her 
general practitioner notices that recent blood tests suggest 
her diabetes is not well controlled. 
 The general practitioner is mainly concerned about 
her diabetes. He sees that Erica is overweight but is un-
sure whether there is enough time to tackle this prob-
lem today and feels unsure about the potential impact 
on her mental health.
 Erica is desperately unhappy about her weight. She 
feels low and miserable, is lonely, and feels unattract-
ive. She wants a family, but has no confidence to find 
herself a boyfriend. Erica wants to give up the injec-
tions which she feels are the cause of her problems.
 Summary 
 Role-play provides a powerful and effective teach-
ing tool. The participant has space for self-reflec-
tion and comment followed by feedback from the 
actor and facilitator. Using video, a recording can 
be played back so that particular points in the in-
teraction can be identified. Feedback is vital with 
the opportunity to then repeat any aspects since 
an experience of success in doing something dif-
ferently consolidates learning. 
 Training Course Designs 
 Intensive experiential postgraduate courses con-
sisting of a 2- or 3-day programmes with a group 
size of no more than 8 participants, involving vid-
eoing and delivered by expert facilitators, are 
most successful  [24, 35, 37] . More pragmatic 
courses include three consecutive small group 
sessions of 3–4 h each, a week or more apart, with 
practice between sessions  [38] . As with patients, 
changing clinicians’ habits is difficult and has to 
start with a belief in the importance and achiev-
ability of the changes. Action plans for imple-
mentation in practice, subsequent review of suc-
cess and troubleshooting closes the training loop 
 [4] . 
 New Models of Learning 
 Some educationalists have called for a broadening 
of concepts of education, away from the conven-
tional pedagogy in medicine where learning is an 
individual enterprise, to a collective activity  [39, 
40] . Clinicians do not work alone and their ac-
tions are determined by many external factors. 
Just as patients have a psychosocial world, so do 
clinicians, and the influence it has on working 
practice should be recognised. The whole culture 
and materiality of the workplace environment af-
fects the daily interactions and practice patterns 
 [1, 41] . An electronic record, for example, that in-
cludes or does not include a section on whether 
comorbidity has been screened for will affect 
practitioners’ behaviour and should be included 
in training about consultations. Such systems’ en-
ablers and barriers need to be recognised for 
training to be real and credible. Observing prac-
tice ‘in situ’ strengthens both learners’ and teach-
ers’ abilities to engage with performance in prac-
tice. As communication within teams is essential 
and liaison and referrals are important, team 
learning is to be promoted. 
 Conclusions 
 This chapter has addressed the importance of 
training for patient-centred consultations on co-
morbidity and principles of learning to guide the 
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methods and structuring of such training. A spi-
ral curriculum is advocated with interdisciplinary 
teaching, using a variety of educational methods 
and incorporating identification and manage-
ment of comorbidity into summative assess-
ments. 
 Training the trainers is an important compo-
nent of an education strategy so that teachers use 
a learner-centred approach consistent with the 
holistic patient-centred consultation model. With 
training that addresses issues of comorbidity, 
communication skills and the ability to plan man-
agement in a shared decision-making approach, 
our students and trainees will be better prepared 
for the reality of high-quality, modern practice in 
whichever field they work. 
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 Management of Comorbidity of Mental and Physical Illness 
 Abstract 
 The Dialogue on Diabetes and Depression (DDD) is an 
international collaborative effort to address the prob-
lems related to the comorbidity of depression and diabe-
tes. The Association for the Improvement of Mental 
Health Programmes, a Swiss-based NGO, established the 
DDD to raise awareness, coordinate research, develop 
training materials, and organise scientific meetings and 
training courses. The DDD developed the Diabetes and 
Depression African Nursing Training Programme in col-
laboration with the International Council of Nurses to ad-
dress identified needs of nurses in Sub-Saharan Africa to 
whom the delivery of primary healthcare often devolves. 
An international faculty of experts delivered the educa-
tional programme to nurses from seven countries in Sub-
Saharan Africa and involved over 175 participants, most 
of whom have responsibility for the education or in-ser-
vice training of nurses. Participants appreciated the pro-
gramme – especially the opportunity to enhance their 
knowledge of these two common disorders and to prac-
tice new skills to recognise and manage comorbid condi-
tions. This programme is an example of a unique and in-
novative educational effort regarding comorbidity with a 
practical clinical approach. It enables nurses to screen, 
recognise and treat diabetes and depression in Sub-Sa-
haran Africa by promoting a patient-centred collabora-
tive approach model with early recognition and manage-
ment of these comorbid conditions in order to improve 
outcomes and life expectancy in this population. 
 © 2015 S. Karger AG, Basel 
 The Dialogue on Diabetes and Depression 
(DDD), established in 2007, is an international 
collaborative initiative addressing research and 
healthcare needs related to the comorbidity of di-
abetes and depression  [1] . Together with the In-
ternational Council of Nurses, the DDD em-
barked on a capacity-building programme, focus-
sing on nurse training in seven countries in Sub-
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Saharan Africa. The programme aimed at ‘train-
ing the trainers’ to increase capacity in frontline 
healthcare staff to recognise and manage these 
comorbid conditions and to enhance the ability of 
nurses to promote and enact educational pro-
grammes of this nature within their own health-
care systems. 
 Background 
 Thomas Willis, a 17th-century English physi-
cian and anatomist described the association be-
tween depression and diabetes, noting that dia-
betes appeared more frequently in those who 
suffered life traumas or long-term sorrow  [2] . 
Contemporary epidemiological studies suggest 
that at least one third of this population suffer 
from depression  [3, 4] and up to 45% of those 
with diabetes have depressive symptoms not 
amounting to the ICD diagnosis of depressive 
disorders  [5] . Additionally, those suffering from 
depression are at an increased risk of developing 
diabetes  [6] . Studies now clearly point to a bidi-
rectional relationship between diabetes and de-
pression, which is complex in terms of the patho-
genesis, pathophysiology and psychological 
mechanisms. Evidence from high-income coun-
tries suggests that depression with diabetes is as-
sociated with socio-economic status, marital sta-
tus, physical activity and chronic somatic diseas-
es. Psychosocial factors may impact on the 
relationship between socio-economic status and 
depression in people with diabetes, including so-
cial isolation, poor social support, limited cop-
ing ability and burden of work. Overall studies 
have shown an inverse relationship, i.e. the risk 
for depression in diabetes is higher with lower 
socio-economic status. However, the relation-
ship may vary depending on the socio-economic 
context of the particular country. In low-income 
countries, a higher socio-economic status is gen-
erally associated with higher levels of chronic 
disease risk factors, whilst the poor often experi-
ence a higher burden of infectious and chronic 
diseases  [7, 8] . 
 Contemporary evidence demonstrates that ef-
fective treatment of depression in people with di-
abetes depends on a multidisciplinary collabora-
tive approach to optimise a comprehensive pack-
age of care ensuring the best outcomes in terms of 
physical and mental well-being  [9, 10] . Interna-
tional programmes have been introduced to man-
age diabetes in a range of settings, most notably 
those by the International Diabetes Federation 
(IDF)  [11] .
 Within well-integrated healthcare services, 
programmes have been developed for the effec-
tive treatment of depression. By contrast, holistic 
programmes to manage people with comorbid 
depression and diabetes are not yet well estab-
lished despite the evidence available for treating 
this specific comorbidity  [12] . The quality of var-
ious conceptual frameworks varies depending on 
the personnel available and the resources within 
the healthcare system. The preparation and train-
ing of healthcare professionals to deal with such 
comorbid conditions is limited, and this situation 
is probably exacerbated within more deprived 
and challenging healthcare systems where both fi-
nancial and human resources are more limited 
and where deep-rooted layers of stigma and ste-
reotyping exist. As a result, the fragmentation of 
services with poor accessibility may lead to inad-
equate care pathways, lack of seamlessness and a 
delay in any meaningful interventions. This may 
culminate in more complications and overall a 
worse prognosis and clinical outcomes for those 
presenting with these two comorbid conditions 
 [13, 14] . It is often the case that mental healthcare 
professionals feel unable to provide adequate ser-
vices for the physical health of the mentally ill 
population; however, the reverse is also probably 
true  [15] due to training inadequacies and lack of 
experience.
 Another challenge in dealing with the com-
plexity of chronic comorbid conditions is the 
need for a range of skills and the expertise of a 
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multicondition collaborative care approach by a 
multidisciplinary team working together across 
specialities, clinics and distances  [10] . The patient 
with comorbid conditions presents with complex 
challenges requiring education to enhance en-
gagement in self-care management to achieve op-
timal outcomes. This is especially important in 
areas of the world where access to care systems is 
challenged with limited capacity and skill mix.
 To initiate programmes addressing multimor-
bidity, it was decided to select a commonly occur-
ring comorbidity and to use the experience gained 
to design other programmes managing multi-
morbidity in general. Both diabetes and depres-
sion are common disorders with increasing inci-
dences and are associated with a high cost burden 
to society. Both disorders are relatively easy to di-
agnose and have recognised effective treatments 
which have had an impact on reducing the stigma 
associated with them.
 Nurses are an essential part of the interdisci-
plinary team and were selected for this training 
programme because of their broad reach and po-
tential impact on care for patients with such con-
ditions. Nurses are the largest group of healthcare 
professionals in most low- and middle-income 
countries, and are at the critical interface with pa-
tients and their carers. This scenario was consid-
ered especially pertinent for Africa. Hence, the 
aim of the programme was to strengthen the 
nurses’ core competencies in the assessment and 
management of patients with comorbid diabetes 
and depression. The programme adopted a train-
the-trainer approach – empowering nurses to 
train others and to enact countrywide and local 
programmes that address healthcare problems 
related to comorbidity.
 Programme Rollout 
 The African Nurse Training Programme on Dia-
betes and Depression was a collaborative effort 
co-ordinated by the DDD and engaged a number 
of organisations including support from the Lun-
dbeck Institute and the International Council of 
Nurses, which represents nursing associations 
from 135 countries and is made up of more than 
13 million nurses worldwide. The International 
Council of Nurses works to ensure high quality in 
nursing care and the advancement of nursing 
knowledge, and promotes the nursing profession 
as a competent workforce worldwide. 
 A steering group was set up that included rep-
resentatives from the DDD, the International 
Council of Nurses, Lundbeck Institute and inter-
national experts to support the implementation 
of the project. The group used a logic model 
framework to steer the project work within stipu-
lated timeframes. The logic model focuses on 
achieving planned actual change and has been ex-
tensively used in planning, application and evalu-
ation of a range of programmes  [16–19] . It forces 
careful reflection on the relationships between 
outcomes (short and long term), the rationale and 
assumptions within the unique context of the 
programme to be delivered with the necessary ac-
tions and resources required to achieve such out-
comes. Immediate and direct outputs versus 
long-term impacts are also outlined.
 The steering group provided the leadership for 
the design and rollout of the DDD African Nurse 
Training Programme. The first series of training 
sessions included nurses from five countries in 
Africa, namely South Africa, Uganda, Botswana, 
Lesotho and Swaziland. The steering group re-
convened after this first set of sessions to review 
feedback and to further fine-tune the programme 
to meet the needs of nurses and patients in clinical 
practice. They then conducted a second set of 
training sessions in Ethiopia and Kenya. The IDF 
recommended local diabetes educators from 
South Africa and Kenya to participate in the 
workshops to strengthen local knowledge and rel-
evance of the skills and to assist in understanding 
local attitudes and values.
 In planning the educational curriculum, the 
steering group was mindful of the importance of 
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the context of the African countries and consid-
ered political, economic, social and psychological 
factors when designing the programme. The 
steering group also considered how the diagnosis 
and treatment of diabetes or depression, or both, 
needed to fit into different cultural value systems 
and social practices. The complex status of the 
healthcare system and the seemingly poor inte-
gration of mental and physical healthcare in many 
of the countries required careful consideration. It 
was also recognised that there might be limited 
integration between primary and secondary care 
systems as well as a lack of integration between 
the medical and nursing competency frameworks 
in such a multiprofessional initiative.
 The nurses who participated in the programme 
were exposed to a total of ten educational mod-
ules. Interactive sessions included role-play, in-
terviewing and assessment, self-management, 
and train-the-trainer guidance to implement the 
programme and deal with the environment. The 
International Faculty Steering Group prepared 
the educational materials in a modular format 
with each participant receiving a binder contain-
ing the programme outline, module outline, nar-
ratives, fact sheets, instruments and tools, and 
evaluation forms. The content used the evidence-
based integrated approach to the recognition and 
management of diabetes and depression with the 
most up-to-date literature in the field.
 The co-ordinators of each of the workshops 
promoted an interactive and participatory teach-
ing and learning approach including opportuni-
ties for role-play, assessment and interviewing 
under their supervision. The last session in each 
of the programmes focused on the development 
of an action plan for the participant to ensure a 
focus on changes in clinical practice and a com-
mitment by each nurse to meet their goals and 
expected outcomes from the course. The Interna-
tional Council of Nurses monitors these action 
plans and the steering group use them for ongo-
ing evaluation of the impact of the programme on 
the practice of these nurses.
 In reflecting on the outcomes as stated by the 
logic model, the following challenges presented 
themselves in the designing and planning of the 
programme.
 Develop Core Competencies and Capacity in the 
Field 
 Teaching the management of a patient with co-
morbid conditions presented a unique education-
al challenge because the relevant skills and knowl-
edge had to be imparted to groups of nurses who 
were either from a mental health or a general 
nursing background. It was important to inte-
grate the new knowledge and skills with the base-
line of knowledge and skills that the nurses had in 
their area of expertise. A questionnaire was sent 
to prospective participants in advance to establish 
baseline knowledge and clinical practices. The 
data from this survey assisted in informing the 
development of the theoretical and applied con-
tent. Comprehensive slide sets, narratives and 
fact sheets were prepared to provide the necessary 
documentary support for all participants, and 
emphasis was placed on interactive teaching and 
learning practices, such as through the use of case 
studies and role-plays to strengthen critical think-
ing and problem-solving skills. 
 The selection of the participants in the courses 
was given careful attention because it was expect-
ed that the nurses participating in the course 
would become ambassadors for the programme, 
drivers of initiatives for better care of patients 
with comorbid diseases and trainers – using the 
educational material provided as a resource and 
basis.
 Facilitate Change in the Environment 
 The steering group considered the rollout of the 
programme and public involvement as important 
aspects of the programme. In most cases, a repre-
sentative of the DDD preceded the arrival of the 
faculty to the country to meet the organisers from 
the national nursing association and to make con-
tact with policy makers, patient and family organ-
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isations, and key contacts in the media. The DDD 
representative organised interaction with local 
government officials and senior healthcare advi-
sors, and considered them as critical to assist in or 
facilitate policy change. The faculty members also 
assumed the roles of advocates, participating in 
local media opportunities (including local radio 
and television interviews) and discussions with 
local politicians. Where feasible, the national 
nursing associations invited important stake-
holders and the media to public meetings where 
patients told their own stories, seamlessly inte-
grating their personal experiences of, for exam-
ple, stigma, assessment and treatment. 
 Within the programme, the faculty made par-
ticipants aware of their own responsibilities 
working in the field of diabetes and depression. 
They encouraged them to consider the potential 
barriers hindering the patients’ commitment to 
changes in lifestyle as well as engagement with 
self-help and treatment. They advocated reflec-
tion on their own clinical practice and the need to 
embrace evidence-based competencies. The or-
ganisation of the workshops with their unique ex-
posure to international experts, well-designed 
material, and contemporary teaching and learn-
ing strategies was intended to make a difference 
in the lives of all concerned. The sessions promot-
ed networking as a strong conduit to address 
quality issues by encouraging collaborative work 
in groups, organisations and within the regional 
political structures.
 Address Issues of Stigma in the Diagnosis of 
Diabetes and Depression 
 The course placed particular importance on the 
recognition of the role of stigma in the manage-
ment of comorbidity  [20] . Although stigmatisa-
tion was not addressed in a specific module, the 
faculty and participants within the group work 
explored the realities of stigma from avoidance of 
recognition to management of the comorbid con-
ditions. It was important to discuss the stigmati-
sation issues within the wider cultural context 
and how they applied to diabetes and depression. 
Context-specific strategies were discussed, espe-
cially in relation to personal and public cam-
paigns and collaborative actions. It is, however, a 
challenge to change the way healthcare users with 
comorbid disease are perceived, assessed and 
treated. These challenges are even more pro-
nounced in lower income countries, in less-effec-
tive healthcare systems and in the presence of 
stigmatisation and stereotyping. 
 Workshop Implementation and Evaluation 
 A total of 175 clinical nurse practitioners and 
nurse educators were trained in the six work-
shops held in South Africa, Botswana, Swaziland, 
Uganda, Ethiopia and Kenya. The DDD, the In-
ternational Council of Nurses and the Lundbeck 
Institute provided the logistical support for the 
identification of participants and organisation of 
workshops. The International Council of Nurses 
worked closely with local nursing organisations 
to identify and select nurses representing a range 
of educational and healthcare settings. The Inter-
national Council of Nurses accredited the work-
shops and provided each participant with a for-
mal certificate of completion. As follow-up, each 
participant developed an action plan to guide 
them in the incorporation of the new knowledge 
and skills into their practice. 
 The steering group developed an evaluation 
instrument that addressed the outcomes of each 
module and items related to the teaching meth-
ods. The latter items were kept constant to facili-
tate ease of use. Participants evaluated each item 
using a Likert scale with 5 being the highest or 
best scoring. An opportunity for open-ended re-
sponses was also provided for each module and a 
final part of the evaluation instrument allowed 
the participants to reflect on the workshop as a 
whole.
 The system of formal participant feedback was 
explained to participants at the start of the pro-
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gramme. At the time of writing this chapter the first 
146 sets of evaluation forms were received, but in-
dividual item responses varied from 106 to 146 be-
cause of various factors. Survey Monkey software 
was used to analyse the quantitative data whilst the 
qualitative responses were transcribed and catego-
rised, and themes developed from the data.
 Results 
 The participants’ overall evaluation of the work-
shop was positive with mean scores not lower 
than 4.69 of a maximum of 5. Participants espe-
cially appreciated the useful exchange of knowl-
edge, values and skills, and considered the public 
event an important achievement. The qualitative 
responses echoed these positive results with clear 
reference to the value of and approach to the 
workshops. Participants considered the work-
shops to be ‘eye opening’ and ‘straightforward’ – 
appreciating the presence and approach used by 
experts throughout. The quality of the organisa-
tion was also highlighted. 
 Within the first rollout, participants made a 
number of recommendations that resonated well 
with the experience and expressed opinions of the 
steering group. These included:
 • Provision of further support and monitoring 
of actions, such as drug fact sheets, 
conversation maps and the involvement of 
local multidisciplinary teams in further 
training 
 • Introduction of even more interactive work 
such as role-plays and group work 
 • Refining some workshop material, the flow of 
certain modules and time allocation for the 
modules on diagnosis and assessment of 
depression in people with diabetes 
 • Fine-tuning of the workshop evaluation 
format and the management of post-
workshop expectations 
 • Identification of barriers to change and 
mechanisms to deal with such; mostly 
through new partnerships and community 
capacity building 
 It was meaningful that the participants high-
lighted specific skills and tools in their feedback. 
The demonstration and introduction of the Pa-
tient Health Questionnaire (PHQ9) for the as-
sessment of depression was considered useful for 
their practical clinical setting  [21] . The partici-
pants considered the PHQ9 ‘wonderful and will 
be embraced’. The nominal group technique  [22, 
23] as adapted by the educational expert in the 
steering group was viewed as meaningful for en-
hancing group participation. Motivational inter-
viewing was considered an essential technique to 
be included in future nursing curricula.
 Discussion 
 Participants and facilitators considered the first 
phase of this project as successful and the feed-
back guided the final phase of the programme 
that incorporated the above. The integration of 
training about the two conditions of depression 
and diabetes within the context of comorbidity 
was challenging and this series of workshops pro-
vided valuable pointers on how to achieve this ef-
fectively. It was clear that nurses and most other 
healthcare professionals still undergo training 
that emphasises systems-based or disease-orient-
ed models. The comorbidity framework provides 
new insights and ways of thinking and implemen-
tation – both in education and clinical practice 
 [10] . This model encourages multiprofessional 
working with case management, a structured 
management plan and enhanced interprofession-
al communication. There is now growing evi-
dence that collaborative care can successfully im-
prove depression and diabetes outcomes with 
cognitive behaviour therapy enhancing diabetes 
self-management, reducing diabetes morbidity, 
improving stability and treating depression effec-
tively. In addition, other risk factors, such as low-
density lipoprotein and cholesterol levels as well 
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as high blood pressure, can be better controlled by 
adoption of this person-centred collaborative 
model of care  [9] . Rushton et al.  [24] confirmed 
the need for health professionals to rethink how 
to manage patients with multiple healthcare con-
ditions, given that the care environment itself re-
mains fragmented. 
 It was clear to the steering group that the selec-
tion of participants for such programmes should 
be more focused and differentiated; for example, 
there is a need to focus more on nurse educators 
in future programmes and to provide a variety of 
modules to meet the needs and backgrounds of 
different groups at different times. It was also ac-
knowledged that multiprofessional collaboration 
is critical and that specific sessions and applied 
exercises are needed to drive home the complexi-
ties of comorbid disease assessment and treat-
ment.
 Limitations of the Programme 
 Being the first round of this type of programme, 
it was considered important to provide partici-
pants with an evaluation form for each module 
and one for the overall workshop. The feedback 
provided valuable insights to the steering group, 
but it is acknowledged that data collection instru-
ments of this nature tend to elicit more subjective 
responses. The Likert scale is relatively easy to 
use, but suffers from traditional concerns such as 
participant honesty, interpretation of the scale, 
feeling-bias and (in this case) a laborious analysis 
process. It is, however, important to note that the 
qualitative data provided by participants corre-
sponded well with the Likert-type scale findings. 
 Next Steps in Comorbidity Training 
 Organising the delivery of services in such a way 
that collaborative and coordinated care is possi-
ble requires the buy-in of not only the other rel-
evant healthcare professionals, but also those in a 
position to restructure the health system and del-
egate responsibilities appropriately. Subsequent 
skill and knowledge training of other primary 
and secondary healthcare professionals would be 
necessary and is recommended as a follow-up to 
nurse training. Additional resources and the 
commitment of the trained trainers to cascade 
the learning from the African Nurse Training 
Programme to other new and practicing nurses 
will be essential to the institutionalisation of the 
concepts and the broad-scale benefits to affected 
patients. 
 The International Council of Nurses and the 
national nursing associations should prioritise 
the further dissemination of the knowledge and 
skills from the African Nurse Training Pro-
gramme by establishing regional centres of excel-
lence to institutionalise the concepts and maxi-
mise their adoption in nursing practice.
 The programme as designed forms a good 
baseline to be adapted for other healthcare pro-
fessionals and multiprofessional groups. Such a 
rollout would provide further strength to the ini-
tiative to better manage and support patients with 
comorbid conditions. Material would also be 
coded for use as half day, full day or 2.5 days – de-
pending on participant needs, timeframe and re-
sources available.
 To further support this aim, an integrated 
manual, which will serve as a comprehensive ref-
erence, is in process. This manual will also in-
clude guidelines for logistical and other arrange-
ments of such a programme, pre-workshop mate-
rial and action plans. Heuristic hints for the 
development of good case studies, role-plays and 
other teaching and learning activities would pro-
vide further guidance.
 Another action relates to the strengthening of 
multiprofessional, and especially nursing, re-
search relating to comorbidity within Africa. An 
example would be PhD and Masters research 
projects that strengthen care outcomes for pa-
tients with comorbid disease.
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 Conclusions 
 Using the comorbidity of disease framework as a 
legitimate springboard for redesigning both for-
mal and informal educational programmes is 
warranted, feasible and acceptable. The frame-
work rings true to the clinical challenges of medi-
cine in the 21st century, with the increasing prev-
alence of comorbidity and how patients present 
in healthcare systems. Stigmatisation remains a 
serious concern in many cultural contexts, and 
good research and clinical work that addresses 
this issue directly and indirectly within a comor-
bidity of disease framework would contribute to 
equitable access and better-quality healthcare. 
 Further follow-up of the participants’ progress 
from the African experience in relation to chang-
es in clinical practice will help to inform and op-
timise the benefits of such future programmes. 
Given the positive African experience, the faculty 
is better equipped and more confident in their 
ability to deliver such comorbidity programmes 
in other culturally challenging environments.
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 Management of Comorbidity of Mental and Physical Illness 
 Abstract 
 This chapter considers the difficulties posed by the direc-
tion in which healthcare has developed across the world, 
in particular problems arising from fragmentation and 
specialisation of care provision. There has been an in-
creasing recognition of the need for improved systems 
of primary care; however, there is no universal model of 
provision, and barriers to the management of physical 
and mental comorbidity can be identified in primary care 
settings. Models of collaborative care which derive from 
the Chronic Care Model have shown some promise in 
management of comorbidity. In order to improve out-
comes for people who present with comorbid and mul-
timorbid health problems, healthcare professionals in all 
settings will need to acquire a range of specific skills. 
These include being able to explore the impact of physi-
cal and mental health problems on the patient, and the 
negotiation of patient-centred goals. 
 © 2015 S. Karger AG, Basel 
 Other chapters in this book have described the 
nature and magnitude of the problems facing 
healthcare in addressing the problem of multi-
morbidity, and the challenges posed by comor-
bidity of physical and mental health problems in 
particular. At the heart of this challenge is the 
need for us not to lose sight of the needs of the 
 person who is seeking help for his/her ailments, 
from the macro-level of designing healthcare 
systems to the micro-level of interaction be-
tween doctor and patient within the consulting 
room. 
 The Fragmentation of Healthcare 
 Heath systems are increasingly fragmented. Even 
the British National Health Service, which histor-
ically has a strong orientation to primary care, has 
become less integrated in the way it delivers care. 
At the organisational level this is reflected in an 
ever-increasing number of different ‘providers’ 
being ‘commissioned’ to deliver care – some prof-
it-making, some not-for-profit – and each one of 
them requiring an army of administrative staff 
(and not a few lawyers) to negotiate the detailed 
contracts, performance management and finan-
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cial arrangements that go with them. Hospitals 
are moving to take over and develop community 
resources such as services for older people to in-
tegrate them ‘vertically’, but in doing so loosen 
the ‘horizontal’ ties they have with other services, 
the most important of these being primary care. 
Within primary care, a payment-for-perfor-
mance system called the ‘Quality and Outcomes 
Framework’ rewards doctors according to criteria 
based on single diseases rather than management 
of multimorbidity  [1] . 
 Take for instance John, who is 58 years old and 
has multiple health concerns, diabetes, coronary 
heart disease, arthritis and severe depression fol-
lowing the death of his wife. In the past he went 
to his general practitioner when he did not feel 
well, but now he does not know where he should 
go. There seem to be far more doctors at the prac-
tice than there used to be, but he does not seem to 
know any of them very well, and it seems harder 
to see the same doctor each time than it once was. 
According to the practice website, the doctors 
now have particular expertise in certain diseases 
(such as diabetes or coronary heart disease). Does 
that mean he should go and see different doctors 
for each problem? He is called in for appoint-
ments with the practice nurse to review how he is 
doing with his diabetes as she works her way 
through the patients on the diabetes register. Next 
week he may be asked to come in for a different 
review appointment for his cardiovascular dis-
ease, generated by another disease register to 
meet the needs of reporting in the Quality and 
Outcomes Framework. John’s experience is of be-
ing ‘under surveillance’ and ‘monitored’  [2] rath-
er than being an active participant in care. The 
practice has put up a sign saying it is now run by 
Angel Healthcare Providers for the NHS. Are not 
they a commercial company?
 In addition to these ‘review’ appointments at 
the general practitioner practice, he has outpa-
tient appointments with specialists at the hospital 
every now and then, for his mental health and ar-
thritis, but each doctor he sees pays attention only 
to their own specific area of expertise. The psy-
chiatrist John sees never seems to know what 
blood tests his doctor has done recently for his 
diabetes, which is not well controlled at the mo-
ment, and says that their computer systems ‘don’t 
talk to each other’. Nobody seems to be able to 
help him prioritise one appointment above an-
other if they clash and he cannot make it to both; 
attending all of them is a great deal of work  [3] , 
sometimes rather like a full-time job. When he 
missed an appointment once, he was discharged 
from a clinic and his general practitioner had to 
re-refer him. He no longer works, but he does not 
think he would be able to anyway, as all this ‘self-
management’ takes so much time.
 It sometimes feels to John as though nobody is 
actually interested in finding out what is worrying 
 him about his health in the midst of all this fre-
netic yet increasingly fragmented ‘provider’ activ-
ity. He muddles through somehow. His daughter 
is worried about him, but she is not sure which 
doctor is the right person to tell and neither is 
John.
 The Consequences of Specialisation and 
Fragmentation 
 There is nothing unusual about John’s story. In 
some countries his story would even be more 
complex as he might also have to become in-
volved in discussion with insurance companies 
about the cost of his care. John has access to more 
scientifically informed healthcare than at any pe-
riod in the past. Yet the expansion in specialist 
information which has been generated has come 
without an improvement in our ability to inte-
grate this knowledge optimally to meet John’s 
personal needs. The World Health Organisation 
(WHO)  [4] has drawn attention to this character-
istic trend that is shaping health systems today: 
 • A disproportionate focus on specialist, 
tertiary care, or ‘hospital centrism’: in 
member countries of the Organisation of 
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Economic Cooperation and Development 
(OECD), the 35% growth in the number of 
doctors between 1990 and 2005 was driven by 
a nearly 50% increase in specialists compared 
with a 20% rise in general practitioners  [5] 
 • Fragmentation as a result of the 
multiplication of specialist programmes and 
projects built around ‘priority programmes’ 
focussed on single-disease control 
 • The pervasive commercialisation of 
healthcare in unregulated healthcare systems 
 In an editorial article in  Annals of Family Med-
icine , Kurt Stange  [6] highlighted the conse-
quences of our increasingly specialised and frag-
mented healthcare systems ( table 1 ). For the per-
son with multimorbidity, the primary care 
professional, doctor or nurse, is a key person in 
helping them to navigate an increasingly complex 
landscape  [7] .
 The Importance of Primary Care 
 The Alma Ata Declaration  [8] defined primary 
care thus: ‘the role of primary health care as the 
local, universally available, essential, first point of 
contact with the health system, based on practi-
cal, scientifically sound and socially acceptable 
methods and technology at a cost the community 
and country can afford’. 
 Numerous studies from multiple countries 
have shown that when systems are organised 
around primary care, outcomes are better with 
improved equity and lower costs. For example, 
when people have a primary care doctor as op-
posed to a specialist as their personal physician, 
their mortality risk drops by nearly 20% and their 
costs are about one third less  [7] .
 The WHO views the development of primary 
healthcare as one of the key challenges for health 
system reform  [4] . More than 30 years after the 
Alma Ata Declaration, the vision of primary care 
for all has yet to be achieved, but according to 
Gunn et al.  [9] the generalist holds the key to pro-
viding truly personalised care (p. 111):
 A fundamental role of the generalist is to balance 
the biotechnical with the biographical. The generalist 
must know and understand how each life story and so-
cial context are constantly influencing and being influ-
enced by physical and emotional health. To achieve the 
balance between the biotechnical and biographical as-
pects of each interaction, the generalist must have the 
skills to reach a mutual understanding of the priorities 
and challenges that individual patients face when man-
aging their health.
Table 1.  The consequences of fragmentation inefficiency: the most fragmented healthcare systems in the world are 
also the most expensive (adapted from Stange [6])
Ineffectiveness spending more on the parts, such as through narrowly focussed pay-for-performance 
schemes does not improve the whole
Inequality in a fragmented healthcare system people fall between a patchwork of ‘safety nets’ and 
specific barriers to access (e.g. for ethnic minority groups) are not addressed
Commoditisation disease management programmes support narrow evidence-based care rather than 
 integrated care; patients become ‘customers’ and doctors become ‘providers’
Commercialisation healthcare becomes ‘market driven’
De-professionalisation professionals become technicians delivering a narrow slice of care
De-personalisation and 
dissatisfaction
both patients and professionals are unhappy with their experience of the system
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 This very personal model of care is neverthe-
less greatly challenged by the forces such as those 
described above  [1] , which seek to fragment the 
process and provision of care in the belief that 
this will lead to improved quality of care  [10] . In-
novations such as the Quality and Outcomes 
Framework in the UK focus on single diseases 
rather than multimorbidity, and solely on dis-
ease-centred outcomes rather than also taking 
into consideration the patient’s goals. This is par-
ticularly problematic when managing people 
with complex comorbid and multimorbid condi-
tions  [1] .
 Across the world, providers of primary care 
include not only doctors who have received spe-
cific vocational training in family medicine (in-
cluding general internal medicine and general 
paediatrics in some countries such as the USA), 
but also non-physician primary care providers 
(such as nurses and physician assistants). Non-
primary care physicians, in particular gynaecolo-
gists but also other specialists including psychia-
trists, may also provide patient care services that 
are usually delivered by primary care physicians. 
These may focus on particular needs related to 
care such as prevention or chronic care, but they 
do not provide these services in the context of 
comprehensive, first contact and continuing care 
which is what characterises family medicine. 
Nevertheless, it is crucial that such specialists 
have a basic understanding of the diseases that are 
comorbid with those in which they specialise; for 
example, the need for psychiatrists to understand 
the role played by cardiovascular disease in the 
excess mortality and morbidity of people with a 
diagnosis of severe and enduring mental illness 
 [11] .
 However, a crucial challenge faced by those 
seeking to develop services for comorbid physical 
and mental health problems is that patients them-
selves vary in how much they want to share their 
emotional problems with those caring for their 
physical health problems. Mental health prob-
lems still carry significant stigma, and addition-
ally a person may feel that, in wanting to raise 
‘personal’ issues, there is a sense that the profes-
sional is trying to dismiss the severity of physical 
symptoms or talk about issues which do not seem 
to the patient to be relevant to the problem they 
present. This is something we have particularly 
observed when patients present with what seem 
to the doctor to be ‘medically unexplained symp-
toms’  [12] ; however, in a recent study of the im-
plementation of a new model of care for depres-
sion and cardiovascular disease, uncertainty was 
also raised by some patients (and professionals) 
about how much they wanted physical and men-
tal healthcare to be more integrated  [13] . We have 
also noted that both primary care doctors, osten-
sibly providing holistic care for the person, and 
patients with long-term conditions may collude 
to avoid discussing emotional problems, prefer-
ring instead to keep to the ‘safer ground’ of phys-
ical health and ‘normalising’ the distress associ-
ated with conditions, such as diabetes and cardio-
vascular disease, rather than daring to try and 
raise the possibility that this might be ‘depression’ 
 [14] . These form significant barriers to both de-
tecting and managing emotional problems in the 
setting of long-term conditions and mean that 
professionals need to work hard to engage people 
sensitively in talking about their emotional prob-
lems (see below).
 Similar barriers occur in the detection and 
management of physical illness in people with 
long-term mental health problems. Many people 
with severe and enduring mental illness do not 
feel stigmatised when receiving treatment in the 
setting of primary care  [15] , but some undoubt-
edly do  [16] . In the UK, a significant minority do 
not attend their general practitioner for the rou-
tine physical health checks for which general 
practitioners are now financially rewarded. The 
degree to which people with severe mental illness 
receive equivalent physical healthcare to the gen-
eral population from either primary care  [17] or 
alternatively within mental health services  [18] 
remains debatable.
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 Developing Novel Models of Care for 
Comorbidity and Multimorbidity 
 In recent years, numerous disease-management 
programs, incorporating clinician interventions 
(education, feedback, reminders) and/or patient 
interventions (education, reminders, financial in-
centives), to improve quality of care and out-
comes for people with long-term conditions have 
been described in the literature. These programs, 
the best known of which is the Chronic Care 
Model developed by Wagner et al.  [19] in Seattle, 
have been developed and extensively evaluated 
for single conditions, but less commonly for dis-
eases in combination. A recent systematic review 
of complex interventions for patients with multi-
morbidity identified 10 randomised controlled 
trials, of which only 3 provided data on mental 
health outcomes  [20] . 
 However, there is now a growing body of lit-
erature on interventions for comorbid diabetes 
and depression. The Chronic Care Model in-
formed the development of collaborative care ( ta-
ble  2 ) which has been extensively evaluated for 
the management of depression  [21, 22] .
 A recent meta-analysis of 14 randomised con-
trolled trials of interventions for depression in the 
setting of diabetes with a total of 1,724 patients 
 [22] showed that treatment was effective in terms 
of reduction of depressive symptoms, but the ef-
fect on glycaemic control was substantially small-
er. Collaborative care (utilising the components 
described below), which provided a stepped care 
intervention with a choice of starting with psy-
chotherapy or pharmacotherapy, to a primary 
care population yielded an effect size of  − 0.292 
(95% CI:  − 0.429 to  − 0.155, n = 1,133) for depres-
sion outcomes. This is a moderate effect size, but 
the studies were based on community samples 
with few exclusion criteria (unlike studies of psy-
chotherapies based in specialist settings), indicat-
ing this effect size could potentially be attained on 
a population scale. The authors concluded by say-
ing, ‘improvement of the general medical condi-
tion including glycemic control is likely to require 
simultaneous attention to both conditions.’
 Reviewing the literature on the content of 
these complex interventions, Piette et al.  [23] sug-
gested an effective organisational management 
strategy for diabetes and depression should in-
clude all the following elements: (1) systematic 
identification of patients with diabetes and de-
pression and quality-of-care reviews, (2) proac-
tive patient monitoring between outpatient en-
counters, (3) intensive efforts to co-ordinate 
treatment across clinicians, (4) increased access 
to cognitive-behavioural or related therapies ad-
dressing patients’ depressive symptoms  and dia-
betes self-care, and (5) an emphasis on promoting 
physical activity to address both depressive symp-
toms and physiologic dysregulation.
 Katon et al. in the TEAMcare study [ 24 ] have 
now both successfully addressed multimorbidity 
and improved physical and mental health out-
comes. A specially trained and supported case 
manager was employed to ‘treat to target’ both 
Table 2.  Elements of collaborative care (adapted from Gunn et al. [30])
Multiprofessional approach to patient care provided by a case manager working with the family doctor under weekly 
supervision from specialist mental health medical and psychological therapies clinicians
A structured management plan of medication support and brief psychological therapy
Scheduled patient follow-ups
Enhanced interprofessional communication of patient-specific written feedback to family doctors via electronic 
 records and personal contact
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depression and other chronic disease-related out-
comes in the primary care setting, achieving sig-
nificant improvements in both. The TEAMcare 
nurse was integrated into primary care and super-
vised weekly by a psychiatrist and primary care 
physician. The intervention improved glycaemic 
control, lipid profile, systolic blood pressure and 
depression symptoms compared to usual primary 
care.
 Implementing collaborative care into routine 
practice poses challenges. In the USA, the 
 IMPACT model for depression care in older peo-
ple with comorbid physical health problems has 
been implemented in a range of healthcare sys-
tems across the country  [25] , and this has also 
been highly influential internationally. Major 
changes (including re-allocation of resources) are 
needed to implement disease management and 
collaborative care models, and investment in clin-
ical electronic information systems is essential 
 [26] . Re-designed systems and care pathways 
must implement more frequent follow-up and 
routine monitoring of outcomes by case manag-
ers, promote integration of specialists into prima-
ry care to provide supervision and support, and 
develop self-management systems for patients 
and professionals. There are also problems in de-
livering such complex interventions in healthcare 
systems where the general practitioner works 
alone without any additional person who might 
take the role of the ‘case manager’. In these set-
tings a more traditional approach to ‘collabora-
tive care’ of developing the skills of the general 
practitioner in systematically following-up peo-
ple with common chronic conditions with the 
support and supervision of specialists may still be 
the way forward  [27] .
 In the USA the concept of the ‘patient-centred 
medical home’ is a delivery system and re-im-
bursement reform that aims to reduce care frag-
mentation and other inefficiencies associated 
with chronic disease management. Its supporters 
describe four ‘cornerstones’ that serve as the con-
ceptual foundation for a successful medical 
home: (1) engaging patients actively in medical 
decision-making and enhancing their access, (2) 
incorporating evidence-based processes of care 
into practice, (3) adopting new payment struc-
tures that reimburse care activities occurring 
outside the traditional office visit and (4) en-
hanced primary care  [28] . There is increasing 
recognition of the crucial role that primary care 
has in providing both mental healthcare for peo-
ple with chronic illness and physical healthcare 
for people with severe mental illness in the ‘med-
ical home’  [29] .
Table 3.  Key skills for managing people with comorbid physical and mental health problems
Sensitively engaging the patient in discussing their worries and concerns
Finding out about the patient’s problems
Exploring the impact of physical and mental health problems on the patient (and on each other)
Eliciting health beliefs
Clarifying and negotiating the patient’s goals (and how these relate to their healthcare including self-management 
of chronic illness)
Motivating the patient to achieve their goals
Developing a therapeutic plan with the patient through shared decision-making
Employing simple psychological strategies (e.g. behavioural activation and problem solving) to help the person to 
achieve their goals
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 Developing the Skills of Professionals 
 Finally, from our knowledge of the potential 
barriers to effective management, it is clear that 
at a micro-level the attitudes of professionals to-
wards changing practices need to be challenged 
and knowledge needs to be acquired about com-
mon comorbidities they are likely to see in prac-
tice. For example, a psychiatrist may not be ac-
tively involved in managing a patient’s diabetic 
care, but they should be able to recognise it and 
be able to work collaboratively with a physician 
in arranging care. Specific skills will need to be 
acquired by health professionals across the spec-
trum (including those who work in mental 
healthcare who cannot be assumed will possess 
all of these skills) to optimise the care for people 
who present with comorbid emotional and 
physical health problems ( table 3 ). Acquisition 
of these skills will need to become embedded 
early in professional training if we are to meet 
the challenge successfully of developing more 
patient-centred services for comorbidity in the 
future. 
 References 
 1 Bower P, Macdonald W, Harkness E, 
Gask L, Kendrick T, Valderas JM, Sib-
bald B: Multimorbidity, service organi-
zation and clinical decision making in 
primary care: a qualitative study. Fam 
Pract 2011; 28: 579–587. 
 2 Chew-Graham CA, Hunter C, Langer S, 
Stenhoff A, Drinkwater J, Guthrie EA, 
Salmon P: How QOF is shaping primary 
care review consultations: a longitudinal 
qualitative study. BMC Fam Pract 2013; 
 14: 103. 
 3 Vassilev I, Rogers A, Blickem C, Brooks 
H, Kapadia D, Kennedy A, Sanders C, 
Kirk S, Reeves D: Social networks, the 
‘work’ and work force of chronic illness 
self-management: a survey analysis of 
personal communities. PLoS One 2013; 
 8:e59723. 
 4 World Health Report 2008: Primary 
Care – Now More than Ever. Geneva, 
WHO, 2008. 
 5 OECD health data; in: World Health 
Report 2008: Primary Care – Now More 
than Ever. Geneva, WHO, 2008, p 10. 
 6 Stange K: The problem of fragmentation 
and need for integrative solutions. Ann 
Fam Med 2009; 7: 100–103. 
 7 Ford D: Optimizing outcomes for pa-
tients with depression and chronic med-
ical illnesses. Am J Med 2008; 121:S38–
S44. 
 8 Primary Health Care Report of the In-
ternational Conference on Primary 
Health Care, Alma Ata, 6–12 September 
1978. Geneva, World Health Organiza-
tion, 1978. 
 9 Gunn JM, Palmer VJ, Naccarella L, Ko-
kanovic R, Pope CJ, Lathlean J, Stange 
KC: The promise and pitfalls of general-
ism in achieving the Alma-Ata vision of 
health for all. Med J Aust 2008; 189: 110–
112. 
 10 Mangin D, Toop L: The Quality and 
Outcomes Framework: what have you 
done to yourselves? Br J Gen Pract 2007; 
 57: 435. 
 11 De Hert M, Dekker JM, Wood D, Kahl 
KG, Holt RI, Möller HJ: Cardiovascular 
disease and diabetes in people with se-
vere mental illness position statement 
from the European Psychiatric Associa-
tion (EPA), supported by the European 
Association for the Study of Diabetes 
(EASD) and the European Society of 
Cardiology (ESC). Eur Psychiatry 2009; 
 24: 412–424. 
 12 Peters S, Rogers A, Salmon P, Gask L, 
Dowrick C, Towey M, Clifford R, Mor-
riss R: What do patients choose to tell 
their doctors? Qualitative analysis of 
potential barriers to reattributing medi-
cally unexplained symptoms. J Gen In-
tern Med 2009; 24: 443–449. 
 13 Knowles SE, Chew-Graham C, Coupe N, 
Adeyemi I, Keyworth C, Thampy H, 
Coventry PA: Better together? A natu-
ralistic qualitative study of inter-profes-
sional working in collaborative care for 
co-morbid depression and physical 
health problems. Implement Sci 2013; 8: 
 110. 
 14 Coventry PA, Hays R, Dickens C, Bundy 
C, Garrett C, Cherrington A, Chew-Gra-
ham C: Talking about depression: a 
qualitative study of barriers to manag-
ing depression in people with long term 
conditions in primary care. BMC Fam 
Pract 2011; 12: 10. 
 15 Lester H, Tritter JQ, Sorohan H: Pa-
tients’ and health professionals’ views 
on primary care for people with serious 
mental illness: focus group study. BMJ 
2005; 330: 1122. 
 16 Schizophrenia Commission. The Aban-
doned Illness: A Report from the Schizo-
phrenia Commission. London, Rethink 
Mental Illness, 2012. 
 17 Osborn DP, Baio G, Walters K, Petersen 
I, Limburg H, Raine R, Nazareth I: In-
equalities in the provision of cardiovas-
cular screening to people with severe 
mental illnesses in primary care: cohort 
study in the United Kingdom THIN Pri-
mary Care Database 2000–2007. 
Schizophr Res 2011; 129: 104–110. 
 18 Lawrence D, Kisely S: Inequalities in 
healthcare provision for people with 
severe mental illness. J Psychopharma-
col 2010; 24(4 suppl):61–68. 
 19 Wagner EH, Austin BT, Von Korff M: 
Organizing care for patients with chron-
ic illness. Milbank Q 1996; 74: 511–544. 
 20 Smith SM, Soubhi H, Fortin M, Hudon 
C, O’Dowd T: Managing patients with 
multimorbidity: systematic review of 
interventions in primary care and com-
munity settings. BMJ 2012; 345:e5025. 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 157–164 ( DOI: 10.1159/000365600 )
164  Gask 
 21 Archer J, Bower P, Gilbody S, Lovell K, 
Richards D, Gask L, Coventry P: Collab-
orative care for depression and anxiety 
problems. Cochrane Database Syst Rev 
2012; 10:CD006525. 
 22 van der Feltz-Cornelis CM, van der Nuy-
en J, Stoop CH, Chan J, Jacobsen AM, 
Katon W, Snoek F, Sartorius N: Effect of 
interventions for major depressive dis-
order and significant depressive symp-
toms in patients with diabetes mellitus: 
a systematic review and meta-analysis. 
Gen Hosp Psychiatry 2010; 32: 380–395. 
 23 Piette JD, Richardson C, Valenstein M: 
Addressing the needs of patients with 
multiple chronic illnesses: the case of 
diabetes and depression. Am J Manag 
Care 2004; 10: 152–162. 
 24 Katon WJ, Lin EH, Von Korff M, Ciech-
anowski P, Ludman EJ, Young B, Mc-
Culloch D: Collaborative care for pa-
tients with depression and chronic 
illnesses. N Engl J Med 2010; 363: 2611–
2620. 
 25 Unützer J, Powers D, Katon W, Langs-
ton C: From establishing an evidence-
based practice to implementation in 
real-world settings: IMPACT as a case 
study. Psychiatr Clin North Am 2005; 28: 
 1079–1092. 
 26 Gunn J, Palmer V, Dowrick C, Herrman 
H, Griffiths F, Kokanovic R, Blashki G, 
Hegarty K, Johnson C, Potiriadis M, 
May C: Embedding effective depression 
care: using theory for primary care orga-
nizational and systems change. Imple-
ment Sci 2012; 5: 62. 
 27 Menchetti M, Sighinolfi C, Di Michele 
V, Peloso P, Nespeca C, Bandieri PV, 
Berardi D: Effectiveness of collaborative 
care for depression in Italy. A random-
ized controlled trial. Gen Hosp Psychia-
try 2013; 35: 579–586. 
 28 Croghan TW, Brown JD: Integrating 
Mental Health Treatment into the Pa-
tient Centered Medical Home. Rockville, 
Agency for Healthcare Research and 
Quality, 2010. 
 29 Croghan TW, Brown JD: Integrating 
Mental Health Treatment Into the Pa-
tient Centered Medical Home. (Prepared 
by Mathematica Policy Research under 
Contract No. HHSA290200900019I 
TO2.) AHRQ Publication No. 10-0084-
EF. Rockville, Agency for Healthcare 
Research and Quality, 2010.
30 Gunn J, Diggens J, Hegarty K, Blashki G: 
A systematic review of complex system 
interventions designed to increase re-
covery from depression in primary care. 
BMC Health Serv Res 2006;6:88.
 Linda Gask, PhD, FRCPsych 
 Centre for Primary Care, Institute of Population Health 
 5th Floor Williamson Building, University of Manchester 
 Oxford Road, Manchester M13 9PL (UK) 
 E-Mail Linda.Gask@manchester.ac.uk 
Sartorius N, Holt RIG, Maj M (eds): Comorbidity of Mental and Physical Disorders. 
Key Issues Ment Health. Basel, Karger, 2015, vol 179, pp 157–164 ( DOI: 10.1159/000365600 )
 Management of Comorbidity of Mental and Physical Illness 
 Abstract 
 This chapter aims to explore the possibilities of prevent-
ing comorbid mental and physical disorders. It presents 
a framework of optional preventive strategies based on 
four explanatory models of comorbidity and six strategic 
dimensions. Addressing common early risk factors is 
 discussed as one of these preventive strategies. Some 
 examples of evidence-based prevention programs are 
presented that might contribute to prevention of comor-
bidity, needs for further research are discussed, and rec-
ommendations are presented for policy makers and prac-
titioners to improve the perspectives for preventing 
mental and physical comorbidity. So far, preventing men-
tal disorders and preventing physical disorders have 
been highly separated fields. It is recommended that 
both fields should broaden the range of baseline and out-
come indicators and include longitudinal designs to un-
derstand the long-term broad-spectrum outcomes of 
preventive interventions better. Future policy plans and 
practices in physical and mental health should be more 
focused at preventing comorbidity, and enhance related 
expertise among policy-makers and practitioners. Finally, 
it is argued that the preventive approach of comorbidity 
should be broadened to ‘smart clusters’ of highly related 
mental, physical and social problems, with the last pos-
sibly referring to important common risk factors. 
 © 2015 S. Karger AG, Basel 
 As is extensively discussed and evidenced in this 
book, comorbidity of mental and physical disor-
ders is a common phenomenon among patients 
in physical and mental healthcare, as well as in 
populations. Comorbidity with physical illnesses, 
particularly chronic physical illnesses, is reported 
especially for depression and anxiety disorders. 
This is in line with conclusions from the WHO 
World Mental Health Surveys in 18 countries, the 
results of which are presented in  Global Perspec-
tives on Mental-Physical Comorbidity  in the WHO 
World Mental Health Surveys (2009)  [1] . This in-
ternational cross-sectional study measured the 
prevalence of mental and physical comorbidity 
during the year preceding data collection. Pooled 
across 18 surveys in developed and developing 
countries, odds ratios (ORs) between 1.8 and 3.3 
were found for depression and dysthymia, and for 
different anxiety disorders in people with chronic 
pain conditions (arthritis, spinal pain, headache); 
among those with a heart disease, the ORs fell in 
the range of 1.9–2.7  [2] . Averaged across coun-
tries, the WHO study found that 36.9% of those 
with a depressive or anxiety disorder also suffered 
from a physical disorder. Prospective studies have 
shown that mental disorders could precede the 
onset of chronic physical disorders, but also that 
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chronic physical disorders could precede the 
 onset of mental disorders  [3] . Mental and physi-
cal comorbidity represents a high burden to soci-
eties, as is illustrated by a recent Australian re-
port  on comorbidity. In 2007, almost 12% of 
 Australians aged 16–85 had a mental disorder 
and a physical condition at the same time  [4] . 
 Comorbidity of mental disorders with physi-
cal disorders and comorbidity in general por-
tends a poorer outcome for the patients and high-
er economic costs  [2] . This includes poorer clini-
cal course, higher risk of chronicity, disability, 
additive work-loss, poorer quality of life and 
mortality, as well as more healthcare utilization, 
poorer treatment adherence and reduced treat-
ment success  [5–7] . All of these outcomes stress 
the need to invest in prevention of comorbid dis-
orders. If effective prevention strategies were im-
plemented, such an investment could result in a 
tremendous reduction in human suffering, utili-
zation of treatment services and huge cost savings 
in healthcare and social security.
 Although the bulk of studies on comorbidity 
date from after 2000, there were studies on mental 
and physical comorbidity in the 1980s and 1990s 
 [8–11] . By the 19th and 20th centuries, most 
mental hospitals had wards devoted to the treat-
ment of physical illness of patients admitted be-
cause of mental illness. From the 1970s, a DSM-
based assessment on the link between mental and 
physical diseases became an essential part of clin-
ical diagnosis. Given this history, it is striking that 
there are very few publications on the prevention 
of comorbidity. Most of the current literature is 
almost exclusively focused on improving treat-
ment for patients who already suffer from comor-
bid mental and physical illness.
 This chapter aims to explore the possibility of 
preventing comorbid mental and physical disor-
ders. It presents a theory-based framework of op-
tional preventive strategies, describes examples of 
evidence-based prevention programs that might 
contribute to prevention of comorbidity, identi-
fies further research needs and presents recom-
mendations for policy makers and practitioners 
to improve the perspectives for preventing co-
morbidity.
 Developments in Preventing Mental Disorders 
 Although the idea of preventing mental illness 
was introduced more than 100 years ago, sci-
ence-based prevention has a history of around 
30–40 years. Over the last decades, much prog-
ress has been made in understanding the risk 
and protective factors for mental disorders, 
which has been translated into a wide range of 
prevention programs. Prevention and health 
promotion, also in the mental health domain, 
have emerged internationally as a significant 
multidisciplinary field of science and practice, 
with a range of peer-reviewed scientific journals 
and specialized university departments and re-
search centers in most continents. Currently, a 
wide range of science- and practice-based pre-
vention programs are available. Thousands of 
controlled studies and a large range of system-
atic reviews and meta-analytic studies have been 
published showing that prevention programs 
targeting mental health can generate a wide 
range of positive outcomes  [12–15] . These in-
clude strengthening protective factors (e.g. so-
cial-emotional skills, parenting competence, ear-
ly parent-child interaction, coping with parental 
death and loss) and reducing the number of risk 
factors (e.g. child maltreatment, insecure attach-
ment, early externalizing problems, bullying, 
substance use). There is also cumulative evi-
dence of reductions in the onset of depression 
 [16] , anxiety symptoms and disorders  [17, 18] , 
eating disorders  [19] , externalizing problems 
and conduct disorders  [20–22] , and substance 
use problems  [23] . Some randomized longitudi-
nal studies have found significant effects even up 
to 15 and 40 years later. A growing number of 
economic evaluations of such programs have 
also provided evidence of their potential cost-ef-
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fectiveness, especially early childhood programs 
 [24] . 
 To date, evidence-based prevention programs 
are internationally exchanged, disseminated and 
implemented, and supported by online interna-
tional and national databases that are freely acces-
sible to policymakers and practitioners. Given the 
steadily growing availability of effective preven-
tion programs and the awareness of the enor-
mous human and economic burden of mental 
disorders, it is likely that investments in prevent-
ing and treating mental disorders will become 
more balanced during this century.
 In spite of these promising developments, 
major challenges exist in preventing mental dis-
orders and promoting mental health. First, re-
views and meta-analyses have shown that on av-
erage the effect sizes of prevention programs are 
small to moderate albeit significant, mostly 
ranging between 0.15 and 0.40. Meta-analyses 
have also shown large differences in effect sizes 
between programs, ranging from highly effec-
tive to showing no effect and in some cases even 
negative effects. This emphasizes the urgent 
need for program improvement and knowledge 
on the moderators and principles of effective-
ness. Secondly, owing to the use of labor-inten-
sive methods in many programs, low levels of 
implementation and poor resources and infra-
structure for prevention, the population reach of 
these preventive interventions is still marginal. 
This contrasts with the much wider implemen-
tation and public reach of programs aimed at re-
ducing the risk of chronic physical diseases such 
as those on reducing risk behaviors (e.g. smok-
ing, substance use, consuming unhealthy food, 
risky driving) and environmental risk factors 
(e.g. air pollution, safe cars and roads, quality of 
food).
 Finally, although Kessler and Price  [25] already 
in 1993 advocated for investment in the preven-
tion of comorbidity in psychiatric disorders, pre-
vention research has only marginally addressed 
this issue. The fields of physical diseases and men-
tal disorders prevention are highly separated. 
Even in cases where risk factors are addressed with 
a potential broad-spectrum outcome, testing their 
impact on the onset of both mental and physical 
illnesses is exceptional. Most disorder prevention 
programs in mental health are targeted at prevent-
ing a single disorder (e.g. depression).
 To understand how to prevent physical and 
mental comorbidity and to measure if interven-
tions are effective in preventing comorbidity, we 
first need to understand what comorbidity means, 
how we can differentiate between types of comor-
bidity and what the causal processes are underly-
ing comorbidity.
 Types of Comorbidity 
 Comorbidity can be defined at an  individual level 
 and  at a population level,  paralleling a clinical and 
a public health approach. This is a relevant dis-
tinction as prevention encompasses both preven-
tive treatment and public health actions.  Clini-
cians in physical and mental healthcare are chal-
lenged to identify the risk of comorbidity in 
individual patients and to act accordingly to pre-
vent comorbidity. This requires widening clinical 
assessment and treatment to address the risk of 
multiple disorders in the physical and mental 
health domains, and, if needed, to involve other 
clinical disciplines. 
 Preventing comorbidity at the population lev-
el requires a public health way of thinking  [26] . 
This includes population-based assessment, 
finding groups at high risk of comorbidity, iden-
tifying risk and protective factors, taking policy 
measures, initiating intervention programs to re-
duce the risk of disorders and comorbidity, and 
rigorously testing their efficacy and effectiveness. 
As discussed in the next section, interventions 
could range across a wide spectrum of optional 
preventive strategies that could start before the 
onset of a primary disorder and even before 
birth.
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 A distinction is commonly made between con-
current comorbidity  and sequential comorbidity. 
 Concurrent comorbidity  refers to a situation in 
which a person has two or more disorders at the 
same time or at least during the same period. In 
such cases, taking timely action to prevent the on-
set of both disorders would be the most desirable 
approach. This is only possible when both disor-
ders have evidence-based common risk or protec-
tive factors that are measurable and malleable 
during the antecedent period. For instance, grow-
ing empirical support exists for serious childhood 
adversities as a risk factor for both mental disor-
ders and chronic physical diseases  [1, 27] . Serious 
motor vehicle accidents with life-threatening ex-
periences represent another example, as they 
could result in both serious physical injuries and 
a posttraumatic stress disorder among survivors. 
The many successful measures that have been ad-
opted in recent decades to reduce serious traffic 
accidents have likely prevented many physical 
diseases or disability as well as comorbid post-
traumatic stress disorders.
 Sequential comorbidity refers to the onset of a 
secondary disease that is significantly associated 
with or influenced by an already existing primary 
disease. A well-known example of sequential co-
morbidity within the mental health domain is the 
relation between child anxiety disorders and ado-
lescent major depression. In their longitudinal 
community study, Wittchen et al.  [28] found that 
in the case of comorbidity, anxiety disorders 
mainly precede the onset of major depression. 
The ORs for later onset of depression ranged 
from 2.5 for specific phobia to 3.7 and 3.8 for pan-
ic disorder and agoraphobia. The time delay be-
tween the onset of the two related disorders could 
be short (e.g. a month or a year) or might even 
extend over one or more decades. The develop-
ment of sequential comorbidity could encompass 
longitudinal pathways from the start of life into 
late adulthood  [28] . It should be stressed, how-
ever, that anxiety symptoms might be an expres-
sion of child depression, which means that the ex-
ample might not reflect the sequential onset of 
two comorbid disorders, but age-related manifes-
tations of a similar underlying long-term depres-
sive disorder.
 The distinction between concurrent and se-
quential comorbidity is less transparent than it 
looks at first sight. Concurrent refers to the co-
occurrence of two disorders during a specific 
period of measurement, which could be the 
preceding week, month or year. In the case of a 
chronic physical disease, the onset of a reactive 
depression might follow months after the onset 
of a chronic heart disease. When their illness 
periods (prevalence) overlap, they could be 
considered as concurrent diseases, but as se-
quential comorbidity when we use onset as the 
criterion. As primary prevention aims to re-
duce onset of diseases, the onset criterion is of 
more strategic value as it offers more informa-
tion on possible causal sequences and timing of 
preventive interventions and their outcomes. 
The onset of a primary disease could then be 
used as a trigger for interventions to prevent 
the onset of a related secondary disease. Fur-
ther, when the secondary disorder is likely to 
start during the episode of the primary disor-
der, it is most practical that clinicians integrate 
efforts to prevent a secondary disorder in their 
treatment of the primary disorder. Finally, even 
when sequential comorbidity is established, 
how disorders are related remains an impor-
tant question. Theory-based prospective stud-
ies are needed to establish if the onset of the 
second disorder is mediated by the features and 
outcomes of the primary disorder, or a delayed 
result from a common risk factor.
 Four Explanatory Models 
 Most research on comorbidity is targeted at in-
creasing the knowledge on prevalence and conse-
quences of comorbidity, and on early detection 
and appropriate treatment. The causes of comor-
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bidity are studied much less  [7] . For prevention 
policies and programs, the latter type of studies are 
crucial, as preventive interventions typically aim 
to influence causes of diseases to lower the risk of 
onset. Designing an effective prevention approach 
to mental and physical comorbidity is only possi-
ble when we have insight into the underlying caus-
al mechanisms. For this reason, this section is fo-
cused on understanding how multiple diseases 
could be related and how risk and protective fac-
tors might contribute to comorbidity. Next, we 
present a comprehensive framework of optional 
preventive strategies to reduce comorbidity. 
 To describe how and why disorders could be 
related, we differentiate between four models: (1) 
common antecedent model, (2) sequential co-
morbidity model, (3) bidirectional comorbidity 
model and (4) accidental comorbidity model.
 The  common antecedent model  assumes that 
common, broad-spectrum factors influence the 
onset of multiple disorders, irrespective of wheth-
er the onset and prevalence of these disorders is 
co-occurring or separated over time. For child-
hood adversities (e.g. child abuse and neglect, pa-
rental mental illness, parental death and divorce), 
especially in the case of an accumulation of child-
hood adversities, extensive evidence exists for a 
wide range of long-term negative outcomes such 
as increased risk of depression, conduct disor-
ders, drug and alcohol abuse, low self-esteem, 
poor emotional competence, risky sexual behav-
ior, suicidal behavior, and adult-onset asthma, 
obesity and hypertension  [1, 3] .
 The  sequential comorbidity model presumes 
that features and outcomes of a primary disorder 
or its treatment increase the onset of a secondary 
disorder. Examples of factors that mediate the 
causal relationship between both disorders are se-
rious stress experiences resulting from the prima-
ry disorder (e.g. pain, psychotrauma, physical 
disability, dependency, unemployment, social 
isolation), harmful coping behaviors (e.g. smok-
ing, alcohol use, inactivity), negative social reac-
tions (e.g. social stigma) or negative side effects of 
medication. Preventive interventions could aim 
to reduce or compensate for these mediating out-
comes. In the  bidirectional model,  two disorders 
and their outcomes are assumed to reinforce each 
other’s development and chronic course. In this 
case, preventive interventions could address me-
diating outcomes of both disorders. Finally, in the 
 accidental comorbidity model comorbid disorders 
are considered to be a random phenomenon, with 
no evidence of mutual influence or common 
causes. Each disorder is assumed to have an inde-
pendent causal trajectory. The prevention of both 
disorders would require the implementation of 
separate primary preventive interventions, each 
addressing a different disorder.
 Strategies to Prevent Comorbidity 
 To prevent comorbid mental and physical ill-
ness, one could choose from different interven-
tion scenarios. Each strategy is defined by the 
combination of choices on a range of target- 
and strategy-related dimensions that roughly 
represent the ‘what-who-why-when frame-
work’. This framework of choices is composed 
of six dimensions: 
(1)  Target . This dimension concerns choices 
such as ‘Which combination of comorbid disor-
ders is targeted?’, ‘Which of them should be pre-
vented?’ and ‘The mental disorder, physical dis-
order, or both?’. 
(2)  Target population . Should the target popu-
lation be chosen through universal, selective or 
indicated prevention? This refers to a choice 
about the width and level of risk of the targeted 
population. Universal prevention targets whole 
populations, selective prevention targets groups 
at risk and indicated prevention targets persons 
or groups at high risk when they show subclinical 
symptoms that might grow into a diagnosable 
disorder. Targeted persons or groups could be at 
risk of the primary disorder, the secondary disor-
der or both. Identifying persons at high risk re-
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quires the use of risk assessment tools that are still 
poorly developed in psychiatry. 
(3)  Factors . Which evidence-based risk or 
protective factors are targeted? This concerns es-
pecially the choice between addressing common 
causal factors or disorder-specific factors. Com-
mon factors are shared by multiple disorders, 
also called broad-spectrum factors. Disorder-
specific factors could be related to either a physi-
cal disorder or a comorbid mental disorder. Risk 
factors for depression include, for instance, a pa-
rental mental illness, negative cognitive style, se-
rious loss experiences, physical illnesses (e.g. dia-
betes, stroke, cardiac disease, loss of hearing), 
poverty and exposure to childhood traumas, 
while parental care, secure attachment, coping 
skills, social-emotional competence and social 
support are considered to protect against depres-
sion. Several of these factors (e.g. poverty, child-
hood maltreatment, secure attachment, social 
support) can also be considered as broad-spec-
trum factors. There is growing evidence that high 
risk is not just defined by single risk factors, but 
by the number of accumulating risk factors  [28–
30] ; reducing this number by targeting the most 
malleable factors might be a cost-effective strat-
egy to prevent disorders. 
(4)  Timing. This refers to choices concerning 
 when to intervene. In the case of sequential co-
morbidity, the options are to provide a preven-
tive intervention prior to, during or after a pri-
mary disorder, or prior to the secondary disor-
der. For instance, some studies suggest that 
depression in children, adolescents and young 
adults increases the risk of adult obesity  [31, 32] . 
To lower the risk of secondary obesity, one 
could aim to prevent depression in adolescents, 
treat first episodes of depression effectively, pre-
vent relapses, educate people with depression 
about healthy lifestyles, or detect and treat early 
eating problems among those with chronic de-
pression. When common factors are targeted, a 
choice needs to be made about when to inter-
vene along the life span. This will depend on 
when a common risk or protective factor emerg-
es and the most sensitive period during which 
such a factor could be influenced. For instance, 
research outcomes suggest that maternal de-
pression, anxiety and chronic stress during 
pregnancy and early child maltreatment may re-
sult in a disturbed emotional brain and stress-
response system (HPA axis) in childhood that is 
associated with long-term vulnerability to men-
tal disorders and weakened immunity against 
chronic diseases. This points to the need to start 
preventive interventions as early as during preg-
nancy and infancy. 
(5)  Provider . Who will provide the preventive 
intervention and from which setting? This could 
be general practitioners, public nurses, mental 
health professionals, medical specialists in hospi-
tals, public health professionals, health educators, 
or peers and experts-by-experience. It is highly de-
sirable to integrate prevention in the work of all of 
these disciplines. Related to this is the choice be-
tween providing preventive support integrated in 
the treatment process (e.g. following a stepped 
care model) or by a referral to separately provided 
prevention programs. 
(6)  Method . This concerns the choice of inter-
vention methods and theories and principles of 
change. Evidence-based prevention programs use 
a wide variety of intervention methods, such as 
home-visiting, parenting education, school-
based programs, group-based courses, internet-
based interventions, self-help books, support 
groups, individual counseling and preventive 
medication. These methods make use of different 
mechanisms of change to influence causal factors, 
such as providing information, feedback, model-
ing, competence training, emotional support and 
biological agents, as well as through environmen-
tal changes. 
 Figure 1 offers an overview of six alternative 
prevention strategies (PS) that could contribute to 
the prevention of comorbidity-based on combina-
tions of choices at the target, target population, 
factor and timing dimensions. Preventive inter-
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ventions could start during pregnancy and infan-
cy to influence the development of common risk 
and protective factors early in life or during child-
hood and adolescence (PS1). Other interventions 
are targeted at disorder-specific risk factors (PS2) 
and prodromal or subclinical symptoms preced-
ing the primary disorder (PS3), at effective treat-
ment of the primary disorder (PS4), reducing neg-
ative outcomes of the primary disorder or its treat-
ment (PS5), and addressing specific risk factors 
and subclinical symptoms of secondary disorders 
(PS6).
 Promising Evidence-Based Preventive 
Programs 
 Following the strategic framework, many avail-
able evidence-based prevention programs 
might be useful as components of an integral 
approach to reduce comorbidity, although they 
were not developed originally for this purpose. 
We do not have the opportunity here to review 
all prevention programs that might be useful to 
reduce comorbidity, but some examples will 
show that effective preventive actions might be 
possible. 
 Preventing Child Abuse and Neglect 
 The first example concerns the prevention of 
early child abuse and neglect, earlier identified 
as a broad-spectrum risk factor for both mental 
disorders and chronic physical diseases. In their 
 Lancet review on interventions to prevent child 
maltreatment in 2009, Macmillan et al.  [33] con-
cluded that some home-visit programs have 
shown significant results in controlled trials. Ef-
fective programs include among others the 
Nurse-Family Partnership program that was 
evaluated in three randomized controlled trials 
across different US regions  [34] . The program 
uses trained nurses that visit low-income first-
time mothers during pregnancy and infancy, 
many of whom are single mothers or who have 
to cope with other life stressors. The nurses offer 
parent education, promote a healthy lifestyle, 
help the mothers to develop supportive relation-
ships, and link them to appropriate health and 















Fig. 1. Model of strategies to prevent comorbidity across the developmental trajectory and targeted at common or 
disorder-specific factors.
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social services. The studies showed a wide vari-
ety of positive outcomes, including healthier 
maternal diets and less smoking, 75% fewer pre-
term deliveries, less irritable and fussy babies, a 
large drop in cases of child maltreatment, fewer 
emergency visits and less injury requiring medi-
cal examination, higher IQ among children of 
smoking mothers, and shorter periods of mater-
nal dependency on social welfare. Fifteen years 
later, children from the intervention group 
showed dramatically less exposure to child abuse 
over this period, and lower levels of adolescent 
substance abuse, arrests and convictions than 
children from the control condition. Several 
other home-visit programs were not successful 
in reducing child maltreatment. Likely condi-
tions for successful programs are a theory base, 
use of trained professionals (nurses) and safe-
guarding program fidelity during implementa-
tion. Also starting home-visiting during preg-
nancy might have significantly contributed to 
the success of the Nurse-Family Partnership 
program. 
 Two other types of programs have shown sig-
nificant benefits in randomized trials, as reported 
by Macmillan et al.  [33] . In the Safe Environment 
for Every Kid (SEEK) program, pediatric resi-
dents were trained to identify family problems 
and to link families to a social worker if needed. 
Families served by these trained residents showed 
fewer child-protection service reports, fewer in-
stances of medical neglect, and less harsh punish-
ment reported by parents, although the results 
were only marginally significant. Triple P is an 
Australian multicomponent program on positive 
parenting that addresses both universal and tar-
geted populations of parents, using a wide variety 
of educational methods (e.g. group work, mass 
media, books, lectures). The results across 48 
controlled studies showed significant reductions 
in ineffective parenting and depression among 
parents and less behavioral problems among their 
children, and in one large randomized trial across 
18 US counties around 1 in 5 less cases of regis-
tered child abuse and less child maltreatment in-
juries  [35, 36] . The program is currently imple-
mented in a wide range of countries around the 
world.
 Selected and Indicated Prevention of Depression 
 Most intervention programs that aim to prevent 
the onset of depression make use of cognitive-be-
havioral treatment principles to educate at-risk 
individuals to challenge negative beliefs, enhance 
positive thinking, and strengthen their problem 
solving and social skills. A wide variety of such 
programs have been standardized for adolescents, 
adults and elderly. The best known are the Coping 
with Depression Course and the Penn Resilience 
Program. These types of programs are provided in 
different formats such as group-based courses, 
self-help books in combination with telephone 
support and as internet-based programs. Each of 
these formats can easily be provided by physical 
and mental health services or by national insti-
tutes or nongovernmental organizations in the 
case of internet-based programs. Several reviews 
and meta-analyses across a large range of con-
trolled trials have shown that these programs are 
effective in reducing depression-prone risk fac-
tors and depressive symptoms in different age 
groups, including older adults  [37, 38] . Face-to-
face, internet-based and self-help formats were all 
found to be effective. A meta-analysis of 19 ran-
domized controlled trials that tested the impact of 
selected and indicated depression prevention pro-
grams found an average 22% reduction in the on-
set of depressive episodes as a result of participa-
tion in comparison to the incidence in the control 
groups  [17] . One randomized controlled trial test-
ed the integration of preventive interventions in a 
stepped care mental health service model for el-
derly with an elevated level of depressive symp-
toms  [39] . Implementation of this prevention-ori-
ented stepped care model resulted in a 50% reduc-
tion in incident depression or anxiety among 
elderly people aged 75 years or older, which was 
sustained over 24 months. 
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 Healthy Lifestyle Programs 
 While chronic physical illnesses increase the 
risk of secondary mental disorders, such as de-
pression and anxiety disorders, one might ex-
pect that public health efforts to prevent physi-
cal illnesses might also result in a lower inci-
dence of secondary mental disorders. For 
instance, meta-analyses and systematic reviews 
have shown that the risk of type 2 diabetes and 
cardiovascular disease can be reduced through 
behavioral counseling to promote physical ac-
tivity and a healthy diet  [40–42] . No insight ex-
ists, however, on the impact of such programs at 
the onset of secondary depression among those 
at risk. 
 Challenges for Research 
 This exploratory paper has revealed a range of 
weaknesses in current knowledge and challenges 
for future prevention research. These challenges 
concern both the development of basic knowl-
edge on the causal mechanisms of comorbidity, 
and the need to understand what works and how 
to prevent comorbidity. 
 The first challenge is to better understand 
what common risk and protective factors and 
shared developmental trajectories are in the etiol-
ogy of mental disorders and chronic physical dis-
eases. The science of developmental psychopa-
thology could serve as a great source for such 
knowledge as this field is typically multidisci-
plinary in nature and studies complex and long-
term etiological trajectories. The aim is to under-
stand the spectrum of long-term mental and 
physical outcomes of common early risk factors 
(multifinality) as well as the different etiological 
paths toward a similar disorder (equifinality). Its 
multidisciplinary nature facilitates the integra-
tion of knowledge from genetic and epigenetic, 
biological, neurological, psychological and social 
research. This cross-fertilization of research ap-
proaches offers great opportunities to understand 
the interplay of biological, behavioral and social 
forces along the life span, and how the develop-
ment of mental and somatic disorders is inter-
twined.
 The growing knowledge on the narrow rela-
tionships between mental and physical disorders 
challenges the current practice in prevention re-
search of treating the mental and physical disease 
domains as completely separated fields. As a con-
sequence, in current prevention studies in the 
physical and mental health domains, major op-
portunities are missed to understand possible 
broad-spectrum effects of prevention programs 
that surpass the originally targeted domain. It is 
likely that both programs could contribute to 
outcomes in the other domain – outcomes that 
have remained undetected so far. Breaking 
through the borders between both domains could 
also open research on innovative approaches 
where prevention programs from both domains 
could be combined to create a higher level of ‘col-
lective impact’. For instance, under what condi-
tions could lifestyle programs contribute to the 
prevention of depression and anxiety? How can 
depression prevention and mental health pro-
motion programs be combined with lifestyle ed-
ucation in order to reduce smoking and obesity 
more effectively?
 To understand the relationship between men-
tal and physical processes and disorders better, it 
is necessary to broaden the range of baseline and 
outcome indicators in prevention studies. In 
prevention studies primarily targeting common 
mental disorders, more physical health indica-
tors should be added, and likewise, mental health 
indicators should be added to studies primarily 
targeting physical disorders. Currently, it is com-
mon practice in trials targeted at the prevention 
of a specific disorder to measure at baseline only 
the presence of that disorder to exclude those 
with the disorder from participation in the trial. 
It is, however, likely that many included subjects 
had other disorders in the preceding year or at 
baseline that remained unnoticed. Including a 
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wider set of health and mental health indicators 
could offer more insight into the impact of pre-
vention trials on comorbidity, as well as in the 
impact of comorbid disorders on the outcomes 
of prevention trials.
 Lastly, it would be desirable to combine the 
use of a wider spectrum of outcome indicators 
with longitudinal research designs in prevention 
studies. Many prevention and mental health pro-
motion programs address early risk and protec-
tive factors (e.g. child maltreatment, parenting, 
social and emotional resilience) that might be re-
lated to a broad spectrum of mediating or long-
term health outcomes. Studies that measure only 
short-term outcomes will likely undervalue the 
potential spectrum of effects of a prevention pro-
gram.
 In conclusion, a major issue for the future re-
search agenda is to study what the potential of 
current evidence-based programs in the mental 
health domain is to prevent comorbidity, to im-
prove both physical and mental health, and to 
learn how physical and mental health are related 
along the lifespan.
 Challenges for Policy and Practice 
 The analysis and findings presented in this chap-
ter show that a wide range of policy- and prac-
tice-based strategies are possible to prevent co-
morbidity, as illustrated in  table 1 . This should 
have implications for the work of individual 
physical and mental health practitioners, as well 
as for national and local public health and pre-
vention policies. 
 Recognizing the interrelatedness of mental 
disorders with chronic physical diseases, and the 
role of common risk and protective factors, fu-
ture policy plans should be more focused at in-
tegrated approaches, addressing mental and 
physical outcomes simultaneously. Currently, 
prevention of mental disorders still occupies a 
marginal and undervalued position in public 
health policies and health budgets worldwide. 
Finding opportunities for shared preventative 
and health promotion approaches might open 
new perspectives for preventing mental disor-
ders. It will offer better opportunities to expand 
the reach in the population. It will also offer op-
Table 1.  Policy- and practice-based strategies to prevent comorbidity of mental and physical disorders
Policy-based
Addressing comorbidity issues in health and mental health policies as well as in prevention and health 
 promotion policies, and enhancing integrated approaches that address ‘smart clusters’ of multiple health and 
social problems
Special focus on prevention and health promotion policies at reducing common early risk factors
(e.g. childhood adversities) and strengthening protective factors (e.g. emotional resilience)
Reducing the barriers between health and mental health policies, and between healthcare and mental 
 healthcare
Define quality standards in care for addressing prevention of comorbidity
Making evidence-based preventive interventions more accessible through international and national databases
Safeguarding professional and financial resources for prevention of comorbidity
Investing in research and development of effective interventions to prevent comorbidity
Practice-based
Adoption of risk assessment practices in primary health services and pediatric care for early identification of 
common risk factors
Training practitioners in risk assessment and interventions to prevent comorbidity in different stages of the 
life span
Enhancing integrated practices that address related health, mental health and social problems
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portunities to increase the resources and profes-
sional capacity to implement prevention for 
mental health. This will be more likely when ev-
idence shows that preventive interventions in 
the mental health domain are successfully tar-
geting risk and protective factors that also have 
an impact on the development of chronic physi-
cal diseases. Given the growing knowledge of the 
impact of stress and depression on the function-
ing of the immune system, such a perspective is 
not imaginary.
 To make practitioners and local health and 
mental health services more willing and capable 
to address the prevention of comorbidity, their 
expertise in preventative strategies and interven-
tions needs to be expanded. This initially re-
quires making prevention and comorbidity a 
standard element in the training of general prac-
titioners, nurses, psychiatrists, psychologists and 
social workers. Secondly, the knowledge and ac-
cessibility of available evidence-based preventa-
tive interventions need to be increased. This 
could be facilitated by easily accessible databases 
of effective prevention programs as these are al-
ready available in some countries, such as the 
USA, the Netherlands, Norway and Germany. 
By establishing an international network of such 
databases, international exchange of new evi-
dence-based programs and best practices could 
be improved.
 Finally, this book is devoted to the relationship 
between mental and physical disorders. There are 
good reasons, however, to assume that the rela-
tionship between both types of problems is caused 
or at least reinforced by existing social problems, 
such as poverty, unemployment, discrimination, 
domestic violence, war-related traumas, housing 
problems, poor social networks, social isolation 
and social stigma. Such social circumstances 
could be considered as common risk factors or 
even as the ‘root of the roots’. For this reason, the 
message of this book is that the single disorder ap-
proach to address mental-physical comorbidity 
should be expanded to focus on social-mental-
physical comorbidity. The public health and pre-
vention approaches in the future should not be 
targeted at single disorders one by one, but at so-
called ‘smart clusters’ of highly related social, 
mental and physical problems, especially those 
clusters that concentrate in low-income coun-
tries, problem areas, disadvantaged communities 
or populations at high risk for an accumulation of 
problems. This challenges health and public 
health managers, health promoters, nongovern-
mental organizations, community leaders, citizen 
groups, private companies, policy makers and 
politicians to sit together and communicate about 
an effective integral preventive approach to such 
clusters of problems. In such a comprehensive ap-
proach, multiple social measures and preventive 
interventions could be combined in a comple-
mentary way, where the collective impact is larger 
and has a broader spectrum than could be 
achieved by stand-alone interventions and pro-
grams. Such a smart cluster and integral approach 
could be concentrated at crucial stages of the life 
span, such as a ‘healthy start in life’ to facilitate 
children growing up in healthy, safe and caring 
environments that enhance their physical, mental 
and social resilience, and immune systems, and 
will contribute to less mental, physical and social 
problems during their adolescence and adult-
hood. Integrating a focus on the social determi-
nants in a mental health approach is in line with 
the core messages of the recent WHO Compre-
hensive Mental Health Action Plan 2013–2020 
 [43] .
 In conclusion, the field of mental health and 
physical health should become more integrated, 
which would make working on the prevention of 
comorbidity a normal phenomenon instead of an 
exception. In the end it will be the well-being of 
the person that will gain most from it. 
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Concluding Remarks
 Abstract 
 The reviews of evidence presented in the chapters of this 
volume lead to several conclusions and four recommen-
dations. The prevalence and incidence of comorbidity of 
mental and physical disorders are high and likely to grow. 
The problems of comorbidity are not the simple addition 
of problems related to the diseases involved, as they 
worsen the prognosis of all diseases involved to a signifi-
cantly greater extent. At present there is no clear strategy 
of action concerning comorbidity at the primary, second-
ary or tertiary levels of healthcare or in the local, provin-
cial, national or international decision-making systems. 
The evidence presented in the book also allows the for-
mulation of recommendations concerning the training of 
healthcare staff and the organization of healthcare. To 
support the changes proposed and to evaluate their ef-
fects it will be necessary to strengthen research concern-
ing comorbidity and seek ways of sharing experience ob-
tained by the use of different models of care catering to 
the needs of people with comorbid illnesses. 
 © 2015 S. Karger AG, Basel 
 Several conclusions emerge from the chapters 
that have been included in this volume. First, co-
morbidity between mental and physical disorders 
is frequent in the population and its prevalence 
grows with age and with successes of medicine 
saving lives (but not curing diseases) [Rosenblat 
et al., pp. 42–53; Holt, pp. 54–65; Monteleone and 
Brambilla, pp. 66–80; Kariuki-Nyuthe and Stein, 
pp. 81–87; Lawrence et al., pp. 88–98; Müller, pp. 
99–113; Gordon et al., pp. 114–128]. Second, co-
morbidity does not simply add problems related 
to one disease to those of the other: by and large 
the simultaneous presence of several diseases 
makes the prognosis of all the diseases involved 
worse, their complications more frequent and 
their treatment more complicated [Fisher et al., 
pp. 1–14; Oldenburg et al., pp. 15–22]. Third, no 
medical discipline has a clear strategy of action 
required when a disease that does not belong to 
its special field of interest accompanies one that is 
within the domain of their specialty. Fourth, the 
current trend of super-specialization and frag-
mentation of medicine may make matters worse 
unless appropriate action is taken promptly 
[Fisher et al., pp. 1–14]. Fifth, primary healthcare 
professionals (e.g. general practitioners or family 
physicians) are aware of the problems related to 
comorbidity because they encounter them even 
more frequently than other medical specialists; 
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however, most have not received specific training 
in the use of skills that might be central in dealing 
with comorbidity [Boeckxstaens et al., pp. 129–
136; Cushing and Evans, pp. 137–147; Gask, pp. 
157–164]. 
 The material presented also indicates direc-
tions of future work at different levels. First, it 
is clear that changes in the delivery of education 
of healthcare personnel are urgently needed 
[Cushing and Evans, pp. 137–147; Millar et al., 
pp. 148–156; Gask, pp. 157–164]. This is true for 
all categories of healthcare professionals includ-
ing nurses, medical assistants, general practitio-
ners and specialists, at both undergraduate and 
postgraduate levels. Problem-based learning 
was seen as an educational method that would 
lead to a better understanding of the problems 
and solutions and that would be in harmony 
with the environment in which the patient lives 
and the service operates. Unfortunately, the 
training materials that were produced by spe-
cialists, who were to lead problem-based learn-
ing as well as the implementation of the train-
ing, have neglected, to a large degree, the co-
morbidity of mental and physical disorders. The 
education of healthcare personnel in institu-
tions which are usually uneasy federations of 
specialized departments did not help in devel-
oping an attitude of dealing with illnesses fully 
aware of the person who suffers from that ill-
ness and possibly from various other ills and 
problems. Teachers of the disciplines are usu-
ally specialists knowledgeable in their own field 
and somewhat distant or even possibly disdain-
ful of other specialists and matters with which 
they deal. In many parts of the world, family 
physicians are rarely invited to train medical 
students and other students of health profes-
sions. By contrast, in the UK general practitio-
ners are invited to teach increasingly often and 
it is to be hoped that this will soon happen else-
where. Carers who often have a vast array of ex-
periences in dealing with comorbid chronic 
mental and physical diseases are only excep-
tionally invited to serve as teachers of health 
professional students.
 The distinction of psychological reactions to 
being ill and mental disorders in a strict sense is 
also a problem. Many of those surrounding the 
patient – professional and nonprofessional car-
ers – are ready to dismiss the notion that the 
patient they have before them has a depressive 
illness that requires specific treatment, prefer-
ring to explain the symptoms in ‘logical’ terms 
as the reaction of patients who were told that 
they have a serious illness and that they have to 
live with it. Occasionally both the patient and 
the doctor realize that a mental disorder as well 
as a physical illness is present, but they are unit-
ed in a tacit collusion about the presence of the 
mental illness which they hope will vanish once 
the treatment of the physical illness has been 
successfully completed and therefore focus on 
the treatment of the physical illness only. This 
way of proceeding is also seen and emulated by 
the medical students who in later years of their 
training often learn by imitating the behavior of 
more experienced general practitioners or other 
specialists.
 A second line of recommendations that could 
be made concerns in-service training of doctors 
and other health personnel. The two examples 
given in the chapters by Cushing and Evans [pp. 
137–147] and Millar et al. [pp. 148–156] concern 
the in-service training of nurses and general 
practitioners. In the chapter by Cushing and Ev-
ans, which describes the training of senior nurs-
es and nurse trainers in African countries, the 
participants are cited as saying they found it use-
ful to discuss how to organize their service in a 
manner that would facilitate the management of 
problems arising for people with comorbid de-
pression and diabetes because they have not 
been trained in ways in which this should be 
done. Bearing in mind that in the countries from 
which the nurses attending the course came, and 
where nurses are the backbone of health service, 
it is clear that the training of nurses about the 
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ways in which their service should be organized 
is a neglected priority in the effort to provide ap-
propriate care to people who have the misfor-
tune of suffering from more than one illness at 
the same time [Beran, pp. 33–41; Millar et al., pp. 
148–156]. Family physicians seem to be clear 
about the need to see the patients in their total-
ity and to pay attention to all of their ills; there 
is, however, no consensus about the ways in 
which this type of approach to the patients they 
see can best be supported by referral and feed-
back arrangement within the health system as a 
whole [Boeckxstaens et al., pp. 129–136].
 A third recommendation that could be for-
mulated concerns funding. At present a consid-
erable proportion of research funding is chan-
neled through institutions which deal with a sin-
gle disease or a group of diseases. This is the 
principle on which the National Institutes of 
Health in the USA as well as many funding agen-
cies in other countries have been constructed. 
Some of the major foundations fund various 
types of research, but even there a major part of 
the funding follows a call for proposals on a sin-
gle disease or disease group. There are very few 
calls for proposals on comorbidity and even few-
er that would specifically invite applications for 
research on comorbid mental and physical disor-
ders [Hosman, pp. 165–177]. Universities, which 
should, if true to their mission, fund research on 
topics of major public health importance and 
could therefore be expected to fund research on 
comorbidity, are increasingly adopting the strat-
egy of making a good part of their living from 
overhead charges to projects which have been 
funded by someone else and only rarely provide 
their researchers funds for projects that would 
express the universities’ public health mission. It 
might therefore be recommended that universi-
ties take it upon themselves to fund research and 
other work related to comorbidity at least until it 
dawns on the other agencies that comorbidity 
should be at the center of their interest rather 
than being seen as a confounding factor. Wheth-
er the universities will be in a position to play the 
role of being leaders in research which is of pub-
lic health importance will to a large extent de-
pend on the support of their governments – 
which unfortunately in recent times they have re-
fused to provide.
 Finally, in addition to the recommendations 
on funding of research and reorientation of train-
ing, a fourth recommendation could be directed 
to the search for opportunities to study and test 
the most appropriate models of service for people 
with comorbid mental and physical disorders. In 
the 19th century, mental hospitals were obliged 
to have wards for inpatients who in addition to 
their mental disorder also had a physical illness. 
These wards were usually run by specialists in in-
ternal medicine who in the course of time ac-
quired considerable experience and knowledge 
about mental disorders. In the early 20th century 
a new category of super-specialists came into ex-
istence – the liaison psychiatrists who often, in 
addition to their postgraduate education in psy-
chiatry, also had attended postgraduate courses 
in internal medicine. To an extent, the existence 
of this group is a sad admission of the fact that the 
vast majority of psychiatrists was not willing or 
able to deal with physical illness in their patients. 
This refusal to perform all that undergraduate 
and postgraduate education gave to these doctors 
has not been typical for other specialties; for ex-
ample, there are no liaison surgeons, liaison der-
matologists or liaison ophthalmologists although 
these specialists, among others, often deal with 
patients who have a mental disorder as well as a 
dermatological illness or problems with their 
eyes. Liaison psychiatry and ‘general hospital 
psychiatry’ are clearly not the best way to a solu-
tion of the comorbidity problem and therefore 
there is an urgent need to develop service models 
that will be better suited to meet the needs of peo-
ple with comorbid illnesses and to provide train-
ing in ways of doing it. 
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